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Summary 
Stroke is a leading cause of death and disability worldwide and remains a largely 
unmet clinical need. Despite decades of pre-clinical stroke research there are 
only two licensed interventions: intravenous delivery of thrombolytic 
recombinant tissue plasminogen activator (rt-PA) within 4.5 hours of stroke or 
mechanical thrombectomy. However, the number of patients eligible to receive 
either treatment is limited. An alternative intervention is needed, one which 
directly address specific aspects of stroke pathophysiology. Through their ability 
to alter the expression of multiple genes involved in stroke pathophysiology 
microRNAs (miRNA or miR) offer a novel therapeutic intervention. miRNA 
expression is altered both in experimental stroke and in patients with stroke. It 
was initially hypothesised that modulation of specific dysregulated miRNAs 
would be therapeutically beneficial in pre-clinical experimental ischaemic 
stroke. Recently, active transport of miRNAs in extracellular vesicles (EV), such 
as exosomes, has been demonstrated pre-clinically between cells in 
atherosclerosis and cardiac hypertrophy disease settings. It was therefore 
hypothesised that miRNAs packaged in exosomes would differ between patients 
with stroke and patients without stroke, raising the potential for novel exosomal 
miRNAs to be used as biomarkers or therapeutic agents for modulation.  
In Chapter 3, investigations were carried out to test the hypotheses that 
modulation of either miR-494 or miR-21 would be therapeutically beneficial in 
pre-clinical in vitro models of stroke. While miR-494 expression was unchanged 
in brain tissue of spontaneously hypertensive stroke prone rats (SHRSP) 
harvested at either 24 or 72 hours following transient middle cerebral artery 
occlusion (tMCAO) its expression was successfully up-regulated in B50 neuronal 
and GPNT cerebral endothelial cell lines following delivery of miR-494 mimic in 
combination with siPORT, a lipid based transfection reagent. mRNA expression of 
putative miR-494 target genes (PTEN, MMP2 and MMP9) was investigated post-
miR-494 modulation but there was no obvious change in their expression. 
Modulation of miR-494 expression did not appear to be therapeutically beneficial 
(or detrimental) when assessed by a cell survival assay (MTS). As the balance of 
evidence did not indicate that miR-494 would be a suitable target for 
modulation in experimental stroke subsequent similar experiments investigated 
the therapeutic potential of miR-21. Its expression was significantly increased in 
xv 
 
    
 
SHRSP brain tissue at 72 hours following ischaemic stroke. miR-21 expression was 
successfully increased in cerebral endothelial cells following delivery of miR-21 
mimics (with siPORT). mRNA expression of putative target genes (PDCD4 and 
PTEN) was unchanged following miR-21 modulation and cell survival (assessed by 
MTS assay) was unaffected. Subsequent experiments looked at vessel reactivity 
of aortae taken from miR-21+/- and miR-21-/- mice in comparison to wild type 
(WT) mice. Treatment of vessels with L-NAME to block endogenous nitric oxide 
(NO) bioavailability resulted in unopposed contraction to U46619 in WT mice 
while there was no change in contraction in miR-21-/- mice aortae, consistent 
with reduced basal NO bioavailability, and a detrimental phenotype associated 
with the loss of miR-21 expression. As the data generated in this study were 
primarily neutral and gave no indication that either miR-494 or miR-21 would be 
therapeutically beneficial in the setting of ischaemic stroke, subsequent studies 
focussed on investigating exosomal miRNA in ischaemic stroke. 
In Chapter 4, exosomal miRNA expression was profiled in blood samples from 
stroke patients and subsequently in pre-clinical rodent stroke models. Patients 
with suspected stroke were recruited and a blood sample taken at 48 hours post-
stroke. All participants gave full informed consent and the study was approved 
by the Scotland A Research Ethics Committee. Exosomes were isolated from 200 
µL serum before RNA was extracted. A miRNA microarray was performed 
(OpenArray™ platform) on samples from 39 patients. Validation of results was 
performed by real-time quantitative polymerase chain reaction using samples 
from 173 patients to determine the expression levels of specific miRNAs. 
Microarray experiments identified 26 exosomal miRNAs that were significantly 
dysregulated between stroke and non-stroke patients or between specific TOAST 
subtypes and non-stroke controls. Of these, changes in 13 miRNAs were 
validated in the larger cohort and levels of 9 miRNAs (-27b, -93, -20b, -17, -
199a, -30a, let-7e, -218 and -223) were found to be significantly increased in 
definitively diagnosed stroke patients as compared to non-stroke patients. 
Differences in exosomal miRNA expression were observed between TOAST 
subtypes with small vessel disease patients consistently having the highest levels 
of these miRNAs. miRNA expression did not correlate with baseline or day 7 
NIHSS score, although there was a trend towards patients with better functional 
outcome post-stroke (as assessed by modified Rankin Score at 1 month) having a 
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higher level of some exosomal miRNAs. Subsequently total and exosomal miR-17 
family (miRNAs -17, -93 and -20b) expression was investigated in pre-clinical 
models of hypertension and stroke. Total circulating miR-17 expression was 
unchanged between the serum of normotensive WKY and hypertensive SHRSP 
rats, whilst exosomal miR-17 expression was significantly increased in SHRSP vs. 
WKY. miR-17 family expression was unchanged in peri-infarct brain tissue of 
SHRSP at both 24 and 72 hours post-tMCAO. Experiments profiling total and 
exosomal circulating miR-17 family expression in serum of SHRSP post tMCAO or 
permanent MCAO revealed that expression was variable and changes observed 
were not significant. Cellular expression of miR-17 family miRNAs was unchanged 
following hypoxic challenge in neuronal, glial and cerebral endothelial cell lines 
and exosomal miRNA expression was highly variable, with no changes detected 
as significant. This study both identified and validated (for the first time) 
changes in exosome packaged miRNA expression in patients with stroke across 
differing stroke subtypes. The pre-clinical experimental findings corroborate the 
human data and support a functional role for these findings. 
In Chapter 5 exosomal packaged miR-17 family miRNAs were delivered in pre-
clinical models of ischaemic stroke (both in vivo and in vitro) to test the 
hypothesis that they would be therapeutically beneficial following in vitro 
hypoxic challenge or in vivo experimental stroke. Bioinformatics analysis 
highlighted a number of important target genes implicated in stroke 
pathophysiology for each miRNA including genes involved in the regulation of the 
cellular response to stress, apoptosis and angiogenesis. miRNAs were artificially 
loaded (by electroporation) into EVs harvested from SHRSP brain. While miRNA 
loaded EVs did not successfully modulate miRNA expression either in vivo or in 
vitro it is believed that this is a result of technical issues with the loading of the 
miRNAs into the EVs. This study should be repeated when miRNAs have been 
successfully loaded into EVs, as these experiments remain of interest. 
In summary, the findings presented in this thesis confirm that packaging of 
miRNAs into exosomes is significantly dysregulated in stroke patients and that as 
a result the circulating exosomal miRNA profile is altered. This will direct future 
studies looking into paracrine signalling in the setting of stroke and the 
modulation of specific miRNAs as a novel therapy in the setting of experimental 
stroke.  
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1.1 Stroke 
1.1.1 Classification 
A stroke has been defined by the WHO as “rapidly developed clinical signs of 
focal (or global) disturbance of cerebral function, lasting more than 24 hours or 
leading to death, with no apparent cause other than of vascular origin" (Aho et 
al., 1980). This is in contrast to a transient ischaemic attack in which symptoms 
recover completely within 24 hours of onset. 
1.1.1.1 Haemorrhagic Stroke 
An intracerebral haemorrhage (ICH) is the result of the rupture of a diseased 
cerebral blood vessel within the cerebrum. This can cause a significant increase 
in pressure within the brain. While hypertension is the primary cause of ICH, 
other causes include trauma and blood vessel abnormalities (e.g. arteriovenous 
malformations). ICH accounts for 10% of all strokes (Intercollegiate Stroke 
Working Party, 2012, Luengo-Fernandez et al., 2013, Mozaffarian et al., 2015). 
A subarachnoid haemorrhage (SAH) is the result of the rupture of a cerebral 
blood vessel into the subarachnoid space. Clinically, SAH is characterised by a 
sudden onset of severe headache and vomiting, with or without the loss of 
consciousness. SAH accounts for 3-5% of all strokes (Mozaffarian et al., 2015, 
Intercollegiate Stroke Working Party, 2012, Luengo-Fernandez et al., 2013). Of 
these approximately 85% are haemorrhages as a result of an intracranial 
aneurysm, 10% are non-aneurysmal peri-mesencephalic haemorrhages and 5% are 
a result of other vascular abnormalities (van Gijn and Rinkel, 2001). 10-15% of 
patients with SAH die before reaching hospital and a further 25% die within 24 
hours of the haemorrhage (Intercollegiate Stroke Working Party, 2012). 
Haemorrhagic strokes are typically associated with increased stroke severity and 
are further associated with a reduced 5-year life expectancy and higher 
mortality risk (vs. ischaemic stroke) within 3 months of stroke onset (Andersen 
et al., 2009, Luengo-Fernandez et al., 2013), even after stroke severity, age, sex 
and cardiovascular risk factors have been adjusted for. 
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1.1.1.2 Ischaemic Stroke 
An ischaemic stroke is the result of an occlusion in a cerebral blood vessel, 
preventing blood (and therefore oxygen and nutrient) supply to the area of the 
brain which the artery or arterioles perfuse, causing rapid and often irreversible 
damage and cell death. Ischaemic stroke accounts for 85-87% of all stroke 
incidence (Mozaffarian et al., 2015, Intercollegiate Stroke Working Party, 2012, 
Luengo-Fernandez et al., 2013). 
When patients with suspected stroke are admitted to hospital national guidelines 
recommend that patients are directly admitted to a hyperacute stroke unit 
where they can be assessed by stroke specialist clinicians (Intercollegiate Stroke 
Working Party, 2016, National Institute for Health and Care Excellence, 2008). 
Hypoglycaemia should be excluded as a cause of neurological symptoms and 
diagnosis of stroke should be provisionally confirmed using a validated tool such 
as ROSIER (Recognition of Stroke in the Emergency Room) (Nor et al., 2005). 
They also recommend that all patients undergo brain imaging urgently, ideally 
within 1 hour of arrival at hospital. Imaging techniques could include computed 
tomography (CT), magnetic resonance imaging (MRI) or CT angiography 
(Intercollegiate Stroke Working Party, 2016, National Institute for Health and 
Care Excellence, 2008). Where imaging results indicate a patient is eligible for 
treatment with Alteplase this should be administered as quickly as possible. If 
patients are eligible for endovascular therapy CT angiography of the aortic arch 
to the skull vertex should be performed as quickly as possible but treatment 
with Alteplase should not be delayed if this is the case. Finally, where there is 
diagnostic uncertainty diffusion-weighted MRI imaging should be performed. 
Further tests such as carotid ultrasound and echocardiography may also be 
performed to further identify cause of stroke. 
Ischaemic strokes are classified according to their underlying stroke aetiology in 
a system devised by neurologists for the Trial of Org 10172 in Acute Stroke 
Treatment (TOAST) (Adams et al., 1993), using the clinical manifestation in each 
case and data collected by computed tomography (CT), magnetic resonance 
imaging (MRI), cardiac imaging, angiography or carotid Doppler ultrasound. 
There are 5 different ischaemic stroke categories: large artery atherosclerosis, 
cardioembolism, small-artery occlusion (or lacunae), acute stroke of other 
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determined aetiology or strokes of undetermined aetiology (Adams et al., 1993). 
Further information on each stroke subtype is given in Table 1.1. While there is 
not a direct relationship, the Oxford Vascular Study reports that cardioembolic 
stroke is associated with highest mortality and strokes as a result of small-vessel 
occlusion or of unknown aetiology are associated with better life expectancy 
(Luengo-Fernandez et al., 2013). 
Table 1.1 – TOAST classification: features of stroke subtypes. 
This classification system was devised by neurologists for the TOAST clinical trial (Adams 
et al., 1993). Features of each ischaemic stroke subtype are described in the table. 
Stroke Subtype Features 
Large-artery 
atherosclerosis 
Clinical: cortical or cerebellar dysfunction 
Imaging: cortical, cerebellar, brain stem, or subcortical infarct > 1.5 
cm diameter 
Tests: Stenosis of extracranial internal carotid artery 
Cardioembolism 
Clinical: cortical or cerebellar dysfunction 
Imaging: cortical, cerebellar, brain stem, or subcortical infarct > 1.5 
cm diameter 
Tests: cardiac source of emboli 
Small-artery 
occlusion 
Clinical: lacunar syndrome 
Imaging: subcortical or brain stem infarct < 1.5 cm diameter (not 
always detected) 
Other cause 
Clinical: cortical or cerebellar dysfunction or lacunar syndrome 
Imaging: cortical, cerebellar, brain stem, or subcortical infarct > 1.5 
cm diameter or subcortical or brain stem infarct < 1.5 cm diameter 
Tests: other abnormality on tests 
 
Another commonly used ischaemic stroke classification system is that reported 
by Bamford and colleagues, and classifies stroke patients according to their 
clinical manifestations only, and divides patients according to the vascular area 
affected by the infarct (Bamford et al., 1991).  
1.1.2 Epidemiology 
The UK age-standardised death rate for stroke has fallen by 78% since 1968 (data 
from 2013) and by 48% over the last decade (since 2003, data from 2013). This 
major improvement in stroke mortality (seen in both sexes, all races and age 
groups) is a result of both reduced stroke incidence and fatality and is 
concurrent with interventions resulting in improved control of cardiovascular risk 
(Mozaffarian et al., 2015, Townsend et al., 2015). Despite this reduction in 
stroke mortality, stroke was the 2nd leading cause of death worldwide in 2012, 
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killing 6.7 million people (World Health Organisation, 2014). In the UK (2014), 
233,261 patients were admitted to National Health Service (NHS) hospitals with 
stroke as their primary diagnosis and 31,787 people (6% of all deaths) died as a 
result of stroke (Townsend et al., 2015). Stroke incidence in the UK is between 
115-150 per 100,000 people (Feigin et al., 2014, Wang et al., 2013).  
Age is the most significant risk factor for stroke: stroke risk doubles every 
decade after the age of 55 (Brown et al., 1996, Wolf et al., 1991). Men have a 
25% higher risk of having a stroke than women and are more likely to have a 
stroke at a younger age (Townsend et al., 2015). Although age-specific incidence 
rates are lower in women than in men, these differences narrow with age, so 
that for the oldest patients, stroke incidence rates are approximately equal 
between women and men (Lewsey et al., 2009, Reeves et al., 2008, Rothwell et 
al., 2005). 
Looking at mortality rates for stroke across the UK, the highest stroke death 
rates are to be found in Scotland: 60% of local authorities with the highest death 
rates are found there (see Figure 1.1 A).  For premature (under the age of 75) 
stroke deaths, Glasgow City has the highest stroke death rate in the country (27 
/ 100,000 deaths) and 50% of local authorities with the highest premature death 
rates are located in Scotland (see Figure 1.1 B). The lowest death and premature 
death rates from stroke are primarily to be found in London and the South East 
of England, showing a clear geographical disparity in both incidence and 
mortality from stroke. This is primarily linked to social deprivation: statistics 
from Public Health England demonstrate that people in the most economically 
deprived areas of England are twice as likely to have a stroke as those from the 
least deprived areas (Public Health England, 2013). 
Data from the Quality and Outcomes Framework used by GPs to register medical 
conditions of their patients (and compiled by the Stroke Association) suggests 
there are over 1.2 million stroke survivors living in the UK (Stroke Association, 
2016). Over 50% of stroke patients are left with a disability (Intercollegiate 
Stroke Working Party, 2015). Furthermore, stroke is the leading cause of severe 
adult disability (even after adjustment for comorbidity and age) and the third 
leading cause of acquired adult disability overall (Adamson et al., 2004). 
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Figure 1.1 – Age Standardised Death Rates from Stroke 
Map of the UK showing age-standardised death rates from stroke for men and women of all 
ages, per 100,000, by local authority in the UK 2011-2013 (A). Map of the UK showing age-
standardised death rates from stroke in men and women under 75, per 100,000, by local 
authority in the UK 2011-2013 (B). Reproduced with permission from (Townsend et al., 
2015). 
Aside from the human cost, the NHS in England alone spent £690 million treating 
patients with stroke (2013-14) and NHS in Scotland spent £127 million (Townsend 
et al., 2015). Caring for patients with stroke accounts for 5% of total UK NHS 
costs (Saka et al., 2009). These sums vastly underestimate the total cost and 
burden of stroke in the UK, as death and long-term disability in working age 
people also contribute significantly. 
Despite the devastating impact of stroke worldwide, research into stroke 
remains significantly under-funded as compared to other diseases with similar 
impact. Although the government and charities in the UK have recently 
increased the amount spent on stroke research (from £23 million in 2008 to £56 
million in 2012), over double this amount was spent on research into dementia 
and coronary heart disease and almost 10 times as much was spent on cancer 
research (£544 million in 2012). The total level of funding is equivalent to £48 
per person with stroke, half of the comparable spend on dementia patients, and 
a fifth of the spend on cancer patients (Luengo-Fernandez et al., 2014, Stroke 
Association, 2016). While research into diseases such as cancer and dementia is 
vital, it is important to remember the scale and impact of stroke. These facts 
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highlight the need for both a greater quantity and quality of research into stroke 
and new therapeutics to tackle the growing disease burden. 
1.1.3 Pathophysiology 
An ischaemic stroke is the result of either transient or permanent occlusion of 
cerebral blood flow following the occlusion of a cerebral artery – this leads to 
irreversible damage (infarct) along with a concomitant neurological deficit 
(permanent or reversible). While the brain makes up a very small percentage of 
total body weight (~2%) it requires 15% of total cardiac output, accounts for 20% 
of total body oxygen consumption and 25% of total body glucose consumption.  
Despite its high energy consumption the brain has a very limited capacity to 
store energy and is dependent on a continuous supply of oxygen and glucose, 
delivered via the cerebral vasculature. It is therefore very sensitive to 
ischaemia. It has been estimated that every minute an acute large artery stroke 
is left untreated, approximately 1.9 million neurons, 14 billion synapses and 12 
km of myelinated fibres are lost (Saver, 2006). 
Under ischaemic conditions, the brains innate inter- and intra-cellular signalling 
mechanisms, typically responsible for information processing, initiate an 
ischaemic cascade of signalling processes, facilitate cellular death and the 
formation of infarcted tissue (summarised in Figure 1.2 and Figure 1.3). While 
differences between stroke subtypes have been described in section 1.1.1, there 
is consistency in the cellular and molecular mechanisms that mediate ischaemic 
stroke. The ischaemic cascade consists of numerous processes including 
excitotoxicity, oxidative stress, inflammation and cell death and these will be 
summarised in this section. 
1.1.3.1 Energy Failure 
Brain tissue (especially neuronal) depends almost entirely on oxidative 
phosphorylation for energy production. Restriction or cessation of cerebral blood 
flow, as occurs in ischaemic stroke, impedes the delivery of substrates for 
oxidative phosphorylation, resulting in a failure of adenosine triphosphate (ATP) 
production. ATP is required for the maintenance of ionic gradient (active 
transport at ion pumps) and so with ATP depletion, membrane potential is lost 
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resulting in depolarisation of neurons and glia (Katsura et al., 1994, Martin et 
al., 1994). Membrane depolarisation results in activation of voltage-dependent 
Ca2+ channels (both pre-synaptic and somatodendritic) and excitatory amino 
acids (EAA), predominantly glutamate, are released into the extracellular space. 
Pre-synaptic and astrocytic re-uptake of EAA is an ATP-dependent process and so 
is disrupted (Nicholls and Attwell, 1990), leading to an even greater 
accumulation of EAAs within the extracellular space. 
 
Figure 1.2 – The Ischaemic Timeline 
A graph representing the temporal profile of the main pathophysiological mechanisms 
underlying acute ischaemic stroke and the impact of each element on final ischaemic infarct 
and outcome. This graph has been modified from a similar figure in (Dirnagl et al., 1999). 
1.1.3.2 Excitotoxicity Mechanisms 
As glutamate builds up in the extracellular space it activates N-methyl-D-
aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
(AMPA) and kainate receptors, resulting in an excessive influx of Na+, Cl- and 
Ca2+ and efflux of K+ ions. This causes repeated membrane depolarisation, 
resulting in further calcium influx and resulting EAA release, intensifying the 
original ischaemic insult. Excitotoxicity is the secondary damage that results 
from excessive glutamate release and the resulting uptake of calcium by 
neurons, causing acute cell death (necrosis), initiating delayed cell death 
(apoptosis) (Ankarcrona et al., 1995) and inflammatory pathways. 
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Figure 1.3 – The Ischaemic Cascade. 
A diagrammatic representation of the numerous processes leading to cell death after focal 
cerebral hypoperfusion. Pathophysiological mechanisms underlying acute ischaemic stroke 
include bioenergetic failure, excitotoxicity, oxidative stress and inflammation. Dotted arrows 
are present only to make this diagram easier to follow and do not represent different types 
of pathway. Abbreviations include: BBB, blood brain barrier; DAMP, danger associated 
molecular pattern; MMP, matrix metalloproteinase; NO, nitric oxide; ROS, reactive oxygen 
species. I have used the information summarised in section 1.1.3 to create this diagram. 
As the influx of Na+ and Cl- is excessive (greater than K+ efflux) water follows 
passively, resulting in cell swelling (and death) and cerebral oedema. Oedema is 
cytotoxic as it affects perfusion of the area surrounding the initially infarcted 
brain region and can have indirect effects on otherwise unaffected brain tissue 
as a result of intracranial pressure, vascular compression and herniation. 
10 
 
    
 
Increasing concentrations of intracellular Ca2+ (acting as a second messenger) 
triggers the generation of free radicals and numerous downstream 
phospholipases, proteases and nucleases that degrade membranes and proteins 
essential for cellular integrity. Activated Ca2+ dependent enzymes cause 
considerable cellular damage and include proteases that destroy extracellular 
matrix proteins (e.g. laminin (Chen and Strickland, 1997)) and cytoskeletal 
proteins (e.g. actin and spectrin, (Furukawa et al., 1997)), calpain, 
endonucleases, adenosine triphosphatase as well as phospholipase A2, 
cyclooxygenase and nitric oxide synthase type I which generate excessive 
amounts of free-radical species, causing lipid peroxidation and membrane 
damage.  
1.1.3.3 Ionic Imbalance 
Although excessive Ca2+ is the primary cause of ionic imbalance post-ischaemic 
stroke, excessive zinc and potassium (Gribkoff et al., 2001) release has also been 
implicated as a mechanism of cell-death.  Several studies (Frederickson et al., 
2006, Kitamura et al., 2006b, Kitamura et al., 2006a, Sorensen et al., 1998) have 
demonstrated changes in zinc concentration following cerebral ischaemia and it 
is believed that vesicles containing zinc, stored in excitatory neurons, are 
released following depolarisation. The decrease in zinc concentration within 
presynaptic terminals is correlated with zinc accumulation within neurons and 
their subsequent cell death (Galasso and Dyck, 2007).  
1.1.3.4 Oxidative and Nitrosative Stress 
Oxidative and nitrosative stress are key mediators of tissue damage following 
ischaemic damage. Endogenous antioxidant defence mechanisms enable cells to 
deal with oxidative stress and include the regulation of reactive oxygen species 
(ROS) production, the elimination of ROS via neutralising enzymes and scavenger 
molecules and the repairing of proteins, lipids and deoxyribonucleic acid (DNA) 
damaged by oxidative stress. However, these have limited capability in the face 
of the high oxidative load and the amount of damage inflicted as a result of 
ischemic injury. As a result, the cell succumbs and will undergo necrosis or 
apoptosis (Shirley et al., 2014). 
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In healthy cells, mitochondria use oxygen and generate ATP (via oxidative 
phosphorylation at the mitochondrial respiratory chain) (Hertz, 2008). Small 
amounts of the ROS superoxide (O2
-) are produced by this reaction in the 
mitochondrial matrix (Boveris and Chance, 1973). O2
- is subsequently converted 
to hydrogen peroxide (H2O2) by superoxide dismutase (SOD) and leaves the 
mitochondria, typically acting as an intracellular messenger (Arnaiz et al., 1999, 
Rice, 2011). However, following ischaemic insult, oxygen is depleted (in the 
penumbra) favouring anaerobic production of ATP via glycolysis (Hertz, 2008) 
resulting in the production of lactic acid, the accumulation of which results in 
decreasing cellular pH and a resulting increase in ROS in parallel with an 
inactivation of antioxidant defence mechanisms, an increase in intracellular iron 
levels (Ying et al., 1999) and increased glutamate-mediated excitotoxicity 
(Lewerenz et al., 2010). 
A second wave of ROS (O2
-) is generated by xanthine oxidase and leakage from 
the mitochondrial electron transport chain, following mitochondrial 
depolarisation (Abramov et al., 2007). Increasing intracellular concentrations of 
Ca2+ and a variety of cytokines result in the activation of nitric oxide synthases I 
and II, which in turn convert L-arginine into nitric oxide (NO), a free radical with 
a half-life of only seconds that is both water- and lipid-soluble (Forstermann et 
al., 1994). Neuronal NOS is also activated directly by NMDA receptors via the 
adaptor postsynaptic density-95 (PSD-95). NO produced by NOS I and II reacts 
with O2- to produce highly toxic peroxynitrite (ONOO-), an oxidant of proteins 
and lipids. ONOO- will spontaneously decompose to produce hydroxyl (OH-), the 
most reactive of the oxygen radicals, causing the most tissue damage.   
A third phase of ROS generation occurs after reperfusion and, therefore, 
reoxygenation. Nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase 
(NOX), a cytoplasmic enzyme, is an important source of ROS and contributes to 
the amplification of oxidative stress following reoxygenation. NOX is thought to 
produce a significant proportion of O2- following NMDA receptor activation and 
ischaemia (Brennan et al., 2009, Girouard et al., 2009). Further ROS are 
produced by mitochondrial uncoupling. 
Free radicals have important cellular effects including the inactivation of 
enzymes, the release of Ca2+ from intracellular stores, protein denaturation, 
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lipid peroxidation, cytoskeletal and DNA damage, chemotaxis, inhibition of 
mitochondrial enzymes, the formation of mitochondrial transition pores, DNA 
damage, PARP activation and TRPM7 channel activation (Ca2+ permeable) 
(Pacher et al., 2007). Cytochrome C, a trigger for apoptosis, is also released 
from mitochondria. Furthermore, nitric oxide post-transcriptionally modifies 
proteins, including caspases and metalloproteinases altering protein function (Gu 
et al., 2002). Oxidative stress therefore makes a significant contribution to cell 
death either through necrosis (severe oxidative stress) or apoptosis (moderate 
oxidative stress). 
1.1.3.5 Inflammatory Pathways 
The inflammatory response to ischaemic stroke begins within several hours of 
ischaemic insult and makes a significant contribution to the secondary insult, 
inducing more cell damage, microvascular stasis and disruption of the blood 
brain barrier (BBB) (reviewed (Iadecola and Anrather, 2011)). 
Immediately following occlusion in a cerebral blood vessel there is hypoxia, 
changes in shear stress and ROS production – these factors combine to activate 
the coagulation cascade, complement, platelet and endothelial cells (Peerschke 
et al., 2010). Activation of the coagulation cascade results in the aggregation of 
fibrin molecules within the cerebral blood vessel which in turn trap platelets, 
clotting factors, leukocytes and erythrocytes, occluding the microvasculature 
(del Zoppo et al., 1991). The aggregation of activated platelets express P-
selectin (an adhesion molecule) (Okada et al., 1994b, Yilmaz and Granger, 2010) 
and release pro-inflammatory signals, including inflammatory cytokines (e.g. IL-
1α) and chemokines (CCL5, CXCL4 and CXCL7) as well as prostanoids, 
leukotrienes and free radicals (Iadecola and Anrather, 2011). As a result of 
oxidative stress there is reduced bioavailable NO which exacerbates the 
microvascular occlusion and so further reduces blood flow to the ischaemic area 
(Carden and Granger, 2000).   
Cell death as a result of excitotoxicity and oxidative stress leads to further 
inflammatory reaction within the brain, causing increased cell damage as well as 
BBB disruption. Both astrocytes and microglia are activated by ROS and release 
numerous pro-inflammatory cytokines.  However the role each cell has to play is 
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not clear cut: astrocytes and microglia can release both cytotoxic and/or 
cytoprotective substances (Iadecola and Anrather, 2011). 
Recruitment of leukocytes into the brain parenchyma is mediated by adhesion 
molecules such as selectins, integrins and immunoglobulins. Increased expression 
of E- and P-selectin (Haring et al., 1996, Huang et al., 2000, Zhang et al., 1998) 
results in leukocyte rolling and recruitment in cerebral vessels within 4-6 hours 
of the ischemic insult. Subsequent to their migration they release or activate 
pro-inflammatory molecules that result in secondary injury (Iadecola and 
Anrather, 2011). Infiltration of neutrophils begins within hours of cerebral 
ischaemia (Buck et al., 2008) whereas infiltration of monocytes begins after 
several days (Che et al., 2001, Grau et al., 2001). 
Cytokines are mediators of the inflammatory response and are produced by 
many types of cell within the brain as well as immune cells (Allan and Rothwell, 
2001, Iadecola and Anrather, 2011). Important pro-inflammatory cytokines 
include interleukin-1 and interleukin-6 (Fassbender et al., 1994, Tarkowski et 
al., 1995, Vila et al., 2000), while interleukin-10 is anti-inflammatory (Vila et 
al., 2003) and TNFα can stimulate both inflammatory signalling leading to 
apoptosis and cell death as well as signalling pathways that lead to cell survival 
and tolerance to ischaemia (Hallenbeck, 2002). Chemokines are important 
mediators of cellular migration and like cytokines are produced by many cells in 
the brain and immune cells. Their (e.g. MCP-1, MIP-1α) increased expression 
following ischemic stroke is associated with further leukocyte recruitment and 
increased blood-brain barrier permeability (Dimitrijevic et al., 2006, Stamatovic 
et al., 2003) and so is believed to be detrimental. 
Increasing intracellular Ca2+ stimulates phospholipase A2 and therefore the 
arachidonic acid cascade, eventually resulting in the production of 
prostaglandins or leukotrienes (chemo-attractants) which are associated with 
BBB dysfunction, oedema and neuronal cell death (Iadecola and Anrather, 2011). 
There is also an up-regulation of NOS type 2 in microglia, endothelial cells and 
leukocytes, which has detrimental effects (as discussed in section 1.1.3.4) and 
an increased production of MMP2 and MMP9 by endothelial cells and leukocytes 
which primarily exacerbates BBB dysfunction and causes further brain damage.  
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The inflammatory response is eventually resolved and tissue homeostasis re-
established – this is now believed to be an active process (Spite and Serhan, 
2010). Resolution of the inflammatory response involves the clearing of dead 
cells by microglia and infiltrating macrophages. Anti-inflammatory cytokines, 
including TGF-β, IL-10, IL-17 and IL-23 are released by T-cells, microglia, 
macrophages and astrocytes (Iadecola and Anrather, 2011). Their release occurs 
concomitantly with the clearing away of dead cells and is believed to protect 
surviving cells within the ischaemic area. Finally, the production (to different 
extents) of growth factors such as BDNF, EPO, FGF, G-CSF, GDNF, HB-EGF, IGF-1, 
NGF and VEGF by microglia, astrocytes, perivascular macrophages, 
macrophages, endothelial cells and neurons (Iadecola and Anrather, 2011) 
promotes post-ischaemic neuronal sprouting, angiogenesis, neurogenesis, 
gliogenesis and matrix reorganisation (Greenberg and Jin, 2006). 
1.1.3.6 Blood Brain Barrier Dysfunction 
The BBB regulates permeability and cellular transport at the endothelial cell 
layer between blood and brain cells. It is made up of pericytes and tight junction 
proteins (e.g. occludin, claudins and junctional adhesion molecules), covered by 
a basal lamina that is primarily composed of collagen (type IV), fibronectin, 
heparan sulfate and laminin. Laminin interacts with integrins to regulate 
permeability and cellular transport across the BBB. 
Disruption of the BBB (Yang and Rosenberg, 2011) is cytotoxic as it results in 
extravasation of various serum components and subsequent vasogenic oedema, 
which can cause further damage. Furthermore, extravasation of erythrocytes 
can result in haemorrhagic transformation and secondary ischemic injury. A 
disrupted BBB also facilitates leukocyte infiltration as discussed previously. 
Disruption of the BBB is bi-phasic (Belayev et al., 1996, Huang et al., 1999, 
Kuroiwa et al., 1985). In the early phase (2 – 24 hours post ischemic insult) BBB 
disruption is primarily mediated by activation of MMP2. This is inhibited by the 
formation of a complex comprised of MMP2, tissue inhibitor of 
metalloproteinases-2 (TIMP-2) and membrane-type 1 MMP which acts to 
significantly limit the activity of MMP resulting in less severe injury to the BBB.  
However, BBB dysfunction may also be mediated by bradykinin (Aschner et al., 
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1997, Kamiya et al., 1993), thrombin (Okada et al., 1994a) and other proteases.  
Furthermore, oxidative stress can up-regulate production of MMP9 by neurons, 
glia and endothelial cells leading to digestion of the endothelial basal lamina 
(Gidday et al., 2005). 
In the later phase (24 – 72 hours post ischemic insult) BBB disruption is 
significantly more severe, irreversible, and is primarily mediated by the release 
of MMP9 from infiltrating neutrophils (Gidday et al., 2005, Rosell et al., 2008).  
MMP9, along with MMP3, expression is induced by cytokines and MMP9 is also 
activated by free radicals. Treatment with tPA (if it crosses the already 
disrupted BBB) can further up-regulate MMP9 expression (Tsuji et al., 2005). 
Unlike MMP2, the action of these metalloproteinases is unrestrained and they act 
on multiple substrates to disrupt the BBB. 
1.1.3.7 Cell Death 
Necrosis and apoptosis are the two primary mechanisms of cell death post 
ischaemic stroke. Necrosis is usually rapid and is characterised by plasma 
membrane failure, cellular (and internal organelle) oedema and finally rupture, 
releasing glutamate and toxins. Apoptosis, on the other hand, is highly regulated 
and cells die with comparatively reduced inflammation and release of genetic 
material. Apoptosis and necrosis can both be triggered by increased intracellular 
Ca2+ concentrations, oxidative stress and mitochondrial dysfunction. 
Necrosis is the principal mechanism of ischemic cell death and is generally 
believed to be unregulated. However, it has been demonstrated that 
phosphorylation of receptor-interacting proteins (RIP) 1 and 3 can trigger pro-
necrotic kinase activity and may act as a molecular switch between TNF induced 
apoptosis and necrosis (Cho et al., 2009, Holler et al., 2000, Zhang et al., 2009).  
Apoptosis is generally associated with less severe ischaemic injury (Bonfoco et 
al., 1995) although severe ischaemic injury has also been linked to caspase-like 
enzyme activation and caspase cleavage early in the ischaemic cascade (Namura 
et al., 1998). Mitochondria mediate cell death in both necrosis and apoptosis 
(Schinzel et al., 2005) as their rupture releases both cytochrome C and a number 
of pro-apoptotic proteins. Cytochrome C initiates caspase-mediated apoptosis 
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through apoptosome complex activation, which subsequently activates caspase 3 
(Green and Reed, 1998). Caspases 1 and 3 especially mediate ischemia 
associated apoptosis (Leist et al., 1997, Namura et al., 1998, Thornberry and 
Lazebnik, 1998). Caspase-independent neuronal cell death (Cho and Toledo-
Pereyra, 2008) is mediated by mitochondrial proteins including apoptosis-
inducing factor (AIF) and B-cell lymphoma-2 (Bcl-2)/adenovirus E1B-interacting 
protein (Yu et al., 2006). Apoptosis can also be triggered non-specifically by 
glutamate receptor activation and resulting cellular injury, mitochondrial 
production of ROS (Dugan et al., 1995), decreased intracellular K+ concentrations 
(Yu et al., 1997) and Zn2+ influx. 
1.1.3.8 Repair Pathways 
The post-ischaemic brain undergoes both neuronal and vascular repair 
(neurogenesis and angiogenesis) and there is a close relationship between the 
pathways. Both neurogenic and angiogenic repair are mediated by numerous 
common mediators and signalling pathways – furthermore, neurogenesis 
stimulates vascular regrowth and vice versa (Arai et al., 2009, Ohab et al., 2006, 
Snapyan et al., 2009, Taguchi et al., 2004). Several studies have demonstrated 
post-ischaemic up-regulation of neurogenesis and the migration of neuroblasts 
towards severely infarcted striatal tissue (Arvidsson et al., 2002, Parent et al., 
2002) where they express markers of developing and mature spiny neurons.  
Although this is believed to be an endogenous repair pathway, studies 
demonstrating functional activity and long-term survival of these neurons are 
lacking (Kernie and Parent, 2010). Angiogenesis and vasculogenesis have been 
detected in the penumbral regions of both human stroke patients and rodent 
models of ischaemic stroke (Ding et al., 2008, Krupinski et al., 1996). 
1.1.3.9 Penumbra 
The changes that have been described in sections 1.1.3.1 to 1.1.3.8 do not 
affect the whole of the ischaemic area equally. Brain tissue within the ischaemic 
core, where blood flow is most severely impaired, is permanently and 
irreversibly injured. Energy failure and the ensuing ischaemic cascade, as 
previously described, rapidly causes widespread cellular necrosis. 
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However, between the ischaemic core and healthy brain tissue lies functionally 
damaged tissue that is still structurally intact: the ischaemic penumbra, first 
described as “zones of complete electrical failure and K+ release… with 
functional inactivation but not yet cell death” (Astrup et al., 1977) (see Figure 
1.4). Subsequent studies have revealed the penumbra to be an area where 
cerebral blood flow is reduced moderately (not to the extent of the ischaemic 
core) and as a result energy metabolism is somewhat preserved (Baron, 1999, 
Markus et al., 2004, Nagesh et al., 1998, Read et al., 1998). Advances in positron 
emission tomography (PET) and MRI scanning now allow for the detection of the 
penumbra (Fisher and Bastan, 2012). 
 
Figure 1.4 – The Ischaemic Penumbra. 
An ischaemic stroke is the result of an occlusion to a cerebral blood vessel and results in 
rapid neuronal death in the infarct core, the region immediately surrounding the occluded 
artery. Surrounding the infarct core is the penumbral region, an area in which neurons may 
die many hours after the critical insult or may survive if reperfusion occurs in a timely 
manner. Image taken with permission from (Allan and Rothwell, 2001). 
Penumbral tissue is often lost, absorbed into the ischaemic core, as the 
ischaemic cascade progresses. However, as the penumbra is a transition zone 
between injury and repair, it can be rescued with reperfusion and therapeutic 
intervention. As has been touched upon in this summary of the pathophysiology 
of stroke, many molecular signals in the ischaemic cascade can play biphasic 
roles (cytotoxic vs cytoprotective) – mechanisms that decide between cellular 
injury and cellular repair have yet to be discovered. While damage to the 
ischaemic core is irreversible, salvage of penumbral tissue is associated with 
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neurological improvement and recovery and so should be the target for new 
acute stroke therapies. 
1.1.4 Therapeutics for Ischaemic Stroke 
1.1.4.1 Therapeutic Challenges  
The extremely complex ischaemic cascade begins within minutes of stroke onset 
and rapidly progresses and develops over a period of several hours. The success 
of any stroke treatment is therefore dependent on early treatment to prevent or 
limit ensuing damage. Penumbral tissue is a primary target for stroke 
intervention therapies and early reperfusion maximises the chance of tissue 
salvage. There is a clear need for novel treatments that not only result in 
reperfusion but also directly address specific aspects of stroke pathophysiology 
including cell death, cerebral oedema, oxidative stress and inflammation. While 
such treatments have shown promise pre-clinically, none have made the 
transition from bench to bedside treatment so far. Finally, therapeutic agents 
used must be able to cross the BBB to prove effective. 
1.1.4.2 Prevention is better than cure 
As currently licensed therapies for stroke are limited, preventative interventions 
are encouraged clinically. A 2010 study which investigated risk for stroke in 2337 
ischaemic stroke patients and 3000 age and gender matched controls found the 
most significant risk factors for stroke, arranged in order of severity, are history 
of hypertension, cardiac causes, ratio of apolipoproteins, current smoking, 
waist-to-hip ratio, alcohol intake, diabetes mellitus, diet, depression and 
psychosocial stress (O'Donnell et al., 2010). Stroke is therefore to some extent a 
systemic disease, and risk factors that predict ischaemic stroke are also 
predictors for many other cardiovascular events including myocardial infarction. 
As a result of improved control of cardiovascular risk both stroke incidence and 
fatality have fallen by 78% since 1968 (data from 2013) and by 48% over the last 
decade (since 2003, data from 2013) (Mozaffarian et al., 2015, Townsend et al., 
2015). This section will expand on modifiable risk factors for stroke and 
interventions that can reduce cardiovascular risk. 
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More than 77% of people are hypertensive on the occasion of their first stroke 
(Mozaffarian et al., 2015) and anti-hypertensive therapy has been associated 
with reductions in stroke incidence in clinical trials (Lackland et al., 2014). Even 
a reduction of only 10 mmHg in systolic blood pressure results in a 41% average 
reduction in stroke risk (Lackland et al., 2014). NICE guidelines recommend that 
patients with hypertension are initially treated with anti-hypertensive drugs such 
as angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor 
blockers (ARB) or calcium channel blockers using a monotherapy approach 
(National Institute for Health and Care Excellence, 2011). If hypertension is not 
successfully reduced using a monotherapy approach, combinations of anti-
hypertensive drugs should be used (National Institute for Health and Care 
Excellence, 2011). Resistant hypertension may be treated using additional drugs 
such as thiazide diuretics. Beta blockers may also be used in patients with 
contraindications to ACE inhibitors or ARBs or in women of child bearing 
potential (National Institute for Health and Care Excellence, 2011). 
Diabetes results in an over two-fold excess risk for ischaemic stroke, 
independent of other risk factors (Emerging Risk Factors Collaboration, 2010). A 
meta-analysis of clinical trials that targeted interventions at people with pre-
diabetes showed this resulted in a 24% relative risk reduction in fatal and non-
fatal strokes (Hopper et al., 2011). 
Atrial fibrillation increases risk of stroke, independent of other risk factors, by 
approximately 5-fold (Wolf et al., 1991). In patients aged 50-59, 1.5% of strokes 
are attributable to atrial fibrillation and this increases to 23.5% in patients aged 
80-89 (Wolf et al., 1991). In England it is estimated that if atrial fibrillation was 
adequately detected and subsequently treated, 7,000 strokes could be 
prevented and 2,100 lives saved (Stroke Association, 2016). NICE recommends 
that patients with atrial fibrillation are treated with anticoagulants to reduce 
the likelihood of blood clot formation (National Institute for Health and Care 
Excellence, 2015). Patients with valvular atrial fibrillation should be given 
vitamin K antagonists (e.g. warfarin) while patients with non-valvular atrial 
fibrillation have the choice of vitamin K antagonists or non-vitamin K antagonist 
oral anticoagulants (e.g. apixaban, dabigatran etc.) (National Institute for 
Health and Care Excellence, 2015).  
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The ratio of non-HDL to HDL cholesterol is associated with increased risk of 
ischaemic stroke, and an even stronger predictor of ischaemic stroke is the ratio 
of circulating ApoB to ApoA1 (O'Donnell et al., 2010). The use of statins in 
patients with a high risk of cardiovascular disease reduces the risk of stroke by 
about 25% (Heart Protection Study Collaborative Group, 2002) and reducing 
cholesterol levels even by 1 mmol/L reduces the risk of stroke by 21% (Amarenco 
and Labreuche, 2009). NICE recommends that patients with increased 
cardiovascular risk or established cardiovascular disease should be encouraged to 
make lifestyle modifications and offered atorvastatin (National Institute for 
Health and Care Excellence, 2014). 
Current smokers have a 2- to 4-fold increased risk of stroke as compared to 
those who don’t smoke or who have not smoked for more than 10 years 
(Mozaffarian et al., 2015, O'Donnell et al., 2010). Finally, increasing levels of 
physical activity and healthier diet are also associated with reduced risk of 
stroke as these can reduce occurrence of other traditional risk factors such as 
hypertension, diabetes mellitus and obesity. 
1.1.4.3 Thrombolysis 
Recombinant tissue plasminogen activator (rt-PA or Alteplase) is the only 
currently licenced pharmacological intervention for the treatment of acute 
ischaemic stroke. rt-PA works by lysing blood clots (more specifically by 
converting plasminogen to plasmin, which promotes the breakdown of fibrin), 
resulting in reperfusion of the previously ischaemic area. 
The first clinical trial to test rt-PA was the Tissue Plasminogen Activator for 
Acute Ischemic Stroke (National Institute of Neurological Disorders and Stroke rt-
PA Stroke Study Group, 1995). Patients were given rt-PA within 3 hours of stroke 
onset and patients receiving rt-PA were 30% more likely than controls to have no 
or minimal disability at 3 months. However, they were significantly more likely 
to have symptomatic intracerebral haemorrhage within 36 hours of stroke onset. 
This trial resulted in FDA approval for the use of Alteplase to treat ischaemic 
stroke. More recently, the subsequent European Cooperative Acute Stroke Study 
III (ECASS III) demonstrated safety and efficacy of Alteplase when used up to 4.5 
hours following stroke (Hacke  et al., 2008). 
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Given the small therapeutic time window in which rt-PA can be administered, 
only a small percentage of acute ischaemic stroke patients receive thrombolysis 
treatment, with statistics from the USA revealing that <10% of patients receive 
rt-PA (Adeoye et al., 2011, Menon et al., 2015, Saver et al., 2013). More recent 
statistics suggest that one in nine patients with acute stroke in the UK are 
treated with rt-PA (Intercollegiate Stroke Working Party, 2016). Therefore every 
effort should be made to improve ‘door to treatment’ times. Of those who do 
receive rt-PA within the appropriate time it has been estimated that only very 
few (~21%) recanalise acutely (Bhatia et al., 2010). Although successful 
recanalisation is one of the strongest predictors of good outcome (Bhatia et al., 
2010) reducing the time in which the patient is treated post-stroke also improves 
outcome. Patients who are treated with thrombolytic agents within 60 minutes 
of stroke onset have reduced mortality and reduced incidence of intracranial 
haemorrhage as compared to patients who receive rt-PA after 60 minutes of 
stroke onset (Fonarow et al., 2011).  
1.1.4.4 Clot Retrieval 
Recently mechanical clot retrieval has been demonstrated to be successful in 
the treatment of ischaemic stroke patients. This involves the endovascular 
insertion of a clot retrieval device, attached to the end of a catheter. This is 
inserted to the site of occlusion and, following inflation of a balloon attached to 
the catheter, a wire net is extended to surround the clot and the catheter is 
subsequently removed, taking the clot with it. 
Although it was previously thought that endovascular treatment (EVT) was not 
superior to intravenous thrombolysis (IVT), recently published multicentre 
clinical trials testing EVT against IVT have generated positive results (Berkhemer 
et al., 2015, Campbell  et al., 2015, Goyal  et al., 2015, Jovin et al., 2015, Saver 
et al., 2015). These trials show that early thrombectomy (vs. rt-PA alone) 
improves reperfusion, early neurological recovery and functional outcome. EVT 
therefore can result in good clinical outcome and has similar symptomatic 
haemorrhage and mortality to IVT. However as the clot must be relatively large 
and proximally situated within the cerebral circulation for successful 
thrombectomy, this may limit the patient cohort in which EVT may be used. 
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In the MR CLEAN trial 500 patients were recruited and of these 89% were given 
intravenous rt-PA (Berkhemer et al., 2015). Subsequent to IVT patients were 
randomised to either receive intra-arterial treatment (47% patients) or usual 
care alone (53% patients). Of those that received intra-arterial treatment, 82% 
of patients were treated using retrievable stents. Patients that received intra-
arterial treatment had a 13.5% improvement in functional independence 
(assessed by modified Rankin score) versus control patients. Patients in this trial 
received intra-arterial treatment within 6 hours of stroke onset. It will be 
interesting to see whether future trials can extend the therapeutic time window 
further. 
1.1.5 Pre-Clinical Models of Stroke 
There are numerous in vitro and in vivo pre-clinical models of stroke. In vitro 
models typically use either primary or cultured cell lines (sometimes co-
cultures) or brain slices which are subsequently subjected to oxygen glucose 
deprivation or high concentrations of excitotoxic agents. Novel therapeutic 
agents can therefore be tested in these systems, and their ability to limit cell 
death and other stroke pathophysiologies can be evaluated. In vitro models can 
be used effectively in proof of concept and mechanistic studies. 
In vivo models typically involve the administration of focal ischaemic insults – 
the result of permanent or transient occlusions of cerebral blood flow that 
results in ischaemic stroke-like pathophysiology. Rodent models are most 
commonly used due to their low cost and reduced ‘ethical cost’. Rodent 
neuroanatomy is well understood as are the molecular mechanisms of stroke 
pathophysiology. Furthermore, comorbid rodent models have been developed, 
enhancing the translatability of these models. 
Both the advantages and disadvantages of pre-clinical models of ischaemic 
stroke have been reviewed thoroughly (Dirnagl et al., 2013, Macrae, 2011). 
Stroke models can predict or parallel a number of clinical phenotypes (Dirnagl et 
al., 2013). Important concepts common to both rodent models and clinical 
phenotype include the penumbra (Astrup et al., 1977), spreading ischaemic 
lesion as stroke pathophysiology progresses (Dreier, 2011), the effectiveness of 
thrombolysis (National Institute of Neurological Disorders and Stroke rt-PA Stroke 
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Study Group, 1995, Zivin et al., 1985), the increased risk of haemorrhage and 
BBB disruption following thrombolysis (Ehrenreich et al., 2009, Zechariah et al., 
2010) and the ability of hypothermia to protect the brain (Hypothermia After 
Cardiac Arrest Study Group, 2002, Bernard et al., 2002, Rosomoff, 1957). 
Despite the clinical relevance of pre-clinical models of stroke, very few 
treatments that show effectiveness in pre-clinical models of stroke are 
ultimately effective in patients (O'Collins et al., 2006). There has been a 
significant failure in the field to translate positive pre-clinical work into positive 
clinical trials. The numerous reasons for this include both the complexity of 
stroke and quality of pre-clinical research carried out (Dirnagl, 2016). 
Stroke has an extremely complex pathophysiology, often under-estimated in pre-
clinical models. There are also obvious and significant differences between 
species. However, many other problems or limitations of pre-clinical research 
could be limited or avoided with careful planning and robust study design. These 
problems include animal studies that are underpowered or where the effect size 
has been over-estimated. Furthermore, many stroke studies use stroke models 
that do not represent the heterogeneous, aged stroke patient population seen in 
the clinic. Homogenous animal populations used are usually young, 
predominantly male and healthy with low genetic variation. Often the timing of 
the therapy administered is not clinically relevant – there are a disproportionate 
number of studies showing efficacy with treatment delivery pre-ischaemic 
stroke. Off-target effects of therapeutic agents used are also rarely investigated 
or considered. Finally, due to negative publication bias, often only positive 
results are reported leading to unnecessary duplication and distortion of 
scientific understanding. 
The STAIR and ARRIVE guidelines amongst others (Fisher et al., 2009, Kilkenny et 
al., 2010, Macleod et al., 2009, STAIR, 1999) provide excellent guidelines and a 
number of recommendations on how to improve the quality and reporting of pre-
clinical stroke research and these should be rigorously adhered to, to encourage 
the translatability of pre-clinical research.  
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1.2 MicroRNAs 
The central dogma of molecular biology (Crick, 1970, Crick, 1958) proposes that 
there is a “transfer of sequential information” from DNA to RNA to protein.  It is 
now understood that genes within DNA are transcribed into molecules of 
messenger RNA (mRNA; transcripts) which are subsequently translated into 
amino acid chains, which can then fold into functional proteins. 
At the completion of the Human Genome Project in 2001 (Lander et al., 2001) it 
was estimated that there were approximately 31,000 genes (less than had been 
previously hypothesised) and that only ~1.5% of the human genome consisted of 
protein coding sequence. Subsequently it has been demonstrated that 
approximately two thirds of genomic DNA is transcribed (Djebali et al., 2012), 
significantly more than the 1.5% that is translated into protein. Some of this 
‘non-coding’ DNA is transcribed into functional non-coding RNA molecules that 
play a primarily regulatory role including, microRNAs (miRNA or miR), small 
nucleolar RNAs (snoRNA), small interfering RNAs (siRNA), long non-coding RNAs 
(lncRNA) as well as ribosomal RNAs (rRNA) and transfer RNAs (tRNA). 
In 1993 a study was published (Lee et al., 1993) in which it was demonstrated 
that lin-4, a gene which partly controlled Caenorhabditis elegans (C. elegans) 
larval development, produced a pair of small RNAs (not proteins, as predicted), 
one of which was only 22 nucleotides in length, the first documented miRNA. 
The second small RNA was 61 nucleotides in length and was proposed to be a 
precursor of the first. These RNAs had antisense complementarity to multiple 
sites in the 3’ UTR of the lin-14 gene and were subsequently shown to mediate 
translational repression of lin-14 (Lee et al., 1993, Wightman et al., 1993).   
miRNAs are a class of small, single stranded regulatory RNAs, approximately 22 
nucleotides in length, which post-transcriptionally regulate expression of target 
mRNAs. A single miRNA has the potential to regulate the expression of hundreds 
of different mRNAs and genes (Selbach et al., 2008). Furthermore, as over 60% 
of human protein-coding genes contain a minimum of 1 conserved miRNA-binding 
site it is hypothesised that the majority of protein-coding genes are regulated in 
some way by miRNAs (Friedman et al., 2009). While miRNA mediated regulation 
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is typically mild in nature, it can have significant biological effect when so many 
genes and proteins are implicated. 
1.2.1 Biogenesis 
miRNAs in humans are mostly encoded by introns of non-coding or coding 
transcripts although some miRNAs can be transcribed from exons. Occasionally 
multiple miRNA loci are located in close proximity (Lee et al., 2002), forming a 
miRNA cluster, from which miRNAs are usually co-transcribed. RNA polymerase II 
(RNA Pol II) transcribes miRNA (Cai et al., 2004, Lee et al., 2004) into primary 
miRNA (pri-miRNA) (see Figure 1.5 for a diagram of miRNA biogenesis). 
Once transcribed the pri-miRNA is processed within the nucleus (Lee et al., 
2002). A pri-miRNA can be over 1kb in length and is made up of a stem (33-
35bp), a terminal loop and single stranded RNA segments on either side. Mature 
miRNA sequences are embedded within the stem-loop structure. The maturation 
process is initiated by the RNase III-type endonuclease Drosha within the nucleus 
which crops the stem-loop structure resulting in the release of a ~65 nucleotide 
long hairpin-shaped RNA, called pre-miRNA (Lee et al., 2003). Cleavage is 
mediated by Drosha in association with an essential cofactor DiGeorge syndrome 
chromosomal region 8 (DGCR8) – together they form a microprocessor (Denli et 
al., 2004, Gregory et al., 2004, Landthaler et al., 2004). The pri-miRNA is 
typically cleaved in such a way that there is an overhang of nucleotides created, 
important for export of the miRNA from the nucleus. 
Following cleavage by Drosha, the pre-miRNA is exported into the cytoplasm. For 
nuclear export to occur the pre-miRNA forms a transport complex with exportin 
5 (EXP5) and RAN·GTP, the GTP-binding nuclear protein (Bohnsack et al., 2004, 
Lund et al., 2004, Yi et al., 2003). As the pre-miRNA translocates through the 
nuclear pore complex, GTP is hydrolysed causing the transport complex to 
disassociate and the pre-miRNA is released into the cytoplasm. 
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Figure 1.5 – miRNA Biogenesis 
miRNAs are initially transcribed in the nucleus, forming pri-miRNAs which are subsequently 
cropped by a microprocessor comprised of Drosha and DCGR8 to form pre-miRNAs. Pre-
miRNAs are exported from the nucleus to the cytoplasm by EXP5 where they are 
subsequently processed by Dicer in association with TRBP to form a double-stranded 
miRNA duplex. A single stand of the miRNA duplex is incorporated into the mature RISC, 
which then acts to inhibit mRNA expression, either by targeting the mRNA for degradation 
of by inhibiting its translation. The passenger strand is usually degraded. This figure was 
inspired by figures found in (Ha and Kim, 2014). 
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The terminal loop of the pre-miRNA is subsequently cleaved by Dicer, resulting 
in the production of dsRNA: a mature miRNA and a passenger strand. Dicer is a 
RNase III-type endonuclease with a catalytic centre and two RNA cleavage sites 
(Zhang et al., 2004) which preferentially binds to pre-miRNA with a 2 nucleotide 
3’ overhang (Zhang et al., 2004). The product of Dicer cleavage is an imperfect 
double-stranded duplex approximately 22 nucleotides in length which is 
subsequently loaded onto an AGO protein, forming a pre-RNA-induced silencing 
complex (pre-RISC) (Hammond et al., 2000, Hammond et al., 2001, Mourelatos 
et al., 2002, Tabara et al., 1999). In humans, all four argonaute proteins (AGO1-
4) are capable of loading miRNA duplexes and there does not appear to be any 
miRNA sorting mechanism in place as all four proteins are associated with a wide 
range of miRNAs (Azuma-Mukai et al., 2008, Dueck et al., 2012, Liu et al., 
2004b, Meister et al., 2004, Su et al., 2009). Loading of miRNA duplexes is an 
ATP-dependent process mediated by a heat shock cognate 70 (HSC70)/heat 
shock protein 90 (HSP90) chaperone complex. 
Once the miRNA-miRNA* duplex has been loaded onto the AGO protein, the pre-
RISC removes the passenger strand (miRNA*) and generates a mature RISC. While 
it has been shown that AGO2 has the ability to slice the passenger strand from 
the guide strand under certain conditions (Diederichs and Haber, 2007, Matranga 
et al., 2005) the majority of miRNA duplexes are unwound in an ATP-
independent mechanism (Kawamata et al., 2009, Kawamata and Tomari, 2010, 
Yoda et al., 2010). Original models of miRNA biogenesis suggested that the 
passenger strand was targeted for degradation (Khvorova et al., 2003) but more 
recently published studies have demonstrated functional roles for miRNA* 
strands (e.g. (Shan et al., 2013, Yang et al., 2013)). 
While the majority of miRNAs are generated by the canonical pathway, as 
described in detail in this section, 1% of miRNAs (Ha and Kim, 2014) follow a 
biogenesis pathway that can be independent of both Drosha and/or Dicer. One 
example of a miRNA produced in this way is miR-451 – it is not processed by 
Dicer but instead is loaded directly onto AGO2 and is subsequently cleaved 
(Cheloufi et al., 2010, Cifuentes et al., 2010, Yang et al., 2010). This produces a 
30 nucleotide intermediate which is then further processed to produce the 
mature miR-451.  Non-canonical biogenesis pathways are still poorly understood. 
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1.2.2 miRNA Function 
1.2.2.1 Target Recognition 
miRNAs recognise their target mRNAs by Watson-Crick base pairing. The mature 
miRNA within the RISC complex acts as a guide to argonaute, directing it to 
specific target mRNAs. miRNAs can recognise partially complementary binding 
sites which are often within the 3’ untranslated region (3’UTR) of the target 
gene (Lee et al., 1993, Wightman et al., 1993). Nucleotides 2-7 at the 5’ end of 
a miRNA are called the seed sequence and base pairing between the seed 
sequence and the mRNA is the most important factor in determining whether or 
not a target will be recognised and whether gene silencing will occur (Lewis et 
al., 2003). Occasionally, when base pairing at the seed sequence is weak (i.e. 
mismatch at some nucleotides) miRNA-mRNA interaction may also be mediated 
by base pairing at the 3’end of the miRNA (Bartel, 2009). 
1.2.2.2 Translational Repression 
Translation is a complex process that mediates the conversion of mRNA to 
protein (Jackson et al., 2010) and it is believed that miRNAs can interfere with 
various stages of this process. Investigations into the mechanism of miRNA-
mediated gene silencing in C. elegans suggested that lin-4 miRNA was able to 
repress translation of lin-14 and lin-28 mRNA without significant effect on mRNA 
abundance (Olsen and Ambros, 1999, Seggerson et al., 2002). It was 
hypothesised that repression occurred post-translation initiation, and that the 
mature RISC complex caused early ribosomal dissociation from the mRNA during 
the elongation stage of translation (Nottrott et al., 2006, Petersen et al., 2006). 
However, conflicting studies suggest that translational repression occurs at the 
translation initiation stage, concluding that miRNAs can inhibit cap-dependent 
translation initiation (Humphreys et al., 2005, Pillai et al., 2005). However, a 
large in vitro ribosomal profiling study suggests that while translational 
repression plays a role in gene silencing it is not the primary method of gene 
silencing (Guo et al., 2010). 
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1.2.2.3 mRNA Degradation and Destabilisation 
An alternative method of miRNA mediated gene silencing is that of miRNA 
directed cleavage of target mRNAs (Llave et al., 2002, Yekta et al., 2004). It is 
hypothesised that perfect base pairing between miRNAs and their target 
sequences on mRNAs results in endonucleolytic cleavage by Argonaute and rapid 
mRNA degradation. Large-scale transcriptome studies demonstrate that 
increasing miRNA abundance is correlated with decreasing target mRNA 
abundance and so indirectly support this hypothesis (Baek et al., 2008, Guo et 
al., 2010, Hendrickson et al., 2009, Selbach et al., 2008). However, as the 
majority of mRNA targets are only partially complementary to the miRNA, mRNA 
destabilisation appears to be the primary mechanism of mRNA degradation. This 
is primarily mediated by glycine-tryptophan repeat-containing (GW182) proteins 
which interact with the mature RISC to recruit deadenylation factors which in 
turn promote mRNA degradation in the 3’-5’ direction (Behm-Ansmant et al., 
2006, Giraldez et al., 2006, Wu et al., 2006). mRNAs are decapped at the 5’ 
termini of the mRNA by decapping enzyme 2 (DCP2) promoting degradation in 
the 5’-3’ direction and are subsequently degraded by cytoplasmic exonucleases 
(Rehwinkel et al., 2005). mRNA degradation and destabilisation by miRNAs is a 
major method of gene repression and probably accounts for >75% of miRNA 
mediated gene silencing (Baek et al., 2008, Guo et al., 2010, Hendrickson et al., 
2009, Selbach et al., 2008).  
1.2.3 miRNA Profiling in Stroke Patients 
Circulating miRNA expression is dysregulated in patients with ischaemic stroke. A 
number of studies have used a non-targeted approach to profile miRNA 
expression in human ischaemic stroke patients. Using microarray analysis with 
subsequent validation of select miRNAs by quantitative real-time PCR (qRT-PCR), 
they have shown that the miRNAome is significantly altered post ischaemic 
stroke (Table 1.2). Other studies have taken a more targeted approach and only 
looked at expression of specific miRNAs that are associated with stroke or risk 
factors associated with ischaemic stroke (Table 1.3). 
Initial studies profiled miRNA expression in whole blood samples collected from 
young stroke patients (age 18-49) within 2-24 months post-stroke (Tan et al., 
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2013, Tan et al., 2009). While group sizes were small, they importantly were 
able to demonstrate miRNA dysregulation by microarray, even at lengthy time 
points post-stroke. While 138 dysregulated miRNAs detected by microarray were 
up-regulated only 19 were down-regulated (Tan et al., 2009). Furthermore, 
validation of results for six miRNAs by qRT-PCR demonstrated expression was 
changed in the same direction but to a greater extent than detected by 
microarray (Tan et al., 2009), highlighting the usefulness of microarray 
technology at detecting and predicting dysregulated miRNA expression. 
Subsequent studies have profiled miRNA expression in ischaemic stroke patients 
at sub-acute and acute time points and have shown that miRNA expression is 
dysregulated (both increased and decreased) at much earlier time points (e.g. 
within 3 hours) following ischaemic stroke onset (Wang et al., 2014b). 
Interestingly, some of the dysregulated miRNAs detected by microarray were 
validated in multiple studies. One example is that of miR-106-5p which was up-
regulated in plasma and serum samples collected acutely from ischaemic stroke 
patients (Li et al., 2015a, Wang et al., 2014b). A targeted study (Kim et al., 
2015) comparing expression of miRNAs between ischaemic stroke patients and 
vascular risk factor control patients (in plasma within 7 days of stroke onset) 
also detected up-regulated miR-106a expression. 
miR-126 expression was decreased in whole blood samples at acute, sub-acute 
and long-term time points following ischaemic stroke (vs. healthy controls) 
(Sepramaniam et al., 2014, Tan et al., 2009). These results were subsequently 
corroborated when miR-126 was shown to be down-regulated from 24h post-
stroke onset until 24 weeks post-stroke in all stroke subtypes (vs. healthy 
controls) (Long et al., 2013). However, when patients with vascular risk factors 
were used as controls (Kim et al., 2015) miR-126 was shown to be unchanged in 
plasma samples collected within 7 days of symptom onset which may suggest 
that down-regulated miR-126 expression is primarily a result of chronic vascular 
disease rather than acute ischaemic stroke. 
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Table 1.2 – miRNA Profiling Studies in Ischaemic Stroke Patients 
Summary of published studies that use microarray technology to profile circulating miRNA expression in human ischaemic stroke patients. Studies are 
listed chronologically. The final column shows the number of miRNAs validated (by qRT-PCR) to be up- or down-regulated; miRNAs with unchanged 
miRNA expression are not included. Abbreviations include: cardioembolic stroke patients (CE); ischaemic stroke patients (IS); intracerebral haemorrhage 
stroke patients (ICH); large artery stroke patients (LA); small vessel disease stroke patients (SVD); unclassified stroke patients (U). 
Reference Tissue Sample Stroke Patients Control Patients 
Number of qRT-PCR 
Validated miRNAs 
(Tan et al., 2009) 
PloS One 
Whole blood samples from 
patients 6-18 months post-stroke 
IS, n=19. LA, n=8; CE, n=5; SVD, n=3; 
U, n=3. Age 18-49 
Array: pooled samples of different 
stroke subtypes and mRS scores 
Healthy, n=5 
5 miRNAs  
1 miRNA  
(Guo et al., 2013) 
Stroke 
Plasma samples from patients 1-
14 days after symptom onset 
Array: IS, n=16; ICH, n=15 Array: healthy, n=8 
Not Attempted  
(for IS patients) 
(Tan et al., 2013) 
Int J Mol Sci 
Whole blood samples from 
patients 2-24 months post-stroke 
IS, n= 8. Age 18-49 Healthy, n=4 Not Attempted 
(Jickling et al., 2014) 
PloS One 
Whole blood samples from 
patients within 72h of stroke 
onset 
IS, n=24. LA=8, CE=8, SVD=8 
Vascular risk factor patients, 
n=24 
2 miRNAs  
6 miRNAs  
(Sepramaniam et al., 
2014) 
Int J Mol Sci 
Whole blood samples collected 
within 24h, 48h and 7 days of 
stroke onset 
IS, n=169 
Array, n=68 (pooled & individual) 
Validation, n=101 
Healthy, n=24. Metabolic 
risk factor patients, 
n=94/98 
5 miRNAs  
5 miRNAs  
(Sørensen et al., 2014) 
Transl Stroke Res 
Plasma and CSF samples 
collected 3 days post-stroke 
IS, n=10. LA=3, CE=3, SVD=1, U=3 
Other Neurological Disease, 
n=10 
Not Attempted 
(Wang et al., 2014b) 
J Stroke Cerebrovasc Dis 
Plasma samples collected 0-24 
hours post-stroke 
IS, n=136. LA=60, CE=23, SVD=51, U=2  
Of these: MRI(+)=76, MRI(-)=60 
Healthy, n=116 
2 miRNAs  
2 miRNAs  
(Li et al., 2015a) 
Cell Mol Neurobiol 
Serum samples collected within 
24 hours of stroke onset 
IS, n=117 
Array: n=4 (4  x pooled from 10) 
Validation: n=24 and n=53 
Healthy, n=82 
Array: n=1 (pooled from 10) 
Validation: n=22 and n=50 
3 miRNAs  
1 miRNAs  
(Zhang et al., 2016b) 
J Affect Disord 
Plasma samples collected on day 
of admission 
Array: IS, n=3 
Validation: IS, n=20 
Array: IS with post-stroke 
depression, n=3 
Validation: n=20 
2 miRNAs  
1 miRNA  
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Table 1.3 – Targeted miRNA Profiling Studies in Ischaemic Stroke Patients 
Summary of published studies that have used a targeted approach – profiling expression of selected miRNAs by qRT-PCR in human ischaemic stroke 
patients. Studies have been listed chronologically. Abbreviations include: cardioembolic stroke patients (CE); internal carotid artery (ICA); ischaemic 
stroke patients (IS); intracerebral haemorrhage stroke patients (ICH); large artery stroke patients (LA); small vessel disease stroke patients (SVD); 
unclassified stroke patients (U). 
Reference miRNAs Tissue Sample Stroke Patients Control Patients 
(Cipollone et al., 
2011) 
Stroke 
miRNAs -100, -127, -
145, -133a, -133b 
(among others) 
Atherosclerotic plaques from 
carotid endarterectomy patients 
with extracranial high-grade 
(>70%) ICA stenosis 
IS, n=22 (Patients with extracranial 
high grade ICA stenosis and recent 
atherothrombotic stroke) 
Patients with extracranial high 
grade ICA stenosis but no stroke, 
n=31 
(Zeng et al., 2011) 
Front Biosci (Elite 
Ed) 
miRNA-210 
Blood samples collected at < 3 
days, 7 days and 14 days post IS 
IS, n=112. <3 days: LA (n=22), CE 
(n=2), SVD (n=31). 7 days: LA 
(n=13), CE (n=2), SVD (n=16). 14 
days: LA (n=15), CE (n=2), SVD (n=9) 
Healthy, n=60 
(Gan et al., 2012) 
Genet Mol Res 
miRNA-145 
Whole blood samples - no 
information on when sample 
collected 
IS, n=32. No information on stroke 
subtype 
Healthy, n=14 
(Tsai et al., 2012) 
J Vasc Res 
miRNAs -21, -221, -
145 
Serum samples collected within 
7 days post-stroke 
IS, n=167 
Healthy, n=157. Atherosclerosis, 
n=66. 
(Zeng et al., 2012) 
Eur Neurol 
miRNA-210 
Plasma samples collected within 
72 hours post-stroke 
IS, n=105. No information on stroke 
subtype. Good outcome, mRS≤2, 
n=40. Poor outcome, mRS>2, n=65. 
No control subjects in this study 
(Long et al., 2013) 
BMC Neurol 
miRNAs -30a, -126, -
let-7b 
Plasma samples collected at 24h 
(n=38), 1 week (n=42), 4 weeks 
(n=40), 24 weeks (n=38), 48 
weeks (n=39). Different patients 
at each time point 
IS, n=197. LA (n=51), SVD (n=48), 
CE (n=50), U(n=48) 
Age matched controls with 
vascular risk, n=50 
Not significantly different from IS 
group for characteristics recorded 
(Duan et al., 2014) 
J Diabetes 
Complications 
miRNAs -223, -146a, -
495, -107 
Plasma samples - no information 
on when sample collected 
IS, n=7. All are LA. 
Healthy, n=8. Diabetes mellitus, 
n=7. Diabetes mellitus and 
ischaemic stroke, n=6. 
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Reference miRNAs Tissue Sample Stroke Patients Control Patients 
(Leung et al., 
2014) 
Clin Chim Acta 
miRNAs -124-3p, -16 
Plasma samples collected within 
24h symptom onset 
Stroke, n=93. IS, n=73 – LA (n=7), 
CE (n=19), SVD (n=28), U (n=20). 
ICH, n=19. 
Healthy, n=23. Age and sex 
matched. 
(Liao et al., 2014) 
J Am Coll Cardiol 
miRNA-let-7g 
Serum samples collected - no 
information on when blood 
samples taken 
Lacunar infarction, n=60 No control subjects in this study 
(Yang et al., 2014) 
Clin Sci 
miRNA-107 
Plasma samples collected within 
24 hours of hospital admission 
IS, n=110. TACI=35, PACI=31, 
LACI=23, POCI=21 
Healthy, n=55 
 
(Zhou and Zhang, 
2014) 
Mol Med Rep 
miRNAs – 21, -24 
Plasma samples collected within 
24 hours of hospital admission 
Acute cerebral infarction, n=68 Healthy, n=21 
(Wang et al., 
2014c) 
BMC Neurol 
miRNA-223 
Leucocyte (from plasma) 
samples collected within 72 
hours of onset of stroke 
symptoms 
IS, n=79. LA (n=37), CE (n=5), SVD 
(n=9), U (n=28) 
Healthy, n=72 
(Jia et al., 2015) 
Cell Biochem Funct 
miRNAs -21, -23a, -
29b, -124, -145, -210, 
-221, -223, -483-5p 
Serum samples collected within 
24 hours, 7 days, 1 month, 6 
months and 2 years from stroke-
onset 
Pilot: IS, n=30 
Validation: IS at 24 hours n=146, 
other time points, n=49 
Pilot: Healthy, n=30 
Validation: Healthy, n=96 
(Kim et al., 2015) 
Transl Stroke Res 
miRNAs -17, -21, -
106a, -126, -200b 
Plasma samples collected within 
7 days of symptom onset 
IS, n=83. LA (n=35), CE (n=31), SVD 
(n=17) 
Vascular risk factors and other 
neurological problems, n=37 
(Liu et al., 2015c) 
J Clin Neurosci 
miRNAs -124, -9, -219 
Serum samples collected within 
24 hours (all patients) and 
within 48 hours (n=8) 
IS, n=31. No information on stroke 
subtype 
Healthy, n=11 
 
(Peng et al., 2015) 
Transl Stroke Res 
miRNAs – let-7e, -338 
Serum and CSF samples 
collected acutely (d1-d7), 
subacutely (d8-d14) and during 
recovery (>d15) 
IS. Serum: acute (n=72), subacute 
(n=68), recovery (n=63). CSF: acute 
(n=11), subacute (n=9), recovery 
(n=8) 
Healthy. Serum : n=51, CSF: 
n=12 
(Huang et al., 
2016) 
Neurosci Lett 
miRNA -132 
Serum samples collected within 
3 days of hospitalisation but 
patients may have had stroke up 
to 1 year previous 
IS with cognitive impairment, n=39 
IS with cognitive normality, n=37 
Healthy, n=38 
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A further example is that of miR-145 which was shown to be sequentially 
increased in whole blood samples of ischaemic stroke patients (vs. healthy 
control patients) from 24 hours post-stroke until 6 months post-stroke 
(Sepramaniam et al., 2014). Up-regulated miR-145 expression was also detected 
in whole blood and serum samples of ischaemic stroke patients (vs. healthy 
controls) (Gan et al., 2012, Jia et al., 2015) but subsequently decreased in 
expression over time (Jia et al., 2015). Interestingly, increased miR-145 
expression was also detected in the atherosclerotic plaques of patients with 
internal carotid artery (ICA) stenosis and recent stroke as compared to patients 
with ICA stenosis but no stroke (Cipollone et al., 2011). Conversely, in a 
conflicting study miR-145 was undetectable in a large number of ischaemic 
stroke patients and its expression unchanged in the remaining patients in 
comparison to healthy control patients (Tsai et al., 2012).  
It is difficult to compare results from these studies as their methodologies vary 
in many different ways. Of the miRNA profiling studies listed in Table 1.2, whole 
blood, plasma and serum samples were all collected from ischaemic stroke 
patients at acute, sub-acute and long-term time points post-stroke onset. In 
some studies patient samples collected at different time points are grouped 
together to make one group of ischaemic stroke patients (e.g. (Sepramaniam et 
al., 2014)). Population sample sizes differ hugely, with the smallest studies 
looking at expression in only 4 patients per group and the largest validating 
changes in over 100 ischaemic stroke patients. Furthermore the majority of 
studies compared miRNA expression of ischaemic stroke patients to that of 
healthy control patients. Therefore, while miRNAs are shown to be dysregulated 
in these studies they may represent changes as a result of hypertension and 
vascular disease (risk factors for stroke) rather than the ischaemic insult itself. 
Increased infarct size and resulting neurological deficit is associated with both 
increased and decreased expression of various miRNAs, reflecting the diverse 
nature of miRNAs, their targets and the role they play in ischaemic stroke. 
Increased expression of miRs-145, -124-3p and -16 has been associated with 
increased infarct size and more severe stroke (National Institute of Health Stroke 
Scale (NIHSS) >5) (Jia et al., 2015, Leung et al., 2014). However decreased 
expression of other miRNAs such as miR-124, -9, -21, -24 and -223 was also 
associated with increased infarct volume and NIHSS score (Liu et al., 2015c, 
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Wang et al., 2014c, Zhou and Zhang, 2014). Conversely, the expression of 
several miRNAs (let-72, miRs-338 and -219) did not correlate with NIHSS score or 
infarct volume (Liu et al., 2015c, Peng et al., 2015). However, several of the 
results quoted here are from studies which have not stated on which day the 
NIHSS score or infarct volume was measured (Leung et al., 2014, Wang et al., 
2014c, Zhou and Zhang, 2014) and another study measured the NIHSS score on 
the same day as blood samples were taken – between 1 and 7 days post stroke 
onset meaning a very diverse range of patients (n=72) will be included, perhaps 
why this study didn’t observe any correlations between miRNA expression and 
NIHSS score, highlighting the importance of careful selection of patient 
population groups (Peng et al., 2015). 
Many of the studies discussed here have used bioinformatics to predict targets 
and pathways that dysregulated miRNAs may regulate. However, as these targets 
are generally predictions and not validated in human patients, they have not 
been discussed here. 
A final point to notice is that many of the changes in circulating miRNA 
expression observed in human patients following ischaemic stroke are very 
modest. Several studies have also only looked at the expression of a very small 
number of miRNAs. Future studies should profile global miRNA expression in 
large, well-controlled, homogeneous patient populations to demonstrate 
whether multiple miRNAs are dysregulated simultaneously and which are truly 
dysregulated as a direct result of ischaemic stroke. Furthermore, without 
comprehensive mechanistic studies to investigate the function of these miRNAs 
it is difficult to understand whether dysregulated miRNA expression is a cause or 
result of ischaemic stroke pathophysiology. 
1.2.4 miRNAs as Biomarkers 
While the need for a biomarker to diagnose ischaemic stroke seems obsolete in 
Western countries, many papers cite the expense and unavailability of MRI 
scanning in less economically developed countries. Very little research into 
circulating biomarkers (other than miRs) to improve diagnosis of stroke has been 
performed, with most studies focussing on biomarkers that indicate increased 
risk of stroke (e.g. (Shoamanesh et al., 2016)), or neuroinflammatory markers 
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that might give indication of stroke prognosis (reviewed (Simats et al., 2016)). 
For a biomarker to be useful it should aid clinical decision making (e.g. whether 
or not to give a specific treatment). As acute treatment for stroke with 
reperfusion therapies is dependent on differentiating ischaemic stroke from 
haemorrhagic stroke and other stroke mimic conditions, treatment can be 
delayed due to limited access to imaging technology. Therefore “early screening 
to allow rapid ischemic stroke identification would speed stroke patient 
management and treatment” (Simats et al., 2016). As any biomarker panel 
would need to be extremely accurate (due to severe complications that could be 
a result of incorrect treatment based on inaccurate diagnosis) it seems unlikely 
that such a biomarker will be discovered before advances in imaging technology 
and better management of acute ischaemic stroke within the hospital make the 
need for it obsolete. Other research groups have attempted to identify 
biomarkers that could be used to predict stroke outcome and response to 
treatment, which might inform decisions about patient management. Non-
modifiable factors (e.g. age and initial stroke severity) are the primary 
predictors of patient outcome but may have increased predictive power when 
combined with inflammatory biomarkers such as CRP, IL-6, TNF-α, ICAM-1 and 
MMP-13 (Rosell et al., 2005, Sotgiu et al., 2006, Whiteley et al., 2009). 
Several studies have investigated the possibility of using miRNA expression as a 
biomarker for either diagnosis or prognosis in ischaemic stroke patients. 
Receiver operator characteristic (ROC) analysis has been used to estimate the 
sensitivity and specificity of certain miRNAs at distinguishing between ischaemic 
stroke and control patient populations. The area under a ROC curve (AUC) is an 
indication of how sensitive and specific a particular miRNA is: a score of 1 
represents 100% specificity and 100% sensitivity. A number of studies have tested 
the ability of single miRNAs to distinguish between ischaemic stroke patients and 
non-stroke control patients. Circulating miRNAs that can distinguish between 
stroke and healthy control patients include miR-24 (<24 hours post-stroke, AUC 
0.76) (Liu et al., 2015c) and let-7e (<7 days post-stroke, AUC 0.86) (Peng et al., 
2015). 6 miRNAs detected within 7 days of stroke had high sensitivity and 
specificity for diagnosing between ischaemic stroke and healthy controls: 
miRNAs -125-2* (AUC 0.95), -27a* (AUC 0.89), -422a (AUC 0.92), -488 (AUC 0.87), 
-627 (AUC 0.84), and -920 (AUC 0.81) (Sepramaniam et al., 2014). However, 
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when these results were validated in a larger patient population the majority of 
AUC values decreased (Sepramaniam et al., 2014). The ability of these miRNAs 
to distinguish between healthy controls and patients with vascular risk but no 
stroke was relatively low (AUC of 0.30 to 0.67) (Sepramaniam et al., 2014). The 
authors conclude that changes in miRNA expression observed were therefore 
directly as a result of ischaemic stroke rather than other risk factors for stroke. 
A further study has demonstrated that circulating miRNAs (<24 hours post-stroke 
onset) can better distinguish between healthy controls and patients with a larger 
stroke than those with a smaller stroke, as detected by MRI (Wang et al., 
2014b). These miRNAs included miR-4306 (AUC 0.88 vs AUC 0.95), miR-320e (AUC 
0.95 vs AUC 0.98), miR-320d (AUC 0.98 vs AUC 0.99) and miR-106b-5p (AUC 0.99 
vs AUC 0.96) (Wang et al., 2014b). 
Alternative investigations have used a ‘cocktail’ of miRNAs and other markers to 
diagnose between ischaemic stroke patients and younger, healthy controls. For 
example, the serum expression of c-reactive protein (CRP) and miR-145, within 
24 hours of stroke onset, gave high sensitivity and specificity (AUC 0.90) (Jia et 
al., 2015). Another study found that serum expression of miR-21 and miR-221 
(within 7 days of stroke) in combination with traditional risk factors had the 
greatest ability to distinguish between ischaemic patients and healthy controls 
(AUC 0.93) (Tsai et al., 2012). These results highlight the need for further 
studies to investigate the sensitivity and specificity of biomarker panels 
consisting of multiple miRNAs. 
Two studies have investigated the biomarker potential of miRNAs and used age 
matched control patients with vascular risk. Plasma samples were collected at 4 
different time points and the ability of 3 miRNAs to differentiate between 
ischaemic stroke patients and controls was calculated (Long et al., 2013). miR-
30a, miR-126 and let-7b were all increased in expression in ischaemic stroke 
patients and at 24 hours post stroke were able to distinguish between patient 
populations with AUC values of 0.91, 0.92 and 0.93 respectively (Long et al., 
2013). The same miRNAs could be used to distinguish between patient 
populations in samples collected at 24 weeks post-stroke, showing that the time 
of sample collection did not significantly affect the ability of these miRNAs to 
differentiate between populations. Increased miR-17 expression has also been 
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associated with ischaemic stroke patients (AUC 0.64) in comparison to vascular 
risk factor control patients (Kim et al., 2015).  
Unfortunately, very few studies have investigated the possibility of using miRNAs 
as biomarkers for prognosis following stroke. miR-210 expression has been 
profiled in patients with both good (mRS<2) and poor (mRS>2) functional 
outcome, as assessed at 3 months post-stroke. Its expression in blood samples 
collected up to 14 days following ischaemic stroke could partly distinguish 
between patients with good and poor functional outcomes (AUC 0.64) (Zeng et 
al., 2011). This study included samples collected at a variety of time points (< 72 
hours, 7 days and 14 days post-stroke) and it is not clear which samples they 
used in their analysis (Zeng et al., 2011). A follow up study demonstrated that 
plasma levels of miR-210, in samples collected within 72 hours of stroke onset, 
could partially distinguish between patients with good and poor functional 
outcome (AUC 0.67). However, when a cocktail of biomarkers was used: 
expression of miR-210, pro-inflammatory cytokine IL-6 and fibrin degradation 
products (FDP) the sensitivity and specificity increased (AUC 0.80). This 
biomarker cocktail was subsequently shown to be more sensitive but less specific 
than NIHSS scores as a predictor of outcome (AUC 0.97) (Zeng et al., 2012). 
Dysregulated miRNA expression has also been associated with stroke recurrence, 
post-stroke cognitive impairment and depression. Higher levels of miR-17 and 
miR-106a in plasma samples collected within 7 days of stroke onset are 
associated with recurrent stroke during a 24 month follow up period. 
Furthermore, increased miR-17 expression was associated with shorter event-
free survival (Kim et al., 2015). Increased expression of miR-132 in serum 
samples collected from patients with historic stroke (<1 year) within 3 days of 
hospitalisation has been negatively correlated with Montreal Cognitive 
Assessment scores, a measure of cognitive impairment (AUC 0.96, vs. patients 
with no impairment) (Huang et al., 2016). Furthermore, increased  plasma miR-
92a-3p, and decreased miR-133a and miR-187-5p expression in samples collected 
on the day of hospital admission for ischaemic stroke are associated with post-
stroke depression as measured by the Hamilton Depression-17 scale at 2 weeks 
post-stroke (Zhang et al., 2016b). These results highlight the need for future 
studies to investigate the prognostic power of miRNAs. If early miRNA expression 
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could predict how well a patient might do functionally, physiotherapy and 
treatment could be directed accordingly, perhaps leading to improved outcome. 
A failure of all of the studies mentioned in this section is that no studies look at 
biomarker potential of miRNAs in relation to stroke subtype. When conventional 
imaging techniques fail to obtain clear images it can be difficult for clinicians to 
make diagnosis of stroke subtype in ischaemic stroke patients and so direct their 
treatment accordingly – it would therefore be beneficial to the field if all 
published studies listed the stroke subtype of their patients and whether 
separation of patients according to subtype had a beneficial or detrimental 
effect on the sensitivity and specificity of miRNAs to assess diagnosis and 
prognosis in ischaemic stroke patients. 
1.2.5 Modulation of miRNAs 
1.2.5.1 Increasing miRNA Expression 
To increase miRNA expression synthetic miRNA duplexes (often called miRNA 
mimics) can be used – ideally, these will be taken up by RISC complexes and 
processed resulting in mRNA degradation or translational repression. The duplex 
contains a guide strand (a duplicate of the miRNA of interest) and a passenger 
strand. While the guide strand may be modified to prevent exonuclease 
degradation (Chiu and Rana, 2003), many modifications can interfere with RISC 
recognition of the miRNA. Typically it is the passenger strand that is chemically 
modified (e.g. by linking to a cholesterol molecule) to improve cellular uptake, 
promote the stability of the miRNA or to prevent loading into a RISC (reviewed 
(van Rooij and Kauppinen, 2014)). Furthermore, the passenger strand may be 
modified to contain nucleotide mismatches to stop it from acting as an anti-miR. 
Some modifications may inhibit degradation of the passenger strand and these 
are typically avoided.  
Lenti-, adeno- and adeno-associated viral vectors can transfect most cell types 
and can all be used to increase miRNA expression. As miRNAs are susceptible to 
degradation by RNases they have a relatively short half-life. Viral vectors are 
therefore an attractive mechanism of miRNA modulation as their transduction 
efficiency is relatively high, and transgene expression can be sustained. Vectors 
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can be designed to express single miRNA mimics from RNA polymerase II 
promoters. More cleverly still, expression of a miRNA polycistron can mediate 
increased expression of multiple miRNAs from a single RNA polymerase II 
transcript. Clinical virus mediated delivery of miRNAs has been hampered by 
safety issues including immunogenicity. Virus mediated miRNA modulation  has 
been reviewed by Liu and Berkhout and will not be further discussed here (Liu 
and Berkhout, 2011). 
1.2.5.2 Inhibiting miRNA Expression 
Inhibition of miRNA function is typically mediated, experimentally, by antisense 
oligonucleotides (anti-miRs). They too are usually chemically modified to 
increase their stability and binding affinity. An example of a typical modification 
includes phosphorothioate (PS) backbone linkage substitutions in the place 
phosphodiester (PO) linkages to improve nuclease resistance (Lennox and 
Behlke, 2010). These modifications reduce their glomerular filtration and 
therefore clearance by mediating enhanced binding to plasma proteins (Levin, 
1999). Other sugar modifications include 2’-O-methyl, 2’-O-Methoxyethyl, 2’-
fluoro at the 2’ sugar group position and locked nucleic acid (LNA), which all act 
to increase the duplex melting temperature and to increase binding affinity and 
nuclease resistance (Lennox and Behlke, 2010, van Rooij and Kauppinen, 2014). 
Initial studies using chemically modified anti-miRs used fully complementary 
oligonucleotides successfully (Krutzfeldt et al., 2005). Subsequently shorter LNA-
modified anti-miRs have proved to be effective. These include anti-miRs fully 
complementary to only the first 16 nucleotides of the 5’ end of a mature miRNA 
(Elmen et al., 2008) and LNA-modified anti-miRs complementary to only the 7-8 
nucleotides of the seed sequence that are capable of inhibiting multiple miRNAs 
in one miRNA family that share a seed sequence (Obad et al., 2011). 
miRNA sponges can also be used to inhibit multiple miRNAs from one family – the 
sponge mRNA contains multiple target sites that are complementary to miRNAs 
of interest and represses whole families of miRNAs via affinity to the seed 
sequence of the miRNA. Their function and use has been reviewed more fully by 
Ebert and Sharp (Ebert and Sharp, 2010). 
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1.2.5.3 Therapeutic Potential of miRNAs 
Working with miRNAs is challenging as miRNA mimics and anti-miRs, even when 
delivered appropriately, need to avoid being degraded by serum endonucleases, 
detected by the immune system and cleared from the blood by the renal system. 
Furthermore, they must extravasate from the blood stream to reach their target 
tissue and miRNA mimics must also be loaded into RISC complexes to have 
functional effect. 
Despite these caveats miRNAs remain attractive candidates for therapeutic 
modulation. Due to their small size and conserved sequence, miRNA mimics and 
anti-miRs are now readily available for most miRNAs and miRNA technology is 
continually being developed. Many pre-clinical studies, both in the setting of 
ischaemic stroke and a wider disease context, have demonstrated therapeutic 
effect following miRNA modulation. As one miRNA may target many hundreds of 
genes and as many of the genes targeted by one miRNA will often function in the 
same or related cellular processes or signalling cascades, even the modest 
modulation of a single miRNA has the potential to have a significant effect 
functionally – the result of accumulated modifications to multiple genes. 
However, the addition of miRNA mimics to restore levels of down-regulated 
miRNAs may result in supra-physiological levels of miRNA, and similarly the 
addition of anti-miRs which are stable and potentially have very long-lasting 
effects may result in ablation of miRNA expression altogether (van Rooij and 
Kauppinen, 2014). Furthermore, given the potential of a miRNA to target many 
hundreds of genes, “off-target effects” are a significant possibility and make 
miRNAs less attractive targets for drug development by pharmaceutical 
companies. This is especially the case when miRNAs are delivered systemically, 
rather than directly to the tissue of interest, resulting in uptake by non-target 
tissues that may not even express the miRNA endogenously (van Rooij and 
Kauppinen, 2014). Therefore, targeted delivery to specific cells or tissues of 
interest should be considered. The use of targeted microvesicles (such as 
exosomes) to deliver miRNA may circumvent this problem (Johnsen et al., 2014). 
Furthermore as miRNA expression levels vary extensively between different 
cells, tissues and as a result of disease, defining appropriate levels of either up- 
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or down-regulation to ensure inhibition or stimulation of mRNA targets will be 
critical (van Rooij and Kauppinen, 2014). 
Despite the challenges described here miRNA-34 in a liposome formulation is 
currently being tested in a Phase I, multicentre, clinical trial to investigate 
safety, pharmacokinetics and pharmacodynamics in patients with unresectable 
primary liver cancer (ID: NCT01829971 (Mirna Therapeutics, 2016)). 
Furthermore two compounds targeting miR-122 are being developed to treat 
hepatitis-C virus (HCV) infection. Miravirsen was the first miRNA-targeted drug 
to go to clinical trial and results from the phase II study were published in 2013 
(Janssen  et al., 2013) showing that treatment with Miravirsen resulted in long-
lasting and dose-dependent antiviral activity, was well tolerated and had no 
toxic side effects or discontinuations as a result of adverse side effects. This 
study proves that modulation of miRNA activity is feasible therapeutically in 
human patients and is an inspiration for many studies seeking to provide 
therapeutic benefit via miRNA modulation. 
1.2.6 miRNA Therapeutics for Stroke 
miRNA profiling in ischaemic stroke patients has been described in section 1.2.3. 
Similar studies profiling miRNA expression in pre-clinical models of stroke will 
not be discussed here, but rather the therapeutic use of miRNAs in pre-clinical 
models of ischaemic stroke. Studies that have modulated miRNA expression in 
pre-clinical in vivo models of ischaemic stroke are summarised in Table 1.4. 
Interestingly there are an equal number of studies demonstrating inhibition of 
miRNA expression is therapeutic for ischaemic stroke as there are those 
demonstrating the reverse. This highlights the diverse role of miRNAs post-
stroke. Some are perhaps endogenous pro-survival miRNAs, repressing 
deleterious mRNAs - increasing expression of these miRNAs therefore increases 
therapeutic benefit. Others miRNAs may act to inhibit therapeutic mRNAs, and 
so inhibition results in de-repression of these mRNAs and therefore therapeutic 
effect. In either case it is evident that ischaemic stroke results in an extremely 
complex pathophysiology and the effects of modulating each miRNA need to be 
fully understood before any miRNA modulating agent could be used clinically. 
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In the studies listed in Table 1.4 there a number of differences between the 
animal and stroke models used. Of the 33 studies listed, only 2 use an animal 
model with co-morbidities relevant to stroke. Two studies modulate miRNA 
expression in spontaneously hypertensive rats (SHR) and of the remaining studies 
32% modulate miRNA expression in healthy rat strains (primarily Sprague Dawley 
rats) and 56% in healthy mice strains (primarily C57BL/6J), with a further 2 
studies using miRNA knock-out mouse models. While therapeutic benefit has 
been demonstrated in all of these studies, young and healthy animal models do 
not represent human stroke patients who are typically aged and present with a 
number of co-morbidities. Rigorous testing of miRNA modulation in appropriate 
pre-clinical models is needed to truly investigate therapeutic effect. 
Furthermore, while over half of the studies used a clinically relevant model of 
ischaemic stroke involving ischaemia and reperfusion, i.e. transient middle 
cerebral artery occlusion (tMCAO), a number used permanent models of stroke, 
with no reperfusion. So while therapeutic benefit was observed further studies 
would need to test the effect of reperfusion on miRNA modulation. This is 
essential as the only two currently licensed treatments for ischaemic stroke are 
thrombolysis or thrombectomy, both of which are used to ensure reperfusion. 
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Table 1.4 - Therapeutic miRNA Modulation in Experimental Ischemic Stroke (in vivo) 
A table summarising published studies that modulate miRNAs therapeutically in in vivo models of ischaemic stroke. Details of the miRNA modulated, 
animal and stroke model used, the delivery method and the time at which animals were sacrificed (post-stroke) are given. Unless otherwise stated all 
animals used were adult males. Abbreviations include: 4VO (4 vessel occlusion), BCCAO (bilateral common carotid artery occlusion), CCA (common 
carotid artery), eMCAO (embolic middle cerebral artery occlusion), H/I (hypoxia/ischaemia injury), MSC (mesenchymal stromal cell), pMCAO (permanent 
middle cerebral artery occlusion), SD (Sprague Dawley rat), SHR (spontaneously hypertensive rat), tMCAO (transient middle cerebral artery occlusion).  
Reference 
MiRNA 
Modulation 
Animal Model Stroke Model Delivery Method 
Animals 
Sacrificed 
(time post-
stroke) 
(Dharap et al., 2009) 
JCBFM 
miR-145 
↓ beneficial 
SHR 
(280-300g) 
1h tMCAO 
Anti-miR via osmotic mini-pump into 
lateral ventricle 2 days pre-tMCAO. 
1 day 
(Sepramaniam et al., 2010) 
JBC 
miR-320a 
↓ beneficial 
SD rats 1h tMCAO 
Mimics & anti-miR via ICV at 
reperfusion. 
1 day 
(Yin et al., 2010) 
Neurobiol Dis 
miR-497 
↓ beneficial 
C57/B6 mice 1h tMCAO 
Anti-miR via ICV infusion to lateral 
ventricle started 2 days pre-tMCAO. 
1 day 
(Harraz et al., 2012) 
PNAS 
miR-223 
↑ beneficial 
C57BL/6 and 
miR-223-/- mice 
(8-12 weeks) 
20min BCCAO 
Adenoviral vector ↑ via stereotactic 
injection. 
6 days 
(Ouyang et al., 2012) 
Neurobiol Dis 
miR-181 
↓ beneficial 
C57/B6 mice 
(25-30g) 
1h tMCAO 
Plasmid (2 days pre-tMCAO) or anti-miR 
+ DOTAP (1 day pre-tMCAO) via ICV 
stereotactic injection. 
1 day 
(Selvamani et al., 2012) 
PLoS One 
let-7f 
↓ beneficial 
Adult female 
rats and age-
matched males, 
no info on strain 
eMCAO 
Anti-miR via ICV injection at 4h post-
MCAO. 
5 days 
(Deng et al., 2013) 
Brain Res Bull 
miR-21 
↓ beneficial 
miR-224 
↓ no effect 
SD rats 
(220-250g) 
10min 4VO 
Anti-miR via stereotactic injection to 
bilateral cerebral ventricles 24h pre-
4VO. 
6h, 12h and 1 
day 
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Reference 
MiRNA 
Modulation 
Animal Model Stroke Model Delivery Method 
Animals 
Sacrificed 
(time post-
stroke) 
(Doeppner et al., 2013) 
Acta Neuropathol 
miR-124 
↑ beneficial 
C57BL6/N mice 
(11-13 weeks) 
45min tMCAO 
Virus ↑ via stereotactic injection at 21 
days pre-MCAO. No info on type of 
virus. 
1, 2, 4, 28 and 
56 days 
(Khanna et al., 2013) 
JCBFM 
miR-29b 
↑ beneficial 
C57BL6/N mice 
(8 weeks) 
1.5h tMCAO 
Lentivirus ↑ via stereotactic injection 
to cortex at 72h pre-tMCAO. 
2 days 
(Liu et al., 2013a) 
Stroke 
miR-124 
↓ beneficial 
C57 mice 
(21-23g) 
pMCAO 
Mimic or anti-miR + lipofectamine via 
ICV stereotactic injection post-tMCAO. 
1 day 
(Liu et al., 2013b) 
JBC 
miR-17-92 
cluster 
↑ beneficial 
C57BL/6 mice pMCAO 
Lentivirus ↑ cluster via stereotactic 
injection to SVZ region, 1 day pre-
pMCAO. 
7 days 
(Moon et al., 2013) 
JCBFM 
miR-181a 
↓ beneficial 
SD rats 
(280-320g) 
Hypotension 
+ 10 min CCA 
clamping 
Anti-miR + DOTAP via stereotactic 
injection to hippocampus, 24 h before 
ischemia. 
1, 3 and 7 days 
(Pandi et al., 2013) 
PLoS One 
miR-29c 
↑ beneficial 
SHR 
(280-300g) 
1h tMCAO 
Mimics via osmotic mini-pump to 
lateral ventricle. siRNA by stereotactic 
injection. 
1 and 3 days 
(Qiu et al., 2013) 
BioMed Res Int 
miR-210 
↑ beneficial 
Neonatal (d7) 
SD rats 
CCA ligation 
+ 2h hypoxia 
Mimics or anti-miRs via stereotactic 
infusion into lateral ventricle. 
3 days 
(Sun et al., 2013) 
CNS Neurosci Ther 
miR-124 
↑ beneficial 
C57BL/6 mice 
(18-22g) 
pMCAO 
Mimics or anti-miRs via tail-vein 
injection daily for 3 days prior to 
MCAO. 
1 day 
(Xin et al., 2013b) 
Stem Cells 
miR-133b 
↑ beneficial 
Wistar rats 
(270-300g) 
2h tMCAO 
MSCs modified to be miR-133b+ or miR-
133b- via IV tail vein injection, 24h 
post-tMCAO. 
14 days 
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Reference 
MiRNA 
Modulation 
Animal Model Stroke Model Delivery Method 
Animals 
Sacrificed 
(time post-
stroke) 
(Zhao et al., 2013) 
Stroke 
miR-424 
↑ beneficial 
C57BL/6J mice 
(20-25g) 
pMCAO 
Lentivirus ↑ + polybrene via ICV 
injection 7 days pre-MCAO or mimic + 
siRNA-MATE via ICV injection 10 min 
post-MCAO. 
Lentiviral 
vector = 8h, 
miRNA mimics 
= 1 day 
(Chi et al., 2014) 
Neuroscience 
miR-134 
↓ beneficial 
C57BL/6J mice 
(18-22g, 6-8 
weeks) 
1h tMCAO 
Lentivirus ↓ via stereotactic injection 
at 3 sites 72h pre-tMCAO. 
1 day 
(Qu et al., 2014) 
Neurobiol Dis 
miR-139-5p 
↑ beneficial 
Neonatal (d10) 
SD rats 
CCA ligation 
+ 2.5h 
hypoxia 
Mimic + lipofectamine via stereotactic 
injection to lateral ventricle at 12h 
post H/I. 
2 and 7 days 
(Vinciguerra et al., 2014) 
Mol Ther 
miR-103-1 
↓ beneficial 
SD rats 
(250-300g) 
 
100min 
tMCAO 
Anti-miR via ICV infusion to lateral 
ventricle for 48h, starting 24h pre-
tMCAO or 20 min post-tMCAO. 
1 and 2 days 
(Wang et al., 2014a) 
Neurochem Res 
miR-30a 
↓ beneficial 
C57BL/6J mice 
(22-25g) 
pMCAO or 1h 
tMCAO 
Lentivirus ↓ via stereotactic injection 
to cortex 5 days pre-MCAO. 
pMCAO = 6h, 
tMCAO = 24h 
(Zhao et al., 2014) 
Brain Res 
miR-23a-3p 
↑ beneficial 
C57BL/6J mice 
(22g) 
1h tMCAO 
Mimic + lipofectamine via stereotactic 
injection (ICV) at 10 min post MACO. 
1h, 4h, 1 day 
(Zhu et al., 2014) 
J Mol Neurosci 
miR-124 
↓ beneficial 
SD rats 
(280-300g) 
2h tMCAO 
Anti-miR via ICV infusion to lateral 
ventricle at 1 day pre-tMCAO. 
1 day 
(Huang et al., 2015) 
CNS Neurosci Ther 
miR-29c 
↓ beneficial 
SD rats 
(280-300g) 
2h tMCAO 
Anti-miR or mimic via ICV infusion at 1 
day pre-tMCAO. 
1 day 
(Liu et al., 2015b) 
Stroke 
miR-424 
↑ beneficial 
C57BL/6 mice 
(22-25g) 
1h tMCAO 
Mimic + lipofectamine via ICV injection 
immediately prior to tMCAO. 
1h, 4h, 1 day 
(Liu et al., 2015a) 
JCBFM 
miR-122 
↑ beneficial 
SD rats 
(7-8 weeks) 
1.5h tMCAO 
Mimic + liposomes via IV (tail vein) or 
ICV injection, 5min post-tMCAO. 
1 day 
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Reference 
MiRNA 
Modulation 
Animal Model Stroke Model Delivery Method 
Animals 
Sacrificed 
(time post-
stroke) 
(Ni et al., 2015) 
Brain, Behav & Immunity 
let-7c-5p 
↑ beneficial 
CD1 mice 
(25-30g) 
1h tMCAO 
Mimic + Entranster TM via stereotactic 
ICV injection, 6 days pre-MCAO. 
1 and 4 days 
(Stary et al., 2015) 
Stroke 
miR-200c 
↓ beneficial 
CB57/B6 mice 
(8-10 weeks) 
1h tMCAO 
Anti-miR or mimics + DOTAP via ICV 
infusion, 24 hours pre-tMCAO. 
1h, 3h, 1 day 
(Wang et al., 2015) 
JCBFM 
miR-29b 
↑ beneficial 
CD-1 mice 
(25-30g) 
pMCAO 
Lentivirus ↑ via stereotactic injection, 
14 days pre-MCAO. 
1 and 3 days 
(Wei et al., 2015) 
Mol Neurobiol 
miR-9 
↑ beneficial 
C57/BL6 mice 
(8 weeks) 
1.5h tMCAO Mimics via IV for 3 days pre-tMCAO. 
1h, 3h, 6h, 
12h, 24h, 30 
days 
(Wen et al., 2015) 
Mol Med 
miR-155 
↑ 
detrimental 
C57/BL6 or miR-
155-/- mice 
(25-30g) 
pMCAO 
Adenovirus via stereotactic injection to 
lateral ventricle, 24h pre-MCAO. 
1 day 
(Xu et al., 2015) 
Exp Neurol 
miR-181 
↓ beneficial 
C57/B6 mice 
(25-30g) 
1h tMCAO 
Anti-miR + DOTAP via ICV to lateral 
ventrical at 2h post-tMCAO or IV to 
internal jugular vein at 1h post-tMCAO. 
1 and 2 days, 4 
weeks 
(Yu et al., 2015) 
J Cell Biochem 
miR-22 
↑ beneficial 
SD rats 
(260-320g) 
1.5h tMCAO 
Adenovirus ↑ via stereotactic injection 
into 2 brain sites, 3 days pre-tMCAO. 
1 day 
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miRNAs have been successfully modulated when delivered in vivo either by the 
use of mimics and anti-miRs (with or without additional transfection reagents) 
(approximately 68%) and viral vectors (29%). The only study to modulate miRNA 
expression differently used modified mesenchymal stromal cells that were either 
miR-133b+ or miR-133b- (this study is discussed further in section 1.3.5).  
The vast majority of studies (90%) which modulated miRNA expression in vivo 
have done so by direct delivery to the brain via stereotactic injection or 
osmotic-mini pump infusion into a lateral ventricle. A number of studies have 
demonstrated successful miRNA modulation by IV delivery, typically to the tail 
vein (Liu et al., 2015a, Wei et al., 2015, Xin et al., 2013b) with one study 
delivering to the internal jugular vein (Xu et al., 2015). IV delivery has been 
compared to intracerebroventricular (ICV) infusion in two separate studies. The 
first compared ICV infusion of a miR-181a anti-miR with IV delivery (Xu et al., 
2015). miR-181a anti-miR was mixed with the cationic lipid DOTAP and infused 
into the lateral cerebral ventricle at 2 hours post-tMCAO in C57/B6 mice or 
delivered IV 1 hour post-tMCAO into the internal jugular vein. ICV infusion of the 
anti-miR reduced miR-181a levels in the brain significantly, infarct size by 35% 
(vs. control anti-miR) at 48h post-tMCAO and significantly improved neurological 
deficits over a 28 day period. IV delivery of the anti-miR also reduced miR-181a 
levels in the brain significantly (although to a lesser degree) and this was also 
associated with significantly reduced infarct size and improved neurological 
score. The second compared ICV and IV delivery of miR-122 mimic (Liu et al., 
2015a). Interestingly, the miR-122 mimic was ‘wrapped’ using PEG-liposomes 
(liposomes containing synthetic polymer poly-(ethylene glycol)). PEG-liposomes 
have been shown to have extended blood-circulation time and reduced 
mononuclear phagocyte system uptake, important when delivering IV, and for 
this reason are sometimes called stealth liposomes (Immordino et al., 2006). 
Sprague Dawley rats were given miR-122 mimic IV or ICV within 5 mins of tMCAO 
(Liu et al., 2015a). Within 24h of tMCAO IV delivery of mimic resulted in up-
regulated circulating expression of miR-122 in a dose-dependent fashion, no data 
are given on expression following ICV delivery. ICV delivery of mimic did not 
reduce infarct size or improve neurological impairment, unlike IV delivery which 
significantly improved both. These studies show that modulating miRNA 
expression by IV delivery of either miRNA mimic or anti-miR, a clinically relevant 
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model of delivery, holds therapeutic potential and can result in significant 
improvements to infarct size and neurological score following ischaemic stroke. 
The majority of studies described in Table 1.4 modulate miRNA expression pre-
ischaemic stroke and go on to demonstrate therapeutic benefit post-ischaemic 
stroke. While these proof of concept studies are necessary, drug delivery pre-
stroke is clearly not appropriate for clinical treatment of stroke. Ten studies 
have shown therapeutic effect with delivery post-stroke, but of these six studies 
deliver within 20 mins post-stroke (usually at the point of reperfusion, although 
not all studies make this clear). While these studies are important, they do not 
extend the therapeutic time window past what is currently available with 
treatment by rtPA within 4.5 hours or thrombectomy within 6 hours. Of the 
remaining studies, miR-181 anti-miR was delivered at 1 and 2 hours post-stroke 
(Xu et al., 2015) and let-7f anti-miR was delivered by ICV to rats at 4 hours-post 
embolic stroke (Selvamani et al., 2012). Furthermore, miR-139-5p mimic was 
delivered by stereotactic injection to neonatal Sprague Dawley rats at 12 hours 
post-hypoxia/ischemia injury (Qu et al., 2014) and modified mesenchymal 
stromal cells (MSCs) were administered IV to Wistar rats at 24 hours post-tMCAO 
(Xin et al., 2013b). Modulating miRNA expression post-stroke can result in 
therapeutic benefit and future studies should focus on delivery post-stroke. 
Over 50% of studies sacrificed animals within 24 hours of stroke, giving a good 
indication of therapeutic benefit as assessed by reduced infarct volume. 
However, in these studies there was limited measurement of functional outcome 
or the impact of the decreased lesion size. It is worth considering that in models 
using tMCAO the lesion would not necessarily be complete at 24 hours post-
stroke. Of 14 studies that sacrificed animals after 24 hours, 11 sacrificed study 
animals within 7 days of stroke and the remaining 3 looked at therapeutic effect 
from 2 weeks to 56 days post-stroke. Delivery of miR-133b modified MSCs post-
tMCAO resulted in functional improvement (assessed by adhesive removal test 
and foot-fault test) up until 14 days post-stroke in Wistar rats (Xin et al., 2013b). 
Mice treated with miR-9 mimic delivered pre-tMCAO had improved functional 
outcome up to 28 days post-stroke as assessed by neurological score, rotarod and 
staircase test (Wei et al., 2015). Finally, viral mediated increases in miR-124 
expression pre-stroke, were associated with improved functional outcome in 
C57BL6/N mice, up to 56 days post-stroke, as assessed by rotarod and tightrope 
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tests and a modified water maze test (Doeppner et al., 2013). Studies that have 
investigated positive therapeutic effect within 24 hours should now look at 
longer-term time points to see if the trend towards therapeutic effect continues 
long-term. 
As has been discussed in section 1.1.3, ischaemic stroke results in an extremely 
complex pathophysiology. Interestingly, the miRNAs modulated in these in vivo 
studies play a part in modulating many of these processes, including cell death 
and apoptosis, cerebral oedema, oxidative stress, BBB dysfunction, inflammation 
and neurogenesis and angiogenesis. While the majority of these studies only look 
at a single or small number of miRNA targets it would be interesting to see if 
multiple miRNAs could be used to target multiple ischaemic stroke processes 
simultaneously and so result in even greater therapeutic benefit. 
A number of studies from separate groups have modified the same miRNA with 
differing results. This is the case for both miR-124 and miR-29. Viral mediated 
increased miR-124 expression in C57BL6/N mice resulted in reduced infarct 
volume, oedema and improved functional outcome (Doeppner et al., 2013). 
Similarly, systemic delivery of miR-124 mimic via tail vein injection 3 days prior 
to permanent MCAO (pMCAO) in C57BL6 mice resulted in reduced infarct volume 
(Sun et al., 2013). However in a conflicting study, delivery of both mimic and 
anti-miR to C57 mice via ICV injection post-stroke revealed that inhibition of 
miR-124 expression resulted in reduced infarct volume and de-repression of 
iASPP (an evolutionarily conserved inhibitor of p53) (Liu et al., 2013a). 
Furthermore, using a miR-124 anti-miR, delivered by ICV infusion 1 day pre-
tMCAO in Sprague Dawley rats resulted in decreased infarct volume and de-
repression of Ku70, a suppressor of Bax-mediated apoptosis (Zhu et al., 2014).  
Several studies have investigated miR-29b and miR-29c modulation in 4 different 
animal models and present results that are similarly complicated. Three studies 
demonstrate that increased miR-29 expression is beneficial with 1 study showing 
the opposite. Inhibition of miR-29c via ICV infusion of anti-miR 1 day pre-tMCAO 
in Sprague Dawley rats resulted in decreased infarct size (assessed by TTC 
staining), improved neurological score, increased Birc2 and Bak1 (anti-apoptotic) 
mRNA and protein expression and decreased apoptosis (Huang et al., 2015). 
Conversely, osmotic infusion of pre-miR-29c into the lateral ventricle of SHR rats 
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resulted in significantly reduced infarct volume (assessed by cresyl violet 
staining) (Pandi et al., 2013). Similarly, lentiviral mediated increased miR-29b 
expression in C57BL6/N mice resulted in reduced lesion volume (assessed by 
MRI), improved functional recovery and attenuated stroke-induced 
neurodegeneration, mediated in part by activity of the 12-lipoxygenase pathway 
(Khanna et al., 2013). Finally, lentiviral mediated increased miR-29b expression 
in CD-1 mice resulted in reduced infarct volume (assessed by cresyl violet 
staining), inhibited aquaporin 4 up-regulation, alleviated brain oedema and 
attenuated BBB breakdown (Wang et al., 2015). 
These conflicting studies investigating the effect of miR-124 and miR-29 
modulation on outcome from stroke are difficult to compare and to interpret as 
different stroke and animal models, delivery method and sacrifice time points 
have been used (see Table 1.4 for further details). It is interesting, however, 
that one miRNA or miRNA cluster can target so many different pathways in 
ischemic stroke and this demonstrates the huge therapeutic potential of miRNA 
modulation in the setting of experimental ischaemic stroke, if thoroughly 
investigated and carefully targeted. 
1.3 Exosomes 
The term extracellular vesicle, defined as a “membrane vesicle containing 
cytosol from the secreting cells enclosed in a lipid bilayer” (Colombo et al., 
2014), describes a number of different vesicles with a diverse range of origins, 
composition, function and size.  
The term exosome was first used for vesicles (40-100 nm) released from a 
number of different cultured cell types (Trams et al., 1981) but was 
subsequently used to describe vesicles of endosomal origin, secreted during 
reticulocyte differentiation (assessed  in in vitro cultures of sheep reticulocytes) 
as a result of the fusion of multivesicular bodies (MVBs) and the plasma 
membrane (Johnstone et al., 1987). 
Exosomes are defined primarily by their size and origin. They are lipid bilayer 
particles, released from cells and are generally agreed to be between 30-120 nm 
in diameter. Some studies have expanded the size range to include particles as 
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small as 20 nm and as wide as 150 nm in diameter (Ibrahim and Marbán, 2016). 
The terms ectosome, microparticle and microvesicle generally refer to much 
larger vesicles released by budding from the plasma membrane, between 150-
1000 nm in diameter. As exosomes (originally intraluminal endosomal vesicles) 
are secreted by the fusion of the endosome with the plasma membrane 
(resulting in release of exosomes into extracellular space) they contain markers 
of their biogenesis. Recently, the International Society for Extracellular Vesicles 
has provided criteria for the definition of exosomes (Lötvall et al., 2014). This 
includes the presence in exosome isolates of a number of “exosome enriched” 
proteins, including transmembrane or lipid-bound extracellular proteins (e.g. 
tetraspanins such as CD9, CD63) and cytosolic proteins with membrane or 
receptor binding capacity (e.g. endosome or membrane-binding proteins such as 
TSG101 and a number of annexins) (Figure 1.6). 
 
Figure 1.6 – Exosome Characteristics. 
Exosomes are small vesicles with a diameter range of 30-120 nm and are secreted by all cell 
types. The lipid bilayer is enriched in cholesterol, ceramide and phosphatidylserine and has 
a differing lipid content to that of the parent cell. Markers present in most exosomes include 
tetraspanins (CD9, CD63, CD81), heat shock proteins, adhesion molecules and markers of 
the endosomal sorting complexes required for transport (LAMP1, TSG101). This figure was 
reproduced with permission from (Ibrahim and Marbán, 2016). 
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Exosomes have now been shown to be released from cells of many different 
organisms and have been isolated from a varied range of bodily fluids, including 
blood, urine, saliva, breast milk, amniotic fluid, ascites, cerebrospinal fluid, bile 
and semen (Figure 1.6).  
1.3.1 Biogenesis 
Unlike microvesicles which are formed by the outward budding of the plasma 
membrane and apoptotic bodies which are shed from dying cells, exosomes are 
released as a result of the fusion of loaded multivesicular bodies (MVBs) with the 
plasma membrane. MVBs typically form via the endocytic pathway. Endosomes 
mature into late (vs. early) endosomes (Stoorvogel et al., 1991) and during this 
process intraluminal vesicles (ILVs) gather within the lumen, formed by inward 
budding of the endosomal membrane. ILVs may contain proteins, lipids and RNAs 
(Ibrahim and Marbán, 2016). MVBs will often be targeted for degradation and so 
fuse with lysosomes containing lysosomal hydrolases that degrade the content of 
the MVB. However, other MVBs are targeted for secretion and these fuse with 
the plasma membrane and release the ILVs, now called exosomes, into the 
extracellular space (Raposo et al., 1996). Microvesicles and apoptotic bodies 
have similar membrane lipid content to the plasma membrane of the cell they 
originate from while exosomes shed from MVBs are likely to have differential 
membrane lipid content to their cell of origin. 
It is now believed that there are multiple MVBs within each cell carrying 
differential markers that result in some being targeted for degradation and 
others being targeted for exocytosis – this targeting of MVBs remains poorly 
understood (Colombo et al., 2014). MVBs targeted for exocytosis are often 
cholesterol positive (Mobius et al., 2003), CD63 positive with an EGF-receptor 
(White et al., 2006) and CD9 positive (Buschow et al., 2009). MVBs targeted for 
degradation contain lysobisphosphatidic acid (White et al., 2006). 
The endosomal sorting complex required for transport (ESCRT) is partly 
responsible for processing within the endocytic pathway. ESCRT is made up of 
~30 proteins that assemble into four different complexes (ESCRT-0, -I, -II and –
III) with a number of associated proteins (e.g. VPS4, VTA1, ALIX and PDCD6IP) 
and is involved in endosome biogenesis and exosome release (Hanson and 
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Cashikar, 2012, Hurley and Hanson, 2010). It is likely that MVB and ILV formation 
(mediated ESCRT-dependently or independently) is related to the cargo sorted 
within each cell (Carayon et al., 2011). Exosome release also appears to be 
differentially regulated, both molecularly and mechanistically, depending on the 
cell type of origin. 
1.3.2 Targeting of Exosomes 
Exosomes are intercellular messengers and secreted exosomes from one cell can 
interact with recipient cells, resulting in functional changes. The specificity of 
these exosome-recipient cell interactions is conferred by surface ligands on both 
the exosome and the plasma membrane of the recipient cell. Examples in the 
literature include: ICAM-1 dendritic cell extracellular vesicles interact with LFA-
1 on dendritic cells (Segura et al., 2005); α2,3-sialic acid positive splenocyte 
extracellular vesicles interact with CD169+ (lectin receptor) macrophages in the 
spleen and lymph node (Saunderson et al., 2014); heparan sulfate proteoglycans 
on tumour cell extracellular vesicles increase cellular uptake into tumour cells 
(Christianson et al., 2013). However, many of these pairings are probably limited 
to specific exosomes from a certain cell type and a specific recipient cell type. 
Exosomes can mediate intercellular communication either with or without 
internalisation into their recipient cells. For example, exosomes bearing MHC 
peptide complexes can be ‘captured’ by dendritic cells, and the MHC peptide 
complexes presented to antigen-specific T-cells without the need for 
internalisation of the exosome or reprocessing (Denzer et al., 2000, Segura et 
al., 2007). However, many studies demonstrate internalisation of exosomes 
occurring by a variety of mechanisms, including (but not limited to): proteolytic 
cleavage of exosomes releasing soluble ligands, lipid membrane fusion, 
internalisation by receptor-mediated endocytosis or uptake by phagocytosis, 
pinocytosis or micropinocytosis (Ibrahim and Marbán, 2016). Larger extracellular 
vesicles (or aggregations of exosomes) are likely to induce phagocytosis whereas 
small exosomes can be internalised by non-phagocytic processes as have been 
described above (Colombo et al., 2014). Similarly to exosome-target 
interactions, the mechanism of uptake is likely to be specific to exosomes from a 
certain cell type and their recipient cells. 
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Membrane fusion of exosomes with either the plasma membrane or the 
endocytic compartment limiting membrane is essential for the release of the 
content of an exosome into the cytosol of a recipient cell. This has been 
demonstrated in three important studies. The addition of exosomes labelled 
with a fluorescent R18 lipid probe to recipient tumour and dendritic cells 
resulted in increased fluorescence in these cells – fusion of the exosome 
membrane with the membrane of the recipient cells was subsequently 
demonstrated (Montecalvo et al., 2012, Parolini et al., 2009). Furthermore, 
when dendritic cells (expressing luciferase) were incubated with luciferin-loaded 
exosomes, the release of internal exosome components into the cytosol of the 
recipient dendritic cells was demonstrated (Montecalvo et al., 2012). 
Interestingly, the content of the exosomes involved in dendritic cell intercellular 
communication included functionally active miRNAs. Finally, a recent study 
investigating anthrax toxin infection demonstrated that the lethal factor 
component of anthrax is contained in exosomes which are protected from 
proteolytic degradation for some time both in vitro and in vivo, before releasing 
the lethal factor into the cytosol by back fusion with the MVB limiting membrane 
(Abrami et al., 2013).  
Exosomes have been detected in a wide variety of biological fluids (see Figure 
1.6) but it is difficult to investigate their fate in vivo, following their secretion 
by a cell within an organ or artificial delivery of exosomes either systemically or 
to a specific organ. Exosomes detected in the blood can bear markers of 
endothelial and immune cells (both found in blood vessels) but also, for 
example, of distant tumours (in cancer patients) - exosomes can therefore travel 
through the endothelium into blood circulation. Initially it was believed that 
exosomes could remain stable in the blood for a significant amount of time but 
more recent studies have demonstrated a very short half-life of exosomes in 
blood following IV injection. Exosomes generated from B16-BL6 murine 
melanoma cells (luciferase labelled) were delivered intravenously to BALB/c 
mice. These exosomes had a half-life of approximately 2 minutes and 
disappeared quickly from blood circulation, distributing first to the liver and 
then to the lungs (preferred sites of metastasis) (Takahashi et al., 2013). A 
similar study isolated exosomes from C57BL/6 splenocytes and labelled them 
with biotin (Saunderson et al., 2014). Labelled exosomes were delivered IV and 
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were rapidly cleared from the blood of C57BL/6 mice, with a half-life of 
approximately 2 minutes (Saunderson et al., 2014). However, exosomes could 
still be detected in the spleen after 2 hours, suggesting that exosome reservoirs 
may still exist after the majority have been cleared from the circulation. These 
studies also highlight how exosomes of differing cellular origins target different 
organs in vivo, an important consideration when using exosomes therapeutically. 
Other studies have successfully demonstrated modification of exosomes to alter 
organ targeting, for example, exosomes generated from engineered dendritic 
cells expressing Lamp2b (an exosomal membrane protein) fused to the neuron-
specific RVG peptide, specifically delivered siRNA to neurons, microglia and 
oligodendrocytes in the brain when delivered IV to C57BL/6 mice (Alvarez-Erviti 
et al., 2011). A recent study has demonstrated that exosome dose, delivery 
method, cellular origin of exosomes and targeting of exosomes all affect bio-
distribution of exosomes in vivo (Wiklander et al., 2015). 
1.3.3 Exosomes and miRNA 
A breakthrough in exosome research came in 2007 when it was demonstrated, 
for the first time, that exosomes could carry nucleic acids (Valadi et al., 2007). 
In a seminal paper exosomes were demonstrated to contain both mRNA and 
miRNA which could be delivered to cells and act functionally. Following the 
delivery of mouse exosomes to human cells, mouse proteins were detected in 
the human cells, which had previously existed as mRNA in the mouse exosomes – 
data consistent with the hypothesis that mRNA shuttled in the mouse exosomes 
had been translated (Valadi et al., 2007). Subsequently miRNAs were also 
detected in vesicles isolated from plasma and glioblastoma tumour cells (Hunter 
et al., 2008, Skog et al., 2008). 
As a result of the fact that different miRNA sequences are preferentially 
secreted or retained within cells it is clear that exosomal miRNAs are not 
randomly secreted. Comparison of intracellular and extracellular miRNA shows 
specific miRNA sequences are selected for extracellular export (Montecalvo et 
al., 2012). Furthermore, miRNAs whose expression was increased in exosomes 
released from breast cancer cells were packaged differently to miRNAs whose 
expression was unaltered by malignancy (neutral miRNAs) (Palma et al., 2012). 
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Neutral miRNAs were packaged in much larger exosomes, enriched in CD44. The 
more complex mechanisms of RNA cargo selection are yet to be elucidated.  
There has been controversy over whether the majority of circulating miRNAs are 
found within exosomes or not. It was initially believed that the majority of 
miRNAs in human serum and plasma co-fractionated with Argonaute2 
ribonucleoprotein complexes (Arroyo et al., 2011) and that only a minority of 
specific miRNAs appeared to be associated with exosomes. It was subsequently 
shown that circulating miRNAs could form complexes with high-density 
lipoproteins (Vickers et al., 2011). However, there is now compelling evidence 
that miRNAs circulating in the serum exist primarily within exosomes (Gallo et 
al., 2012). Isolating exosomes from human serum was shown to increase the 
sensitivity of miRNA detection (Gallo et al., 2012). 
Within the brain it has been proposed that exosomal mediated miRNA release is 
a method of adjusting gene silencing levels, for example in synaptic plasticity 
(Goldie et al., 2014). Exosome mediated inter-cellular communication has also 
been demonstrated between primary cortical neurons and astrocytes in vitro 
resulting in alterations in target protein expression (Morel et al., 2013). 
Furthermore, administration of exosomes from young rats, enriched in miR-219, 
promoted myelination in older rats (Pusic and Kraig, 2014). 
Exosomal miRNAs have been shown to be involved in cancer (e.g. (Melo et al., 
2014))  and cardiovascular disease. Active transport of miRNAs in exosomes was 
demonstrated pre-clinically in atherosclerosis (Hergenreider et al., 2012). Cells 
transduced with KLF2 (Kruppel-like factor 2, a shear-response transcription 
factor) generated exosomes that were enriched in specific miRNAs, including the 
miR-143/145 cluster. These exosomes were shown to mediate a reduction in 
atherosclerotic lesion formation in ApoE-/- mice. Studies in cardiac hypertrophy 
demonstrated that fibroblasts secreted miR-21* enriched exosomes (Bang et al., 
2014a), unusual in that miRNA passenger (*) strands are conventionally believed 
to undergo intracellular degradation. miR-21* enriched exosomes were shown to 
mediate cardiomyocyte hypertrophy: their uptake through an endocytic pathway 
resulted in the down-regulation of several targets, which effectively triggered 
hypertrophy. Other studies have demonstrated the involvement of exosomal 
miRNAs in arrhythmia and cardiomyopathy (Ibrahim and Marbán, 2016).  
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1.3.4 Therapeutic Potential of Exosomes 
Exosomes have huge potential as vehicles for delivering therapeutic agents to 
the brain (Johnsen et al., 2014). Their small size means that they can cross the 
BBB (e.g. (Alvarez-Erviti et al., 2011). The use of  self-derived exosomes means 
that undesired immunogenicity is limited (if not absent), meaning exosomes are 
a very safe way to deliver therapeutic agents (Lakhal and Wood, 2011). 
Exosomes can also be modified to target certain organs or tissues, and so drug 
delivery can be very specific, even if administered intravenously. For example, 
exosomes engineered to express a peptide that specifically binds to the 
acetylcholine receptor, containing BACE1 siRNA significantly reduced BACE1 
expression in the brain of C57BL/6 mice following systemic administration 
(Alvarez-Erviti et al., 2011). Additionally, miRNAs can be rapidly degraded by 
RNases in the blood and so exosomes are an excellent tool to protect miRNAs 
and provide stability and to enable the delivery of intact miRNAs to target cells. 
However, the involvement of exosomes in health and disease is poorly 
understood. Important aspects of exosome biology, including the biogenesis, 
secretion, uptake and targeting of exosomes, are not yet fully established. 
Furthermore, exosomes can mediate the replication and propagation of 
transmissible pathogens. Exosomes are clearly a valuable tool for the delivery of 
therapeutic agents but must be used in a careful and controlled manner. 
1.3.5 Exosomes and Stroke 
To date very little has been published concerning exosomes in the setting of 
ischaemic stroke. Circulating miRNA expression was profiled in a small number 
of ischaemic stroke and ICH patients (Guo et al., 2013) in a study which went on 
to isolate CD63+ microvesicles by ultracentrifugation and to compare expression 
of 5 miRNAs between total plasma isolates and microvesicle isolates in healthy 
control and ICH patients. miRNAs-365, -27a, -150*, -34c-3p and -24 were not 
present in the plasma of healthy controls (n=3-4) but were detected in the 
plasma of ICH patients (n=3-5). Furthermore, microvesicle expression of these 
miRNAs was increased in ICH patients as compared to healthy controls, although 
no indication of the statistical significance of this increase is given. 
Unfortunately the patient populations used in this study were extremely small 
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and microvesicle miRNA expression was not investigated in the ischaemic stroke 
patient cohort. Despite these caveats this study is the first to demonstrate 
compartmentalisation of miRNAs in the setting of stroke. 
Total and exosomal circulating expression of miR-126 has been compared in 
transient and permanent in vivo models of ischemic stroke (Chen et al., 2015). 
Exosomes were isolated by precipitation. miR-126 was detected in both total and 
exosomal isolates harvested from the serum of Wistar rats following either 
tMCAO or pMCAO (n=27/group) or sham procedure (n=5) at 3 hours and 24 hours 
post-stroke. miR-126 exosomal expression was decreased at 3 hours following 
both tMCAO and pMCAO but normalised close to pre-ischemic baseline levels at 
24 hours. Total serum expression of miR-126 was decreased at 3 hours in the 
permanent model but not the transient and it is clear that serum miR-126 
expression was much more variable, consistent with more highly regulated 
exosomal miRNA expression. However, expression of miR-126 in sham operated 
animals is not shown making results harder to interpret. Serum but not exosomal 
miR-126 expression (at 3 hours) correlated significantly with infarct volume. 
Previous work within our own group (Breen, 2015) profiled expression of specific 
miRNAs (miR-19b, miR-93, miR-106a and miR-532) in the serum of SHRSP at 24 
and 72 hours post-tMCAO. The expression of several miRNAs was significantly up-
regulated at 24 hours (miR-19b, miR-532) and 72 hours (miR-532) post-tMCAO. 
However, the exosomal expression of a number of miRNAs was up-regulated at 
24 hours (miR-19b, miR-106a) and at 72 hours (miR-19b, miR-93, miR-106a) to a 
much greater extent than had been observed in the total serum analysis. 
Comparison of miRNA expression at specific time points would suggest that miRs 
-19b, -93 and -106a are compartmentalised within the exosomes. 
These studies suggest that circulating exosomes containing miRNAs are present 
in both human stroke patients and in in vivo pre-clinical models of ischaemic 
stroke. Further studies should be performed to elucidate the full extent of 
exosomal miRNA expression in ischaemic stroke patients and whether these 
exosomally packaged miRNAs have a functional role to play in ischaemic stroke. 
Two studies published by Michael Chopp’s research group have demonstrated the 
therapeutic use of exosomes in the setting of pre-clinical ischaemic stroke. The 
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first involved IV delivery of MSC exosomes to Wistar rats at 24 hours post-tMCAO 
(Xin et al., 2013a). MSCs were cultured from bone marrow harvested from 
healthy Wistar rats. Treatment with exosomes isolated from MSCs did not reduce 
lesion volume at 28 days post-stroke but did significantly improve functional 
outcome as assessed by foot fault test and neurological score. Furthermore, 
treatment with exosomes isolated from MSCs increased axonal density, 
synaptophysin staining (an indicator of synaptic plasticity) and appeared to 
promote neurogenesis and angiogenesis post-stroke (as assessed by increased 
Brd-U staining, a marker of cell proliferation, co-localised with markers for 
migrating neuroblasts or sprouting capillaries) within the ischaemic boundary 
zone (or penumbra) (Xin et al., 2013a). 
Subsequently MSCs were modified to have up-regulated or down-regulated miR-
133b expression (Xin et al., 2013b). These MSCs were shown to produce 
exosomes that were miR-133b+ or miR-133-. Similarly to their previous study 
Wistar rats were given miR-133b+, miR-133b- MSCs, naïve MSCs or PBS at 24 
hours post-tMCAO. All types of MSC improved functional recovery (assessed by 
adhesive-removal and foot fault test) at day 14 post-tMCAO. However, compared 
to naïve MSC treatment, miR-133b+ MSCs significantly improved and miR-133b- 
MSCs significantly decreased functional recovery. MSCs were (again) shown to 
improve angiogenesis and neurogenesis and the effect was enhanced with miR-
133b+ MSCs. In this study MSCs were also transfected with a plasmid containing a 
CD63-GFP fusion protein gene and rats were subsequently treated with these 
cells post-tMCAO. Exosomes released by MSCs (CD63-GFP+) were detected in 
adjacent astrocytes and neurons of the ischemic boundary zone demonstrating 
communication between MSCs and neural cells. These studies demonstrate the 
potential of using exosomes to modulate miRNA expression therapeutically in the 
setting of ischaemic stroke. 
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1.4 General Aims 
Ischaemic stroke is a devastating condition and remains a largely unmet clinical 
need, with only a limited percentage of stroke patients eligible to receive rt-PA 
or thrombectomy. Stroke is therefore a significant cause of death and disability 
worldwide. This thesis will investigate whether miRNAs (especially those 
packaged within exosomes) are dysregulated following ischaemic stroke and 
whether they can be modulated therapeutically to improve outcome. 
My hypothesis is that as miRNAs are modulated following ischaemic stroke and 
play a functional role in stroke pathophysiology, modulation of miR-494 and miR-
21 (dysregulated miRNAs) will be a novel therapy in pre-clinical experimental 
ischaemic stroke, resulting in inhibition of stroke pathophysiology and/or 
promotion of recovery. 
Furthermore, I hypothesise that the packaging of miRNAs into exosomes will be 
significantly dysregulated in human stroke patients and that as a result the 
circulating miRNA/exosome profile will be significantly altered. 
Specifically, the aims of this project include: 
1. To modulate specific miRNAs in in vitro models of ischaemia, namely 
hypoxia-reoxygenation injury, to assess resulting functional outcome and 
to determine regulation of gene targets by specific miRNAs. 
2. To characterise exosomal miRNA expression in the serum of a human 
ischaemic stroke patient population and identify miRNAs that are 
differentially regulated as a result of ischaemic stroke. 
3. To assess the use of exosomes as a method for the delivery of miRNA 
modulating agents and to modulate miRNA expression of specific miRNAs 
dysregulated in human ischaemic stroke patients, using exosomes, in in 
vitro and in vivo models of pre-clinical ischaemic stroke. 
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2.1 General laboratory practice 
Laboratory reagents and equipment were of the highest commercially available 
standard. Hazardous chemicals were handled and disposed of in compliance with 
Control of Substances Hazardous to Health (COSHH) guidelines. Laboratory coats, 
nitrile powder-free gloves and fume hoods were used where appropriate. 
2.2 Cell Culture 
All tissue culture was performed under sterile conditions in standard biological 
safety class II vertical laminar flow cabinets. Cabinets were cleaned with 1% 
Virkon and 70% ethanol before and after use. Cells were grown in humidified 
incubators at 37˚C in a 5% CO2 atmosphere. 
2.2.1 Maintenance of Established Cell Lines 
Cells were maintained with appropriate cell culture media (see Table 2.1) and 
grown in a monolayer, replenishing media between passages when necessary.  
Cells were passaged upon reaching 80% confluence using 0.05% (1X) trypsin-
ethylenediamine tetra-acetic acid (trypsin-EDTA; Gibco, Paisley, UK) with 
regular passaging preventing overgrowth and loss of surface contact.  Trypsin is 
a proteolytic enzyme that acts to disrupt proteins mediating cell-cell 
interactions and EDTA chelates divalent cations that act to strengthen these 
interactions. Cells were washed twice with Dulbecco’s Phosphate Buffered 
Saline, without calcium (Ca2+) or magnesium (Mg2+) (DPBS; Gibco, Paisley, UK) 
before 3-5 mL of trypsin-EDTA was added. Cells were incubated with trypsin-
EDTA at 37ºC for several minutes until the majority of adherent cells had 
detached from the surface of the flask and before cell death occurred. An equal 
volume of complete media (containing serum) was immediately added to 
prevent further trypsinisation. The cell suspension was centrifuged at 1500 rpm 
for 5 minutes to remove remaining trypsin-EDTA and the cell pellet resuspended 
in complete media.  When necessary a haemocytometer was used to count cells 
to allow for the accurate seeding of cells to a specific seeding density. 
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Table 2.1 - Details of the cell lines used and their culture medium. 
All media and supplements obtained from Gibco®, Paisley, UK or Sigma-Aldrich®, Irvine, UK.. 
Cell Type Description Cell Culture Medium 
B50 
Immortalised 
rat neuronal 
cells from a 
neuroblastoma 
Dulbecco’s Modified Eagle Medium (DMEM): low glucose (1g/L), sodium pyruvate [without L-glutamine, 
Phenol Red, HEPES] supplemented with 10% (v/v) Heat Inactivated Fetal Bovine Serum (FBS), 1% (v/v) 
penicillin (100 units/mL), 100 µg/mL streptomycin and 2 mM L-Glutamine. 
B92 
Immortalised 
rat glial cells 
from a 
neuroblastoma 
Dulbecco’s Modified Eagle Medium (DMEM): low glucose (1g/L), L-glutamine, sodium pyruvate and phenol 
red [without HEPES] supplemented with 10% (v/v) Heat Inactivated Fetal Bovine Serum (FBS), 1% (v/v) 
penicillin (100 units/mL), 100 µg/mL streptomycin and 2 mM L-Glutamine. 
GPNT 
Immortalised 
rat cerebral 
endothelial 
(vascular) cells 
Ham’s F-10 Nutrient Mix: L-Glutamine and Phenol Red [without HEPES] supplemented with 10% (v/v) Heat 
Inactivated Fetal Bovine Serum (FBS), 1% (v/v) penicillin (100 units/mL), 100 µg/mL streptomycin, 2 mM L-
Glutamine, 2 ng/mL basic fibroblast growth factor (bFGF) and 80 µg/mL heparin. 
 
N.B. All plasticware used for the culture of GPNT cells was pre-coated for 5 hours (minimum) with 10 
µg/cm2 collagen (Type I solution from rat tail). Plasticware was rinsed twice with DPBS before use. 
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Cells were checked visually for bacterial or fungal infection on a daily basis. 
Cells used throughout the laboratory were tested for mycoplasma infection on a 
regular basis by laboratory technicians using qRT-PCR (LookOut® mycoplasma 
qPCR detection kit, Sigma-Aldrich). 
2.2.2 Modulation of microRNAs in vitro 
2.2.2.1 Modulation of microRNAs via Transfection Agent 
GPNT cells were transfected with miR-21 and miR-494 miRNA mimics and anti-
miRs using siPORT™ NeoFX™ Transfection Agent (Invitrogen). To investigate the 
effect of modulating miRNA expression cells were seeded in 12 well plates at 5 x 
104 cells/well (if harvesting RNA) and in 6 well plates at 1 x 105 cells/well (if 
harvesting protein) and in 96 well plates at 2 x 103 cells/well (if using cells for 
MTS assay). 
When modulating miR-21 expression, cells were transfected on Day 1 following 
seeding on Day 0 (see Figure 2.1, A and B). When transfecting cells in a 12 well 
plate, miRNA mimics and anti-miRs (and their scrambled controls) were diluted 
appropriately with OPTI-MEM® Reduced Serum Medium (Invitrogen) to make a 
total volume of 50 µL. Similarly siPORT™ NeoFX™ Transfection Agent (Invitrogen) 
was diluted with OPTI-MEM® to a total volume of 50 µL (3µL siPORT™ NeoFX™ + 
47 µL OPTI-MEM® = 50 µL). The diluted miRNAs and siPORT™ NeoFX™ were mixed 
and allowed to incubate for 10 minutes at room temperature before the 
complete solution (100 µL) was added to 900 µL of fresh media to give a final 
concentration of 30 nM for mature miRNA mimics (and controls) and 100 nM for 
anti-miRs (and controls). When transfecting a 96 well plate 0.5 µL of siPORT was 
added to 9.5 µL OPTI-MEM®, added to 10 µL diluted miR and delivered into 80 µL 
of fresh media.  When transfecting a 6 well plate 5 µL of siPORT was added to 95 
µL OPTI-MEM®, added to 100 µL diluted miR and delivered into 1.8 mL of fresh 
media. 
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Figure 2.1 – Protocol for transfecting cells with miRNA mimics and anti-miRs. 
This diagram illustrates the protocol for delivering mature miRNA mimics and anti-miRs (A) to GPNT cells and a more complicated protocol (B) to be used 
when limited effect of transfection with the anti-miR alone is observed, and the conditions/controls used in each experiment (B and D).
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When optimising a protocol to modulate miR-494 expression, limited down-
regulation of miRNA expression was observed following transfection with miR-
494 anti-miR. To overcome this hurdle, cells were transfected with mature 
miRNA mimics, anti-miRs or their respective controls over 2 days following 
seeding, as illustrated in Figure 2.1 (C and D).  On the first day following seeding 
cells were transfected with mature miRNA mimics and their controls and on the 
second day with a repeated delivery of the mature miRNA mimic, followed by 
delivery of the anti-miR. miRNA mimics and anti-miRs were delivered using 
siPORT™ NeoFX™ Transfection Agent as described above. Cells were allowed to 
rest for 48 hours following transfection before being subjected to hypoxic 
challenge. 
Pre-miR™ miRNA Precursor rno-miR-21-3p, Pre-miR™ miRNA Precursor rno-miR-
494-3p and their control Cy™3 dye-labelled Pre-miR™ Negative Control #1 and 
miRVana® miRNA Inhibitor rno-miR-21-3p, miRVana® miRNA Inhibitor rno-miR-
494-3p and its control miRVana™ miRNA Inhibitor Negative Control #1 were 
purchased from Invitrogen and made up to a stock concentration of 30 µM. 
2.2.2.2 Modulation of microRNAs via miRNA Loaded Exosomes 
To investigate the effect on miRNA expression of delivering exosomes loaded 
with miRNAs of interest, B50 cells were grown in 12 well plates and miRNA 
loaded exosomes were delivered both pre- and post-hypoxia. 
When investigating pre-hypoxic challenge delivery, B50 cells were seeded at 5 x 
104 cells/well on Day 0 and 875 ng of either naïve exosomes, miR-20b loaded 
exosomes or miR-93 loaded exosomes were delivered directly to the cell culture 
medium on Day 1.  The cells were subject to hypoxic challenge on Day 2 and 
harvested for RNA on Day 3 (Figure 2.2, A and B).   
When investigating post-hypoxic challenge delivery, B50 cells were seeded on 
Day 0 at 2.5 x 104 cells/well.  Cells were subject to a 9 hour hypoxic challenge 
on Day 2 and immediately following reoxygenation, 875ng of either naïve 
exosomes, miR-20b loaded exosomes or miR-93 loaded exosomes were delivered 
directly to the cell culture media.  The cells were harvested for RNA on Day 4.  
The protocol is illustrated in Figure 2.2 (C and D).  
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Figure 2.2 – Protocol for delivering miRNA loaded exosomes to B50 neuronal cells. 
This diagram illustrates the protocol for delivering miRNA loaded exosomes pre-hypoxia (A) and post-hypoxia (C) and the number and nature of the 
conditions and controls used in each experiment (B and D).
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2.2.3 Hypoxic Challenge 
Cells (in cell culture plates) were washed once with DPBS before an appropriate 
volume of serum free media was added. The cell culture plate was placed inside 
the hypoxic chamber (Modular Incubator Chamber Mic-101, Bilrups-Rothenberg) 
which was subsequently semi-sealed. The hypoxic chamber was perfused with 
gas (1% O2, 5% CO2 and balance N2) at a rate of 20 L/minute for 4 minutes, 
ensuring all atmospheric air had been flushed out of the chamber. The hypoxic 
chamber was then completely sealed before being placed in a 37ºC incubator for 
9 hours. Typically, cells were removed from the chamber and serum free media 
replaced with complete media, before being left for 24 hours of reoxygenation, 
after which the cells were harvested or processed for subsequent analysis. 
2.2.4 Harvesting of Cells 
When harvesting RNA, the cells were washed twice with DPBS before 700 µL (per 
well) of QIAzol Lysis Reagent (Qiagen, Manchester, UK) was added. Adherent 
cells were gently rubbed away from the surface of the cell culture plate using 
the rubber end of a sterile 1 mL syringe plunger. The lysed cell suspension was 
transferred to a 1.5 mL eppendorf and placed on dry ice until transferred to a -
80ºC freezer for long term storage. 
When harvesting protein, cells were washed twice with DPBS before 500 µL (per 
well) of Radio-Immunoprecipitation Assay buffer (RIPA; 20 mM Tris pH 7.5, 150 
mM NaCl, 2.5 mM sodium pyrophosphate, 1 mM EDTA, 1 mM ethylene glycol 
tetraacetic acid (EGTA), 1 mM β-glycerophosphate, 1 mM sodium orthovanadate, 
1mM phenylmethylsulfonyl fluorid (PMSF), 1 µg/mL leupeptin, 1% (v/v) Triton-X-
100) was added. A smaller volume of RIPA buffer was added when a more 
concentrated protein sample was required. RIPA buffer efficiently lyses cells and 
solubilises proteins but does not degrade proteins or interfere with their 
biological activity. 
2.2.5 Cryo-Preservation and Recovery of Cultured Cell Lines 
To harvest cells for cryo-preservation, cells were trypsinised and centrifuged as 
described in section 2.2.1.  The cell pellet was then resuspended in 2 mL 
complete media supplemented with 10% (v/v) dimethyl sulphoxide (DMSO; 
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Thermo Scientific™). The cell suspension was aliquoted (1 mL per aliquot) into a 
cryo-preservation vial and cooled at a constant -1ºC / minute to -80ºC using a Mr 
Frosty™ Freezing Container (Thermo Scientific™) containing isopropanol. Frozen 
cells were stored indefinitely in liquid nitrogen. 
To recover cryo-preserved cells, frozen vials were removed from liquid nitrogen 
and rapidly thawed, before 10 mL of pre-warmed (to 37ºC) complete media was 
added slowly, allowing for a gradual change in the osmotic gradient. Cells were 
centrifuged at 1500 rpm for 5 minutes to remove any remaining DMSO, the cell 
pellet was resuspended in complete media and the total volume added to a T-75 
cm3 cell culture flask. 
2.3 Functional In Vitro Assays 
2.3.1 Western Blotting 
Early in the presented study (Chapter 3) western blots were carried out on cell 
lysates to detect changes in the expression of cellular proteins such as 
phosphatase and tensin homolog (PTEN). The antibodies used are summarised in 
Table 2.2. 
2.3.1.1 Quantification of Protein Concentration 
The protein concentration of each individual cell lysate was determined using a 
Pierce BCA Protein Assay Reagent (Thermo Scientific) with reference to a 
standard curve generated using bovine serum albumin (BSA). Clear 96 well plates 
containing protein samples mixed with BCA Protein Assay Reagent were left to 
incubate for 30 minutes at 37ºC before they were read using a 
spectrophotometer at an absorbance of 562 nm.  
2.3.1.2 Western Blots with ECL detection 
Protein lysates were denatured using a sample denaturation buffer (62.5 mM Tris 
[pH 6.8], 2% (w/v) sodium dodecyl sulfate (SDS), 10% (v/v) glycerol, 1.25% (v/v) 
β-mercaptoethanol and 0.01% (w/v) bromophenol blue), which induced a 
negative charge on the protein via the association of SDS which promoted the 
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migration of the protein towards the anode. The solution was heated in either a 
heat block or a thermal cycler to 95˚C for 5 minutes. 
GPNT cell protein lysates (3.9 – 12.1 µg, maximum protein concentration 
possible) were loaded onto precast gels (4-20% Mini-Protean® TGX™ Precast Gels, 
10 well, 30µL/well; Bio-Rad) and separated and resolved by SDS – polyacrylamide 
gel electrophoresis (SDS-PAGE) at 200 V. A ladder of molecular weight markers 
(Amersham ECL Rainbow Molecular Weight Markers, GE Healthcare Life Sciences) 
was used as a reference for the proteins detected. 
Proteins were transferred overnight (at 4˚C) to a 0.45 µM (pore size) 
polyvinylidene difluoride (PVDF) membrane (Amersham Hybond™-P, GE 
Healthcare Life Sciences) using a wet transfer system. Transfer buffer was made 
up to a final concentration of 0.25 M Tris, 1.92 M Glycine, 1% (w/v) SDS and 20% 
(v/v) methanol. When protein transfer was completed, membranes were blocked 
by incubation in either 10% (w/v) non-fat milk (Marvel) or 10% (w/v) BSA, if 
investigating the activity of phosphorylated proteins, for 6-8 hours at room 
temperature, with agitation. 
After removal of the blocking agent the primary antibody (made up in 5% BSA in 
1 X TBS) was added and left to incubate overnight at 4˚C. The membrane was 
then washed 6 times with Tris buffered saline containing 0.1% tween-20 (1 X 
TBS-T) for 10 minutes. When investigating phosphorylated protein expression, 
the initial 4 washes were with 5% (w/v) BSA made up in 1 X TBS-T. 
Appropriate horse radish peroxidase (HRP) coupled secondary antibodies (made 
up in 5% (w/v) BSA in 1 X TBS) were then added and left to incubate for 1 – 1.5 
hours at room temperature with agitation. Polyclonal swine anti-rabbit 
immunoglobulins HRP coupled secondary antibody (DAKO) was diluted at 1:2000 
in 5% (w/v) BSA (in 1 X TBS-T) and incubated with the membrane for 1 - 1.5 
hours. Washes (as above) were repeated and the membrane was then developed 
using Amersham™ ECL™ Western Analysis System (GE Healthcare Life Sciences) 
according to the manufacturer’s instructions. 
Western blots were then scanned using a ChemiDoc™ XRS+ System (Bio-Rad) and 
quantified using Quantity One® 4.6.8. software using the “Volume” function. 
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Table 2.2 – Antibodies used for Western Blot. 
This table summarises the antibodies used, their antibody type, their product number, the 
company they were purchased from and the dilution they were used at in this study. 
Antibody Antibody 
Type 
Company Product 
No. 
Dilution 
Used 
PTEN Rabbit 
Monoclonal 
Cell Signalling #9559 1:1000 
Phospho-PTEN 
(Ser380/Thr382/383) 
Rabbit 
Polyclonal 
Cell Signalling #9554 1:1000 
Akt Rabbit 
Polyclonal 
Cell Signalling #9272 1:1000 
Phospho-Akt (Ser473) Rabbit 
Polyclonal 
Cell Signalling #9271 1:1000 
GAPDH Rabbit 
Monoclonal 
Cell Signalling #2118 1:1000 
 
2.3.2 Gelatin Zymography 
GPNT cell protein lysates were re-suspended in 1 X Zymogram Sample Buffer 
without reducing agent (62.5 mM Tris-HCl [pH 6.8], 25% (v/v) glycerol, 4% (w/v) 
SDS, 0.01% (w/v) Bromophenol Blue; Bio-Rad). 1.7 – 3.5 µg of protein lysate 
(maximum concentration possible) was loaded onto precast gels (Ready Gel® 10% 
Zymogram Gel, Bio-Rad) and separated and resolved by electrophoresis at 100 V.  
A ladder of molecular weight markers (Amersham ECL Rainbow Molecular Weight 
Markers, GE Healthcare Life Sciences) was used as a reference for the proteins 
detected. 
Following electrophoresis the gel was re-natured by incubation with 2.5% Triton 
X-100 (1 X Renaturation Buffer; Bio-Rad) for 30 minutes at room temperature, 
with gentle agitation. Subsequently the gel was incubated in a development 
buffer containing 50 mM Tris-HCl [pH 7.5], 200 mM NaCl and 5 mM CaCl2 (1 X 
Development Buffer; Bio-Rad) for 36-48 hours at 37˚C. Gels were then stained by 
incubation (with agitation) for 1 hour at room temperature with 0.5% (w/v) 
Coomassie Blue made up in 10% (v/v) acetic acid and 40% (v/v) methanol. Gels 
were later repeatedly washed with de-staining solution (10% (v/v) acetic acid 
and 40% (v/v) methanol) until clear bands appeared on the blue background. 
Typically 1 hour of washes were required. 
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Zymogram gels were then scanned using a ChemiDoc™ XRS+ System (Bio-Rad) and 
quantified using Quantity One® 4.6.8. software using the “Volume” function – 
this expresses results in arbitrary units as a sum of the intensities of the pixels 
within the volume boundary area multiplied by the pixel area. 
2.3.3 MTS Assay 
To assess cell viability post-transfection with miRNAs, a CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (Promega) was used. GPNT cells were cultured 
in 96 well plates, transfected with miRNA mimics or anti-miRS and subjected to 
hypoxic challenge as described in sections 2.2.2.1 and 2.2.3. 
24 hours after reoxygenation (following hypoxic challenge or control normoxic 
conditions) the cells were washed twice with DPBS and 100 µL of fresh media 
was then added to each well. 20 µL of CellTiter 96® AQueous One Solution 
Reagent was then added directly to each well. This was carried out in a 
darkened tissue culture hood, due to the light sensitive nature of the solution. 
Adding 20µL of reagent gave a final concentration of 333µg/mL MTS (3-(4,5-
dimethylthiazol-2-yl)–5-(3-carboxymethoxyphenyl)–2-(4-sulfophenyl)-2H-
tetrazolium) and 25 µM phenazine methosulfate (PMS). 
The cells were subsequently incubated for 1-3 hours at 37˚C in a humidified, 5% 
CO2 atmosphere. Viable cells were able to bio-reduce MTS into a formazan 
product, soluble in tissue culture medium, which caused a colourimetric change 
in the cell culture media.  The absorbance was recorded every 30 minutes at 490 
nm using a SpectraMax M2 plate reader (Molecular Devices) until the assay 
reached maximum sensitivity. The quantity of formazan product produced as 
measured by absorbance at 490 nm was taken to be directly proportional to the 
number of viable, living cells in cell culture. Absorbance was also measured in a 
well containing media and MTS reagent, but no cells, to measure background 
absorbance. 
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2.4 General Molecular Biology Techniques 
2.4.1 RNA Extraction 
Throughout this study RNA was extracted from cells, tissue, serum and exosomes 
using the Qiagen miRNeasy Micro Kit (Qiagen, Crawley, UK). RNA extractions 
were performed in a standard biological safety class II vertical laminar flow 
cabinet to prevent exposure to toxic phenol fumes. 
Cells were vortexed with 700 µL QIAzol lysis reagent to homogenise the sample.  
Tissue samples, stored at -80˚C, were cut on dry ice (to approximately 50 mg) to 
prevent degradation of RNA at room temperature, before being placed into 700 
µL QIAzol reagent and being homogenised using a Qiagen TissueLyser (at 25 Hz, 
for 30 seconds, repeated 2 times). When isolating RNA from serum samples, 1000 
µL of QIAzol was added to 200 µL total serum and homogenised by a brief vortex. 
When isolating RNA from exosomes, the exosome pellet was resuspended in 100 
µL DPBS before 700 µL of QIAzol was added and the sample vortexed.  To release 
all of the RNA contained in a sample it was important that plasma membranes of 
cells and organelles were completely disrupted and so thorough homogenisation 
of samples was vital. 
Following the addition of QIAzol and homogenisation the sample was incubated 
at room temperature for 5 minutes to promote the dissociation of nucleoprotein 
complexes. 140 µL of chloroform (200 µL for serum samples) was then added to 
the sample and vortexed for 15 seconds to ensure thorough mixing, important 
for phase separation. The sample was subsequently centrifuged at 12,000 x g for 
15 minutes at 4˚C. Following centrifugation a clear separation of sample was 
visible: a pink organic phase, a white interphase and an upper colourless 
aqueous phase which contained the RNA. The upper aqueous phase was 
transferred to a new collection tube using a Gilson pipette before approximately 
1.5 X volume of 100% ethanol was added, typically around 600 µL (900 µL for 
serum samples). This was mixed thoroughly by pipetting up and down. 
700 µL of the ethanol/sample mix was then added to a RNeasy Mini spin column 
in a collection tube and centrifuged at 10,000 x g for 30 seconds at room 
temperature to allow the RNA to bind to the silica membrane of the spin 
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column. The flow through was discarded and the step was repeated with any 
remaining sample. The column was washed to remove any impurities, using two 
buffers supplied with the kit. Initially 700 µL RWT Buffer was added to the 
column and centrifuged briefly and the flow through discarded. RPE Buffer (500 
µL) was added and the column centrifuged (repeated once) before the column 
was spun at 16,000 x g for 1 minute to dry the spin column membrane, ensuring 
no ethanol was carried over during RNA elution as this can interfere with 
downstream analysis of RNA expression. 
Finally the RNeasy Mini spin column was transferred to a new 1.5 mL RNase-free 
eppendorf. An appropriate volume of RNase-free water (typically 30-50 µL) was 
then pipetted directly on to the spin column membrane and left for 1 minute 
before being centrifuged for 1 minute at 10,000 x g to elute the RNA. The eluate 
was then pipetted back onto the spin column membrane and centrifuged again 
to give a higher yield of RNA. The spin column was discarded and RNA stored at -
80˚C until used. 
The concentration and quality of each RNA sample was determined by taking an 
average of 2 readings using a NanoDrop™ (ND-1000 spectrophotometer; Thermo 
Scientific). 
2.4.1.1 DNase Treatment of RNA 
When extracting RNA from cells or tissue, samples were treated with DNase to 
remove contaminating genomic DNA – this is important when using the RNA in 
applications sensitive to very small amounts of genomic DNA including reverse 
transcription polymerase chain reaction (RT-PCR). This step was not performed 
when extracting RNA from serum or exosomes. 
To DNase treat the RNA, after the addition of 350µL RWT buffer (usually 700µL) 
and centrifugation at 10,000 x g for 30 seconds, 80 µL of DNase (made up in RDD 
Buffer according to manufacturer’s instructions) was pipetted directly onto the 
spin column membrane and left at room temperature for 15 minutes. 
Subsequently a further 350 µL of RWT Buffer was added and the spin column 
centrifuged again at 10,000 x g for 30 seconds. The remaining part of the RNA 
extraction protocol was carried out as described in section 2.4.1. 
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2.4.2 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
2.4.2.1 RT-PCR for Investigating microRNA Expression 
Reverse transcription reactions were performed for each specific miRNA of 
interest and for a control miRNA, to allow for normalisation of the data 
generated. When investigating miRNA expression in rat tissue (in vivo or in vitro) 
U87 was used as a control and when investigating miRNA expression in serum or 
exosomes, samples were spiked with a known amount of C. elegans miRNA-39.  
To create cDNA for miRNA analysis the Taqman® microRNA Reverse 
Transcription Kit (Life Technologies) was used. A single reaction contained 1 mM 
of each dNTP, 3.33 U/µL Multiscribe™ Reverse Transcriptase, 1 X Reverse 
Transcription Buffer, 0.25 U/µL RNase Inhibitor (provided with the kit), 1 X 
TaqMan® microRNA Reverse Transcription primer (Life Technologies) and a total 
of 5 ng RNA. Nuclease-free water was added to make a reaction volume of 7.5 
µL. Non-template controls (NTC) were used for each specific miRNA primer - 
nuclease-free water was added in the place of RNA. Reverse transcription was 
carried out using a thermal cycler (PTC-225, MJ Research): 16ºC for 30 minutes 
(this allows for the binding of the miRNA primer), 42ºC for 30 minutes (this is 
when reverse transcription takes place) and 85ºC for 5 minutes (to inactivate the 
reverse transcription enzyme). cDNA samples were stored at -20ºC until used. 
2.4.2.2 RT-PCR for Investigating Gene Expression 
To create cDNA for gene analysis the TaqMan Reverse Transcription Reagents kit 
(Life Technologies) was used. A single reaction contained 1 X Reverse 
Transcription Buffer, 5.5 mM MgCl2, 0.5 mM of each dNTP, 2.5 µM random 
hexamers, 0.4 U/µL RNase Inhibitor and 1.25 U/µL Multiscribe™ Reverse 
Transcriptase and between 200-1000 ng of total RNA (this was kept consistent 
within experiments).  Nuclease-free water was added to make a reaction volume 
of 20 µL. Non-template controls (NTC) were used in which nuclease-free water 
was added in the place of RNA. Reverse transcription was carried out using a 
thermal cycler (PTC-225, MJ Research): 25ºC for 10 minutes (this allows for the 
annealing of primers), 48ºC for 30 minutes (when reverse transcription takes 
place) and 95ºC for 5 minutes (to inactivate the reverse transcriptase enzyme). 
When the reaction had completed each sample was diluted by the addition of 30 
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µL nuclease-free water, this did not significantly affect gene expression levels 
but ensured plenty of cDNA was available for future experiments. Samples were 
then stored at -20ºC until used. 
2.4.3 qRT-PCR 
TaqMan® qRT-PCR was used to quantify the expression of specific mRNAs and 
miRNAs within cells, tissue, serum and exosomes. To measure the expression of 
a specific mRNAs/miRNAs, fluorescent signal, produced proportionally during the 
amplification of cDNA was measured. 
Each TaqMan® qRT-PCR assay is labelled with a fluorescent reporter dye (5’ end, 
e.g. VIC or FAM) and a quencher molecule (3’ end). During amplification, if the 
target mRNA/miRNA sequence is present the TaqMan probe binds and anneals 
and Taq DNA polymerase (within the reaction mix) degrades the TaqMan® probe, 
resulting in the cleavage the quencher molecule from the probe. This allows the 
fluorescent reporter dye to be detected. If a TaqMan® probe binds to a target 
sequence, the amount of fluorescence produced in each amplification cycle is 
proportional to the amount each specific mRNA/miRNA is amplified each cycle. 
Conversely, if the target mRNA/miRNA sequence is not present, the TaqMan 
probe does not bind and so remains intact, meaning any fluorescence released 
from the reporter dye is transferred to the quencher molecule, and no 
fluorescence is detected - this is known as fluorescence resonance energy 
transfer (FRET). 
The fluorescence of miRNA/genes of interest was normalised to that of control 
(‘housekeeper’) miRNA/genes, which were chosen for their relatively stable 
expression throughout a particular set of samples, allowing for the comparison of 
expression levels between all samples. 
To investigate miRNA expression TaqMan® miRNA RT-PCR probes were used (see 
Table 2.3). Each reaction was made up of 1 X TaqMan® Universal PCR Master Mix 
II (no UNG), 1 X TaqMan® miRNA qRT-PCR probe and nuclease-free water was 
added to make a total volume of 9.3 µL, to which was added 0.7 µL of cDNA 
produced at the miRNA RT-PCR step (see section 2.4.2.1). 
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To investigate mRNA expression TaqMan® Gene Expression assays were used (see 
Table 2.4). Each reaction was made up of 1 X TaqMan® Universal PCR Master Mix 
II (no UNG), 1 X TaqMan® Gene Expression probe and nuclease-free water was 
added to make a total volume of 8.5 µL, to which was added 1.5 µL of diluted 
cDNA produced at the mRNA RT-PCR step (see section 2.4.2.2).  
Experiments were performed in 384-well plates using an ABI Prism 7900HT 
Sequence Detection System (Applied Biosystems). The reaction was initiated by 
heating the sample mixture to 95ºC for 10 minutes (denaturation) which was 
followed by 40 cycles of 95ºC for 15 seconds (further denaturation) and 60ºC for 
60 seconds (primer and probe annealing and primer extension). 
Data were collected when PCR amplification was in the exponential phase and 
analysed using the ΔΔCt method (Livak and Schmittgen, 2001). The cycle 
threshold (Ct) of a particular sample is the number of amplification cycles 
required for the fluorescence dye emissions to reach a specific level. The data 
are normalised by calculating the ΔCt, the difference between the Ct of the 
miRNA or gene of interest and the Ct of the control (housekeeper) miRNA or 
gene. The mean ΔCt of a number of biological replicates for the same 
mRNA/miRNA was then calculated.  ΔΔCt was subsequently calculated using the 
following equation: 
∆∆𝐶𝑡 =  ∆𝐶𝑡 (𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒𝑠) −  ∆𝐶𝑡 (𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑜𝑟 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑠𝑎𝑚𝑝𝑙𝑒𝑠) 
Relative quantification (RQ), which is essentially the fold increase or decrease in 
miRNA/mRNA expression between a group of treated samples and the control 
samples, is calculated using the following equation: 
𝑅𝑄 = 2−∆∆𝐶𝑡 
RQ of a specific miRNA/mRNA is always given relative to the expression in the 
control group, whose expression is always given as 1. qRT-PCR analysis was 
performed using Microsoft Excel and GraphPad Prism. 
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Table 2.3 – List of miRNA TaqMan® assays used in this study. 
The table also gives details of their miRBase Identifier (accession number) and their 
respective assay IDs (as used by Life Technologies). 
Assay Name miRNA miRBase 
Identifier 
Assay ID 
cel-miR-39 cel-miR-39-3p MIMAT0000010 000200 
hsa-let-7e hsa-let-7e-5p MIMAT0000066 002406 
hsa-miR-17 hsa-miR-17-5p MIMAT0000070 002308 
hsa-miR-20b hsa-miR-20b-5p MIMAT0001413 001014 
hsa-miR-27b hsa-miR-27b-3p MIMAT0000419 000409 
hsa-miR-29b hsa-miR-29b-3p MIMAT0000100 000413 
hsa-miR-30a-5p hsa-miR-30a-5p MIMAT0000087 000417 
hsa-miR-31 hsa-miR-31-5p MIMAT0000089 002279 
hsa-miR-32 hsa-miR-32-5p MIMAT0000090 002109 
hsa-miR-34b hsa-miR-34b-5p MIMAT0000685 000427 
hsa-miR-93 hsa-miR-93-5p MIMAT0000093 001090 
hsa-miR-199a-3p hsa-miR-199a-3p MIMAT0000232 002304 
hsa-miR-206 hsa-miR-206 MIMAT0000462 000510 
hsa-miR-218 hsa-miR-218-5p MIMAT0000275 000521 
hsa-miR-223* hsa-miR-223-5p MIMAT0004570 002098 
hsa-miR-323-3p hsa-miR-323a-3p MIMAT0000755 002227 
hsa-miR-376a hsa-miR-376a-3p MIMAT0000729 000565 
hsa-miR-451 hsa-miR-451a MI0001729 001141 
hsa-miR-454 hsa-miR-454-3p MIMAT0003885 002323 
hsa-miR-520b hsa-miR-520b MIMAT0002843 001116 
hsa-miR-549 hsa-miR-549a MIMAT0003333 001511 
hsa-miR-660 hsa-miR-660-5p MIMAT0003338 001515 
hsa-miR-1291 hsa-miR-1291 MIMAT0005881 002838 
rno-miR-21 rno-miR-21-5p MIMAT0000076 000397 
rno-miR-494 rno-miR-494-3p MIMAT0003193 462468_mat 
U87 U87 NCBI Accession: 
AF272707 
001712 
 
 
Table 2.4 – List of mRNA TaqMan® assays used in this study. 
The table also gives details of their respective Assay IDs (as used by Life Technologies). 
Gene Name Assay ID 
UBC Rn01789812_g1 
GAPDH Rn01482168_m1 
β-ACT Rn01447976_m1 
18S Rn03928990_g1 
B2M Rn00560865_m1 
MMP2 Rn01538170_m1 
MMP9 Rn00579162_m1 
PTEN Rn01538170_m1 
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2.4.4 DNA Extraction/Purification 
DNA was extracted using a PureLink® Genomic DNA Mini Kit (Invitrogen). Ear 
clips from miR-21+/- and miR-21-/- mice pups were placed in an eppendorf and 
immersed in a mixture of 180 µL PureLink Genomic Digestion Buffer and 20 µL 
Proteinase K. The eppendorf containing the ear clip and digestion buffer was 
incubated at 55˚C in a water bath for a minimum of 4 hours, typically overnight.  
The eppendorf was vortexed to ensure complete lysis and then centrifuged at 
16,000 x g for 3 minutes at room temperature to remove any particulate 
materials. The supernatant was then transferred to a fresh, sterile eppendorf. 
20 µL RNase A was added to the lysate, to remove transcript copies from the 
sample, which was subsequently vortexed and incubated at room temperature 
for 2 minutes. 200 µL PureLink Genomic Lysis/Binding Buffer was added and the 
solution vortexed. This was followed by the addition of 200 µL 100% ethanol and 
further vortexing to precipitate the DNA. 
The complete lysate, approximately 640 µL, was added to a PureLink Spin 
Column sitting in a collection tube, and the column was centrifuged for 1 minute 
at 10,000 x g, to allow the sample to bind to the membrane. The collection tube 
with the flow through was discarded and the spin column placed in a fresh 
collection tube. Next the sample was washed with buffers supplied with the 
extraction kit to remove impurities: 500 µL Wash Buffer 1 was added to the 
column and the column centrifuged at 10,000 x g for 1 minute. The collection 
tube with the flow through was again discarded and the spin column placed in a 
fresh collection tube, to which was added 500 µL Wash Buffer 2. The column was 
centrifuged at 16,000 x g for 3 minutes, before being placed in a 1.5 mL 
eppendorf, and the previous collection tube discarded. Finally, 30 µL PureLink 
Genomic Elution buffer was added to the column which was then incubated for 1 
minute at room temperature before being centrifuged at 16,000 x g for 1 
minute. The resulting eluate contained genomic DNA and was re-added to the 
spin column and centrifuged again at 16,000 x g for 1.5 minutes to give a higher 
yield of genomic DNA. The spin column was then discarded and the DNA stored 
at -20˚C until needed for further experiments. 
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2.4.5 Genotyping of Transgenic Animals 
2.4.5.1 Genotyping of miR-21-/- Mice 
PCR was carried out using primers specific for the miR-21 region of the genome 
(Forward: 5’-GGG CGT CGA CCC GGC TTT AAC AGG TG-3’ and Reverse: 5’-GGG 
CGT CGA CGA TAC TGC TGC TGT TAC CAA G-3’; Eurofins MWG Operon). 
A master mix was prepared for each PCR reaction, comprised of 5 µL 5 X Green 
GoTaq® Flexi Buffer, 3 µL 25 mM MgCl2 solution, 0.5 µL 10 mM PCR nucleotide 
mix, 1 µL 10 µM forward primer, 1 µL 10 µM reverse primer, 0.125 µL GoTaq® 
DNA Polymerase (5U/µL) and 12.88 µL nuclease free water. To this was added 
1.5 µL of 20 ng/µL DNA making a solution that contained 1 X Green GoTaq® Flexi 
Buffer, 3 mM MgCl2 solution, 0.2 mM of each dNTP, 0.4 µM forward primer, 0.4 
µM reverse primer and 0.625 U GoTaq® DNA polymerase. Aside from the primers, 
all components for the master mix were purchased from Promega. 
To amplify the transcript of interest, the sample was heated to at 95˚C for 2 
minutes, followed by 35 cycles of 95˚C for 15 seconds, 62.3˚C for 35 seconds, 
72˚C for 30 seconds. A final cycle of 72˚C for 5 minutes completed the PCR. If 
not being used immediately PCR products were stored at -20˚C. 
PCR product was subsequently loaded into a 2% agarose gel containing ethidium 
bromide and run at 100 V for approximately 30 minutes. They were then 
visualised using a ChemiDoc™ XRS+ System (Bio-Rad). Genotype was determined 
by the size of specific bands on the gel: the knock-out allele band was at 330 bp 
and the wild type allele band at 469 bp, see Figure 2.3. 
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Figure 2.3 – Genotyping of miR-21
-/-
 Mice. 
Lane 1: 100 bp ladder. Lane 2: control sample (PCR master mix, no DNA). Lane 3: 469 bp 
band is visible indicating a WT mouse. Lane 4: 330 bp band is visible indicating a miR-21
-/-
 
(knockout) mouse. Lane 5: 469 bp band is visible indicating a WT mouse. 
2.4.5.2 Genotyping of miR-21+/- Mice 
PCR was carried out using primers specific for a GFP tag (Forward: 5’-TCT TCT 
TCA AGG ACG ACG GCA ACT-3’ and Reverse: 5’-TGT GGC GGA TCT TGA AGT TCA 
CCT-3’; Eurofins MWG Operon). 
A master mix was prepared for each PCR reaction, comprised of 5 µL 5 X Green 
GoTaq® Flexi Buffer, 2 µL 25 mM MgCl2 solution, 1 µL 10 mM dNTPs, 1 µL 10 µM 
forward and reverse primer mix, 0.25 µL GoTaq® DNA Polymerase (5U/µL) and 
14.75 µL nuclease free water. To this was added 1 µL of 20ng/µL DNA making a 
solution that contained 1 X Green GoTaq® Flexi Buffer, 2 mM MgCl2 solution, 0.4 
mM of each dNTP, 0.4 µM forward primer, 0.4 µM reverse primer and 1.25 U 
GoTaq® DNA polymerase. Aside from the primers, all components for the master 
mix were purchased from Promega. 
To amplify the transcript of interest, the sample was heated to at 95˚C for 2 
minutes, followed by 32 cycles of 95˚C for 30 seconds, 60˚C for 30 seconds, 
72˚C for 60 seconds. A final cycle of 72˚C for 5 minutes completed the PCR.  If 
not being used immediately the PCR products were stored at -20˚C. 
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PCR product was loaded into a 2% agarose gel containing ethidium bromide and 
run at 100 V for approximately 30 minutes. They were then visualised using a 
ChemiDoc™ XRS+ System (Bio-Rad). Genotype was determined by the presence of 
a specific band on the gel, the 216bp GFP band (see Figure 2.4). 
 
Figure 2.4 – Genotyping of miR-21
+/-
 Mice. 
Lane 1: 100 bp ladder. Lane 2: control sample (PCR master mix, no DNA). Lane 3: 216 bp 
GFP band is visible indicating a heterozygous miR-21
+/- 
mouse. Lane 4: 216 bp GFP band is 
not visible indicating WT mouse.  
2.5 Working with Exosomes 
2.5.1 Exosome Isolation 
2.5.1.1 Exosome Isolation from Serum 
Exosomes were isolated from both human and rat serum using Total Exosome 
Isolation Reagent (from serum) (Invitrogen). Serum samples were thawed at 
room temperature and placed on wet ice until needed. The samples were then 
centrifuged for 30 minutes at 2,000 x g at 4˚C to remove any remaining cellular 
debris. 200 µL of supernatant was removed without disturbing the pellet and 
transferred to a fresh eppendorf. To this 40 µL of Total Exosome Isolation 
Reagent was added and the mixture vortexed until homogenous before being 
incubated at 4˚C for 30 minutes to precipitate exosomes. The mixture was 
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subsequently centrifuged for 10 minutes at 10,000 x g at room temperature. The 
supernatant was removed by pipette and the remaining exosome pellet was 
gently resuspended in 100 µL of DPBS and vortexed before being stored at 4˚C 
(short-term) or -80˚C (long-term). 
2.5.1.2 Exosome Isolation from Cell Culture Media 
Exosomes in this study were isolated from cell culture media by ultra-
centrifugation. Cells were grown in 6 well plates. After initial seeding (Day 0) 
cells were incubated as normal (see section 2.2) until hypoxic challenge (Day 2). 
After cells were subjected to 9 hours of hypoxic or normoxic conditions media 
was collected and replaced with fresh cell culture media. Subsequently, cell 
culture media was collected (Day 3) prior to the cells being harvested, 24 hours 
post-reoxygenation. In total, for each biological ‘n’, approximately 24 mL of 
‘normoxic’ media was collected and 18 mL of ‘hypoxic’ media. 
To isolate exosomes from cell culture media, the media was filtered through a 
0.22 µM syringe filter (Minisart® NML 16534K, cellulose acetate membrane; 
Sartorius) into Ultra-Clear™ Tubes (Thinwall, 17 mL, 16 x 102 mm; Beckman 
Coulter) before being ultra-centrifuged at 25.4 k rpm (~82,000 x g) for 2 hours at 
4˚C (SW 32.1 Ti rotor, Optima™ L-80 XP Ultracentrifuge; Beckman Coulter). The 
supernatant was poured off and the tubes inverted on to tissue paper to drain.  
The exosome pellets (usually not visible) in each tube were resuspended in 1 mL 
DPBS (or more if required) and all samples were then pooled into 1 Ultra-Clear™ 
Tube before being ultra-centrifuged again at 25.4 k rpm for 1.5 hours at 4˚C.  
The supernatant was again poured off and the tube inverted on top off tissue 
paper before the final exosome pellet was resuspended in a small volume of 
DPBS (typically 300 – 500 µL) and stored at -80˚C until used. 
2.5.1.3 Exosome Isolation from Brain Tissue 
The protocol for isolating exosomes from brain tissue was optimised for use in 
our laboratory by Dr. Emily Ord and was developed using the protocol published 
by Perez-Gonzalez and colleagues (Perez-Gonzalez et al., 2012). Typically, 
exosomes were isolated from 6 brain hemispheres at one time. Initially, each 
brain hemisphere was incubated in 20 U/mL Papain (Sigma-Aldrich) made up in 3 
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mL of Hibernate®-E Medium (Gibco) for 15 minutes at 37˚C. Papain is a cysteine 
protease with wide specificity and is used here as it is more efficient and less 
destructive than other proteases and so suitable for the isolation of exosomes. 
Hibernate®-E Medium is a basal nutrient media (serum free) used for the short-
term maintenance of brain tissue. 
The brain hemispheres were subsequently removed from the Papain solution and 
placed into fresh 15 mL falcon tubes containing 6 mL ice-cold Hibernate®-E 
solution before the brain tissue was gently homogenised using a 5 mL syringe and 
serially smaller needle gauges (18G, 19G, 21G, 23G and 25G). Once fully 
homogenised a further 1 volume of ice-cold Hibernate®-E was added to the brain 
homogenate, which was homogenised again if required. The brain homogenate 
was filtered using a Falcon® 40 µM Cell Strainer (Corning) into a petri dish. The 
filtrate was then transferred into numerous 2 mL eppendorfs. The petri dish was 
washed with Hibernate®-E to make sure no sample was wasted and added to 
further 2 mL eppendorfs. The aliquoted filtrate was then centrifuged at 2,000 x 
g for 30 minutes at 4˚C to remove cellular debris. The supernatant was removed 
and placed in fresh 2 mL eppendorfs before being centrifuged at 12,000 x g for 
45 minutes at 4˚C. Subsequently, the supernatant was filtered through a 0.22 µM 
syringe filter (Minisart® NML 16534K, cellulose acetate membrane; Sartorius)  
into an Ultra-Clear™ Tube (Thinwall, 17 mL, 16 x 102 mm; Beckman Coulter) 
before being ultra-centrifuged at 25.4 k rpm for 2 hours at 4˚C (SW 32.1 Ti 
rotor, Optima™ L-80 XP Ultracentrifuge; Beckman Coulter). The supernatant was 
poured off and the tubes inverted on to tissue paper to drain. The exosome 
pellets (usually visible) in each tube were resuspended in 1 mL DPBS (or more if 
required) and all samples were then pooled into 1 Ultra-Clear™ Tube before 
being ultra-centrifuged again at 25.4 k rpm for 1.5 hours at 4˚C. The 
supernatant was again poured off and the tube inverted on top off tissue paper 
before the final exosome pellet was resuspended in a small volume of DPBS 
(typically 300 – 500 µL) and stored at -80˚C until used. 
2.5.2 NanoSight 
Exosomes were visualised and their concentration quantified using Nanoparticle 
Tracking Analysis (NTA) on a NanoSight LM10 (Malvern). Approximately 500 µL of 
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diluted exosome sample (1:100 or 1:1000 in DPBS) was injected into the LM10 
Viewing Unit using a syringe. The viewing unit was then placed onto the 
microscope stage, the laser was turned on and the stage adjusted until a clear 
view of the particles present in the solution was obtained, using a 20 X 
magnification microscope (with camera attached). The laser beam passing 
through the sample chamber illuminated particles in the path of the beam. Once 
a clear image could be seen through the microscope oculars, the image was 
diverted to the camera. The position and focus were adjusted as needed and a 
60 second movie recorded, recording the particles moving under Brownian 
motion. NTA software tracked the movement of individual particles and 
calculated their hydrodynamic diameter using the Stokes-Einstein equation. A 
minimum of 3 recordings were taken for each sample and a representative 
recording picked. The operator was blinded to the sample name and subtype to 
prevent systematic bias in the selection of representative recordings.   
2.5.3 Loading of microRNA into exosomes 
The protocol for synthetically loading miRNA into exosomes was optimised by Dr. 
Emily Ord and based on a previously published protocol (El-Andaloussi et al., 
2012). To load miRNAs into exosomes, miRNA mimic was mixed in an equal ratio 
with exosomes and electroporated using Geneflow Electroporation Cuvettes 
(Sterile, 1mm electrode, Red Cap; Geneflow) and a Bio-Rad MicroPulser™ 
Electroporator. 
Initially the concentration of an exosome sample was calculated by BCA assay 
and exosomes diluted to a concentration of 0.56 µg/µL in 50 mM Trehalose 
(Sigma-Aldrich). Subsequently an equal volume (to the diluted exosome sample) 
of 0.56 µg/µL miRNA mimic was made up in 50 mM Trehalose. These were mixed 
together and left on wet ice for 45 minutes. Trehalose was used to prevent the 
exosomes aggregating, ensuring efficient transfer of miRNA to exosome. 
Subsequently 125 µL of exosome/miRNA mimic mixture was added to an 
electroporation cuvette and given a 400 V pulse using a Bio-Rad MicroPulser™ 
Electroporator. Immediately following the electroporation pulse 875 µL of ice 
cold 1% (w/v) BSA (Sigma-Aldrich) was added to the cuvette and mixed by 
pipetting. The complete sample was then transferred to a falcon tube sitting in 
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wet ice. Once the complete amount of exosome/miRNA mixture had been 
electroporated it was left on ice for approximately 30 minutes. 
The electroporated exosome mixture was then transferred into an Ultra-Clear™ 
Tube (Thinwall, 17 mL, 16 x 102 mm; Beckman Coulter) before being ultra-
centrifuged at 25.4 k rpm for 1.5 hours at 4˚C (SW 32.1 Ti rotor, Optima™ L-80 
XP Ultracentrifuge; Beckman Coulter). The supernatant was poured off and the 
tubes inverted on to tissue paper to drain. The electroporated exosome pellet 
(usually visible) was resuspended in 1 mL DPBS (or more if required) and ultra-
centrifuged again at 25.4 k rpm for 1.5 hours at 4˚C. The supernatant was again 
poured off and the tube inverted on top off tissue paper before the final 
exosome pellet was resuspended in a small volume (100 – 300 µL) of sterile DPBS 
(if being used in vitro) or sterile 0.9% (w/v) sodium chloride (Baxter, Newbury, 
UK) (if being used in vivo) and stored at -80˚C until used. 
2.6 Human Patient Exosomal miRNA Study 
2.6.1 Patient Recruitment 
This study was approved by the Scotland A Research Ethics Committee 
(reference number: 11/SS/0077) and all patients involved gave informed, 
written consent. Between the 31st January 2012 and 19th August 2014 217 
patients were recruited at the Acute Stroke Unit, Western Infirmary, Glasgow. 
Patients presenting at the Western Infirmary with stroke-like symptoms were 
referred to the Acute Stroke Unit where they were assessed by stroke-specialist 
clinicians and subsequently re-assessed at 48 hours, 7 days, 1 month and 3 
months post-presentation.   
Initially a detailed cardiovascular patient history was taken, prescription 
medication recorded and a medical examination performed. Diagnosis was aided 
by one or several of the following investigations: CT scan, MRI scan, Carotid 
Doppler ultrasound, angiography, echocardiogram, electrocardiogram and 
cardiac monitor. Patients were then officially diagnosed as having a definite 
ischaemic stroke, a possible ischaemic stroke or as a non-stroke patient. Non-
stroke patients usually presented with symptoms of stroke but were 
subsequently given a differential diagnosis: for example, severe migraine. 
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Definite stroke patients were classified according to TOAST criteria (Adams et 
al., 1993) which categorises patients according to their stroke pathophysiology, 
as having a stroke as a result of large artery atherosclerosis, a cardioembolism, a 
small vessel occlusion or a stroke with an unknown aetiology. 
At each visit stroke severity was assessed using the 42-point NIHSS, and at 1 and 
3 months post-stroke outcome from stroke was assessed using mRS (a measure of 
disability), the Barthel Index (assesses performance in activities of daily living) 
and the Stroke Impact Scale (a measure of how stroke has affected quality of life 
for the patient). 
After initial recruitment at the Western Infirmary a number of patients withdrew 
their consent. For a further number of patients there was an insufficient volume 
of serum harvested or remaining and so in the present study serum samples from 
173 patients were used. In the OpenArray exosomal miRNA expression was 
profiled in 39 patients: of which there were non-stroke (n=10), large artery 
(n=9), cardioembolic (n=10) and small vessel (n=10) patients. Expression of 
carefully selected miRNAs was validated by qRT-PCR in a larger population of 
173 patients: of which there were non-stroke (n=34) and stroke (n=139) patients.  
In the stroke patient population there were large artery (n=22), cardioembolic 
(n=40), small vessel (n=37) and unclassified (n=40) patients. 
2.6.2 Sample Collection 
Peripheral blood samples were collected when patients presented at the 
Western Infirmary, and subsequently at 48 hours, 7 days, 1 month and 3 months 
post-stroke or presentation at the Acute Stroke Unit, in the case of non-stroke 
patients.  In this study blood samples collected at 48 hours post-incident onset 
were used. To isolate serum, blood samples were allowed to clot for 20 minutes 
and then were centrifuged at 3,000 x g for 15 minutes. The isolated serum was 
aliquoted and stored at -80˚C until used.   
2.6.3 miRNA OpenArray 
In this study miRNA expression was profiled in exosomes isolated from the serum 
of human patients. Exosomes were isolated as described in section 2.5.1 and 
resuspended in 100 µL PBS. Total RNA was extracted from the exosome 
89 
 
suspension using a miRNeasy Micro Kit (as described in section 2.4.1). The 
OpenArray experiment consisted of reverse transcription of RNA, pre-
amplification of cDNA, and qRT-PCR on the OpenArray panel. A diagram 
summarising the OpenArray workflow is shown in Figure 2.5. 
2.6.3.1 Reverse Transcription 
cDNA was synthesised from total exosomal RNA harvested from serum of human 
patients using the TaqMan® MicroRNA Reverse Transcription Kit (Applied 
Biosystems). As a result of low RNA yield from the exosomes isolated from serum 
an optimised low sample input protocol was used (Life Technologies, 2011). 
For each sample, cDNA was synthesised for two pre-defined pools of different 
miRNAs (Pool A or Pool B; 750 miRNA in total with 375 covered by each primer 
pool) – this allowed for the simultaneous reverse transcription of hundreds of 
miRNAs and endogenous controls. A total of 9.9 ng RNA was loaded into each 
reaction (3.3 µL of RNA at 3 ng/µL). Each reaction was also spiked with 2.5 ng of 
an exogenous spike-in control (Arabidopsis thaliana: ath-miR-159a). In summary, 
each reaction was made up of 1 X Megaplex™ RT Primers (Pool A or Pool B), 1 X 
dNTPs with a dTTP Inhibitor (29 U/µL), Multiscribe™ Reverse Transcriptase (10 
U/µL), 1 X Reverse Transcription Buffer, 3 mM MgCl2, RNase Inhibitor (0.25 U/µL) 
to which was added 2.5 ng of ath-miR-159a and a total of 9.9 ng exosomal RNA, 
all made up to a total volume of 7.5 µL with nuclease-free water. 
Reverse transcription was performed in a 96 well plate and underwent 
sequential incubation in a thermal cycler: 16˚C for 2 minutes, 40˚C for 1 minute 
and 50˚C for 1 second (repeated for another 39 cycles) followed by an 
incubation at 85˚C for 5 minutes to complete the thermal cycling. cDNA was 
stored at -20˚C until pre-amplification was performed. 
2.6.3.2 Pre-Amplification of cDNA 
cDNA synthesised by RT-PCR was pre-amplified using TaqMan® PreAmp Master 
Mix and Megaplex™ PreAmp Primer Mix (Pool A or Pool B). Each reaction 
contained 1 X TaqMan® PreAmp Master Mix, 1 X Megaplex™ PreAmp Primer Mix, 
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the complete volume of cDNA synthesised previously (7.5 µL) and nuclease-free 
water to make a total volume of 40 µL. 
Pre-amplification was performed in a 96 well plate which underwent sequential 
incubation: at 95˚C for 10 minutes, 55˚C for 2 minutes, 72˚C for 2 minutes, 
[95˚C for 15 seconds and 60˚C for 4 minutes, repeated for another 15 cycles] 
followed by an incubation at 99.9˚C for 10 minutes. 
Each reaction was then diluted 1:20 using 0.1 X Tris-EDTA (TE) buffer, to make a 
total volume of 60 µL. The diluted pre-amplified cDNA was then stored at -20˚C 
until the OpenArray® experiment was performed. The diluted pre-amplified 
cDNA is only stable for 10-14 days following pre-amplification and so the 
OpenArray® experiments were completed in a timely fashion. 
2.6.3.3 OpenArray® 
The OpenArray® experiment was run using TaqMan® OpenArray® Human 
MicroRNA Panels. To load samples onto the OpenArray® panels, 12.5 µL of 
diluted (Pool A or Pool B) pre-amplified sample was first added to 36.75 µL of 
TaqMan® OpenArray® Real-Time PCR Master Mix, making a total volume of 49.25 
µL. 5 µL of this was transferred (by pipetting) into one well in an OpenArray® 
384-Well Sample Plate. This was repeated a further 7 times, making a total of 8 
wells each containing 5 µL of a particular sample (either Pool A or Pool B). 
Samples were subsequently loaded (from each 384-Well Sample Plate) onto a 
TaqMan® OpenArray® Human MicroRNA Panel using a QuantStudio™ 12K Flex 
AccuFill™ System. To prevent systematic bias as a result of card data generation, 
samples from each stroke subtype were randomised across 13 TaqMan® 
OpenArray® Human MicroRNA Panels. Loaded MicroRNA panels were then loaded 
into an OpenArray® Real-Time PCR instrument and panels underwent thermal 
cycling at 50˚C for 2 minutes, 95˚C for 10 minutes and (95˚C for 15 seconds and 
60˚C for 1 minute, repeated for another 39 cycles). 
 
 
9
1
 
 
Figure 2.5 – OpenArray Workflow 
This diagram summarises steps in the OpenArray workflow including reverse transcription of total RNA, the pre-amplification of cDNA and qRT-PCR 
performed on OpenArray™ MicroRNA Panels. In the reverse transcription step, cDNA was synthesised for two pre-defined pools of different miRNAs (Pool 
A or Pool B, 375 miRNAs in each primer pool) allowing for simultaneous reverse transcription of hundreds of miRNAs. This figure was adapted from 
information provided by Life Technologies. 
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2.6.3.4 OpenArray® Data Analysis 
Data generated was analysed using DataAssist™ software. Data was normalised to 
the exogenous spike-in control (ath-miR-159a) and ∆Ct values calculated and 
compared to non-stroke patient (control) values. Results for each individual 
miRNA were analysed using a two-tailed, Student’s unpaired t-test. 
2.6.4 OpenArray Validation by qRT-PCR 
The expression of 13 miRNAs, detected as being differentially expressed by the 
OpenArray, was validated by qRT-PCR in a larger patient population. If possible 
all miRNAs whose expression was identified as being significantly changed by 
OpenArray would have been validated by qRT-PCR in the larger patient 
population. However, budget constraints meant that only 13 miRNAs could be 
validated in this way. miRNAs whose expression was determined to be 
significantly dysregulated by t-test (either in stroke vs. non-stroke or stroke 
subtype vs. non-stroke) were prioritised as were those miRNAs whose expression 
appeared to be ‘turned on’ in ischaemic stroke patients. Finally, those miRNAs 
whose expression appeared to be ‘turned off’ in all stroke subtypes or in small 
vessel disease stroke patients were taken forward for validation in the larger 
patient population. miRNAs altered in small vessel disease patients were 
prioritised over those ‘turned off’ in large artery and cardioembolic disease 
patients as small vessel disease stroke was hypothesised to be biologically and 
phenotypically quite different to large vessel and cardioembolic stroke. 
2.6.4.1 Reverse Transcription 
RNA was extracted from exosomes isolated from serum, as described earlier. 
RNA concentration and purity was determined and RNA diluted to a 
concentration of 2 ng/µL. 
cDNA was synthesised by RT-PCR from the total RNA of isolated exosomes using 
the TaqMan® MicroRNA Reverse Transcription Kit. Each reaction contained 1 mM 
dNTPs, 3.33 U/µL Multiscribe™ Reverse Transcriptase, 1 X Reverse Transcription 
Buffer, 0.25 U/µL RNase Inhibitor, 1 X Reverse Transcription Buffer, 5 ng 
C.Elegans miR-39 (exogenous spike-in control) and 5 ng of sample RNA. RT-PCR 
was performed in 96 well plates and samples under sequential incubation: 16˚C 
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for 30 minutes, 42˚C for 30 minutes and 85˚C for 5 minutes. cDNA was stored at 
-20˚C until pre-amplification was performed. To control for the presence of 
contaminating RNA, a PCR-only experiment was carried out using otherwise 
identical conditions without input template RNA. 
2.6.4.2 Pre-Amplification of cDNA 
cDNA synthesised by RT-PCR was pre-amplified using TaqMan® PreAmp Master 
Mix. A pooled assay mix was created by mixing TaqMan® probes for 14 miRNAs of 
interest: C.Elegans miR-39, hsa-miR-27b, mmu-miR-93, hsa-miR-520b, hsa-miR-
660, hsa-miR-20b, hsa-miR-30a-5p, hsa-miR-218, hsa-miR-17, hsa-miR-199a-3p, 
hsa-miR-223#, hsa-miR-376a, hsa-miR-549, hsa-let-7e. TaqMan® probes were 
mixed, giving a final concentration of 0.2 X for each probe. 
Each pre-amplification reaction contained 1 X TaqMan® PreAmp Master Mix, 0.05 
X pooled assay mix and 8.25 ng cDNA, made up to a total volume of 50 µL using 
nuclease free water. Reactions underwent sequential incubation in a 96 well 
plate at 95˚C for 10 minutes, followed by 95˚for 15 seconds and 60˚C for 4 
minutes, repeated for another 13 cycles. The pre-amplified cDNA product was 
then diluted 1:5 with 1 X TE buffer. Diluted pre-amplified cDNA was stored at -
20°C until qRT-PCR was performed. 
2.6.4.3 qRT-PCR 
To profile miRNA expression qRT-PCR was performed using TaqMan® miRNA RT-
PCR probes. Each reaction contained 1 x TaqMan® Universal PCR Master Mix II 
(no UNG), 1 X TaqMan® miRNA RT-PCR probe and nuclease-water added to make 
a total volume of 8 µL to which was added 2 µL of diluted pre-amplified cDNA.  
Duplicate reactions were run for each sample on a 384-well plate which was 
incubated as previously described in section 2.4.3. 
2.6.4.4 Statistical Analysis 
Data generated in the OpenArray Validation study were analysed as previously 
described in section 2.4.3. Data were normalised to the expression of the 
exogenous spike-in control: C.Elegans miR-39. RQ values were compared to the 
values for non-stroke patients. Results were analysed using a one-way-ANOVA 
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with post-hoc Dunnett’s test. Statistical significance was taken at p<0.05. 
Statistics were calculated using GraphPad Prism. 
2.7 In Vivo Methods 
All animals were housed in controlled environmental conditions: ambient 
temperatures (20 - 26˚C) and humidity (40 - 70%) were maintained along with 
alternating 12 hour light and dark cycles. All animals were kept in standard 
polycarbonate cages in small groups of two to three and were fed ad libitum 
standard rat chow (rat and mouse No. 1 maintenance diet, Special Diet Services, 
UK) and untreated water. Work with experimental animals was in accordance 
with the Animal Scientific Procedures Act 1986 under the project licence held by 
Dr Delyth Graham, PPL 60/4286. All studies were approved by the University of 
Glasgow’s Ethics Review Committee. 
2.7.1 Animal Models 
An inbred colony of stroke-prone spontaneously hypertensive rats (SHRSP) was 
maintained “in-house” by brother – sister mating. Lab microsatellite screening 
was carried out routinely to confirm the homozygosity of all loci within a random 
group from the colony. SHRSP demonstrate several physiological markers of 
cardiovascular disease, including hypertension, altered glucose handling and 
increased basal inflammatory status and are therefore comorbid and so are ideal 
candidates for modelling clinical stroke. 
Transgenic mice were used in studies investigating the effect of miR-21 
expression in vivo.  Adult male miR-21-/- mice, with a mixed genetic background 
of S129/C57, and their WT littermates, were used to investigate the effect of 
knock-out of miR-21 expression. The mice were obtained by the University of 
Glasgow in collaboration with Professor Rhonda Bassel-Duby and Ms Cheryl Nolen 
(Olson Laboratory, UT Southwestern Medical Center, TX, USA). A local colony 
was set up at the University of Glasgow and animals were bred in house and 
males placed on procedure when they weighed 25-30 g. PCR of the miR-21 
flanking region confirmed the genotype (see section 2.4.5.1). 
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Adult male miR-21+/- mice, with a B6/C3/F1 background, and their WT 
littermates, were used to investigate the effect of over-expression of miR-21.  
The mice were originally obtained by the University of Glasgow in collaboration 
with Dr Mark Hatley (St Jude Children’s Research Hospital, Memphis, TN, USA).  
A colony was set up at the University of Glasgow and mice for these studies were 
bred in house and males used for experimental procedure when they weighed 
25-30 g. PCR of GFP determined whether the mouse was heterozygous for the 
transgene (see section 2.4.5.2). 
2.7.2 Preparation of animals for surgery 
To prepare for any aseptic animal surgery, the operating table and surrounding 
area was initially disinfected using chlorhexidine solution before being covered 
with sterile drapes. All surgical instruments were autoclaved and instruments 
were also sterilised between surgeries to ensure every animal was operated on 
using sterile surgical instruments. Sterilised instruments were only placed within 
the sterile area of the table. Consumables used such as swabs, needles and 
suture materials, were sterile and only used within their stated expiry dates. 
The surgeon wore a sterile gown and sterile gloves. 
Anaesthesia in SHRSP rats was induced in a Perspex chamber using 1.5 L/min 
100% oxygen and 5% isoflurane. When the rat was sufficiently anaesthetised 
(typically after several minutes) an intubation tube (16-guage cannula) was 
inserted into the trachea, using a metal guide wire. To ensure sufficient 
visibility the mouth was held open using a plastic speculum and a surgical lamp 
was used to illuminate the throat and therefore the oesophageal-tracheal 
junction. SHRSP animals were artificially ventilated throughout experimental 
procedures: 0.3 L/min 100% oxygen, 2.5 mL stroke volume at 65 beats/minute 
(Harvard Model 683, Small Animal Ventilator; Harvard Apparatus, Cambridge, 
UK). Isoflurane levels were monitored throughout the duration of experimental 
procedures to maintain an appropriate depth of anaesthesia (typically ~3%). 
During surgical procedures a rectal probe (VetTech Solutions Ltd, UK) was used 
to monitor body temperature and a heat lamp was used to keep temperature 
within appropriate physiological limits (37.5˚C ± 1˚C).  
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2.7.3 Cranial Burrhole 
To improve survival in SHRSP rats following 45 minute tMCAO surgery, pre-stroke 
cranial burrhole surgery was carried out 4 or 5 days prior to stroke surgery. A 
previous study carried out within our group (Ord et al., 2012) has demonstrated 
that pre-stroke general anaesthesia combined with cranial burrhole surgery 
improved survival and reduced the weight loss associated with tMCAO surgery, 
whilst not affecting systolic blood pressure, infarct volumes or neurological 
deficit. This is therefore an important methodological refinement for the tMCAO 
procedure, especially when it is carried out in SHRSP, an animal model that has 
many co-morbidities associated with clinical stroke. 
SHRSP rats were anesthetised, intubated and ventilated as previously described 
(section 2.7.2). Animals were then placed in the prone position in a stereotaxic 
frame (Ultra Precise Lab Standard Stereotaxic Frame for Rat; Stoelting, Dublin, 
Ireland) and positioned carefully, as illustrated in Figure 2.6. The head was 
secured in place using stereotaxic ear bars. The skin covering the skull was first 
shaved before being disinfected using chlorhexidine solution. 
 
Figure 2.6 – Cranial burrhole surgery. 
Photographs illustrating surgical set-up for pre-stroke cranial burrhole surgery. SHRSP rat 
is intubated, artificially ventilated and positioned in stereotaxic frame. Sutured incision 
above the skull is visible. 
When the head was secure and the skin disinfected, a small incision was made in 
skin above the skull and the superficial fascia gently rubbed away using sterile 
cotton buds. Small retractors were used when necessary to keep the surgical 
area clear. A 1mm diameter burrhole was drilled (Tech 2000 Handpiece, 
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Microtorque Control Box; Ram Products, Dayton, NJ, USA). The dura was then 
pierced using a 24G Hamilton syringe needle. The burrhole was later sealed 
using dental cement (Prontolute; Wright Cotterell, UK). The procedure typically 
lasted about 30 minutes, not exceeding 40 minutes at any time. 
To recover the animal, the isoflurane supply was turned off but mechanical 
ventilation with 100% oxygen at 0.3 L/min was maintained until independent 
breathing was observable.  After the animal reached full consciousness it was 
moved to a recovery room where it was checked regularly. 
2.7.4 Transient Middle Cerebral Artery Occlusion (tMCAO) 
SHRSP rats were anesthetised as previously described (section 2.7.2). 
Intraluminal filaments (Doccol Corporation, CA, USA) were used to occlude the 
origin of the middle cerebral artery (MCA) inducing experimental stroke, a 
modified version of the protocol first described in 1989 (Longa et al., 1989) 
(illustrated in Figure 2.7). Throughout the surgery an operating microscope 
(M651, Leica Microsytems, UK) was used. 
Initially, an area on the neck was shaved, and the area disinfected with 
chlorhexidine solution before a midline neck incision was made, and 
subcutaneous fatty tissue dissected. The left common carotid artery (CCA) was 
exposed and two retractors placed between the digastric, sternomastoid and 
sternohyoid muscles to keep the CCA visible. The CCA was exposed at the point 
of its bifurcation into the internal and external carotid arteries. The CCA was 
occluded – a ligature made of 5/0 silk suture (Sofsilk; Covidien, UK) was used to 
tie a square knot. The occipital artery was electrocoagulated using bayonet 
pointed tip bipolar forceps (Eschmann, Lancing, UK). The external carotid artery 
(ECA) was then temporarily ligated and a loose suture loop was tied around the 
internal carotid artery (ICA) and tension was applied. The pterygopalatine artery 
(PPA) was also temporarily ligated to ensure the intraluminal filament was 
advanced correctly up the ICA. 
Tension was applied to the CCA, ECA and ICA and a small incision was made 
immediately below the bifurcation of the CCA using microscissors. A silicone-
coated nylon filament, 0.37 mm in diameter (Doccal Corporation, CA, USA), was 
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inserted through the incision and advanced approximately 22 mm up the ICA, 
until resistance was felt. The origin of the middle cerebral artery (MCA) was 
occluded as a result. The filament was kept in place for 45 minutes using a 
ligature (Figure 2.7 A-C). If a sham procedure was being performed the filament 
was advanced as has been described but then immediately withdrawn and the 
surgery was continued as is subsequently described. 
 
Figure 2.7 – tMCAO Surgery 
Photograph illustrating surgical set up for tMCAO procedure (A). SHRSP is intubated and 
artificially ventilated, in supine position and in an aseptic surgical area. CCA, ECA, ICA and 
PPA ligated with silk sutures (B). Bifurcation of CCA to ICA/ECA visible. Intraluminal 
filament inserted at bifurcation of CCA, filament left in place for 45 minutes, occluding origin 
to MCA (C) After 45 minutes intraluminal filament is removed, incision electrocoagulated, 
ligatures removed and wound sutured using absorbance sutures (D). 
After 45 minutes the intraluminal filament was removed and the incision of the 
CCA sealed by electrocoagulation. Ligatures were removed from the PPA and 
ECA and the suture loop from the ICA. The ligature on the CCA was left in place 
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and surplus suture cut away. Retractors were removed and the muscles of the 
neck gently massaged into place. Finally the neck wound was sutured using 4/0 
vicryl absorbance suture (FS-2 needle, Ethicon, Livingston, UK) (Figure 2.7D). 
To recover the animal, the isoflurane supply was turned off but mechanical 
ventilation with 100% oxygen at 0.3 L/min was maintained until independent 
breathing was observable. While the animal was recovering 2 mL of 0.9% (w/v) 
sodium chloride (Baxter, Newbury, UK) was given subcutaneously to prevent 
dehydration. After the animal reached full consciousness it was moved to a 
recovery room where it was checked regularly. 
2.7.5 Tail-Cuff Plethysmography 
To measure conscious systolic blood pressure in SHRSP rats a non-invasive 
computerised tail-cuff was used. SHRSP rats were warmed using heat lamps for 
20 minutes. To restrain the free movement, each rat was gently wrapped in a 
surgical drape. A pneumatic pressure cuff and pneumatic pressure sensor were 
placed on the tail, the sensor distal to the cuff – both were controlled by a 
Programmed Electro Sphygmomanometer. Average systolic blood pressure 
measurements were calculated using a minimum of six consistent separate 
indirect pressure measurements. SHRSP rats were trained to become habituated 
to the pressure cuff and sensor before actual measurements were recorded. 
2.7.6 Intra-nasal Delivery of Exosomes 
Anaesthesia was induced in SHRSP rats as described in section 2.7.2, but rats 
were only allowed to become lightly anaesthetised. They were then placed in 
the supine position, with their nose inside a nose cone where they continued to 
receive light isoflurane anaesthesia (1.5 L/min 100% oxygen with 2-3% isoflurane) 
for the duration of the intra-nasal administration, typically several minutes. 
Immediately prior to each intra-nasal dose the rat was pulled away from the 
nose cone and the tip of a Gilson pipette (range: 2 - 20 µL) was placed at the tip 
of the rat’s nare. 7.5 µL of solution (either 0.9% sterile saline or 2.5 µg/µL 
exosomes) was then delivered to the nare in one bolus. The head was placed 
inside the nose cone again and the rat was allowed to inhale the solution for 
approximately 30 seconds. A matching dose was then delivered in the same way 
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to the opposite nare. This was repeated twice so that each rat received a total 
volume of 30 µL, 15 µL in each nare. The rat was then placed in its cage in the 
supine position and allowed to recover from the anaesthesia.   
2.7.7 Animal Sacrifice 
Naïve rats and mice were killed using Schedule 1 methods of termination, whilst 
SHRSP rats put on procedure were killed by transcardiac perfusion fixation or 
removal of the heart under terminal anaesthesia. 
2.7.7.1 Schedule 1 
Naïve rats were typically killed by exposure to carbon dioxide in rising 
concentrations. Each rat was placed into a chamber into which carbon dioxide 
(CO2) gas was subsequently flushed (8 L/min of 100% CO2). When the animal was 
observed to be unconscious a maximal flow of CO2 (10 L/min of 100% CO2) was 
flushed into the chamber for 2 minutes. The carbon dioxide was then turned off 
and the rat left inside the sealed chamber for a further 2 minutes. The rat was 
then checked for any signs of life. If signs of life were present the rat was 
replaced inside the chamber and if absent death was ensured by neck 
dislocation. 
Mice were typically killed by concussion of the brain by striking the cranium 
against the side of a bench. This caused immediate loss of consciousness and/or 
death. Death was ensured by neck dislocation. This Schedule 1 method was only 
carried out by fully trained animal technicians. 
2.7.7.2 Cardiac Puncture Blood Sampling 
In this study cardiac puncture blood samples were only taken terminally.  
Anaesthesia was induced (as described in section 2.7.2), and the rat was left 
within the induction box until very deeply anaesthetised. The rat was then 
placed in the supine position, with the head inside a nose cone where it 
continued to receive deep isoflurane anaesthesia (1.5 L/min 100% oxygen with 
5% isoflurane). A transverse incision was then made below the sternum to expose 
the thoracic cavity and rib cage. The rib cage was cut at either side to expose 
the beating heart. A 19-gauge needle attached to a 5 mL syringe was then 
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inserted into the left ventricle and blood was removed slowly to prevent the 
heart collapsing. Animals were then euthanised as described in sections 2.7.7.3 
or 2.7.7.4. 
Typically 5 mL of blood was easily removed. This was injected into 2 mL 
eppendorfs and allowed to clot for approximately 30 minutes at room 
temperature. The clotted blood samples were then centrifuged for 2000 x g for 
10 minutes at 4ºC. The clear supernatant (serum) was immediately removed 
using a Gilson pipette and transferred to a fresh eppendorf. Serum aliquots were 
frozen at -80ºC until used for further analysis.  
2.7.7.3 Perfusion Fixation 
Chemical fixation was used as a method of euthanasia to preserve tissue.  
Typically chemical fixation was achieved using 4% paraformaldehyde (PFA) which 
maintains cellular definition of tissue, stabilising cell morphology and disabling 
proteolytic enzymes. It also strengthens the tissue to withstand downstream 
processing and/or staining. 
To perfusion fix SHRSP rats, the rat was deeply anaesthetised and the heart 
exposed as described in section 2.7.7.2. A 16-gauge needle (blunted) was 
inserted into the apex of the heart and advanced until visible in the aorta. A 
hemostat was used to clamp the needle into place. An incision was then made on 
the right atrium and the process of exsanguination begun. Simultaneously 
pressure was applied (120 mmHg) resulting in the perfusion of heparinised (10 
U/mL) saline. The rat was perfused with heparinised saline until the liver 
appeared ‘clear’ of blood and the outflow from the right atrium was free from 
blood. The animal was then perfused with 4% PFA until firm and stiff to touch. 
The head was removed and submerged in 4% PFA for a further 24 hours. The 
brain was then carefully removed and stored in 4% PFA for another 24 hours 
before being placed in PBS, to be kept until tissue processing was carried out.  
2.7.7.4 Euthanasia to allow harvesting of fresh tissue 
If fresh (rather than fixed) tissue was required, the animal was terminally 
anaesthetised and the thoracic cavity and heart exposed as described in section 
2.7.7.2. The heart was then removed to ensure permanent cessation of 
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circulation. Any organs being used for further analysis were removed from the 
body as quickly as possible, placed in eppendorfs and stored in liquid nitrogen 
until they could be placed in a -80ºC freezer for long-term storage. 
2.8 Ex Vivo Methods 
2.8.1 Isolation of Aorta 
Adult male miR-21-/- mice, miR-21+/- mice and their wild type litter mates were 
killed as described in section 2.7.7.1. The aorta was carefully removed and ring 
segments of aorta arterial tissue (2-3 mm in length) were dissected, taking care 
not to denude the endothelium. 
2.8.2 Wire Myography 
The endothelium-intact aorta ring was then mounted on a small vessel wire 
myograph (DMT). The vessels were bathed at 37˚C in gassed Krebs physiological 
saline solution (118 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM 
KH2PO4, 24 mM NaHCO3 and 11 mM glucose; PSS). Aortic rings were mounted 
under 1.0 g resting tension and changes in isometric tension were recorded using 
signal transducers and displayed using a Powerlab data acquisition unit and 
LabChart software (ADInstruments).  
The tissue was allowed to equilibrate for approximately 60 minutes (tension was 
gradually increased) before each experiment and aorta rings were initially 
contracted with a high concentration (125 mM) potassium solution (KPSS; made 
by equimolar substitution of KCl for NaCl in PSS).  
9,11-Dideoxy-11α-epoxymethanoprostaglandin F2α (U46619, Sigma-Aldrich), a 
stable analogue of endoperoxide prostaglandin H2 and a thromboxane (TP) 
receptor agonist (Abramovitz et al., 2000) was added to the organ bath (1x10-9 M 
– 3x10-6 M) so that cumulative concentration-response curves could be 
constructed. Contractile responses to U46619 were calculated as a percentage of 
the maximum contraction and are expressed as the mean ± S.E.M. The influence 
of endogenous nitric oxide on the response to U46619 in endothelium-intact 
tissue was investigated using the nitric oxide synthase inhibitor, L-nitro-arginine 
methyl ester (L-NAME; 1x10-4 M).  
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Acetylcholine chloride (Sigma-Aldrich), a muscarinic receptor agonist and 
vasodilator and carbachol (or carbamylcholine, Sigma-Aldrich) a more stable 
analogue of acetylcholine, were added to the organ bath (1x10-8 M – 3x10-5 M) so 
that a cumulative concentration-response curve could be constructed. The 
relaxation responses were calculated as a percentage of the maximum 
contraction, following a dose of U46619, calculated to contract the vessel to 80% 
of its original maximum contraction.  
2.9 Bias and Blinding of Experiments 
In the in vitro experiments the experimenter was not blinded to the treatment 
being given to each well. However, efforts were made to ensure that treatments 
were allocated to cell culture plates in such a way that no one group would be 
especially exposed to evaporation (for example). When cells were harvested 
from each well and collected into eppendorfs for downstream analysis, each 
eppendorf was labelled only with a number to ensure the experimenter was not 
aware of the treatment the cells had received when performing RNA analysis or 
other downstream analysis. 
When analysing miRNA expression in human serum samples (Chapter 4) the 
experimenter was blinded to the stroke subtype and was not given access to 
phenotypic data concerning the patient. During RNA extractions, RT-PCR and 
qRT-PCR experiments samples were arranged according to sample number, and 
therefore the order in which patients were recruited into the study. The 
experimenter remained blinded until data analysis was complete. 
In the in vivo experiments described in Chapter 5 the experimenter was not 
blinded to the nature of treatment being given to each animal. As these were 
pilot experiments blinding to treatment was not deemed necessary. Animals 
were not formally randomised to a particular treatment group. However, only a 
small number of animals were available to use each week (due to low animal 
stock in the animal unit and only a small percentage of these animals meeting 
weight and age requirements) and so all the animals available were typically 
used. In each week the experiments were performed all treatments were given 
(i.e. if there were 3 animals being used in 1 week, each would receive a 
different treatment: sterile saline, miR-93 loaded exosomes or miR-20b loaded 
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exosomes).  Had the full animal study been carried out, efforts would have been 
made to ensure the experimenters were completely blinded and animals 
randomised to treatment groups to prevent bias. 
2.10 Statistical Analysis of Results 
Results described in the text are typically expressed as mean ± standard error of 
the mean (SEM). Statistical analysis was carried out using GraphPad Prism 
software. If ‘n’ numbers were sufficient (minimum n=8 in each group) data was 
tested for normality using the D’Agostino & Pearson omnibus normality test 
function on GraphPad Prism. On normally distributed data the most commonly 
used statistical tests were unpaired two-tailed Student’s t-test and one-way 
analysis of variance (ANOVA) with either Bonferroni, Dunnet or Tukey post-hoc 
correction for multiple comparisons. If data was not normally distributed, a 
Mann Whitney test was used instead of a t-test and a Kruskal-Wallis test instead 
of a one-way ANOVA. When performing correlation analysis, if data was normally 
distributed a Pearson product-moment correlation coefficient calculation was 
used – where these have been calculated results are displayed as R2 values. If 
data was not normally distributed a Spearman’s Rank-Order Correlation 
calculation was used – where these have been calculated results are displayed as 
ρ values. 
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3.1 Introduction 
Numerous studies have shown that modulation of miRNA expression may be 
therapeutically beneficial in the setting of pre-clinical ischaemic stroke. These 
studies have been discussed in greater detail in section 1.2.6. miR-494 and miR-
21 are potential candidates for modulation in the setting of experimental stroke. 
Here studies that present evidence implicating the importance of these miRNAs 
in the setting of ischaemic stroke will be introduced.  
3.1.1 miR-494 
miR-494 is located on chromosome 14 and is part of the 14q32 miRNA cluster 
(Figure 3.1). This is one of the largest polycistronic clusters and in humans is 
comprised of 54 different miRNAs. A miRNA cluster denotes miRNAs processed 
together in one primary transcript. miR-494 is expressed ubiquitously with 
highest expression in reproductive tissue such as the cervix, placenta, ovary, 
testes and prostrate (miRNA Map 2.0) (Hsu et al., 2008). Studies to date 
investigating miR-494 expression and modulation have been primarily cancer 
focussed and these are summarised by Tay and colleagues (Tay et al., 2016). 
 
Figure 3.1 – Schematic Illustration of the 14q32 miRNA Cluster 
MicroRNAs are listed by number and not in order of their chromosomal location. 
Abbreviations include: DMR, DNA methylated region; lncRNA, long noncoding RNA; 
snoRNA, small nucleolar RNAs. Figure adapted from (Dimmeler and Yla-Herttuala, 2014). 
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3.1.1.1 miR-494 and Cardiovascular Disease 
miR-494 expression is increased (~2-fold; non validated microarray data) in ex 
vivo murine ischaemic hearts subjected to 45 minutes of global no-flow 
ischaemia followed by 2 hours of reperfusion (Ren et al., 2009). miR-494 was 
subsequently shown to be significantly increased in vivo in murine hearts 
following 30-minute left anterior descending artery occlusion in comparison to 
sham operated animals (Wang et al., 2010). It was further increased with 1 hour 
of reperfusion but was significantly decreased after 24 hours of reperfusion 
(Wang et al., 2010). Conversely, miR-494 was decreased (~1.5-fold; non 
validated microarray data) in the left ventricle of human hearts in end-stage 
heart failure in comparison to normal hearts (Thum et al., 2007). miR-494 was 
also down-regulated in plasma samples taken from patients in heart failure and 
in patients with heart failure with reduced left ventricular ejection fraction 
(HFREF) but not in patients with heart failure with preserved left ventricular 
ejection fraction (HFPEF) in comparison to healthy control patients (Wong et al., 
2015). However, miR-494 was not found to be a particularly good biomarker for 
either heart failure or HFREF as assessed by ROC analysis (Wong et al., 2015). 
Transgenic mice with cardiac-specific over-expression of miR-494 had improved 
functional recovery (assessed by contractile performance) following global no-
flow ischaemia/reperfusion injury (Langendorff system, ex vivo), and also 
reduced lactate dehydrogenase release and apoptosis (Wang et al., 2010). 
Furthermore, in vivo, miR-494 transgenic mice had a reduced infarct size 
following myocardial infarct in comparison to WT control mice (Wang et al., 
2010). In this setting miR-494 was found to negatively regulate a number of pro-
apoptotic (ROCK1, PTEN, CAMKIIδ) and anti-apoptotic (FGFR2 and LIF) proteins 
both in vivo in miR-494 transgenic mice hearts and in vitro in adult 
cardiomyocytes (Wang et al., 2010). 
Other studies investigating miR-494 in cardiovascular disease have shown, 
conversely, that miR-494 knockdown is beneficial and miR-494 over-expression 
detrimental. Over-expression of miR-494 contributed to acute kidney injury (AKI) 
in C57BL/6 mice following experimentally induced ischaemia/reperfusion injury 
(following bilateral renal artery occlusion) (Lan et al., 2012). Lentiviral vectors 
designed to over-express miR-494 were injected into the renal artery of mice 
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and decreased kidney function, increased renal apoptosis, reduced expression of 
activating transcription factor 3 (AFT3) and induced inflammatory markers such 
as IL-6, MCP-1, P-selectin and NFκB (Lan et al., 2012). Urinary (but not serum) 
expression of miR-494 was subsequently shown to be up-regulated in human AKI 
patents in intensive care in comparison to both healthy control patients and 
intensive care patients with no AKI (Lan et al., 2012). 
miR-494 knockdown via administration of gene silencing oligonucleotides (GSOs) 
prior to experimentally induced hind limb ischemia (induced by single femoral 
artery ligation) improved blood flow recovery (Welten et al., 2014). mRNA 
expression of target genes of miR-494: toll-like receptor 4 (TLR4), ADP-
ribosylation factor 6 (ARF6) and fibroblast growth factor receptor 2 (FGFR2) 
were found to be increased in vivo in the left adductor muscle following 
treatment with GSO-miR-494 (Welten et al., 2014). In vitro experiments showed 
an increase in proliferation of primary human umbilical arterial myofibroblasts 
following treatment with GSO-miR-494 but no change in the proliferation of 
human umbilical arterial endothelial cells or human umbilical arterial smooth 
muscle cells (Welten et al., 2014). Increased outgrowth of neo-vessels was 
observed in 5-day collagen-embedded murine thoracic aortic ring explants 
following GSO-miR-494 treatment (Welten et al., 2014). However, the 
mechanisms by which miR-494 knockdown improved blood flow recovery are 
unclear as GSO-miR-494 treatment did not affect capillary density or 
arteriogenesis in vivo (Welten et al., 2014). A follow up paper demonstrated 
reduced carotid artery atherosclerotic lesion development and increased plaque 
stability in hypercholesterolemic ApoE-/- mice following IV delivery of GSO-miR-
494 4 days following placement of semi-constrictive collars around both carotid 
arteries to induce carotid artery plaque formation (Wezel et al., 2015). Knock-
down of miR-494 expression in carotid arteries resulted in up-regulated mRNA 
expression of miR-494 targets: IL33, TIMP3 and TGFβ2 (Wezel et al., 2015). 
These studies, taken in combination with the fact that miR-494 can regulate 
expression of both pro- and anti-apoptotic proteins suggest that miR-494 plays a 
complex role in the regulation of tissue homeostasis. 
109 
 
3.1.1.2 miR-494 and Stroke 
miR-494 expression was up-regulated in whole blood samples of young (aged 18-
49 years) ischaemic stroke patients collected between 2-24 months post-stroke 
(Tan et al., 2013) and in whole blood samples collected from patients within 24 
hours of stroke onset (Sepramaniam et al., 2014) in comparison to healthy 
control patients (non-validated microarray data). Expression of miR-494 was also 
increased approximately 15-fold in plasma samples collected from haemorrhagic 
stroke patients between 1-14 days post-symptom onset in comparison to healthy 
control patients (Guo et al., 2013). Although these changes are interesting, none 
have been validated by qRT-PCR. 
A study profiling miRNA expression in male SD rats post-tMCAO found that miR-
494 expression was increased in both brain tissue and blood at 24 and 48 hours 
post-stroke (Jeyaseelan et al., 2008). The increase in expression peaked at 24 
hours in brain tissue but still remained elevated at 48 hours in comparison to 
sham tissue. Within blood samples its expression was essentially unchanged at 24 
hours but substantially increased at 48 hours post-stroke (Jeyaseelan et al., 
2008). Subsequently a putative target of miR-494, Visinin-like 1 (VSNL1), was 
shown to be down-regulated in the brains of SD at 24 hours post-reperfusion, 
negatively correlating with the increase in miR-494 expression (Jeyaseelan et 
al., 2008). These results were confirmed in a separate study where miR-494 was 
shown to be increased in ipsilateral brain tissue of male SD rats at 24 hours post-
tMCAO in comparison to sham operated rats and Bcl-2, a target of miR-494, was 
decreased in the same tissue (Zhai et al., 2012). Adult male Fischer rats 
subjected to pMCAO had increased miR-494 expression at 30 minutes and 6 hours 
post-stroke (as assessed by microarray) – expression returned to basal levels at 7 
days post-stroke and was decreased at 14 days but in comparison to healthy 
animals rather than sham operated animals (Gubern et al., 2013). In this study 
(Gubern et al., 2013) increases in miR-494 expression were shown to occur at 
the critical time point post-pMCAO when the penumbra is evolving and being 
absorbed into the infarct (Hossmann, 2012) - this suggests that miR-494 may be 
relevant to the acute evolution of ischaemic damage. 
The only study (published to date) to modulate miR-494 expression within the 
brain did so in C57BL/6 mice 2 weeks prior to a Parkinson’s Disease (PD) 
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phenotype being induced (by IP injection of MPTP neurotoxin) via stereotactic 
injection of lentiviral vectors designed to increase miR-494 expression (Xiong et 
al., 2014). miR-494 was shown to inhibit DJ-1 expression, an oxidative sensor 
protein thought to help protect cells from oxidative insult. DJ-1 expression is 
also reduced in the substantia nigra of PD patients. miR-494 over-expression 
enhanced neurodegeneration as assessed by a swim test and a loss of 
dopaminergic neurons in the substantia nigra (Xiong et al., 2014). 
Endogenous increases in circulating and brain miR-494 expression in response to 
ischaemic insult suggest that this is either an endogenous repair response that is 
insufficient to protect tissue or that it is part of the ischaemic injury cascade, 
contributing to cell death. The majority of studies discussed here have 
demonstrated that increased miR-494 expression is detrimental to functional 
outcome following ischaemic insult. However, these studies were predominantly 
investigating miR-494 modulation within the peripheral vasculature. The role of 
miR-494 within the brain and following ischaemic stroke is yet to be elucidated. 
By modulating miR-494 expression we may be able to influence final infarct 
volume, vascular function, apoptosis and neurological deficit.  
3.1.2 miR-21 
miR-21 is a highly conserved miRNA, located on chromosome 17. It is expressed 
ubiquitously with highest expression in the lung, followed by the kidney and 
bladder (miRNA Map 2.0) (Hsu et al., 2008). miR-21 has an important role to play 
in a wide range of biological processes including development, cancer, 
cardiovascular disease and inflammation. It is classified as an oncomiR as it has 
been found to be differentially regulated in many forms of cancer but more 
recently has also been found to play a role in numerous cardiovascular and 
pulmonary diseases, for example, cardiac and pulmonary fibrosis and myocardial 
infarction (Jazbutyte and Thum, 2010, Krichevsky and Gabriely, 2009). 
3.1.2.1 miR-21 and Cardiovascular Disease 
Elevated miR-21 expression has been associated with myocardial infarction (MI). 
miR-21 has been shown to be increased in plasma of patients with acute MI in 
comparison to healthy age-matched controls, patients with acute heart failure, 
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angina or chest pain syndrome (Olivieri et al., 2014, Yao et al., 2011). However, 
in a separate study, circulating miR-21 expression was significantly decreased at 
2 days post-MI in comparison to control patients but increased at 5 days post-MI 
before returning to normal by 90 days post-MI (Zile et al., 2011). Increased miR-
21 expression has also been associated with angina and cardiac hypertrophy 
(Cheng et al., 2007, Ren et al., 2013, Sayed et al., 2007, van Rooij et al., 2006). 
miR-21 is involved in vascular remodelling, affecting both smooth muscle cells 
and endothelial cells. As miR-21 has been shown to be significantly up-regulated 
within the cerebral vasculature of SHRSP following tMCAO (assessed by in situ 
hybridisation) (Breen, 2015) the expression and regulation of miR-21 within the 
vasculature is of special interest in the context of stroke. 
Expression of miR-21 is increased following vascular injury (Ji et al., 2007) and 
hypoxia (Sarkar et al., 2010), is post-transcriptionally induced by TGF-β and BMP 
signalling (Davis et al., 2008, Kang et al., 2012) and is increased in human 
arteries with arteriosclerosis obliterans (Wang et al., 2011). Furthermore its 
circulating (serum) expression is sequentially decreased in patients with 
calcified and non-calcified coronary artery plaques in comparison to control 
patients (with chest pain but no coronary plaques), but increased sequentially in 
macrophages of patients with calcified and non-calcified plaques in comparison 
to control patients (Fan et al., 2014). Furthermore circulating miR-21 expression 
negatively correlated with serum MMP9 expression (Fan et al., 2014). miR-21 
expression was also increased in atherosclerotic plaques obtained from aortic, 
carotid and femoral arteries in comparison to non-atherosclerotic left internal 
thoracic arteries (Raitoharju et al., 2011). 
miR-21 signalling negatively regulates the expression of PDCD4 (Davis et al., 
2008, Sarkar et al., 2010, Wang et al., 2012), PTEN (Ji et al., 2007), Sprouty 2 
(SPRY2) (Sarkar et al., 2010), peroxisome proliferator-activated receptor-α 
(PPARα) (Sarkar et al., 2010), tropomyosin1 (TPM1) (Wang et al., 2011), 
transcription factor specificity protein-1 (SP1) (and subsequently cystathionine 
gamma-lyase, a major H2S generating enzyme) (Yang et al., 2012) and increases 
expression of phosphorylated Akt, Bcl-2 (Ji et al., 2007), smooth muscle α-actin 
(SMA) and calponin (Davis et al., 2008). 
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These proteins have targets which in turn regulate cell proliferation (Ji et al., 
2007, Sarkar et al., 2010, Wang et al., 2011, Yang et al., 2012), migration 
(Sarkar et al., 2010, Wang et al., 2012), differentiation (Yang et al., 2012) and 
apoptosis (Ji et al., 2007) as well as the induction of a contractile phenotype 
(Davis et al., 2008) in vascular smooth muscle cells. miR-21 signalling also plays 
a role in the proliferation and apoptosis of vascular adventitial fibroblasts and 
myofibroblasts (Wang et al., 2012) as well as neo-intimal lesion formation (Ji et 
al., 2007). 
Within endothelial cells miR-21 is highly expressed (Kuehbacher et al., 2007) and 
has been found to play an important regulatory role. Expression of miR-21 was 
induced by shear stress in human umbilical vein endothelial cells (HUVECs) 
(Weber et al., 2010, Zhou et al., 2011), but reduced in late passage senescent 
human aorta endothelial cells (in comparison to early passage) (Rippe et al., 
2012) and following treatment with bFGF in HUVECs (Sabatel et al., 2011). 
miR-21 signalling in endothelial cells modulated expression of downstream 
targets including PTEN (Weber et al., 2010), PPARα, vascular cell adhesion 
molecule-1, monocyte chemotactic protein-1 (Zhou et al., 2011), RhoB (Sabatel 
et al., 2011), collagen I and III, elastin, Smad2, Smad5, Smad7, CTGF, MMP2, 
MMP10 and TIMP-4 (Zhang et al., 2013). 
Overexpression of miR-21 reduced apoptosis, increased eNOS phosphorylation 
and levels of nitric oxide in endothelial cells (Weber et al., 2010), promoted 
monocyte adhesion, part of a pro-inflammatory response to shear stress (Zhou et 
al., 2011) and also impaired cell proliferation, migration and angiogenesis in 
HUVECs (Sabatel et al., 2011). Reduction in miR-21 expression was associated 
with decreased cell proliferation and eNOS but increased apoptosis and 
inflammation in human aortic endothelial cells (Rippe et al., 2012). Reduced 
miR-21 expression was also associated with reduced proliferation, migration and 
tube forming capacity in retinal microvascular endothelial cells (Guduric-Fuchs 
et al., 2012). Interestingly, endothelial specific miR-21 knock-out mice 
demonstrated both structural and functional aorta remodelling (Zhang et al., 
2013). miR-21 knock-out in this setting resulted in decreased diastolic blood 
pressure, maximal tension depression, impaired endothelium-dependent 
relaxation and a decrease in compliance (Zhang et al., 2013). 
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This evidence suggests that miR-21 has an important role to play in modulating 
both vascular smooth muscle and endothelial cell biology. Furthermore inhibition 
of apoptosis and promotion of proliferation are, in theory, interesting treatment 
strategies for regenerative medicine in the cardiovascular system. 
3.1.2.2 miR-21 and Stroke 
Circulating miR-21 expression has been profiled in a number of human ischaemic 
stroke patient populations and these are summarised in Table 3.1. 
Table 3.1 – miR-21 Expression in Ischaemic Stroke Patients. 
A table summarising published studies that have profiled circulating miR-21 expression in 
human ischaemic patients by qRT-PCR. Abbreviations: IS, ischaemic stroke; * indicates 
change in expression was statistically significant. 
Reference 
miR-21 
Expression  
Sample Used Control Patients 
(Tan et al., 2009) 
*↑ IS vs. 
control 
Whole blood collected 
6-18 months post IS 
Healthy, no details of age 
(Tsai et al., 2012) 
*↑ IS vs. 
control 
Serum collected <7 days 
post IS onset 
Healthy, younger but p-
values adjusted for age 
(Wang et al., 2014b) 
*↑ IS vs. 
control 
 Plasma collected <24 
hours post IS onset 
Healthy, age-matched 
(Jia et al., 2015) 
Not changed 
IS vs. control 
Serum collected < 24 
hours post IS onset 
Healthy, age-matched 
(Kim et al., 2015) 
Not changed 
IS vs. control 
Plasma collected < 7 
days post IS onset 
Some vascular risk 
factors, age-matched 
(Zhou and Zhang, 2014) 
*↓ IS vs. 
control 
Plasma collected < 24 
hours post IS onset 
Healthy, younger (not 
significant) 
 
In contradictory studies circulating miR-21 expression was shown to increase 
(Tan et al., 2009, Tsai et al., 2012, Wang et al., 2014b), remain unchanged (Jia 
et al., 2015, Kim et al., 2015) and to decrease (Zhou and Zhang, 2014) following 
ischaemic stroke. miRNA expression was profiled in differently processed blood 
samples that had been collected at differing time points post-stroke so the 
results are not directly comparable. However, the most important discrepancies 
appear to be between the patient (and control) populations used. Only three of 
the studies provide information on the stroke subtype breakdown of their 
patient populations (Kim et al., 2015, Tsai et al., 2012, Wang et al., 2014b) and 
so it is impossible to know whether differences in miR-21 expression observed 
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are a result of differing stroke subtypes within the patient populations used. Of 
note, the only studies that observed differences in miR-21 expression used 
healthy control patients. Had miR-21 expression been compared to age-
matched, vascular risk factor controls, it is possible that no differences would 
have been observed, as is the case in the study published by Kim and colleagues. 
Similarly, miR-21 expression was significantly increased in serum samples 
collected from ischaemic stroke patients within 7 days of stroke in comparison 
to healthy control patients but was not significantly increased in comparison to 
samples collected from asymptomatic patients with carotid atherosclerosis (Tsai 
et al., 2012). 
In pre-clinical models of stroke in situ hybridisation has been used to show up-
regulated miR-21 expression in coronal brain sections of Wistar rats following 
embolic MCAO in comparison to its expression in the contralateral hemisphere 
(Buller et al., 2010). miR-21 expression was especially increased in neuronal 
cells of the ischaemic boundary zone (peri-infarct) at 2 and 7 days post-stroke 
(Buller et al., 2010). Furthermore, increased miR-21 expression was associated 
with areas of reduced TUNEL staining, suggesting reduced apoptosis in these 
areas (Buller et al., 2010). In a separate study qRT-PCR analysis demonstrated 
increased miR-21 expression in the hippocampus of SD rats at 24 hours post 
ischaemia/reperfusion injury (induced by transient 4 vessel occlusion) in 
comparison to sham operated animals (Deng et al., 2013). Furthermore, 
increases in miR-21 expression correlated with increases in MMP9 expression 
(Deng et al., 2013). In vitro cell culture experiments have also demonstrated 
increased miR-21 expression in secondary neuronal (N2A) cells following hypoxic 
insult with 24 hours of reoxygenation (Zhou and Zhang, 2014). Conversely, miR-
21 expression was decreased in primary rat microglial cells at 3, 6 and 12 hours 
post hypoxic insult (with reoxygenation) (Zhang et al., 2012). These studies 
suggest that miR-21 is differentially expressed between cell subtypes following 
ischaemic or hypoxic insult. 
Up-regulation of miR-21 expression (via delivery of miRNA mimics) protected 
primary cortical neurons in vitro from oxygen and glucose deprivation (Buller et 
al., 2010). Protection was hypothesised to be mediated by miR-21 induced down-
regulation of Fas ligand (part of the TNFα family), a cell death inducing ligand 
(Buller et al., 2010). Consistent with this, increased miR-21 expression (via 
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delivery of miRNA mimic) was shown to induce repression of Fas ligand – this 
protected against activated microglia induced neuronal apoptosis following 
hypoxic insult in vitro (Zhang et al., 2012). Finally, stereotactic injection of 
anti-miR-21 to bilateral cerebral ventricles 24 hours prior to 4 vessel occlusion in 
Sprague Dawley rats resulted in a down-regulation of MMP9 expression (Deng et 
al., 2013). However, data on the effect of anti-miR-21 on infarct volume and 
other functional measures of outcome was not presented or commented on in 
this study (Deng et al., 2013). 
A number of studies have demonstrated that over-expression of miR-21 is 
therapeutically beneficial following traumatic brain injury, reducing lesion 
volume, brain oedema and BBB damage (Ge et al., 2015, Ge et al., 2016, Ge et 
al., 2014). miR-21 targeted PTEN, Angiopoietin-1, Tie-2, NF-κB and a number of 
inflammatory cytokines – resulting in an inhibition of apoptosis and a promotion 
of angiogenesis (Ge et al., 2015, Ge et al., 2016, Ge et al., 2014).  
The evidence presented here suggests that miR-21 has an important role to play 
within the brain and vasculature following ischaemic stroke and therefore may 
have an influence on final infarct volume, apoptosis, vascular function, 
angiogenesis and neurological deficit – supporting the hypothesis that miR-21 
modulation may prove to be an effective novel therapeutic in the setting of 
experimental stroke. 
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3.1.3 Hypotheses 
The hypotheses of the present study were as follows: 
 Modulation of miR-494 (and concomitant modulation of its gene targets) 
will be therapeutically beneficial in pre-clinical models of experimentally 
induced stroke. 
 Modulation of miR-21 (and concomitant modulation of its gene targets) 
will be therapeutically beneficial in pre-clinical in vitro models of stroke. 
3.1.4 Aims 
The aims of the present study were as follows: 
 To assess the extent of miR-494 modulation following delivery of miR-494 
mimics and anti-miRs to secondary neuronal and cerebral endothelial 
cells. 
 To assess the effect of miR-494 modulation in vitro by quantifying 
changes in expression and activity of miR-494 gene targets and by 
assessing measures of functional outcome, such as cell survival, following 
hypoxic challenge. 
 To assess the extent of miR-21 modulation following delivery of miR-21 
mimics and anti-miRs to a secondary cerebral endothelial cell line. 
 To assess the effect of miR-21 modulation in vitro by quantifying changes 
in expression of its target genes and by assessing measures of functional 
outcome, such as cell survival, following hypoxic challenge. 
 To assess the effect of miR-21 modulation ex vivo by quantifying changes 
in vessel contraction and relaxation using wire myography in the aortae of 
transgenic miR-21-/- and miR-21+/- mice.  
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3.2 Results 
3.2.1 miR-494 
Pilot data, collected prior to the start of the presented study (by a research 
student in our group), demonstrated that miR-494 expression was increased in 
the brain of SHRSP post-tMCAO (data not shown here). miR-494 expression was 
significantly increased in ischaemic infarct tissue of SHRSP rats at 3, 6 and 24 
hours post-tMCAO, as compared to its expression in matched tissue from sham 
operated rats. The increase in expression was most marked at 24 hours. miR-494 
expression was moderately decreased in ischaemic periphery (or peri-infarct) 
tissue of SHRSP rats at 3 hours, unchanged as compared to sham operated rats at 
6 hours and significantly increased at 24 hours but not to the extent observed in 
the ischaemic core. This data suggested that miR-494 was dysregulated in the 
brain of SHRSP rats following stroke. This data, in combination with the studies 
discussed in the introduction of this chapter, suggested that miR-494 was a good 
candidate miRNA for modulation in pre-clinical models of stroke. 
The expression of miR-494 and several of its putative target genes was 
subsequently profiled in ipsilateral infarct, peri-infarct and remainder (i.e. non-
infarcted ipsilateral) brain tissue of SHRSP rats, collected at both 24 and 72 
hours post-tMCAO. The brain tissue used in this study was previously collected in 
a study carried out by Dr. Emily Ord. A T2-weighted MRI scan was performed 
prior to animal sacrifice to allow for the accurate dissection of the infarct and 
peri-infarct brain regions. In the pilot study, discussed above, infarct and peri-
infarct tissue was assessed visually only. 
miR-494 expression was not significantly increased in ipsilateral infarct, peri-
infarct or remainder tissue at either 24 or 72 hours post-stroke as compared to 
sham operated animals: 24 hours infarct (RQ 0.85 ± 0.12 vs. 1.00 ± 0.05); 24 
hours peri-infarct (RQ 1.13 ± 0.16 vs. 1.00 ± 0.17); 24 hours remainder (RQ 1.35 
± 0.17 vs. 1.00 ± 0.24); 72 hours infarct (RQ 0.74 ± 0.10 vs. 1.00 ± 0.13); 72 
hours peri-infarct (RQ 0.93 ± 0.05 vs. 1.00 ± 0.13); 72 hours remainder (RQ 1.09 
± 0.12 vs. 1.00 ± 0.09) (Figure 3.2). 
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Figure 3.2 – miR-494 Expression in SHRSP tMCAO Brain 
The expression of miR-494 was assessed in infarct (A, B), peri-infarct (C, D) and remainder 
(E, F) brain tissue of SHRSP rats at 24 hours (A, C, E) and 72 hours (B, D, F) following 45 
min tMCAO (coloured bars) or sham operation (grey bars) (n=6/group). Statistical probability 
of differences in expression observed were calculated using unpaired Student’s t-test with 
Bonferroni corrections, vs. sham operated rats. Change in miRNA expression was assessed 
by qRT-PCR and relative quantification (RQ) calculated from ΔΔCt following normalisation 
to a housekeeper miRNA, U87, and compared to miRNA expression in the sham operated 
rats. Data shown is RQ ± RQmax/RQmin. Brain tissue collected by and used with 
permission of Dr. Emily Ord. 
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When analysing the data presented in Figure 3.2 - Figure 3.5 a Bonferroni 
correction was applied to each t-test performed to correct for the fact that 
miRNA or gene expression was being examined in three different brain tissue 
sections (infarct, peri-infract and remainder) from the same animals (e.g. sham 
and tMCAO SHRSP rats at 24 hours). To make the Bonferroni correction we 
divided the critical P value (α) by the number of comparisons being made. 
Therefore, with a α value of 0.05, and three comparisons (infarct, peri-infarct 
and remainder), the new p-value required for significance was: 
0.05
3
 = 0.0167. 
The mRNA expression of PTEN, a validated target of both miR-494 and miR-21, 
was significantly decreased in infarct, peri-infarct and remainder tissue at both 
24 and 72 hours post-stroke as compared to sham operated animals: 24 hours 
infarct (RQ 0.48 ± 0.05 vs. 1.00 ± 0.08); 24 hours peri-infarct (RQ 0.69 ± 0.11 vs. 
1.00 ± 0.14); 24 hours remainder (RQ 0.63 ± 0.09 vs. 1.00 ± 0.12); 72 hours 
infarct (RQ 0.25 ± 0.08 vs. 1.00 ± 0.05); 72 hours peri-infarct (RQ 0.50 ± 0.12 vs. 
1.00 ± 0.04); 72 hours remainder (RQ 0.62 ± 0.09 vs. 1.00 ± 0.12) (Figure 3.3). 
The mRNA expression of MMP2, a putative target of miR-494 and validated target 
of miR-21, was significantly increased in infarct tissue at 24 hours post-tMCAO as 
compared to sham operated animals (RQ 1.50 ± 0.13 vs. 1.00 ± 0.09) but 
unchanged in peri-infarct (RQ 1.08 ± 0.15 vs. 1.00 ± 0.18) and in remainder 
tissue (RQ 1.21 ± 0.10 vs. 1.00 ± .16) (Figure 3.4). MMP2 expression was 
significantly increased in infarct, peri-infarct and remainder tissue at 72 hours 
post-tMCAO as compared to sham operated animals: infarct (RQ 2.55 ± 0.28 vs. 
1.00 ± 0.14); peri-infarct (RQ 2.61 ± 0.35 vs. 1.00 ± 0.11); remainder (RQ 2.14 ± 
0.30 vs. 1.00 ± 0.03) (Figure 3.4). 
The mRNA expression of MMP9 (a predicted target of miR-494 and validated 
target of miR-21) was also profiled. MMP9 was significantly increased in infarct, 
peri-infarct and remainder tissue at 24 hours post-tMCAO as compared to sham 
animals: infarct (RQ 3.46 ±1.64 vs. 1.00 ± 0.54); peri-infarct (RQ 2.95 ± 1.01 vs. 
1.00 ± 0.28); remainder (RQ 5.08 ± 1.14 vs. 1.00 ± 0.38) (Figure 3.5). However, 
MM9 expression was unchanged in brain tissue of SHRSP rats at 72 hours as 
compared to sham operated rats: infarct (RQ 1.21 ± 0.30 vs. 1.00 ± 0.20); peri-
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infarct (RQ 1.94 ± 0.81 vs. 1.00 ± 0.17); remainder (RQ 1.22 ± 0.73 vs. 1.00 ± 
0.32) (Figure 3.5). 
Despite the fact that miR-494 expression was not altered in the brain tissue of 
SHRSP rats at 24 and 72 hours following tMCAO in the present study it was 
hypothesised that modulation of miR-494 expression could still be therapeutic in 
the setting of ischaemic stroke as a number of its putative gene targets are 
implicated in ischaemic stroke. Furthermore, their expression (PTEN, MMP2 and 
MMP9) is significantly dysregulated in stroke and modulation of miR-494 may 
lead to therapeutic benefit via modulation of the expression of these target 
genes. 
121 
 
 
Figure 3.3 – PTEN Expression in SHRSP tMCAO Brain 
The expression of PTEN was assessed in infarct (A, B), peri-infarct (C, D) and remainder (E, 
F) brain tissue of SHRSP rats at 24 hours (A, C, E) and 72 hours (B, D, F) following 45 min 
tMCAO (coloured bars) or sham operation (grey bars) (n=6/group). Statistical probability of 
differences in expression observed were calculated using unpaired Student’s t-test with 
Bonferroni corrections, vs. sham operated rats: *p<0.05; **p<0.01; ***p<0.001. Change in 
mRNA expression was assessed by qRT-PCR and relative quantification (RQ) calculated 
from ΔΔCt following normalisation to a housekeeper mRNA, β-actin, and compared to 
mRNA expression in the sham operated rats. Data shown is RQ ± RQmax/RQmin. Brain 
tissue collected by and used with permission of Dr. Emily Ord. 
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Figure 3.4 – MMP2 Expression in SHRSP tMCAO Brain 
The expression of MMP2 was assessed in infarct (A, B), peri-infarct (C, D) and remainder (E, 
F) brain tissue of SHRSP rats at 24 hours (A, C, E) and 72 hours (B, D, F) following 45 min 
tMCAO (coloured bars) or sham operation (grey bars) (n=6/group). Statistical probability of 
differences in expression observed were calculated using unpaired Student’s t-test with 
Bonferroni corrections, vs. sham operated rats: **p<0.01; ***p<0.001. Change in mRNA 
expression was assessed by qRT-PCR and relative quantification (RQ) calculated from ΔΔCt 
following normalisation to a housekeeper mRNA, β-actin, and compared to mRNA 
expression in the sham operated rats. Data shown is RQ ± RQmax/RQmin. Brain tissue 
collected by and used with permission of Dr. Emily Ord. 
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Figure 3.5 – MMP9 Expression in SHRSP tMCAO Brain 
The expression of MMP9 was assessed in infarct (A, B), peri-infarct (C, D) and remainder (E, 
F) brain tissue of SHRSP rats at 24 hours (A, C, E) and 72 hours (B, D, F) following 45 min 
tMCAO (coloured bars) or sham operation (grey bars) (n=6/group). Statistical probability of 
differences in expression observed were calculated using unpaired Student’s t-test with 
Bonferroni corrections, vs. sham operated rats: *p<0.05; **p<0.01; ***p<0.001. Change in 
mRNA expression was assessed by qRT-PCR and relative quantification (RQ) calculated 
from ΔΔCt following normalisation to a housekeeper mRNA, β-actin, and compared to 
mRNA expression in the sham operated rats. Data shown is RQ ± RQmax/RQmin. Brain 
tissue collected by and used with permission of Dr. Emily Ord. 
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miR-494 expression was initially modulated in vitro, in B50 neuronal and GPNT 
cerebral endothelial cells, via the delivery of mature miRNA mimics and miRNA 
anti-miRs, delivered using siPORT, a lipid based transfection agent (Figure 3.6). 
miR-494 expression was unchanged in NTC B50 cells following hypoxic challenge 
as compared to normoxic cells (1/∆Ct 0.156 ± 0.0052 vs. 0.170 ± 0.0016) (Figure 
3.6A). miR-494 expression was also unchanged in both normoxic and hypoxic B50 
cells following delivery of siPORT, the mature mimic control (+C) or the anti-miR 
control (-C) as compared to their NTC treated counterparts. miR-494 expression 
was significantly increased following delivery of miR-494 mimic in normoxic (RQ 
175.51 vs. 1.00 ± 0.04) and hypoxic (RQ 195.96 ± 7.67 vs. 1.00 ± 0.17) cells in 
comparison to matched NTC control cells (Figure 3.6A). However, miR-494 
expression was not significantly modulated following delivery of miR-494 anti-
miR to B50 cells: normoxic (RQ 1.18 ± 0.09 vs. 1.00 ± 0.04); hypoxic (RQ 0.72 ± 
0.05 vs. 1.00 ± 0.17) (Figure 3.6A). 
miR-494 expression was subsequently modulated in GPNT cerebral endothelial 
cells (Figure 3.6B). miR-494 expression was unchanged in NTC GPNT cells 
following hypoxic challenge as compared to normoxic cells (1/∆Ct 0.098 ± 0.002 
vs. 0.092 ± 0.0005). miR-494 expression was also unchanged in both normoxic 
and hypoxic GPNT cells following delivery of siPORT, the mature mimic control 
(+C) or the anti-miR control (-C) as compared to their NTC treated  
counterparts. miR-494 expression was increased to an even greater extent in 
GPNT cells than was observed in the B50 cells following delivery of miR-494 
mimic as compared to expression in NTC control cells: normoxic (RQ 6999.12 ± 
967.43 vs. 1.00 ± 0.04); hypoxic (RQ 1911.75 ± 257.96 vs. 1.00 ± 0.16) (Figure 
3.6B). Surprisingly, miR-494 expression was also significantly increased following 
delivery of miR-494 anti-miR to GPNT cells in comparison to its expression in 
NTC control cells: normoxic (RQ 6.62 ± 2.57 vs. 1.00 ± 0.04); hypoxic (RQ 3.43 ± 
3.73 vs. 1.00 ± 0.16) (Figure 3.6B). 
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Figure 3.6 – miR-494 Modulation in B50 and GPNT Cells 
B50 (A) and GPNT (B) cells were transfected with the transfection agent alone (siPORT C), 
mature mimic control (+C), mature miR-494 mimic (+494), anti-miR control (-C) or anti-miR-
494 (-494) or did not receive any treatment (NTC). miR-494 expression was assessed in cell 
lysates harvested 24 hours following hypoxic challenge (pink) or control normoxic 
conditions (grey) (n=2). Change in miRNA expression was assessed by qRT-PCR and 
relative quantification (RQ) calculated from ΔΔCt following normalisation to a housekeeper 
miRNA, U87, and compared to miRNA expression in the NTC control cells. Data shown is 
RQ ± RQmax/RQmin. Raw Ct values are given above each column. Statistical probability of 
differences in expression observed were calculated using unpaired Student’s t-test with 
Tukey’s Multiple Comparisons Test. Selected statistical significances are shown on the 
graph: ****p<0.0001 vs. normoxic NTC cells; p<0.05, p<0.0001 vs hypoxic NTC cells.  
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As we were interested in the effects of both miR-494 over-expression and knock-
down a refined transfection protocol was designed in which cells were 
transfected with miR-494 modulating agents over 2 days (Figure 3.7 A and B). On 
the first day GPNT cells were transfected with mature miR-494 mimic or mimic 
control and on the second with a repeated dose of miR-494 mimic and either 
anti-miR-494 or an anti-miR control. This protocol was designed to show knock-
down of miR-494 following artificial up-regulation so that the effect of both 
over-expression and subsequent knock-down of miR-494 expression could be 
examined. 
As before, miR-494 expression was unchanged in NTC hypoxic GPNT cells as 
compared to normoxic NTC cells (1/∆Ct 0.036 ± 0.0001 vs. 0.037 ± 0.0002) 
(Figure 3.7 C). miR-494 expression was also unchanged in both normoxic and 
hypoxic GPNT cells following delivery of siPORT, the mature mimic control/anti-
miR control (+C + -C) or mature mimic control/anti-miR-494 (+C + -494) as 
compared to their NTC treated counterparts. miR-494 expression was 
significantly increased following delivery of miR-494 mimic/anti-miR control 
(+494 + -C) in both normoxic (RQ 5986.66 ± 279.71 vs. 1.00 ± 0.12) and hypoxic 
(RQ 10031.14 ± 148.15 vs. 1.00 ± 0.04) cells as compared to matched NTC 
control cells (Figure 3.7 C). Although miR-494 expression was significantly 
increased in normoxic cells treated with miR-494 mimic/anti-miR-494 as 
compared to NTC treated cells (RQ 8.02 ± 1.92 vs. 1.00 ± 0.12), its expression 
was significantly down-regulated in comparison to +494 + -C treated cells. 
Similarly, miR-494 expression was significantly increased in hypoxic cells treated 
with mature miR-494/anti-miR-494 in comparison to NTC treated cells (RQ 
465.98 ± 245.88 vs. 1.00 ± 0.04) but was significantly down-regulated in 
comparison to +494 + -C treated cells. Furthermore, there was a significant 
difference in miR-494 expression between normoxic and hypoxic +494 + -494 
treated cells (1/∆Ct normoxic 0.042 ± 0.0006 vs. 0.053 ± 0.0016) (Figure 3.7 C).  
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Figure 3.7 – miR-494 Modulation in GPNT Cells 
GPNT cells were transfected over 2 days according to the protocol shown (A and B). GPNT 
cells were transfected with either transfection agent alone (siPORT C), mature mimic control 
followed by anti-miR control (+C + -C), mature mimic control followed by anti-miR-494 (+C + 
-494), mature miR-494 mimic followed by anti-miR control (+494 + -C), mature miR-494 mimic 
followed by anti-miR-494 (+494 + -494) or did not receive any treatment (NTC). miR-494 
expression was assessed in cell lysates harvested 24 hours following hypoxic challenge 
(pink) or control normoxic conditions (grey) (n=3). Change in miRNA expression was 
assessed by qRT-PCR and relative quantification (RQ) calculated from ΔΔCt following 
normalisation to a housekeeper miRNA, U87, and compared to miRNA expression in the 
NTC control cells. Data shown is RQ ± RQmax/RQmin. Raw Ct values are given above each 
column. Statistical probability of differences in expression observed were calculated using 
one-way ANOVA with Tukey’s Multiple Comparisons Test. Selected statistical significances 
are shown on the graph: ****p<0.0001 vs. normoxic NTC cells; p<0.0001 vs hypoxic NTC 
cells; ####p<0.0001 for selected pair.  
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Gene expression of putative miR-494 target genes (PTEN, MMP2 and MMP9) was 
subsequently analysed in the GPNT cells in which miR-494 expression had been 
modulated. However, as the expression of housekeeper genes traditionally used 
in our research (GAPDH and β-actin) were unstable in GPNT cells following 
hypoxic challenge it was important that another endogenous control gene was 
found that remained stable in GPNT cells following hypoxic challenge. To this 
end a TaqMan Array Rat Endogenous Control 96-well Plate (Applied Biosystems®) 
was run. The plate contained 16 gene expression assays for genes previously 
shown to be good candidates for housekeeper genes. The genes tested were as 
follows: 18S, ARBP, ACTB, B2M, GAPDH, GUSB, HMBS, HPRT, PGK1, PPIA, PPIB, 
RPLP2, TBP, TFRC, UBC and YWHAZ. In this experiment expression of the 16 
housekeeper genes were evaluated in 3 normoxic and 3 hypoxic GPNT cell 
lysates. The average Ct of each gene in the 6 cell lysates tested is given in Table 
3.2 along with the standard deviation. The gene with the highest standard 
deviation in the 6 samples tested was TBP (average Ct 29.92, SD 2.04). The gene 
with the lowest standard deviation in the samples tested was UBC (average Ct 
20.45, SD 1.10). While a standard deviation of under 0.5 is desirable for any 
housekeeper gene, the expression of UBC was more stable than that of GAPDH 
and β-actin in these cell lysates. 
The results were subsequently validated by comparing expression of β-actin and 
UBC in GPNT cells in which miR-494 expression had been modulated (Figure 3.8). 
The average expression of β-actin in these cells was 21.62 (Ct), with a standard 
deviation of 0.98. The average expression of UBC in these cells was 24.34 (Ct) 
with a standard deviation of 0.90. While the expression of UBC was more stable 
than that of β-actin it was still considered too variable in this particular 
experiment to be used as a housekeeper when calculating relative quantification 
of miR-494 target genes. 
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Table 3.2 – Housekeeper Optimisation Results 
Gene expression was assessed in GPNT cell lysates harvested 24 hours following hypoxic 
challenge or control normoxic conditions (n=3/condition). Gene expression was assessed 
by qRT-PCR using a TaqMan Array Rat Endogenous Control 96-Well Plate. Data shown is 
average Ct and standard deviation. 
Housekeeper Average Ct Standard Deviation 
TBP 29.92 2.04 
PPIB 22.02 1.50 
ARBP 22.60 1.42 
HMBS 28.34 1.39 
YWHAZ 25.63 1.39 
PPIA 20.91 1.38 
GUSB 29.09 1.37 
HPRT 23.97 1.37 
TFRC 32.50 1.36 
ACTB 20.86 1.30 
RPLP2 20.63 1.29 
18S 21.45 1.27 
PGK1 24.18 1.27 
GAPDH 23.67 1.26 
B2M 20.08 1.16 
UBC 20.45 1.10 
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Figure 3.8 – Housekeeper Expression post miR-494 Modulation 
GPNT cells were transfected over 2 days with either transfection agent alone (siPORT C), 
mature mimic control followed by anti-miR control (+C + -C), mature mimic control followed 
by anti-miR-494 (+C + -494), mature miR-494 mimic followed by anti-miR control (+494 + -C), 
mature miR-494 mimic followed by anti-miR-494 (+494 + -494) or did not receive any 
treatment (NTC). β-actin (A) and UBC (B) expression was assessed in cell lysates harvested 
24 hours following hypoxic challenge (grey) or control normoxic conditions (black) (n=3, 
representative graph shown here of 1 experiment). Change in gene expression was 
assessed by qRT-PCR. Data shown is raw Ct values. 
PTEN, MMP2 and MMP9 expression was assessed in GPNT cells following 
modulation of miR-494. Although miR-494 expression was robustly modulated in 
vitro there were no obvious changes in expression of target genes in relation to 
miRNA modulation (Figure 3.9). However, it was difficult to analyse the data 
properly as expression of target genes varied hugely, even within treatment 
groups and this was more pronounced when looking at expression of MMP2 and 
MMP9, where endogenous levels of mRNA expression were low (Ct values of over 
32).  
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Figure 3.9 - Gene Expression post-miR-494 Modulation  
GPNT cells were transfected over 2 days with either transfection agent alone (siPORT C), 
mature mimic control followed by anti-miR control (+C + -C), mature mimic control followed 
by anti-miR-494 (+C + -494), mature miR-494 mimic followed by anti-miR control (+494 + -C), 
mature miR-494 mimic followed by anti-miR-494 (+494 + -494) or did not receive any 
treatment (NTC). PTEN (A), MMP2 (B) and MMP9 (C) mRNA expression was assessed in cell 
lysates harvested 24 hours following hypoxic challenge (grey) or control normoxic 
conditions (black) (n=3, representative graph shown here of n=1 experiment). Change in 
gene expression was assessed by qRT-PCR. Data shown is raw Ct values. 
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miRNAs can regulate target gene expression by degrading (initially by 
destabilising) the target mRNA. However, miRNAs can also act to repress the 
translation of target mRNA or inhibit translation initiation without significantly 
affecting transcriptome expression. Although rapid mRNA degradation probably 
accounts for >75% of miRNA mediated gene silencing (Baek et al., 2008, Guo et 
al., 2010, Hendrickson et al., 2009, Selbach et al., 2008) it is plausible that 
modulation of miR-494 expression could affect the protein expression of target 
genes without affecting their transcriptome expression. 
As no significant changes in the transcriptome expression of PTEN, MMP2 and 
MMP9 were observed following miR-494 modulation in vitro, the activity of 
target genes were assessed by western blot and gelatin zymography. PTEN acts 
to inhibit phosphorylation of Akt, a protein kinase that acts downstream of 
PTEN. To investigate the expression of PTEN and Akt, cell lysates were separated 
by gel electrophoresis and Western blot analysis was performed. Antibodies for 
PTEN, total and phosphorylated Akt proteins and a housekeeper protein, GAPDH, 
were bought and experiments were carried out to optimise the conditions 
necessary for this experiment (Figure 3.10). However the phosphorylated Akt 
bands were difficult to quantify meaningfully due to high background staining. 
 
Figure 3.10 – Western Blot Optimisation 
Phosphorylated and total Akt and GAPDH protein expression was assessed in GPNT cell 
lysates. GPNT cells were transfected over 2 days with either transfection agent alone 
(siPORT C), mature miR-494 mimic followed by anti-miR control (+494 + -C), mature miR-494 
mimic followed by anti-miR-494 (+494 + -494) or did not receive any treatment (NTC). Protein 
expression was assessed in cell lysates harvested 24 hours following hypoxic challenge (H) 
or control normoxic conditions (N). Change in protein expression was assessed by gel 
electrophoresis and Western blot. Western blots were scanned using Quantity One® 4.6.8 
software. Representative graph is shown of 1 optimisation experiment. 
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To investigate MMP2 and MMP9 activity in vitro following miR-494 modulation 
gelatin zymography was performed. miR-494 expression was modulated as 
described previously in GPNT cells – GPNT cell lysates were subsequently 
separated by gel electrophoresis in gelatin containing polyacrylamide gels. 
Protein lysates were not denatured prior to gel electrophoresis and subsequent 
Coomassie staining of the gels (blue) allowed bands of proteolytic activity 
(white) to be visualised. Although the experiments were carefully optimised it 
was difficult to obtain clear images of the white bands showing protein activity 
due to the fact that they were very small (see results from an optimisation 
experiment, Figure 3.11 A). Quantification of the zymogram gel revealed no 
obvious changes in either MMP2 or MMP9 activity following miR-494 modulation 
in GPNT cells (Figure 3.11 B and C). The experimental protocol needed to be 
further refined before additional experiments were carried out. 
As the difficulties in assessing protein expression of miR-494 target genes 
became apparent, the importance of carrying out assays to investigate the 
functional effect of miR-494 modulation in vitro became clear. To assess the 
functional significance of miR-494 modulation a MTS cell viability assay was 
performed on GPNT cells in which miR-494 had been previously modulated. A 
MTS assay is a colorimetric method of determining the number of viable cells in 
a cell culture experiment. MTS is bio-reduced by cells into a formazan product 
that is soluble in tissue culture medium. The absorbance can subsequently be 
measured directly from the cell culture plate and is directly proportional to the 
number of living cells in culture.  
Following hypoxic challenge in GPNT cells there was a significant reduction in 
cell viability of NTC treated cells (arbitrary units 0.80 ± 0.03 vs.1.28 ± 0.06) as 
was expected (Figure 3.12). However following treatment with either siPORT C, 
mimic control/anti-miR control (+C + -C), mimic control/anti-miR-494 (+C + -
494), miR-494 mimic/anti-miR control (+494 + -C) and miR-494 mimic/anti-miR-
494 (+494 + -494) there were equivalent reductions in cell viability following 
hypoxic challenge (Figure 3.12). Normoxic +C + -C treated cells also had 
significantly reduced cell viability as compared to normoxic NTC cells (1.08 ± 
0.03 vs. 1.28 ± 0.06). These results indicated that modulation of miR-494 
expression (either over-expression or subsequent knock-down) did not have any 
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therapeutic effect on the survival of GPNT cerebral endothelial cells following 
hypoxic challenge. 
 
Figure 3.11 - Gelatin Zymography Optimisation 
MMP2 (A, C) and MMP9 (A, B) activity was assessed in GPNT cell lysates. GPNT cells were 
transfected over 2 days with either transfection agent alone (siPORT C), mature miR-494 
mimic followed by anti-miR control (+494 + -C), mature miR-494 mimic followed by anti-miR-
494 (+494 + -494) or did not receive any treatment (NTC). MMP2 and MMP9 activity was 
assessed in cell lysates harvested 24 hours following hypoxic challenge (H, light grey) or 
control normoxic conditions (N, dark grey). Changes in MMP2 and MMP9 were assessed by 
gelatin zymography. Zymogram gels were scanned and analysed using Quantity One® 4.6.8 
software. Arbitrary units represent the intensity of the pixels multiplied by the volume of the 
band. Representative graphs are shown of 1 optimisation experiment. 
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Figure 3.12 – Cell Survival post miR-494 Modulation 
GPNT cells were transfected over 2 days with either transfection agent alone (siPORT C), 
mature mimic control followed by anti-miR control (+C + -C), mature mimic control followed 
by anti-miR-494 (+C + -494), mature miR-494 mimic followed by anti-miR control (+494 + -C), 
mature miR-494 mimic followed by anti-miR-494 (+494 + -494) or did not receive any 
treatment (NTC). Cell viability was assessed by a MTS cell viability assay following hypoxic 
challenge (pink) or control normoxic conditions (grey) (n=3). The quantity of formazan 
product as measured by absorbance at 490nm is directly proportional to the number of 
living cells in culture. Data shown is the absorbance in arbitrary units. Statistical probability 
of differences in cell viability observed were calculated using one-way ANOVA with Tukey’s 
Multiple Comparisons Test: ***p<0.001 vs. normoxic counterpart cells; #p<0.05 for pair 
shown.  
It is plausible that miR-494 modulation affected (or could affect) the expression 
of target genes such as PTEN, MMP9 and MMP2, although there is no obvious 
indication of this in our pilot, optimisation data. However, this is not important 
therapeutically if overall miR-494 modulation has no functional effect. We have 
demonstrated that robust up-regulation of miR-494 expression had no effect 
(either for better or worse) on cell survival following hypoxic challenge. It was 
therefore determined that the balance of evidence indicated that miR-494 was 
not a suitable therapeutic target for modulation in experimental stroke. 
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3.2.2 miR-21 
3.2.2.1 In Vitro miR-21 Modulation 
Modulation of miR-21 as a potential novel therapy in the setting of ischaemic 
stroke was subsequently investigated in pre-clinical models of ischaemic stroke. 
This work was carried out in conjunction with an in vivo study performed by Dr. 
Christopher Breen as part of his PhD project in which he tested whether 
transgenic mouse models with miR-21 over-expression or knock-down had 
altered outcome and/or functional recovery from experimentally induced 
ischaemic stroke. 
Data collected by Dr. Emily Ord showed that miR-21 expression was increased in 
peri-infarct ipsilateral tissue of SHRSP rats at both 24 hours and 72 hours post-
tMCAO (Figure 3.13). miR-21 expression was increased, non-significantly, almost 
four-fold in ipsilateral peri-infarct tissue at 24 hours in comparison to expression 
in matched tissue from sham operated animals (RQ 3.91 ± 0.49 vs. 1.00 ± 1.09) 
and two-fold in contralateral peri-infarct tissue (RQ 1.98 ± 0.45 vs. 1.00 ± 0.18) 
at the same time point (Figure 3.13 A and C). At 72 hours miR-21 expression was 
increased over seven-fold in ipsilateral peri-infarct tissue in comparison to 
expression in matched tissue from sham operated animals (RQ 7.53 ± 1.86 vs. 
1.00 ± 0.93) and increased to a much smaller, but still significant, extent in 
matched contralateral tissue (RQ 3.72 ± 0.64 vs. 1.00 ± 0.28) (Figure 3.13 B and 
D).  
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Figure 3.13 – miR-21 Expression in SHRSP Rat Brain post-tMCAO 
The expression of miR-21 was assessed in ipsilateral (A, B) and contralateral (C, D) peri-
infarct brain tissue of SHRSP rats at 24 hours (A, C) and 72 hours (B, D) following 45 min 
tMCAO (coloured bars) or sham operation (grey bars) (n=6/group). Statistical probability of 
differences in expression observed were calculated using unpaired Student’s t-test with 
Bonferroni corrections, vs. sham operated rats. Change in miRNA expression was assessed 
by qRT-PCR and relative quantification (RQ) calculated from ΔΔCt following normalisation 
to a housekeeper miRNA, U87, and compared to miRNA expression in sham operated rats. 
Data shown is RQ ± RQmax/RQmin. Data courtesy of Dr. Emily Ord. 
miR-21 expression was modulated in GPNT cerebral endothelial cells in vitro via 
the delivery of mature miRNA mimics and miRNA anti-miRs, delivered using 
siPORT transfection agent (Figure 3.14). miR-21 expression was unchanged in 
NTC GPNT cells following hypoxic challenge as compared to normoxic cells (1∆Ct 
1.34 ± 0.19 vs. 1.66 ± 0.47) (Figure 3.14). miR-21 expression was also unchanged 
in both normoxic and hypoxic GPNT cells following delivery of siPORT and the 
mature mimic control (+C). Following treatment with the anti-miR control (-C) 
miR-21 expression was decreased in normoxic cells as compared to normoxic NTC 
treated cells (RQ 0.70 ± 0.11 vs. 1.00 ± 0.12). However expression of miR-21 in 
hypoxic –C treated cells was not significantly decreased in comparison to hypoxic 
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NTC treated cells (RQ 0.88 ± 0.08 vs. 1.00 ± 0.09). miR-21 expression was 
successfully increased following delivery of miR-21 mimic in normoxic (RQ 3.26 ± 
0.41 vs. 1.00 0.12) and hypoxic (RQ 1.69 ± 0.18 vs. 1.00 ± 0.09) cells in 
comparison to matched NTC control cells (Figure 3.14). However similarly to 
what we observed following miR-494 modulation, miR-21 expression was not 
significantly decreased following delivery of miR-21 anti-miR to GPNT cells: 
normoxic (RQ 0.73 ± 0.08 vs. 1.00 ± 0.12); hypoxic (RQ 0.78 ± 0.12 vs. 1.00 ± 
0.09) (Figure 3.14). 
 
Figure 3.14 – miR-21 Modulation in GPNT Cells 
GPNT cells were transfected with the transfection agent alone (siPORT C), mature mimic 
control (+ C), mature miR-21 mimic (+ miR-21), anti-miR control (- C) or anti-miR-21 (- miR-
21) or did not receive any treatment (NTC). miR-21 expression was assessed in cell lysates 
harvested 24 hours following hypoxic challenge (blue) or control normoxic conditions (grey) 
(n=3). Change in miRNA expression was assessed by qRT-PCR and relative quantification 
(RQ) calculated from ΔΔCt following normalisation to a housekeeper miRNA, U87, and 
compared to miRNA expression in NTC control cells. Data shown is RQ ± RQmax/RQmin. 
Raw Ct values are shown above each column. Statistical probability of differences in 
expression observed were calculated using unpaired Student’s t-test with Tukey’s Multiple 
Comparisons Test. Selected statistical significances are shown on the graph: *p<0.05, 
***p<0.001 vs. normoxic NTC cells; p<0.001 vs hypoxic NTC cells, ###p<0.001 vs. for 
selected pair.  
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Gene expression of experimentally validated miR-21 target genes (PTEN, PDCD4, 
SPRY1, MMP9 and MMP2) was subsequently analysed in the GPNT cells in which 
miR-21 expression had been modulated. PTEN expression was unchanged in 
hypoxic NTC treated cells as compared to normoxic NTC treated cells (1/∆Ct 
0.15 ± 0.004 vs. 0.155 ± 0.003) (Figure 3.15A). Expression of PTEN was also 
unchanged following treatment with controls (siPORT C, mimic control or anti-
miR control). Furthermore, despite robust up-regulation of miR-21 in vitro there 
was no observable change in PTEN expression in comparison to NTC treated 
cells: normoxic (RQ 0.91 ± 0.03 vs. 1.00 ± 0.08); hypoxic (RQ 0.88 ± 0.01 vs. 1.00 
± 0.13) (Figure 3.15A). Similarly PDCD4 expression was unchanged in hypoxic 
NTC treated cells as compared to normoxic NTC treated cells (1∆Ct 0.12 ± 0.008 
vs. 0.14 ± 0.006) (Figure 3.15B). Expression of PDCD4 was also unchanged 
following treatment with controls and also miR-21 mimic despite significant up-
regulation of miR-21 expression: normoxic (RQ 0.78 ± 0.18 vs. 1.00 ± 0.25) and 
hypoxic (RQ 1.19 ± 0.20 vs. 1.00 ± 0.51) (Figure 3.15B).  
Expression of target genes was variable following miR-21 modulation, even 
within treatment groups, as was also observed following miR-494 modulation. 
This was especially pronounced in the case of SPRY1, MMP2 and MMP9 where 
endogenous levels of mRNA expression were low (data not shown). The data was 
so variable that it was difficult to interpret and so the results are not presented 
here. 
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Figure 3.15 – Gene Expression post-miR-21 Modulation 
GPNT cells were transfected with the transfection agent alone (siPORT C), mature mimic 
control (+ C), mature miR-21 mimic (+ miR-21), anti-miR control (- C) or anti-miR-21 (- miR-
21) or did not receive any treatment (NTC). PTEN (A) and PDCD4 (B) expression was 
assessed in cell lysates harvested 24 hours following hypoxic challenge (coloured bars) or 
control normoxic conditions (grey) (n=3). Change in mRNA expression was assessed by 
qRT-PCR and relative quantification (RQ) calculated from ΔΔCt following normalisation to a 
housekeeper mRNA, UBC, and compared to mRNA expression in the NTC control cells. Data 
shown is RQ ± RQmax/RQmin. Statistical probability of differences in expression observed 
was calculated using unpaired Student’s t-test with Tukey’s Multiple Comparisons Test. 
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To assess the functional significance of miR-21 up-regulation a MTS cell viability 
assay was performed on GPNT cells in which miR-21 had been modulated. 
Following hypoxic challenge in GPNT cells there was a significant reduction in 
cell viability of NTC treated cells (arbitrary units 0.75 ± 0.07 vs.1.38 ± 0.03) 
(Figure 3.16), similar to what was observed previously (Figure 3.12). Treatment 
with control agents (siPORT C, mimic control and anti-miR control) did not result 
in any changes in cell viability following hypoxic challenge in comparison to their 
normoxic matched cells (Figure 3.16). Despite significant up-regulation of miR-
21 in the GPNT cells there was no change in cell survival following treatment 
with miR-21 mimic in hypoxic cells in comparison to hypoxic NTC treated cells: 
(0.79 ± 0.05 vs. 0.75 ± 0.07). Treatment with anti-miR-21 did result in a 
significant reduction in cell viability in normoxic cells in comparison to normoxic 
NTC treated cells (1.11 ± 0.06 vs. 1.38 ± 0.03). miR-21 up-regulation did not 
appear to have any therapeutic benefit on the cell survival of GPNT cerebral 
endothelial cells following hypoxic challenge. 
 
Figure 3.16 – Cell Survival post miR-21 Modulation 
GPNT cells were transfected with the transfection agent alone (siPORT C), mature mimic 
control (+ C), mature miR-21 mimic (+ miR-21), anti-miR control (- C) or anti-miR-21 (- miR-
21) or did not receive any treatment (NTC). Cell viability was assessed by a MTS cell viability 
assay following hypoxic challenge (blue) or control normoxic conditions (grey) (n=3). The 
quantity of formazan product as measured by absorbance at 490nm is directly proportional 
to the number of living cells in culture. Data shown is the absorbance in arbitrary units. 
Statistical probability of differences in cell viability observed were calculated using one-way 
ANOVA with Tukey’s Multiple Comparisons Test: **p<0.01, ***p<0.001 vs. normoxic 
counterpart cells; #p<0.05 for pair shown.  
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3.2.2.2 Myography 
Studies carried out within our group had previously shown that miR-21 is 
increased in the cerebrovasculature of SHRSP following tMCAO (Breen, 2015). To 
further investigate the possible effects of an increase in miR-21 expression on 
the vasculature wire myography experiments were carried out using aorta from 
miR-21 transgenic mice models. Two mouse models were used: a miR-21-/- with 
global knock-out of miR-21 (and its background WT strain as a control) and a 
miR-21+/- strain with heterozygous global over-expression of miR-21 (and its 
background WT strain as a control). 
U46619 (1x10-9 – 3x10-6 M) was used to induce concentration dependent 
contraction of endothelium intact rings of male mouse aortae (Figure 3.17 and 
Figure 3.18). U46619 is a stable synthetic analogue of endoperoxide 
prostaglandin (PGH2) and acts as a thromboxane A2 receptor agonist, causing 
smooth muscle contraction. L-NAME is a nitric oxide synthase inhibitor that 
allows vasoconstriction to happen unopposed by inhibiting basal NO release. Pre-
treatment of aortae with L-NAME (1x10-4) therefore resulted in increased 
maximal contraction of the aortae following treatment with U46619 in both WT 
strains: miR-21 knock-out WT strain (p<0.0001) (Figure 3.17A) and miR-21 over-
expression WT strain (p=0.0001) (Figure 3.18A). The increased maximal 
contraction obtained following treatment with L-NAME was consistent with 
inhibition of basal nitric oxide activity. In miR-21-/- mice this enhancement of 
contraction, following treatment with L-NAME, was completely ablated 
(p=0.847) (Figure 3.17B) suggesting there was no (or very limited) endothelial 
basal NO activity consistent with a detrimental phenotype associated with the 
specific loss of miR-21 expression. In aortae from miR-21+/- heterozygous mice 
there was enhanced sensitivity to U46619 in comparison to the WT aortae and an 
increase in maximal contraction in the presence of L-NAME (Figure 3.18B). The 
aortae from the miR-21+/- mice demonstrated the most significant change in 
contraction following  L-NAME treatment as not only was contraction enhanced 
overall (p<0.0001), there was as a significant increase in sensitivity, 
demonstrated by a significant difference between the EC50 values following 
treatment with L-NAME (U46619 EC50: 5.28 x 10
-8 vs. U46619 + L-NAME EC50 3.53 
x 10-8; p=0.0011). 
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Figure 3.17 – Vessel Contractility in Aorta of miR-21
-/-
 Mice 
The concentration-dependent contractile effect of U46619 (1x10
-9
 – 3x10
-6
 M) was examined 
following pre-treatment with L-NAME (1x10
-4
 M) in WT (A) and miR-21
-/-
 mice (B). Each point 
is the mean ± SEM of several observations: (A) n=9 (B) n=7. Statistical significance was 
assessed by two-way-ANOVA with Bonferroni’s Multiple Comparisons Test: probability 
values for overall difference in contraction following pre-treatment with L-NAME are given 
on the graph; ***p<0.001 significant difference in contraction of aortae treated with L-NAME 
vs. aortae treated with U46619 alone for a specific concentration. Statistical significance of 
differences between EC50 values was assessed by extra sum of squares F test. 
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Figure 3.18 – Vessel Contractility in Aorta of miR-21
+/-
 Mice 
The concentration-dependent contractile effect of U46619 (1x10
-9
 – 3x10
-6
 M) was examined 
following pre-treatment with L-NAME (1x10
-4
 M) in WT (A) and miR-21
+/-
 mice (B). Each point 
is the mean ± SEM of several observations: (A) n=9 (B) n=9. Statistical significance was 
assessed by two-way-ANOVA with Bonferroni’s Multiple Comparisons Test: probability 
values for overall difference in contraction following pre-treatment with L-NAME are given 
on the graph; *p<0.05, **p<0.01; ***p<0.001 significant difference in contraction of aortae 
treated with L-NAME vs. aortae treated with U46619 alone for a specific concentration. 
Statistical significance of differences between EC50 values was assessed by extra sum of 
squares F test: p<0.01. 
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Acetylcholine (1x10-8 – 3x10-5 M) was used to induce concentration dependent 
relaxation of endothelium-intact rings of male mouse aortae. While 
acetylcholine did induce relaxation of miR miR-21-/- and WT aortae (as assessed 
by two-way ANOVA, p=0.0001) this was primarily in the WT aortae (Figure 
3.19A). A sigmoidal curve could not be fitted this data. There was no difference 
in the relaxation curves between the two mouse strains (p=0.866) (Figure 
3.19A). These results were possibly a result of experimental error and/or the 
unstable nature of acetylcholine as a drug. Before adding acetylcholine to the 
organ bath the aortae were pre-contracted to approximately 80% of their 
original maximal contraction using an appropriate dose of U46619. However, it 
took some time to work out an appropriate level of pre-contraction and so these 
experiments will need to be repeated to get a true result. Furthermore, 
acetylcholine can be rapidly degraded – for this reason carbachol was used to 
investigate vessel relaxation in miR-21+/- and WT mice. Carbachol (1x10-8 – 3x10-5 
M) induced concentration dependent relaxation of miR-21+/- and WT mice aortae 
(p<0.0001) but there was no difference in the relaxation induced between the 
miR-21+/- and WT mice aortae (p=0.138) (Figure 3.19B). 
The results from the myography experiments looked interesting and were 
consistent with our hypothesis that miR-21 modulation could have a therapeutic 
effect in the setting of ischaemic stroke although further work is needed to 
complete these experiments and to expand on them. However, in the light of 
the negative results obtained following miR-21 modulation in the in vitro study 
(presented here) and the in vivo study (Breen, 2015) it was decided to stop the 
experiments early and focus on a new study, presented as part of this thesis in 
Chapter 4 and Chapter 5. 
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Figure 3.19 – Vessel Relaxation in Aorta of miR-21
-/-
 and miR-21
+/-
 Mice 
The concentration-dependent relaxation effect was examined following treatment with 
acetylcholine (1x10
-8
 – 3x10
-5
 M) (A) or carbachol (1x10
-8
 – 3x10
-5
 M) (B) in the aorta of male 
WT and miR-21
-/-
 mice (A) and WT and miR-21
+/-
 mice (B). Each point is the mean ± SEM of 
several observations: (A) n=7-9/group (B) n=9/group. Statistical significance was assessed 
by two-way-ANOVA with Bonferroni’s Multiple Comparisons Test: probability values for 
overall difference in relaxation between WT and either miR-21
-/-
 or miR-21
+/-
 aortae are given 
on the graph 
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3.3 Discussion 
It was hypothesised that modulation of two candidate miRNAs, miR-494 and miR-
21, would prove therapeutically beneficial in pre-clinical ischaemic stroke 
studies. The presented studies focussed on assessing the extent of miRNA 
modulation in vitro following delivery of miRNA mimics and anti-miRs. 
Subsequently the effect of miR modulation was assessed by profiling the 
expression of putative miRNA target genes and carrying out functional assays to 
measure cell survival following ischaemic insult. To investigate the effect of 
miR-21 on the vasculature wire myography experiments were performed on 
vessels taken from miR-21 transgenic mice. 
Initial results demonstrated that, unlike pilot data and previously reported 
studies, miR-494 was not up-regulated at either 24 or 72 hours post-stroke in 
ipsilateral brain tissue of SHRSP rats following 45 minute tMCAO. SHRSP have a 
number of comorbidities that are often present in human patients including 
hypertension, hypertriglyceridemia, hypercholesterolemia, nephropathy, insulin 
resistance and hyperinsulinemia (Nagaoka et al., 1976). miR-494 had previously 
been shown to be up-regulated post-stroke in the brain tissue of healthy, 
normotensive rats such as SDs (Jeyaseelan et al., 2008, Zhai et al., 2012) and 
Fischer (Gubern et al., 2013). Circulating miR-494 expression was also increased 
in human ischaemic stroke patients but this microarray data was not validated 
and was compared to expression in healthy control patients (Sepramaniam et 
al., 2014, Tan et al., 2013). Therefore, if basal miR-494 expression is increased 
as a result of comorbidities such as hypertension, increased miR-494 expression 
may appear enhanced in these studies and might not have been observed if 
unhealthy, co-morbid controls had been used. Pilot data collected by a student 
in our group suggested that miR-494 was significantly increased in SHRSP at 24 
hours post-tMCAO, especially in the ischaemic infarct and to a lesser extent in 
the ischaemic peri-infarct (penumbra), even when compared to hypertensive 
SHRSP sham operated animals. However, group sizes in the pilot study were 
approximately half (n=2-4/group) of those in the presented study (n=6/group). 
Furthermore, in the present study the infarct and peri-infarct areas were 
identified by T2-weighted MRI scan and tissue was isolated very carefully. In the 
pilot study peri-infarct tissue was only visually assessed before dissection 
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meaning that data shown here is more likely to be a true representation of what 
is occurring biologically.  
miR-21 expression was increased in ipsilateral and contralateral peri-infarct 
SHRSP brain tissue following tMCAO. This is consistent with a number of pre-
clinical and clinical studies where miR-21 expression was shown to be increased 
in brain tissue post embolic MCAO or 4 vessel occlusion in Wistar and SD rats 
(Buller et al., 2010, Deng et al., 2013) and in blood samples collected from 
ischaemic stroke patients at a number of time points post-stroke in comparison 
to healthy control patients (Tan et al., 2009, Tsai et al., 2012, Wang et al., 
2014b). Interestingly, circulating miR-21 expression was unchanged in stroke 
patients when compared to patients with vascular risk or other neurological 
problems (Kim et al., 2015). 
Transcriptome expression of PTEN, MMP2 and MMP9 was significantly altered in 
brain tissue of SHRSP rats following tMCAO. These three genes are validated 
targets of miR-21 and while only PTEN is a validated target of miR-494, MMP9 
and MMP2 are predicted targets. miRNAs usually act to negatively regulate gene 
expression and in the present study up-regulated miR-21 expression is associated 
with down-regulated PTEN expression in peri-infarct tissue at both 24 and 72 
hours post-stroke. Increased miR-21 expression is also associated with decreased 
PTEN and increased pAkt expression in VSMCs and HUVECs (Ji et al., 2007, Weber 
et al., 2010). Furthermore, following ICV infusion with miR-21 mimic the protein 
(but not transcriptome) expression of PTEN was decreased and that of pAkt 
increased (Ge et al., 2014) in the brains of SD following traumatic brain injury. 
In the present study MMP2 mRNA expression was increased significantly in infarct 
tissue at 24 hours post-tMCAO and in infarct, peri-infarct and remainder tissue at 
72 hours post-tMCAO. Furthermore, MMP9 mRNA expression was shown to be 
significantly up-regulated in all brain tissue at 24 hours post-tMCAO but 
unchanged at 72 hours post-tMCAO. Activation of MMP2 following reperfusion is 
associated with early phase BBB disruption (Yang and Rosenberg, 2011). MMP9 is 
increased as a result of oxidative stress and is also released from infiltrating 
neutrophils and is primarily linked with later phase (24 to 72 hours post 
ischaemic insult) BBB disruption (Yang and Rosenberg, 2011). A study 
investigating MMP9 expression in a rodent model of stroke demonstrated 
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significant increases in MMP9 expression at 3, 6, 12 and 24 hours post-stroke, but 
did not investigate expression at later time points (Park et al., 2009). It is 
possible that the time points assessed in the present study do not adequately 
reflect the rapidly evolving changes in MMP2 and MMP9 expression post-
ischaemic insult, which would explain why we do not observe significant 
increases in MM9 mRNA expression at 72 hours post-stroke in the present study.  
Previously, mice with endothelial specific miR-21 knock out had increased MMP2 
expression when compared to WT mice (Zhang et al., 2013). This would suggest 
that up-regulated MMP2 expression in the present study is not connected to 
increased miR-21 expression. 
Human macrophages treated with miR-21 mimic had increased expression and 
secretion of MMP9 (Fan et al., 2014) although decreased miR-21 expression in 
the serum of patients with non-calcified coronary plaques was also associated 
with increased MMP9 expression (Fan et al., 2014). Increased miR-21 expression 
in SD rats following transient 4 vessel occlusion positively correlated with 
increased MMP9 expression and treatment with anti-miR-21 resulted in 
decreased MMP9 expression in vivo (Deng et al., 2013). The increased MMP9 
expression observed in the present study is therefore consistent with MMP9 being 
a target of miR-21. 
miR-494 and miR-21 expression was successfully up-regulated in vitro using 
mature miRNA mimics. However, there was no decrease in miRNA expression 
following delivery with either miR-494 or miR-21 anti-miRs, although miR-494 
expression was down-regulated when anti-miRs were delivered after first up-
regulating miR-494 expression with miR-494 mimics. Despite robust increases in 
both miR-21 and miR-494 expression following treatment with miRNA mimics 
there was no obvious effect of increased miRNA expression on transcriptome 
expression of target genes. If it had been possible to carry out a screening 
experiment to assess the whole transcriptome this may have detected changes in 
novel targets of miR-494 and miR-21 not considered in the present study. 
Numerous studies have demonstrated differential transcriptome and protein 
expression following miRNA modulation so it is possible that while transcriptome 
expression of target genes was unchanged protein expression was modulated. 
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For this reason we had planned to assess PTEN and Akt expression by Western 
Blot and MMP2 and MMP9 activity by gelatin zymography. Unfortunately in the 
time we had to carry out these experiments we were not able to optimise the 
methodology sufficiently to get usable results. However, if the protein 
expression of target genes such as PTEN (which regulates Akt activity as part of 
an endogenous pro-survival pathway) was changed we would have expected to 
see changes in cell survival, as assessed by MTS assay. In the present study there 
was no change in cell survival following treatment with miRNA mimics post-
hypoxic insult. 
One hypothesis for why there was no observable change in target transcriptome 
expression or cell survival following increased miR-494 or miR-21 expression is 
that miRNA expression was increased to supraphysiological levels, inducing 
counter regulatory mechanisms to counteract the increase (van Rooij and 
Kauppinen, 2014). This could especially be the case with miR-494 modulation 
where its expression was increased over 5000-fold following treatment with miR-
494 mimic. The dose of miRNA mimic used had been optimised previously 
(Breen, 2015) and it was hypothesised that if a lower dose was given it might not 
have sufficiently perturbed the cellular homeostasis to induce the modulation of 
target genes. The same dose of both miR-494 and miR-21 mimic was used but 
resulted in much greater over-expression of miR-494 than miR-21, reflecting the 
lower endogenous expression of miR-494.  
An alternative hypothesis for why we did not observe any changes in cell survival 
following increased miR-494 or miR-21 expression is that the mimics delivered in 
vitro were not being processed by the cells to which they were delivered. 
Recently, total levels of miRNA expression (assessed by qRT-PCR) were 
compared to the expression of miRNAs bound to Argonaute (assessed by 
Argonaute immunoprecipitation) following transfection with miRNA mimics 
(Thomson et al., 2013). MDA-MB-231 cells were transfected with miRNA mimic 
using Lipofectamine or HiPerfect transfection reagents. Significant increases in 
miRNA expression (assessed by qRT-PCR) were observed following transfection 
with miRNA mimic but also when the mimic was added following cell lysis. 
miRNAs must be incorporated into RISC to be functional - these results therefore 
demonstrate that qRT-PCR data does not necessarily reflect true functionality of 
the miRNA. Argonaute immunoprecipitation revealed that the amount of RISC 
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associated miRNA expression was much lower than what had been demonstrated 
by qRT-PCR, suggesting that most of the transfected mimic was not bound to 
Argonaute and was therefore non-functional (Thomson et al., 2013). They 
subsequently demonstrated that the majority of transfected miRNA co-localised 
with lysosomes suggesting that miRNA mimics are retained (non-functionally) 
within vesicles and then amplified by qRT-PCR following cell lysis (Thomson et 
al., 2013). 
The lack of functional effect following transfection with miRNA mimics in vitro 
in the presented study is consistent with the hypothesis that miRNA mimics were 
not functionally processed by the cells to which they were delivered. However, 
there is not enough data to support this conclusion. In the present study mimics 
and anti-miRs for both miR-21 and miR-494 were purchased from Invitrogen. 
miR-21 mimics (Sabatel et al., 2011, Wang et al., 2012, Weber et al., 2010, Yang 
et al., 2012, Zhou et al., 2011) and anti-miRs (Sarkar et al., 2010, Wang et al., 
2012, Weber et al., 2010, Zhou et al., 2011) also purchased from Invitrogen, 
have been successfully used (by several studies already cited in this chapter) to 
modulate miR-21 expression with functional effect. The miR-21 modulating 
agents were used at similar concentrations in the present study to those used by 
previous studies in a number of primary and secondary cell types. Therefore, to 
fully understand the results presented here it would have been beneficial to 
carry out similar argonaute immunoprecipitation experiments to assess the level 
of miRNA that was being functionally incorporated into the cells. To further 
assess the effect of miRNA modulation in the present study it would have been 
useful if experiments to assess the protein expression and activity of target 
genes had been fully optimised and if other functional assays, to measure cell 
death, apoptosis and angiogenesis (for example), had been performed. 
Wire myography experiments in the present study revealed differences in the 
contractility of aortae of transgenic mice with either global knock-down or over-
expression of miR-21. In WT mice strains the maximal contraction of the aorta 
following pre-treatment with L-NAME was increased, consistent with inhibition 
of basal nitric oxide activity. In miR-21-/- this increase in contraction was 
completely ablated suggesting abnormal endothelial basal nitric oxide activity 
consistent with a detrimental phenotype associated with a loss of miR-21 
expression. In miR-21+/- heterozygous mice the increase in maximal contraction 
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in the presence of L-NAME was significantly enhanced as compared to WT mice 
consistent with a beneficial effect of the increase in miR-21 expression. These 
results are consistent with those of Zhang and colleagues who demonstrated 
abnormal endothelial activity in mice with endothelium specific miR-21 knockout 
(Zhang et al., 2013). In their study the aorta of miR-21 knock-out mice were 
shown to have reduced maximal contraction in response to norepinephrine and 
endothelial dysfunction was further demonstrated by decreased sensitivity to 
acetylcholine when assessing endothelium dependent relaxation (Zhang et al., 
2013). In the present study acetylcholine was not successful at inducing vessel 
relaxation in either WT or miR-21-/- mice. Although these experiments were 
further optimised and carbachol was successfully used to induce endothelium 
dependent relaxation in miR-21+/- mice, the vessel relaxation experiments in 
miR-21-/- mice were not repeated due to lack of time. However, in general the 
results are consistent with those of Zhang and colleagues and suggest that vessel 
contractile response and the ability of the endothelium to produce nitric oxide 
are impaired in miR-21-/- mice. This is also consistent with experiments 
demonstrating increased eNOS phosphorylation (at serine 1177) and NO 
production in HUVECs transfected with miR-21 mimic (Weber et al., 2010). 
HUVEC transfection with anti-miR-21 also reduced eNOS phosphorylation (Weber 
et al., 2010). 
miR-21+/- mice were not protected from ischaemic stroke in vivo but there was a 
significant increase in mortality of miR-21-/- mice post-tMCAO as compared to 
WT mice suggesting a detrimental phenotype associated with loss of miR-21 
expression (Breen, 2015). These results are consistent with those obtained in the 
present study. To investigate this further it would have been interesting to 
expand on the myography experiments performed on the aorta, part of the 
peripheral vasculature, and characterise the vessel reactivity of the 
cerebrovasculature of miR-21 transgenic mice, including the middle cerebral 
artery. If it had been possible to do this it would have provided information as to 
the importance of miR-21 modulation in the brain and context of ischaemic 
stroke. There are numerous differences between the peripheral and cerebral 
vasculature, including higher NADPH oxidase activity in intracranial vessels in 
association with increased Nox4 expression (Miller et al., 2005). Further 
experiments could also be expanded to compare endothelium-dependent and 
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endothelium-independent relaxation, so that the results could be compared 
more directly to those of previous studies (Zhang et al., 2013). 
While the data generated in the present study was primarily neutral microRNAs-
494 and -21 remain interesting candidates for modulation as novel therapeutic 
agents for the treatment of ischaemic stroke. If more time had been allotted to 
this project, allowing for further optimisation of experiments, interesting data 
may have been generated. 
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Chapter 4 Exosomal Packaged microRNAs in 
Clinical and Pre-Clinical Stroke 
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4.1 Introduction 
The discovery of miRNAs and other non-coding RNAs has demonstrated that there 
are additional levels of cell-type specific gene regulation, important in both 
health and disease. Various miRNAs have been implicated as being dysregulated 
in both human stroke patients (Table 1.2 - Table 1.3) and in pre-clinical models 
of stroke. Importantly, a number of publications have shown modulation of 
miRNA expression to be effective therapeutically in pre-clinical models of stroke 
(Table 1.4). 
miRBase (v21), the online registry of miRNAs, lists 1881 human miRNA stem loop 
sequences. For every stem loop sequence there are two individual miRNAs (guide 
and passenger strands; -5p and -3p strands). Every year many new miRNAs are 
discovered and the latest version of miRBase contains 5441 new mature miRNAs, 
including the first miRNAs in 17 species (Kozomara and Griffiths-Jones, 2014). 
While qRT-PCR is the gold standard methodology for sensitive, quantitative 
profiling of both mRNA and miRNA expression, it is limited in the number of 
samples and miRNAs that can be assessed at one time. Microarray screening 
technology is therefore the methodology of choice for global analysis of miRNA 
expression and produces unbiased (non-targeted), genome wide miRNA profiles.  
While a number of microarray technologies exist TaqMan® OpenArray® MicroRNA 
Panels (used in this study) run 1000s of 33 nL reactions simultaneously on 3072-
well microfluidic OpenArray® Plates that contain dried TaqMan® primers and 
probes for up to 758 miRNAs and controls. The fluorescence from each individual 
reaction is read and quantified by specialised microarray scanners. As each panel 
can hold up to 3 samples and 3 panels can be run simultaneously in a matter of 
hours, this allows for very high throughput miRNA screening in a large number of 
samples. Furthermore, this technology can profile miRNA expression using as 
little as 10-100 ng of input RNA. 
Many high profile studies have successfully used large-scale microarray assays to 
profile miRNA expression in a range of tissue types (Liu et al., 2004a) or to 
profile changes in miRNA expression during the onset and development of 
disease, including cardiovascular disease and cancer (Chen et al., 2008, 
Fichtlscherer et al., 2010, Lu et al., 2005). Furthermore, miRNA expression has 
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been profiled in human stroke patients using array technology (Table 1.2) (Guo 
et al., 2013, Jickling et al., 2014, Li et al., 2015b, Sepramaniam et al., 2014, 
Sørensen et al., 2014, Tan et al., 2013, Tan et al., 2009, Wang et al., 2014b, 
Zhang et al., 2016b). 
While circulating miRNA expression has been profiled in stroke patients, many of 
these studies profile expression in a very small number of stroke patients, do not 
look at the effect of stroke subtype on miRNA expression and compare 
expression in stroke patients to healthy control patients (as discussed more fully 
in section 1.2.3). These studies demonstrate how microarray technology can be 
used effectively to highlight candidate miRNAs of interest. There is, however, a 
clear need for a larger scale study that takes these additional factors into 
consideration, and attempts to more fully validate (by qRT-PCR) the changes 
observed by microarray. 
Furthermore, very little is known about how exosomal miRNA expression differs 
from that of total circulating miRNA expression in the setting of ischaemic 
stroke. Only one published study, to date, has investigated exosomal miRNA 
expression in human stroke patients (Guo et al., 2013). This study performed a 
microarray on pooled samples from healthy control patients, ischaemic stroke 
patients and intracerebral haemorrhage (ICH) patients. They subsequently 
selected 5 miRNAs dysregulated in ICH patients but unaffected by patient gender 
and validated their expression by qRT-PCR in ICH patients. Of these miRs, 3 were 
detected by microarray to be also dysregulated in ischaemic stroke (IS) patients, 
the remaining 2 were unchanged in IS patients in comparison to control patients. 
The supernatant and multivesicular expression of these miRs was then compared 
in healthy controls and ICH patients. Although they did not investigate the 
multivesicular miRNA expression of IS patients, this study is the first to 
demonstrate compartmentalisation of miRNAs in the setting of stroke. 
Pre-clinically, exosomal miR-126 expression has been shown to be down-
regulated in serum of Wistar rats at 3 hours post-tMCAO or pMCAO but 
normalised close to pre-ischaemic levels at 24 hours post-stroke (Chen et al., 
2015). Total serum expression of miR-126 was decreased at 3h post-pMCAO but 
not tMCAO, therefore the dysregulation of miR-126 was exosome specific in this 
case. Furthermore, serum expression of miR-126 was more variable than the 
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exosomal expression, hinting at more highly regulated exosomal miRNA 
expression. 
Previous work within our own group used microarray technology to profile total 
serum miRNA expression in human patients (n=16 stroke, n=14 vascular risk 
factor controls) at 48 hours post-stroke (Breen, 2015). Validation of candidate 
miRNAs (miRs -19b, -20b, -21, -27a, -93, -106a, -139, -331, -374, -532, -590-5p 
and -885) was attempted by qRT-PCR in a larger patient population (n=55 stroke, 
n=20 vascular risk factor controls). Changes in expression of the 12 candidate 
miRNAs did not validate when assessed by qRT-PCR in the validation study 
patient population. However, when expression of these miRNAs was broken down 
in terms of stroke subtype there appeared to be differences in expression of 
some miRNAs between different stroke subtypes (miRs -19b, -21, -93, -331, -374, 
-590-5p and -885), with miRNA expression being especially up-regulated in large 
artery stroke patients (non-significantly). Exosomal expression of 4 miRs (-19b, -
93, -106a and -139) was investigated in the serum of human patients and their 
expression was found to be increased as compared to non-stroke patients but not 
significantly. Finally the total and exosomal expression of 4 miRs (-19b, -93, -
106a and -532) was compared in SHRSP serum at 24 and 72 hours post-tMCAO and 
the exosomal expression (but not the total expression) of miRs-19b, -93 and -
106a were found to be significantly upregulated in SHRSP serum at 72 hours 
post-stroke. Total miR-532 expression was increased as compared to sham 
operated animals but not exosomal miR-532 expression. 
These studies suggest that circulating exosomes containing miRNAs are present 
both in human stroke patients and in pre-clinical models of ischaemic stroke and 
hint at the importance of exosomal packaged miRNAs, as compared to miRNAs 
circulating freely in the serum. This work could be successfully built on by 
harnessing the power of microarray technology to profile exosomal packaged 
miRNA expression in a large number of stroke patients. Dysregulated exosomal 
miRNAs could then be investigated further to test the hypothesis that these 
miRNAs have a functional role to play in the setting of ischaemic stroke. 
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4.1.1 Hypotheses 
The hypotheses of the present study were as follows: 
 Packaging of miRNAs into exosomes will be significantly dysregulated in 
ischaemic stroke patients and as a result of this the circulating exosomal 
miRNA profile will be significantly altered. 
 Exosomal miRNA profiles will be useful in phenotyping patients where 
clinical imaging has proved inconclusive and may serve to direct patient 
care or to predict functional outcome of patients. 
 miRNAs dysregulated in ischaemic stroke patients will be similarly 
dysregulated in pre-clinical models of ischaemic stroke and comparison of 
total and exosomal miRNA expression in these models may provide 
insights into the functional role of exosomal packaged miRNAs following 
stroke. 
4.1.2 Aims 
The aims of this chapter were as follows: 
 To profile miRNA expression in exosomes isolated from the serum of 
ischaemic stroke patients at 48 hours post-stroke by miRNA OpenArray 
experiment and to identify dysregulated miRNAs. 
 To validate candidate miRNAs (as identified by OpenArray) by qRT-PCR in 
a large ischaemic stroke patient population. 
 To relate changes in exosomal miRNA expression to stroke subtype and 
clinical outcome from stroke. 
 To profile expression of selected miRNAs (dysregulated in ischaemic 
stroke patients) in pre-clinical models of ischaemic stroke. 
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4.2 Ischaemic Stroke Patient Results 
4.2.1 Characterisation of Exosomes Isolated from Human Patients 
Extracellular vesicles were isolated from serum taken from ischaemic stroke 
patients at 48 hours post-stroke onset. To verify that isolated vesicles were 
indeed exosomes (as hypothesised), vesicles were visualised, measured and 
quantified using NanoSight technology and transmission electron microscopy. 
4.2.1.1 NanoSight 
Extracellular vesicles were isolated by precipitation from 200µL of human serum 
using Exosome Isolation Reagent (Life Technologies). They were then visualised 
and quantified using a NanoSight LM10 (Figure 4.1). An example NanoSight trace 
for a representative serum sample shows that the majority of extracellular 
vesicles are found within the size range 30-120 nm (Figure 4.1A), with a small 
number of larger vesicles present (all <~450 nm). The average concentration of 
vesicles (within the size range 30–120 nm) in the serum of stroke patients was 
more than double the concentration of vesicles of the same size in non-stroke 
patients (5.2 ± 0.7 x108 particles/mL vs. 2.4 ± 0.4 x108 particles/mL), although 
this change was not statistically significant (Figure 4.1B). Furthermore, there 
were no significant differences in average concentration of extracellular vesicles 
found in the serum of different stroke patient subtypes (Figure 4.1C). 
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Figure 4.1 – Exosome Quantification by NanoSight 
The concentration of exosomes (between 30-120 nm) isolated from 200 µL of human serum 
was determined for each sample using a NanoSight LM10. An example NanoSight trace for a 
representative sample is shown (A). The black trace indicates the concentration of 
exosomes with increasing particle size, while the blue trace shows the cumulative 
percentage of exosomes with increasing particle size. The concentration of exosomes was 
assessed in stroke patients (n=48) and non-stroke patients (n=9) (B). Exosome sample 
concentrations were also evaluated in different stroke subtypes: large artery (n=9), 
cardioembolic (n=12), small vessel disease (n=14) and unclassified (n=13) (C). Probability 
was assessed using unpaired Student’s t-test, vs. non-stroke control patients (B) and one-
way-ANOVA with a Dunnett’s Multiple Comparison Test (C). 
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4.2.1.2 Transmission Electron Microscopy 
Exosomes were subsequently visualised on a transmission electron microscope 
(TEM). To isolate exosomes for this procedure, exosomes were precipitated from 
serum using Exosome Isolation Reagent. The exosome pellet was subsequently 
resuspended in 2% paraformaldehyde before being fixed onto Formvar-carbon 
coated electron microscope (EM) grids according the protocol provided in 
Current Protocols in Cell Biology (Théry et al., 2006). Samples were contrasted 
using uranyl oxalate before being contrasted and embedded in a mixture of 4% 
uranyl acetate and 2% methyl cellulose. In this experiment it was difficult to 
obtain clear images where the methyl cellulose film was too thick. Furthermore, 
the exosome preparations were contaminated by other membranes and proteins 
that were also precipitated with the exosomes during the exosome isolation 
procedure. Exosomes were embedded and prepared for electron microscopy by 
Mrs Margaret Mullin. 
Electron microscopy of exosomes, from extracellular vesicle isolations from two 
human patients, revealed both cup-shaped and more rounded membrane vesicles 
(Figure 4.2 A and B). Representative images were selected from the images 
taken and the diameter of every vesicle present in each image measured. 
Patient A had suffered a cardioembolic stroke; their median vesicle size was 
63.0 nm, with an inter-quartile range (IQR) of 53.8 – 84.5 nm (Figure 4.2C). 
Patient B had suffered a small vessel disease stroke; their median vesicle size 
was 40.0 nm, with an IQR of 31.8 – 53.0 nm (Figure 4.2C). While the median 
vesicle isolated from the cardioembolic patient was ~58% bigger than that of the 
small vessel patient it is impossible to tell how representative these results are 
without visualising exosomes from further human patients by electron 
microscopy. These results primarily serve to show that the vast majority of 
vesicles isolated by precipitation fall within the exosome size range of 30 – 120 
nm. 
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Figure 4.2 – TEM of Human Extracellular Vesicles 
Electron-microscopic observation of whole-mounted exosomes purified from human serum 
by precipitation. Representative images of exosome isolates from two human patient 
samples (A - cardioembolic and B – small vessel) obtained by transmission electron 
microscopy showing both larger microvesicles and exosomes. A box and whisker plot to 
show the diameter of vesicles in representative images (n=4) (C). Plots show 5
th
 percentile, 
Q1, Q2, Q3 and 95
th
 percentile with values outside of this represented by scatter dots. 
Diameter was measured twice on every vesicle in each representative image and the longest 
diameter value was taken for each vesicle to create this graph. 
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4.2.2 OpenArray® Screen Design & Analysis 
Microarray analysis was performed using the TaqMan® OpenArray® Human 
MicroRNA Panels (Life Technologies). Each panel contained 3 individual arrays 
and each array can profile 754 unique human miRNA sequences (plus 4 control 
sequences) for one sample. Sequence data for the array was sourced from 
miRBase (Kozomara and Griffiths-Jones, 2014). Samples were prepared and 
experiments completed as described in section 2.6.3. In the OpenArray 
experiment described here 13 TaqMan® OpenArray® Human MicroRNA Panels 
were used, profiling miRNA expression in 39 patient samples.  
4.2.2.1 Normalisation and Data Analysis 
Raw data collected from the OpenArray experiments was combined using 
DataAssist™ software. DataAssist™ was used to perform quality control analysis 
on the raw data, to perform sample normalisation for each assay and to perform 
quality control analysis on the normalised data. The data were subsequently 
exported and ∆Ct values were calculated by normalising data to the exogenous 
spike-in control (Arabidopsis thaliana miR-159a; ath-miR-159a). ∆Ct values for 
stroke patients were compared to non-stroke patient (control) values. Statistical 
significance for each individual miRNA was calculated using a two-tailed, 
Student’s unpaired t-test. 
4.2.2.2 Experimental Design 
In order to profile exosomal miRNAs differentially regulated in ischaemic stroke 
patients, RNA was extracted from exosomes that had been isolated from serum 
harvested from ischaemic stroke patients at 48 hours post-stroke onset. The 
experiment was designed to document significant changes in miRNA expression 
between non-stroke control patients and ischaemic stroke patients but also to 
highlight differences between ischaemic stroke subtypes. A total of 39 patient 
samples were analysed by OpenArray of which 10 were non-stroke control 
patients and 29 were ischaemic stroke patients: large artery (n=9), 
cardioembolic (n=10) and small vessel (n=10). 
Comparisons were made between ∆Ct values of ischaemic stroke patients and 
non-stroke control patients to highlight exosomal miRNAs dysregulated primarily 
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as a result of cerebrovascular ischaemia. Furthermore, comparisons were made 
between individual stroke subtypes and non-stroke control patients. It was 
hypothesised that this would give more detailed information about whether 
miRNAs were dysregulated specifically in connection with differing stroke 
subtypes or only as a direct result of ischaemia in general. The majority of 
studies published to date, looking at miRNA expression in stroke patients, either 
make no comparison between stroke subtype and miRNA expression or do not 
give information as to the breakdown of their patient population with regard to 
stroke subtype. 
4.2.3 OpenArray® Study Patient Population Demographics 
The demographics of patients used in the OpenArray study are summarised in 
Table 4.1 and Table 4.2. In the OpenArray study serum samples from 39 patients 
(from the full cohort of 173 patients) were used. Serum samples were initially 
collected from patients who presented at the Western Infirmary with stroke-like 
symptoms and were referred to the Acute Stroke Unit where they were assessed 
by stroke-specialist clinicians. Patients were reassessed at 48 hours, 7 days, 1 
month and 3 months post-symptom onset and serum samples were collected at 
each time point when possible. 
Non stroke control patients were those patients who presented with symptoms 
of stroke but were subsequently given a differential diagnosis following medical 
imaging and clinical examination: for example, severe migraine. Importantly the 
non-stroke control patients were aged, hypertensive and on similar medication 
to the stroke patients, but this will be discussed more fully in section 4.2.5. 
Table 4.1 and Table 4.2 demonstrate that patient groups in the OpenArray study 
were matched as closely as possible for age, gender and medical history. There 
are no significant differences between non-stroke control and ischaemic stroke 
patients in any category recorded (Table 4.1). After examining demographical 
data for stroke patients in relation to stroke subtype it is clear that there are no 
significant differences in gender or age although large artery patients are 
slightly younger (median age 63 years vs. 70-73.5 years in other stroke 
subtypes). A higher number of cardioembolic stroke patients are in atrial 
fibrillation than any other patient subtype (50% vs. non-stroke 30%; large artery 
0%; small vessel 0%) but this is expected for this stroke subtype. Differences in 
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miRNA expression observed in the OpenArray study can therefore be assumed to 
be a result of differences in patient subtype rather than of the age or general 
health of the patients. 
Table 4.1 – OpenArray Patient Characteristics 
This table summarises demographical data for the patients used in the OpenArray study. 
The gender, median age and number of patients positive for a number of risk factors for 
stroke and/or on prescribed medication are recorded. A Fisher’s Exact Test was used to 
calculate whether differences observed between non-stroke control and ischaemic stroke 
patients were statistically significant.  indicates a Student’s t-test was used to calculate 
probability. 
  
Non-
Stroke 
Stroke 
p 
(Fisher’s test) 
Age & 
Gender 
n 10 29 n/a 
Male, % (n) 70.0 (7) 75.9 (22) 0.696 
Median Age 70 73 0.544 
Risk 
Factors for 
Ischaemic 
Stroke 
Hypertension, % (n) 70.0 (7) 51.7 (15) 0.464 
Atrial Fibrillation, % (n) 30.0 (3) 17.2 (5) 0.399 
Diabetes (Type 1 or 2), % (n) 30.0 (3) 24.1 (7) 0.696 
Hyperlipidaemia, % (n) 30.0 (3) 31.0 (9) 1.000 
PVD, % (n) 0.0 (0) 0.0 (0) 1.000 
Smoker, % (n) 30.0 (3) 31.0 (9) 1.000 
Ex-Smoker, % (n) 30.0 (3) 20.7 (6) 0.669 
Previous TIA, % (n) 0.0 (0) 3.4 (1) 1.000 
Previous Stroke, % (n) 20.0 (2) 13.8 (4) 0.636 
Family History, % (n) 10.0 (1) 13.8 (4) 1.000 
Medication 
rtPA, % (n) n/a 34.5 (10) n/a 
ACE, % (n) 40.0 (4) 17.2 (5) 0.197 
Alpha Blocker, % (n) 10.0 (1) 0.0 (0) 0.256 
Anticoagulant, % (n) 10.0 (1) 3.4 (1) 0.452 
Antiplatelet, % (n) 60.0 (6) 27.6 (8) 0.124 
ARB, % (n) 0.0 (0) 10.3 (3) 0.556 
Beta Blocker, % (n) 40.0 (4) 31.0 (9) 0.704 
Blood Pressure Treatment, % (n) 70.0 (7) 51.7 (15) 0.464 
CCB, % (n) 40.0 (4) 10.3 (3) 0.057 
Loop Diuretic, % (n) 30.0 (3) 13.8 (4) 0.344 
Oral Hypoglycaemic Drugs, % (n) 20.0 (2) 6.9 (2) 0.267 
Spironolactone, % (n) 10.0 (1) 3.4 (1) 0.452 
Statin, % (n) 60.0 (6) 44.8 (13) 0.480 
Thiazide, % (n) 20.0 (2) 6.9 (2) 0.267 
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Table 4.2 – Open Array Patient Characteristics (Stroke Subtype) 
This table summarises demographical data for the patients used in the OpenArray study. The gender, median age and number of patients positive for a 
number of risk factors for stroke and/or on prescribed medication are recorded. A Chi-Square Test was used to calculate whether differences observed 
between patient groups were statistically significant.  indicates a One-Way ANOVA with Tukey’s multiple comparisons test was used to calculate 
probability. 
  Non-Stroke Large Artery Cardioembolic Small Vessel 
p 
(Chi-square test) 
Age & 
Gender 
n 10 9 10 10 n/a 
Male, % (n) 70.0 (7) 88.9 (8) 70 (7) 70 (7) 0.730 
Median Age 70.0 63.0 73.5 73.5 0.192 
Risk 
Factors for 
Ischaemic 
Stroke 
Hypertension, % (n) 70.0 (7) 33.3 (3) 70.0 (7) 50.0 (5) 0.306 
Atrial Fibrillation, % (n) 30.0 (3) 0.0 (0) 50.0 (5) 0.0 (0) 0.013 
Diabetes (Type 1 or 2), % (n) 30.0 (3) 22.2 (2) 30.0 (3) 20.0 (2) 0.936 
Hyperlipidaemia, % (n) 30.0 (3) 22.2 (2) 50.0 (5) 20.0 (2) 0.459 
PVD, % (n) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) - 
Smoker, % (n) 30.0 (3) 55.6 (5) 30.0 (3) 10.0 (1) 0.126 
Ex-Smoker, % (n) 30.0 (3) 33.3 (3) 20.0 (2) 10.0 (1) 0.611 
Previous TIA, % (n) 0.0 (0) 0.0 (0) 10.0 (1) 0.0 (0) 0.395 
Previous Stroke, % (n) 20.0 (2) 11.1 (1) 10.0 (1) 20.0 (2) 0.879 
Family History, % (n) 10.0 (1) 11.1 (1) 20.0 (2) 10.0 (1) 0.890 
Medication 
rtPA, % (n) n/a 44.4 (4) 30.0 (3) 30.0 (3) 0.751 
ACE, % (n) 40.0 (4) 11.1 (1) 10.0 (1) 30.0 (3) 0.312 
Alpha Blocker, % (n) 10.0 (1) 0.0 (0) 0.0 (0) 0.0 (0) 0.395 
Anticoagulant, % (n) 10.0 (1) 11.1 (1) 0.0 (0) 0.0 (0) 0.526 
Antiplatelet, % (n) 60.0 (6) 22.2 (2) 40.0 (4) 20.0 (2) 0.219 
ARB, % (n) 0.0 (0) 0.0 (0) 20.0 (2) 10.0 (1) 0.285 
Beta Blocker, % (n) 40.0 (4) 22.2 (2) 40.0 (4) 30.0 (3) 0.813 
Blood Pressure Treatment, % (n) 70.0 (7) 33.3 (3) 60.0 (6) 60.0 (6) 0.423 
CCB, % (n) 40.0 (4) 11.1 (1) 0.0 (0) 20.0 (2) 0.122 
Loop Diuretic, % (n) 30.0 (3) 11.1 (1) 20.0 (2) 10.0 (1) 0.630 
Oral Hypoglycaemic Drugs, % (n) 20.0 (2) 11.1 (1) 10.0 (1) 0.0 (0) 0.536 
Spironolactone, % (n) 10.0 (1) 0.0 (0) 10.0 (1) 0.0 (0) 0.572 
Statin, % (n) 60.0 (6) 44.4 (4) 60.0 (6) 30.0 (3) 0.478 
Thiazide, % (n) 20.0 (2) 11.1 (1) 10.0 (1) 0.0 (0) 0.536 
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4.2.4 OpenArray® Results 
553 miRNAs (out of possible 754 miRNAs) were detected by the microarray. Of 
these 93 were detected in ≥ 30% of patients in at least one patient subtype (i.e. 
non-stroke, large artery, cardioembolic or small vessel). Ideally candidate 
miRNAs would have expression in >90% patients. Very few miRNA met these 
criteria. Although this could be a result of using a low sample input (LSI) 
protocol (see section 2.6.3), the RNA input (ng of RNA) used was that 
recommended by Life Technologies for their LSI protocol. In a report published 
by Life Technologies the LSI protocol was demonstrated to detect 92% of the 
miRNAs detected using the standard protocol (Life Technologies, 2011). As a 
result of the small number of miRNAs detected in >90% of patients we examined 
differences in expression of miRNAs present in a much smaller proportion of 
patients than we would have otherwise. Where possible an unpaired Student’s t-
test was used to calculate statistical significance of differences observed 
between patient groups.  
A number of miRNAs: hsa-miR-27b, hsa-miR-93, hsa-miR-520b and hsa-miR-660 
were dysregulated in the exosomes of ischaemic stroke patients as compared to 
non-stroke patient controls (Figure 4.3). Of these, 3 miRNAs were increased in 
stroke patients and only hsa-miR-660 was significantly decreased in stroke 
patients. These results are summarised in Table 4.3. 
Other exosomal miRNAs were either exclusively or especially dysregulated in one 
specific stroke subtype (Figure 4.4 - Figure 4.6). hsa-miR-93 and hsa-miR-20b 
were increased in large artery patients while hsa-miR-30a-5p was decreased 
(Figure 4.4). hsa-miR-520b was increased in cardioembolic patients while hsa-
miR-660 and hsa-miR-218 were down-regulated in these patients (Figure 4.5). 
Finally, hsa-miR-17, hsa-miR-93 and hsa-miR-199a-3p were increased in small 
vessel disease stroke patients whilst hsa-miR-660 was downregulated (Figure 
4.6). These results are summarised in Table 4.3. 
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Figure 4.3 – miRNAs Dysregulated in Stroke Patients 
Exosomal expression of hsa-miR-27b, hsa-miR-93, hsa-miR-520b and hsa-miR-660 was 
profiled in stroke patients. Exosomal miRNA expression was assessed from miRNA 
extracted from exosomes harvested from the serum of control non stroke patients (n=10) 
and large artery (n=9), cardioembolic (n=10) and small vessel disease (n=10) stroke patients. 
Changes in miRNA expression were assessed by OpenArray and data shown are ΔCt 
values. Data was normalised to a spike housekeeper miRNA, ath-miR-159a. Probability 
values were calculated using unpaired Student’s t-test, vs. non stroke control patients. 
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Figure 4.4 – miRNAs Dysregulated in Large Artery Stroke Patients 
Exosomal expression of hsa-miR-93, hsa-miR-20b and hsa-miR-30a-5p was profiled in large 
artery stroke patients. Exosomal miRNA expression was assessed from miRNA extracted 
from exosomes harvested from the serum of control non stroke patients (n=10) and large 
artery (n=9) stroke patients. Changes in miRNA expression were assessed by OpenArray 
and data shown are ΔCt values. Data was normalised to a spike housekeeper miRNA, ath-
miR-159a. Probability values were calculated using unpaired Student’s t-test, vs. non stroke 
control patients. 
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Figure 4.5 – miRNAs Dysregulated in Cardioembolic Stroke Patients 
Exosomal expression of hsa-miR-520b, hsa-miR-660 and hsa-miR-218 was profiled in 
cardioembolic stroke patients. Exosomal miRNA expression was assessed from miRNA 
extracted from exosomes harvested from the serum of control non stroke patients (n=10) 
and cardioembolic (n=10) stroke patients. Changes in miRNA expression were assessed by 
OpenArray and data shown are ΔCt values. Data was normalised to a spike housekeeper 
miRNA, ath-miR-159a. Probability values were calculated using unpaired Student’s t-test, 
vs. non stroke control patients. 
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Figure 4.6 – miRNAs Dysregulated in Small Vessel Disease Stroke Patients 
Exosomal expression of hsa-miR-17, hsa-miR-93, hsa-miR-199a-3p and hsa-miR-660 was 
profiled in small vessel disease stroke patients. Exosomal miRNA expression was assessed 
from miRNA extracted from EVs harvested from the serum of control non stroke patients 
(n=10) and small vessel disease (n=10) stroke patients. Changes in miRNA expression were 
assessed by OpenArray and data shown are ΔCt values. Data was normalised to a spike 
housekeeper miRNA, ath-miR-159a. Probability values were calculated using unpaired 
Student’s t-test, vs. non stroke control patients. 
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Table 4.3 – Dysregulated miRNAs detected by OpenArray 
A table summarising miRNAs that were shown to be dysregulated by OpenArray and whether they were selected for validation. The average Ct value for 
each miRNA in each patient group is given with the direction of change and the probability of changes being statistically significant (as assessed by two-
tailed Student’s unpaired t-test) in comparison to non-stroke control patients. Black text indicates changes that were statistically significant, as opposed to 
the grey text which indicates miRNAs where the change in miRNA expression was not statistically significant. Exosomal miRNA expression was assessed 
from miRNA extracted from exosomes harvested from the serum of control non stroke patients (n=10) and large artery (n=9), cardioembolic (n=10) and 
small vessel disease (n=10) stroke patients. 
miRNA 
Average Ct Value 
T-Test p-value (calculated from dCt) Selected for 
Validation? 
Non Stroke Stroke (All) Large Artery Cardioembolic Small Vessel 
hsa-miR-27b 34.51 
27.81 
↑ p=0.011 
28.38 
↑ p=0.248 
27.42 
↑ p=0.139 
27.76 
↑ p=0.191 
 
mmu-miR-93 31.18 
29.13 
↑ p=0.014 
28.34 
↑ p=0.008 
30.11 
↑ p=0.169 
29.38 
↑ p=0.024 
 
hsa-miR-520b 29.30 
26.42 
↑ p=0.026 
25.28 
↑ p=0.100 
26.66 
↑ p=0.007 
27.45 
↑ p=0.064 
 
hsa-miR-660 26.49 
29.30 
↓ p=0.046 
28.36 
↓ p=0.421 
29.44 
↓ p=0.010 
30.58 
↓ p=0.040 
 
hsa-miR-20b 32.43 
28.72 
↑ p=0.056 
26.49 
↑p=0.020 
30.47 
↑ p=0.171 
29.79 
↑ p=0.168 
 
hsa-miR-30a-5p 27.30 
28.09 
↓ p=0.177 
29.17 
↓ p=0.044 
26.84 
↑ p=0.255 
27.99 
↓ p=0.743 
 
hsa-miR-218 25.59 
25.79 
↓ p=0.915 
25.01 
↑ p=0.646 
27.92 
↓ p=0.035 
25.28 
↑ p=0.508 
 
hsa-miR-17 26.07 
25.03 
↑ p=0.118 
25.07 
↑ p=0.123 
25.78 
↑ p=0.793 
24.26 
↑ p=0.015 
 
hsa-miR-199a-3p 29.09 
26.07 
↑ p=0.265 
23.33 
↑ p=0.185 
28.21 
↑ p=0.278 
26.68 
↑ p=0.036 
 
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In other cases, where miRNAs appeared to be either ‘switched on’ or ‘switched 
off’ no probability could be calculated and so these miRNAs were labelled as 
‘ON-OFF’ or ‘OFF-ON’ (Table 4.4 - Table 4.5). hsa-miR-223* was turned on in 
large artery patients, while hsa-miR-454 and hsa-miR-323-3p were turned on in 
cardioembolic patients and hsa-miR-376a in small vessel disease patients (Table 
4.4). Other miRNAs appeared to be switched off following ischaemic stroke. hsa-
miR-31 and hsa-miR-1291 appeared to be switched off in all stroke subtypes as 
compared to non-stroke patients (Table 4.5). hsa-miR-338-5p and hsa-miR-572 
were turned off in large artery and cardioembolic patients whilst hsa-miR-508 
was turned off in cardioembolic and small vessel disease stroke patients, as 
compared to non-stroke control patients (Table 4.5). hsa-let-7d was switched off 
in large artery patients (Table 4.5). A number of miRNAs were switched off in 
cardioembolic patients alone: hsa-miR-1274a, hsa-miR-186, hsa-miR-192, mmu-
miR-374-5p and hsa-miR-766 (Table 4.5). miRNAs hsa-let-7e and hsa-miR-549 
were turned off in small vessel disease patients alone (Table 4.5). 
The 26 unique miRNAs identified here as candidate miRNAs of interest are 
summarised in Table 4.3 - Table 4.5. While microarray experiments are very 
useful for the discovery of dysregulated miRNAs, variability in microarray results 
and limited dynamic range can limit the sensitivity and specificity of microarray 
experiments. Furthermore, extremely small reaction volumes (33 nL) and false 
positives can reduce the reliability of microarray data. Changes observed 
therefore must be independently validated by qRT-PCR to ensure that miRNAs of 
interest are indeed dysregulated and to investigate to what extent. 
Of the 26 candidate miRNAs identified 17 were selected for validation by qRT-
PCR (a selection had to be made due to budget constraints). All miRNAs with 
statistically significant differences between patient groups (as assessed by t-
test) were selected for validation. All miRNAs that appeared to be switched on 
following stroke were also selected for validation. Of the 13 miRNAs that 
appeared to be switched off following ischaemic stroke, the 2 miRNAs that were 
switched off in all patient groups were selected. Furthermore the 2 miRNAs that 
were switched off only in small vessel disease patients were selected as small 
vessel disease stroke is the most phenotypically different to the other stroke 
subtypes and so we were keen to investigate differences in this stroke subtype. 
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Table 4.4 – miRNAs turned on following stroke (OpenArray) 
A table summarising miRNAs that were shown to be turned on following stroke, as detected by OpenArray, and whether or not they were selected for 
validation. The average Ct value for each miRNA in each patient group is given with the direction of change in comparison to non-stroke control patients. 
Black text indicates where miRNA expression was detected as being turned on, grey text indicates where miRNA expression was not detected. ‘Not 
detected’ indicates miRNA expression was non-detectable in ≥ 90% of patients. Exosomal miRNA expression was assessed from miRNA extracted from 
exosomes harvested from the serum of control non stroke patients (n=10) and large artery (n=9), cardioembolic (n=10) and small vessel disease (n=10) 
stroke patients. 
miRNA 
Average Ct Value 
T-Test p-value (calculated from dCt) Selected for 
Validation? 
Non Stroke Stroke (All) Large Artery Cardioembolic Small Vessel 
hsa-miR-223* Not detected 
29.13 
OFF - ON 
29.81 
OFF - ON 
28.56 
OFF - ON 
28.60 
OFF - ON 
 
hsa-miR-454 Not detected 
28.25 
OFF - ON 
Not detected 
OFF - OFF 
30.93 
OFF - ON 
Not detected 
OFF – OFF 
 
hsa-miR-323-3p Not detected 
29.82 
OFF - ON 
30.86 
OFF - ON 
30.05 
OFF - ON 
28.83 
OFF - ON 
 
hsa-miR-376a Not detected 
29.34 
OFF - ON 
29.00 
OFF – ON 
29.67 
OFF – ON 
29.29 
OFF - ON 
 
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Table 4.5 – miRNAs turned off following stroke (OpenArray) 
A table summarising miRNAs that were shown to be turned off following stroke, as detected by OpenArray, and whether or not they were selected for 
validation. The average Ct value for each miRNA in each patient group is given with the direction of change and the probability of changes being 
statistically significant (as assessed by two-tailed Student’s unpaired t-test) in comparison to non-stroke control patients. Black text indicates where 
miRNA expression was detected as being turned off, grey text indicates where miRNA expression remained detectable. ‘Not detected’ indicates miRNA 
expression was non-detectable in ≥ 90% of patients. Exosomal miRNA expression was assessed from miRNA extracted from exosomes harvested from the 
serum of control non stroke patients (n=10) and large artery (n=9), cardioembolic (n=10) and small vessel disease (n=10) stroke patients. 
miRNA 
Average Ct Value 
T-Test p-value (calculated from dCt) Selected for 
Validation? 
Non Stroke Stroke (All) Large Artery Cardioembolic Small Vessel 
hsa-miR-31 29.18 
28.84 
↑ p=0.571 
Not detected 
ON - OFF 
Not detected 
ON - OFF 
Not detected 
ON - OFF  
hsa-miR-1291 28.64 
24.39 
↑ p=0.993 
Not detected 
ON - OFF 
Not detected 
ON - OFF 
Not detected 
ON - OFF  
hsa-miR-338-5p 31.50 
31.92 
↓ p=0.785 
Not detected 
ON - OFF 
Not detected 
ON - OFF 
33.80 
↓ p=0.516  
hsa-miR-508 28.98 
25.10 
↑ p=0.170 
26.03 
↑ p=0.359 
Not detected 
ON - OFF 
Not detected 
ON - OFF  
hsa-miR-572 28.04 
29.14 
↑ p=0.715 
Not detected 
ON - OFF 
Not detected 
ON - OFF 
29.22 
↓ p=0.960  
hsa-let-7d 29.84 
28.42 
↑ p=0.155 
Not detected 
ON - OFF 
28.61 
↑ p=0.396 
28.44 
↑ p=0.289  
hsa-miR-1274a 31.48 
27.51 
↑ p=0.055 
27.16 
↑ p=0.066 
Not detected 
ON - OFF 
28.22 
↑ p=0.118  
hsa-miR-186 29.83 
30.71 
↓ p=0.539 
28.04 
↑ p=0.154 
Not detected 
ON - OFF 
32.25 
↓ p=0.122  
hsa-miR-192 28.43 
29.43 
↓ p=0.735 
32.35 
↓ p=0.220 
Not detected 
ON - OFF 
26.51 
↑ p=0.428  
mmu-miR-374-5p 30.02 
27.49 
↑ p=0.260 
26.76 
↑ p=0.221 
Not detected 
ON - OFF 
27.82 
↑ p=0.609  
hsa-miR-766 28.16 
27.42 
↑ p=0.685 
27.81 
↑ p=0.752 
Not detected 
ON - OFF 
26.71 
↑ p=0.494  
hsa-let-7e 30.15 
28.05 
↑ p=0.338 
26.38 
↑ p=0.248 
28.69 
↑ p=0.743 
Not detected 
ON - OFF  
hsa-miR-549 30.93 
31.39 
↓p=0.678 
30.59 
↑ p=0.614 
32.22 
↓ p=0.089 
Not detected 
ON - OFF  
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4.2.5 Validation Study Patient Population Demographics 
Demographical information for the full cohort of patients used in the validation 
study is listed in Table 4.6 (non stroke vs. stroke) and Table 4.7 (non stroke vs. 
stroke subtype).  
There is no significant difference between the gender or age of the non-stroke 
and ischaemic stroke patient populations. However the stroke patients are 
moderately older (median age of 68 years vs. 63.5 years for non-stroke) (Table 
4.6). This is because cardioembolic patients are significantly older than all other 
stroke-subtypes (median age of 75 years vs. non stroke, 63.5 years; large artery 
62.5 years; small vessel, 64 years; unclassified, 67 years) (Table 4.7). The 
patients of other stroke subtypes are not significantly older than the non-stroke 
control patients.  
While the percentage of stroke patients in atrial fibrillation is not significantly 
higher than that of the non-stroke control patients (15.6% vs. 8.8%), when the 
difference is broken down in terms of stroke subtype it is clear that a 
significantly higher proportion of cardioembolic patients are in atrial fibrillation 
than any other patient subgroup (60% vs. non-stroke 8.8%, large artery 0%, small 
vessel 2.7% and unclassified 5%). Fisher’s exact test also detected statistically 
significant differences between the percentage of patients who were ex-smokers 
(32.4% non-stroke vs. 13.3% stroke) or who had a history of TIA (23.5% non-stroke 
vs. 8.1% stroke) between the ischaemic stroke and non-stroke control patients. 
However, in both these cases the non-stroke patients had a higher percentage of 
these patients, indicating that differences we observe in exosomal miRNA 
expression will not be as a result of comparing stroke population expression to 
healthy non-stroke control patients. Furthermore, when the differences are 
broken down to represent stroke subtype (Table 4.7) it is clear there are no 
significant differences between any particular stroke subtype and the non-stroke 
patients. 
There are no statistically significant differences between the prescribed 
medication that non-stroke and stroke patients received prior to their arrival at 
hospital. 
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As was discussed in sections 1.1.2 and 1.1.4.2 some of the most important risk 
factors for ischaemic stroke include age, hypertension, ratio of apolipoproteins, 
current smoking and diabetes. For these factors (excepting age, as discussed) 
there is no significant difference between our patient populations. This gives 
confidence that any changes in exosomal miRNA expression observed are a direct 
result of stroke pathophysiology and aren’t confounded as a result of co-
morbidity or medication. 
Table 4.6 – Validation Study Population Characteristics 
This table summarises demographical data for the full cohort of patients used in the 
validation study. The gender, median age and number of patients positive for a number of 
risk factors for stroke and/or on prescribed medication are recorded. A Fisher’s Exact Test 
was used to calculate whether differences observed between non-stroke control and 
ischaemic stroke patients were statistically significant.  indicates a Mann Whitney U Test 
was used to calculate probability. 
  
Non-
Stroke 
Stroke 
p 
(Fisher’s test) 
Age & 
Gender 
n 34 173 n/a 
Male, % (n) 55.9 (19) 63.0 (109) 0.446 
Median Age 63.5 68 0.055 
Risk 
Factors for 
Ischaemic 
Stroke 
Hypertension, % (n) 38.2 (13) 32.9 (57) 0.557 
Atrial Fibrillation, % (n) 8.8 (3) 15.6 (27) 0.427 
Diabetes (Type 1 or 2), % (n) 20.6 (7) 13.9 (24) 0.303 
Hyperlipidaemia, % (n) 17.6 (6) 20.8 (36) 0.817 
PVD, % (n) 5.9 (2) 0.6 (1) 0.071 
Smoker, % (n) 26.5 (9) 26.0 (45) 1.000 
Ex-Smoker, % (n) 32.4 (11) 13.3 (23) 0.011 
Previous TIA, % (n) 23.5 (8) 8.1 (14) 0.014 
Previous Stroke, % (n) 14.7 (5) 11.0 (19) 0.559 
Family History, % (n) 11.8 (4) 12.7 (22) 1.000 
Medication 
rtPA, % (n) n/a 22.5 (39) n/a 
ACE, % (n) 23.5 (8) 18.5 (32) 0.483 
Alpha Blocker, % (n) 0.0 (0) 0.6 (1) 1.000 
Anticoagulant, % (n) 5.9 (2) 4.6 (8) 0.670 
Antiplatelet, % (n) 41.2 (14) 29.5 (51) 0.225 
ARB, % (n) 2.9 (1) 5.2 (9) 1.000 
Beta Blocker, % (n) 29.4 (10) 20.2 (35) 0.258 
Blood Pressure Treatment, % (n) 41.2 (14) 39.3 (68) 0.850 
CCB, % (n) 14.7 (5) 14.5 (25) 1.000 
Loop Diuretic, % (n) 2.9 (1) 8.7 (15) 0.480 
Oral Hypoglycaemic Drugs, % (n) 5.9 (2) 5.8 (10) 1.000 
Spironolactone, % (n) 2.9 (1) 1.2 (2) 0.418 
Statin, % (n) 47.1 (16) 34.7 (60) 0.179 
Thiazide, % (n) 8.8 (3) 8.7 (15) 1.000 
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Table 4.7 – Validation Study Population Characteristics 
This table summarises demographical data for the patients used in the validation study. The gender, median age and number of patients positive for a 
number of risk factors for stroke and/or on prescribed medication are recorded. A Chi-Square Test was used to calculate whether differences observed 
between patient groups were statistically significant.  indicates that a Kruskal-Wallis Test was used to calculate probability. 
  Non-Stroke Large Artery Cardioembolic Small Vessel Unclassified 
p 
(Chi-square test) 
Age & 
Gender 
n 34 22 40 37 40 n/a 
Male, % (n) 55.9 (19) 77.3 (17) 70.0 (28) 70.3 (26) 47.5 (19) 0.076 
Median Age 63.5 62.5 75.0 64.0 67.0 0.0012 
Risk 
Factors for 
Ischaemic 
Stroke 
Hypertension, % (n) 38.2 (13) 36.4 (8) 45.0 (18) 32.4 (12) 47.5 (19) 0.667 
Atrial Fibrillation, % (n) 8.8 (3) 0.0 (0) 60.0 (24) 2.7 (1) 5.0 (2) <0.0001 
Diabetes (Type 1 or 2), % (n) 20.6 (7) 13.6 (3) 20.0 (8) 13.5 (5) 20.0 (8) 0.884 
Hyperlipidaemia, % (n) 17.6 (6) 13.6 (3) 30.0 (12) 21.6 (8) 32.5 (13) 0.343 
PVD, % (n) 5.9 (2) 0.0 (0) 0.0 (0) 0.0 (0) 2.5 (1) 0.256 
Smoker, % (n) 26.5 (9) 54.5 (12) 25.0 (10) 37.8 (14) 22.5 (9) 0.066 
Ex Smoker, % (n) 32.4 (11) 22.7 (5) 15.0 (6) 10.8 (4) 20.0 (8) 0.200 
Previous TIA, % (n) 23.5 (8) 9.1 (2) 7.5 (3) 13.5 (5) 10.0 (4) 0.276 
Previous Stroke, % (n) 14.7 (5) 9.1 (2) 7.5 (3) 18.9 (7) 17.5 (7) 0.553 
Family History, % (n) 11.8 (4) 4.5 (1) 10.0 (4) 18.9 (7) 25.0 (10) 0.163 
Medication 
rtPA, % (n) n/a 36.4 (8) 25.0 (10) 27.0 (10) 27.5 (11) 0.810 
ACE, % (n) 23.5 (8) 22.7 (5) 17.5 (7) 24.3 (9) 27.5 (11) 0.882 
Alpha Blocker, % (n) 0.0 (0) 4.5 (1) 0.0 (0) 0.0 (0) 0.0 (0) 0.141 
Anticoagulant, % (n) 5.9 (2) 4.5 (1) 15.0 (6) 2.7 (1) 0.0 (0) 0.052 
Antiplatelet, % (n) 41.2 (14) 31.8 (7) 47.5 (19) 24.3 (9) 40.0 (16) 0.282 
ARB, % (n) 2.9 (1) 9.1 (2) 7.5 (3) 2.7 (1) 7.5 (3) 0.731 
Beta Blocker, % (n) 29.4 (10) 22.7 (5) 42.5 (17) 16.2 (6) 17.5 (7) 0.053 
Blood Pressure Treatment, % (n) 41.2 (14) 45.5 (10) 55.0 (22) 37.8 (14) 55.0 (22) 0.438 
CCB, % (n) 14.7 (5) 18.2 (4) 20.0 (8) 13.5 (5) 20.0 (8) 0.918 
Loop Diuretic, % (n) 2.9 (1) 4.5 (1) 15.0 (6) 13.5 (5) 7.5 (3) 0.318 
Oral Hypoglycaemic Drugs, % (n) 5.9 (2) 4.5 (1) 7.5 (3) 2.7 (1) 12.5 (5) 0.522 
Spironolactone, % (n) 2.9 (1) 0.0 (0) 2.5 (1) 2.7 (1) 0.0 (0) 0.786 
Statin, % (n) 47.1 (16) 50.0 (11) 52.5 (21) 29.7 (11) 42.5 (17) 0.317 
Thiazide, % (n) 8.8 (3) 18.2 (4) 10.0 (4) 2.7 (1) 15.0 (6) 0.310 
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4.2.6 Validation Study Results 
As the microarray experiment included a pre-amplification step, it was decided 
that a trial qRT-PCR experiment should be carried out to decide whether a pre-
amplification step would also be needed in the validation study. The exosomal 
expression of the 17 candidate miRNAs selected for validation and the 
housekeeper miRNA, Caenorhabditis elegans miR-39 (cel-miR-39), were 
therefore profiled in 6 randomly chosen patient samples (Table 4.8).  
Table 4.8 – Exosomal miRNA Expression (standard qRT-PCR) 
miRNA expression of 18 miRNAs was assessed in 6 randomly chosen patient samples. 
miRNA expression was assessed by qRT-PCR in exosomes isolated from serum samples 
and collected at 48 hours post-stroke. In the table the average Ct, standard deviation and 
SEM of the expression of each miRNA has been given. 
miRNA Average Ct 
Standard 
Deviation 
SEM 
cel-miR-39-3p 22.70 0.04 0.02 
hsa-let-7e-5p 28.18 0.77 0.31 
hsa-miR-17-5p 30.53 1.02 0.42 
hsa-miR-93-5p 30.86 0.52 0.21 
hsa-miR-30a-5p 31.30 0.86 0.35 
hsa-miR-199a-3p 31.94 1.38 0.56 
hsa-miR-660-5p 32.20 1.10 0.45 
hsa-miR-27b-3p 32.34 1.11 0.45 
hsa-miR-20b-5p 33.15 1.54 0.63 
hsa-miR-218-5p 33.87 0.86 0.35 
hsa-miR-520b 33.95 2.19 0.90 
hsa-miR-454-3p 35.75 1.46 0.60 
hsa-miR-223-5p 35.95 2.56 1.04 
hsa-miR-376a-3p 36.85 1.74 0.71 
hsa-miR-549a 37.15 0.77 0.31 
hsa-miR-31-5p 37.83 2.48 1.01 
hsa-miR-1291 38.56 1.58 0.64 
hsa-miR-323-3p 38.65 1.53 0.62 
 
Where miRNAs had Ct values between 30 and 35 expression was deemed 
adequate. Where miRNAs had Ct values of over 35 expression was considered to 
be low and a pre-amplification step was deemed necessary. The majority of 
miRNAs investigated had adequate miRNA expression in the 6 samples profiled 
(Table 4.8). However, it was hypothesised that if the expression of these miRNAs 
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was decreased in the remaining 167 samples not profiled, in comparison to these 
samples, then the expression of these miRNAs could fall below a Ct of 35 (i.e. ≥ 
35). It was therefore decided essential that a pre-amplification step was 
introduced to the protocol (for all miRNAs) to ensure sufficient expression of 
miRNAs for accurate detection and quantification by qRT-PCR. 
Subsequently a small experiment was carried out to test the effectiveness of 
pre-amplification and to investigate whether this would introduce variability into 
the data (Figure 4.7 and Table 4.9). Expression of each miRNA was assessed by 
standard qRT-PCR in a number of samples and then subsequently assessed by 
qRT-PCR in samples in which a pre-amplification step had been performed as 
part of the protocol. In the majority of samples miRNA expression pre-amplified 
evenly in comparison to standard miRNA expression (Figure 4.7A). However, in 
samples with very low endogenous miRNA expression, miRNAs did not always 
pre-amplify equally, with examples including hsa-miR-323-3p and hsa-miR-1291 
(Figure 4.7B). The difference (average number of cycles) between standard 
miRNA expression and pre-amplified miRNA expression, for each miRNA tested, 
is shown in Table 4.9. As a result of this experiment 4 miRNAs were not taken 
forward for validation by qRT-PCR in the full patient cohort: hsa-miR-323-3p, 
hsa-miR-1291, hsa-miR-454 and hsa-miR-31. 
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Figure 4.7 – Pre-Amplification of miRNA 
miRNA expression of 18 miRNAs was assessed in randomly chosen patient samples (n=4-
5). Expression of 4 representative miRNAs is shown here. cel-miR-39, hsa-let-7e (A) hsa-
miR-323-3p and hsa-miR-1291 (B) miRNA expression was assessed by qRT-PCR in 
exosomes isolated from serum samples and collected at 48 hours post-stroke. miRNA 
expression was profiled with and without a pre-amplification step. Data shown is raw Ct 
values. 
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Table 4.9 – Pre-Amplification of miRNA 
miRNA expression of 18 miRNAs was assessed in randomly chosen patient samples (n=4-
5). miRNA expression was assessed by qRT-PCR in exosomes isolated from serum samples 
and collected at 48 hours post-stroke. miRNA expression was also assessed by qRT-PCR in 
the same samples that had been subjected to a pre-amplification step. Data shown is the 
average raw Ct value for each miRNA and the average differences in the number of cycles 
between the two methods has been calculated. 
miRNA 
qRT-PCR 
(Average Ct) 
qRT-PCR + 
PreAmp 
(Average Ct) 
No. Cycles 
Improved 
cel-miR-39 22.88 13.80 9.08 
hsa-let-7e 28.53 23.13 5.40 
hsa-miR-17 30.77 19.93 10.84 
hsa-miR-93 30.85 24.55 6.29 
hsa-miR-30a-5p 31.30 25.69 5.61 
hsa-miR-199a-3p 32.08 25.35 6.73 
hsa-miR-660 32.54 26.26 6.27 
hsa-miR-27b 32.82 27.53 5.29 
hsa-miR-520b 33.43 29.19 4.24 
hsa-miR-218 33.84 30.79 3.05 
hsa-miR-20b 33.96 23.74 10.22 
hsa-miR-31 35.05 40.00 -4.95 
hsa-miR-454 35.05 25.88 9.17 
hsa-miR-223# 35.79 28.34 7.45 
hsa-miR-376a 35.79 29.77 6.02 
hsa-miR-549 36.31 29.92 6.39 
hsa-miR-1291 37.10 32.95 4.20 
hsa-miR-323-3p 37.95 34.80 3.93 
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The exosomal expression of 13 miRNAs was assessed in the validation study 
cohort (n=173). Of these patients, 37 were unable to have their diagnosis of 
ischaemic stroke confirmed by conventional imaging and so they are termed 
‘possible’, the diagnosis for all remaining ischaemic stroke patients is termed 
‘definite’. Possible stroke patients may have a milder stroke phenotype and so 
we have compared expression between non-stroke and all stroke patients, and 
non-stroke and only definite stroke patients, to see if this difference affects 
miRNA expression. 
Exosomal hsa-miR-27b is significantly increased in all stroke patients as 
compared to non-stroke patients (RQ 1.62 ± 0.16 vs. 1.00 ± 0.18) (Figure 4.8A) 
and is also significantly increased in definite stroke patients as compared to non-
stroke controls (RQ 1.72 ± 0.20 vs. 1.00 ± 0.18) (Figure 4.8B). Furthermore, 
while its expression is moderately increased in large artery stroke patients, it is 
significantly increased in small vessel disease patients, as compared to non-
stroke control patients (RQ 2.24 ± 0.47 vs. 1.00 ± 0.18) (Figure 4.8C). 
Interestingly, expression of hsa-miR-27b is unchanged in unclassified patients 
relative to non-stroke patients. There is no correlation between hsa-miR-27b and 
the age (R2 = 0.00766) or gender of the patients (Figure 4.8 D and E). Although 
has-miR-27b expression is increased (non-significantly) in male large artery 
patients as compared to female patients, this probably reflects the small 
number of female patients in this particular stroke subtype (n=5). 
Other miRNAs were dysregulated in a similar manner.  
hsa-miR-93 is not significantly increased in the exosomes of all stroke patients 
as compared to non-stroke patients (RQ 1.51 ± 0.15 vs. 1.00 ± 0.18)  (Figure 
4.9A) but is significantly increased in definite stroke patients as compared to 
non-stroke controls (RQ 1.61 ± 0.19 vs. 1.00 ± 0.18) (Figure 4.9B). Its expression 
is slightly increased in large artery and cardioembolic stroke patients but is only 
significantly increased in small vessel disease patients as compared to non-stroke 
control patients (RQ 2.23 ± 0.47 vs. 1.00 ± 0.18) (Figure 4.9C). Expression of hsa-
miR-93 is unchanged in unclassified patients relative to non-stroke patients. 
There is no correlation between hsa-miR-93 and the age (R2 = 0.00115) or gender 
of the patients (Figure 4.9 D and E). 
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Exosomal hsa-miR-20b is significantly increased in all stroke patients as 
compared to non-stroke patients (RQ 1.66 ± 0.17 vs. 1.00 ± 0.19) (Figure 4.10A) 
and is also significantly increased in definite stroke patients as compared to non-
stroke controls (RQ 1.75 ± 0.20 vs. 1.00 ± 0.19) (Figure 4.10B). While its 
expression is moderately increased in large artery and cardioembolic stroke 
patients, it is only significantly increased in small vessel disease patients as 
compared to non-stroke control patients (RQ 2.36 ± 0.47 vs. 1.00 ± 0.19) (Figure 
4.10C). Expression of hsa-miR-20b is unchanged in unclassified patients relative 
to non-stroke patients. There is no correlation between hsa-miR-20b and the age 
(R2 = 0.000259) or gender of the patients (Figure 4.10 D and E). 
hsa-miR-17 is also significantly increased in the exosomes of all stroke patients 
as compared to non-stroke patients (RQ 1.54 ± 0.15 vs. 1.00 ± 0.16) (Figure 
4.11A) and is similarly increased in definite stroke patients as compared to non-
stroke controls (RQ 1.55 ± 0.19 vs. 1.00 ± 0.16) (Figure 4.11B). hsa-miR-17 is 
significantly increased in small vessel disease patients as compared to non-stroke 
patients (RQ 2.15 ± 0.40 vs. 1.00 ± 0.16) (Figure 4.11C). There was no 
correlation between hsa-miR-17 and patient age (R2 = 0.0000134) or patient 
gender (Figure 4.11 D and E). 
Interestingly three miRNAs with up-regulated exosomal expression in stroke 
patients as compared to non-stroke patient controls (in the present study) 
belong to one miRNA family.  hsa-miR-17, hsa-miR-93 and hsa-miR-20b all belong 
to the miR-17 family (Figure 4.12).  While these miRNAs are transcribed from 
separate chromosomes (hsa-miR-17 from chromosome 13, hsa-miR-93 from 
chromosome 7 and hsa-miR-20b from chromosome X) they have similar 
sequences and identical seed sequences (Figure 4.12A).  The seed sequence is 
important for miRNA-target interaction and so miRNAs with identical seed 
sequences are thought to have mRNA targets in common. 
miRWalk 2.0 was used to generate a list of predicted targets for the three 
miRNAs. Predicted genes from 12 databases were looked at: miRWalk, Microt4, 
miRanda, mirbridge, miRDB, miRMap, miRNAMap, Pictar2, PITA, RNA22, 
RNAhybrid and Targetscan. Only gene targets that were predicted by 7 or more 
databases were counted as a positive hit, and of these miRNAs -17-5p, -93-5p 
and -20b-5p have 1873 predicted gene targets in common (Figure 4.12C).  
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miRWalk and miRTarBase were used to generate a list of experimentally 
validated microRNA-gene target interactions, of these miRNAs -17-5p, -93-5p 
and -20b-5p only have 2 gene targets in common.  This is primarily because very 
few targets of hsa-miR-20b-5p have been experimentally validated to date. 
A significant number (over 100) of the predicted gene targets for miRNAs in this 
family are involved in the regulation of programmed cell death and apoptosis.  
Furthermore, a number of these targets are specifically believed to be involved 
in the regulation of neuron apoptosis. A slightly smaller number of predicted 
targets (approximately 90) are involved in the cellular response to stress and of 
these some are specifically involved in the response to oxygen levels and 
hypoxia. A large proportion of these miRNA-gene target interactions have been 
validated experimentally and these will be discussed further in Chapter 5. 
miRNAs -17-5p, -93-5p and 20b-5p have a very similar pattern of expression in 
relation to stroke subtype (Figure 4.9 - Figure 4.11). The expression of all three 
miRNAs increased more than 2-fold in small vessel disease stroke patients as 
compared to non-stroke control patients. As these three miRNAs from the same 
family are dysregulated in such a similar way we have increased confidence in 
the biological significance of these results. 
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Figure 4.8 – hsa-miR-27b Validation 
The exosomal expression of hsa-miR-27b was profiled in all stroke patients (this includes 
possible stroke patients) (n=139) (A) and in definite stroke patients (n=102) (B) as compared 
to non-stroke patients (n=34). Probability values were calculated using unpaired Student’s t-
test, vs. non-stroke control patients, *p<0.05. hsa-miR-27b expression was also assessed 
specifically in large artery (n=22), cardioembolic (n=40), small vessel (n=37) and 
unclassified (n=40) stroke patients and compared to non-stroke patients (n=34) (C). 
Probability values were calculated using one-way-ANOVA with post-hoc Dunnett’s test, 
**p<0.01. Change in miRNA expression was assessed at 48 hours post-stroke by qRT-PCR 
and relative quantification (RQ) calculated from ΔΔCt following normalisation to a spike 
housekeeper miRNA, cel-miR-39 and compared to miRNA expression in the non-stroke 
control patients. Data shown is RQ ± RQmax/RQmin. Patient age was correlated against 
hsa-miR-27b exosomal expression (D). Data shown are ΔCt values. R
2
 value was calculated 
by Pearson product-moment correlation coefficient. The effect of gender on hsa-miR-27b 
expression was investigated (E). Data shown is 1/ΔCt (±SEM). Probability was calculated 
using a one-way-ANOVA with a Bonferroni Multiple Comparison Test. 
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Figure 4.9 – hsa-miR-93 Validation 
The exosomal expression of hsa-miR-93 was profiled in all stroke patients (this includes 
possible stroke patients) (n=139) (A) and in definite stroke patients (n=102) (B) as compared 
to non-stroke patients (n=34). Probability values were calculated using unpaired Student’s t-
test, vs. non-stroke control patients, *p<0.05. hsa-miR-93 expression was also assessed 
specifically in large artery (n=22), cardioembolic (n=40), small vessel (n=37) and 
unclassified (n=40) stroke patients and compared to non-stroke patients (n=34) (C). 
Probability values were calculated using one-way-ANOVA with post-hoc Dunnett’s test, 
**p<0.01. Change in miRNA expression was assessed at 48 hours post-stroke by qRT-PCR 
and relative quantification (RQ) calculated from ΔΔCt following normalisation to a spike 
housekeeper miRNA, cel-miR-39 and compared to miRNA expression in the non-stroke 
control patients. Data shown is RQ ± RQmax/RQmin. Patient age was correlated against 
hsa-miR-93 exosomal expression (D). Data shown are ΔCt values. R
2
 value was calculated 
by Pearson product-moment correlation coefficient. The effect of gender on hsa-miR-93 
expression was investigated (E). Data shown is 1/ΔCt (±SEM). Probability was calculated 
using a one-way-ANOVA with a Bonferroni Multiple Comparison Test. 
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Figure 4.10 – hsa-miR-20b Validation 
The exosomal expression of hsa-miR-20b was profiled in all stroke patients (this includes 
possible stroke patients) (n=139) (A) and in definite stroke patients (n=102) (B) as compared 
to non-stroke patients (n=34). Probability values were calculated using unpaired Student’s t-
test, vs. non-stroke control patients, *p<0.05. hsa-miR-20b expression was also assessed 
specifically in large artery (n=22), cardioembolic (n=40), small vessel (n=37) and 
unclassified (n=40) stroke patients and compared to non-stroke patients (n=34) (C). 
Probability values were calculated using one-way-ANOVA with post-hoc Dunnett’s test, 
**p<0.01. Change in miRNA expression was assessed at 48 hours post-stroke by qRT-PCR 
and relative quantification (RQ) calculated from ΔΔCt following normalisation to a spike 
housekeeper miRNA, cel-miR-39 and compared to miRNA expression in the non-stroke 
control patients. Data shown is RQ ± RQmax/RQmin. Patient age was correlated against 
hsa-miR-20b exosomal expression (D). Data shown are ΔCt values. R
2
 value was calculated 
by Pearson product-moment correlation coefficient. The effect of gender on hsa-miR-20b 
expression was investigated (E). Data shown is 1/ΔCt (±SEM). Probability was calculated 
using a one-way-ANOVA with a Bonferroni Multiple Comparison Test. 
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Figure 4.11 – hsa-miR-17 Validation 
The exosomal expression of hsa-miR-17 was profiled in all stroke patients (this includes 
possible stroke patients) (n=139) (A) and in definite stroke patients (n=102) (B) as compared 
to non-stroke patients (n=34). Probability values were calculated using unpaired Student’s t-
test, vs. non-stroke control patients, *p<0.05. hsa-miR-17 expression was also assessed 
specifically in large artery (n=22), cardioembolic (n=40), small vessel (n=37) and 
unclassified (n=40) stroke patients and compared to non-stroke patients (n=34) (C). 
Probability values were calculated using one-way-ANOVA with post-hoc Dunnett’s test, 
*p<0.05. Change in miRNA expression was assessed at 48 hours post-stroke by qRT-PCR 
and relative quantification (RQ) calculated from ΔΔCt following normalisation to a spike 
housekeeper miRNA, cel-miR-39 and compared to miRNA expression in the non-stroke 
control patients. Data shown is RQ ± RQmax/RQmin. Patient age was correlated against 
hsa-miR-17 exosomal expression (D). Data shown are ΔCt values. R
2
 value was calculated 
by Pearson product-moment correlation coefficient. The effect of gender on hsa-miR-17 
expression was investigated (E). Data shown is 1/ΔCt (±SEM). Probability was calculated 
using a one-way-ANOVA with a Bonferroni Multiple Comparison Test. 
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Figure 4.12 – miR-17 Family 
miRNAs -17, -93 and -20b have identical seed sequences (in blue, underlined) (A) and 
belong to the miR-17 family (B) despite being transcribed from separate chromosomes. 
miRNAs -17, -93 and -20b share a number of predicted and experimentally validated gene 
targets (C). 
hsa-miR-199a-3p is not significantly increased in the exosomes of all stroke 
patients as compared to non-stroke patients (RQ 1.56 ± 0.18 vs. 1.00 ± 0.20) 
(Figure 4.13A) but is significantly increased in definite stroke patients as 
compared to non-stroke patients (RQ 1.66 ± 0.30 vs. 1.00 ± 0.20) (Figure 4.13B). 
hsa-miR-199a-3p is significantly increased in small vessel disease patients as 
compared to non-stroke control patients (RQ 2.29 ± 0.48 vs. 1.00 ± 0.20) (Figure 
4.13C) but not in large artery and cardioembolic patients. Its expression was 
unchanged in unclassified patients as compared to non-stroke patients (RQ 0.96 
± 0.24 vs. 1.00 ± 0.20). There was no correlation between hsa-miR-199a-3p 
expression and the patients age (R2 = 0.00425) or gender (Figure 4.13 D and E). 
Exosomal hsa-miR-30a-5p is also not significantly increased in all stroke patients 
as compared to non-stroke patients (RQ 1.47 ± 0.14 vs. 1.00 ± 0.19) (Figure 
4.14A) but is significantly increased in definite stroke patients as compared to 
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non-stroke patients (RQ 1.53 ± 0.17 vs. 1.00 ± 0.19) (Figure 4.14B). hsa-miR-30a-
5p is moderately increased in large artery and cardioembolic stroke patients but 
only significantly increased in small vessel disease patients as compared to non-
stroke control patients (RQ 1.97 ± 0.36 vs. 1.00 ± 0.19) (Figure 4.14C). Its 
expression was unchanged in unclassified patients as compared to non-stroke 
patients (RQ 1.00 ± 0.20 vs. 1.00 ± 0.19). There was no correlation between hsa-
miR-30a-5p expression and the patients age (R2 = 0.00215) or gender (Figure 4.14 
D and E). 
hsa-let-7e is not significantly increased in the exosomes of all stroke patients as 
compared to non-stroke patients (RQ 1.38 ± 0.12 vs. 1.00 ± 0.14) (Figure 4.15A) 
but is significantly increased in definite stroke patients as compared to non-
stroke patients (RQ 1.45 ± 0.15 vs. 1.00 ± 0.14) (Figure 4.15B). hsa-let-7e is 
somewhat increased in large artery and cardioembolic stroke patients but only 
significantly increased in small vessel disease patients as compared to non-stroke 
control patients (RQ 1.85 ± 0.33 vs. 1.00 ± 0.14) (Figure 4.15C). Its expression 
was unchanged in unclassified patients as compared to non-stroke patients (RQ 
0.97 ± 0.19 vs. 1.00 ± 0.14). There was no correlation between hsa-let-7e 
expression and the patients age (R2 = 0.00198) (Figure 4.15D). Male unclassified 
patients had a significantly higher level of hsa-let-7e expression than 
corresponding female patients (1/∆Ct 0.093 ± 0.003 vs. 0.085 ± 0.003) (Figure 
4.15E). 
Exosomal hsa-miR-218 is not significantly increased in all stroke patients as 
compared to non-stroke patients (RQ 1.45 ± 0.14 vs. 1.00 ± 0.30) (Figure 4.16A) 
but is significantly increased in definite stroke patients as compared to non-
stroke patients (RQ 1.64 ± 0.20 vs. 1.00 ± 0.30) (Figure 4.16B). hsa-miR-218 is 
not significantly increased in any stroke patient subtype as compared to non-
stroke control patients (Figure 4.16C). Furthermore, there was no correlation 
between hsa-miR-218 expression and the patients age (R2 = 0.0215) or gender 
(Figure 4.16 D and E). 
hsa-miR-223 is not significantly increased in the exosomes of all stroke patients 
as compared to non-stroke patients (RQ 3.96 ± 1.17 vs. 1.00 ± 0.81) (Figure 
4.17A) but is significantly increased in definite stroke patients as compared to 
non-stroke patients (RQ 4.71 ± 1.61 vs. 1.00 ± 0.81) (Figure 4.17B). hsa-miR-223 
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was not detected in a number of samples (i.e. Ct >40). For the purposes of data 
analysis these samples were given a Ct of 40. This resulted in the data being 
non-normally distributed but appropriate statistical tests were used to 
compensate for this. hsa-miR-223 was not significantly increased in any specific 
stroke subtype as compared to non-stroke controls although it was increased 
eight-fold in cardioembolic patients (RQ 8.06 ± 3.51 vs. 1.00 ± 0.81) (Figure 
4.17C). There was no correlation between hsa-miR-223 expression and the 
patients age (ρ = 0.0471) or gender (Figure 4.17 D and E). 
The exosomal expression of four miRNAs was unchanged as a result of ischaemic 
stroke: miR-520b, miR-660, miR-376a and miR-549a (Figure 4.18 - Figure 
4.21). Their expression was not significantly altered in either all stroke patients 
or definite stroke patients (Figure 4.18 - Figure 4.21 A and B) or in any particular 
stroke subtype (Figure 4.18 - Figure 4.21 C). There was no correlation between 
their expression and patient age (Figure 4.18 - Figure 4.21 D). Furthermore, 
patient gender did not appear to have any effect on their expression (Figure 
4.18 - Figure 4.21 E), with the exception that male large artery stroke patients 
had a significantly higher level of miR-376a expression than their female 
counterparts (Figure 4.20E). There was no effect of gender on miR-376a 
expression observable in other stroke patient subtypes. 
The effect of treatment with rtPA on exosomal miRNA expression was also 
investigated. Treatment with rtPA did not have any effect on the expression of 
the miRNAs already discussed here (data not shown). 
In the present study we have found 3 miRNAs significantly increased in the 
exosomes of all stroke patients vs. controls, 9 exosomal miRNAs that are 
significantly increased in definite stroke patients vs. controls and 7 miRNAs that 
are significantly increased in small vessel disease patients vs. non-stroke control 
patients. Interestingly, for all of these miRNAs, unclassified patients have, on 
average, a very similar level of miRNA expression to non-stroke patients. 
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Figure 4.13 – hsa-miR-199a-3p Validation 
The exosomal expression of hsa-miR-199a-3p was profiled in all stroke patients (this 
includes possible stroke patients) (n=139) (A) and in definite stroke patients (n=102) (B) as 
compared to non-stroke patients (n=34). Probability values were calculated using unpaired 
Student’s t-test, vs. non-stroke control patients, *p<0.05. hsa-miR-199a-3p expression was 
also assessed specifically in large artery (n=22), cardioembolic (n=40), small vessel (n=37) 
and unclassified (n=40) stroke patients and compared to non-stroke patients (n=34) (C). 
Probability values were calculated using one-way-ANOVA with post-hoc Dunnett’s test, 
*p<0.05. Change in miRNA expression was assessed at 48 hours post-stroke by qRT-PCR 
and relative quantification (RQ) calculated from ΔΔCt following normalisation to a spike 
housekeeper miRNA, cel-miR-39 and compared to miRNA expression in the non-stroke 
control patients. Data shown is RQ ± RQmax/RQmin. Patient age was correlated against 
hsa-miR-199a-3p exosomal expression (D). Data shown are ΔCt values. R
2
 value was 
calculated by Pearson product-moment correlation coefficient. The effect of gender on hsa-
miR-199a-3p expression was investigated (E). Data shown is 1/ΔCt (±SEM). Probability was 
calculated using a one-way-ANOVA with a Bonferroni Multiple Comparison Test. 
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Figure 4.14 – hsa-miR-30a-5p Validation 
The exosomal expression of hsa-miR-30a-5p was profiled in all stroke patients (this 
includes possible stroke patients) (n=139) (A) and in definite stroke patients (n=102) (B) as 
compared to non-stroke patients (n=34). Probability values were calculated using unpaired 
Student’s t-test, vs. non-stroke control patients, *p<0.05. hsa-miR-30a-5p expression was 
also assessed specifically in large artery (n=22), cardioembolic (n=40), small vessel (n=37) 
and unclassified (n=40) stroke patients and compared to non-stroke patients (n=34) (C). 
Probability values were calculated using one-way-ANOVA with post-hoc Dunnett’s test, 
*p<0.05. Change in miRNA expression was assessed at 48 hours post-stroke by qRT-PCR 
and relative quantification (RQ) calculated from ΔΔCt following normalisation to a spike 
housekeeper miRNA, cel-miR-39 and compared to miRNA expression in the non-stroke 
control patients. Data shown is RQ ± RQmax/RQmin. Patient age was correlated against 
hsa-miR-30a-5p exosomal expression (D). Data shown are ΔCt values. R
2
 value was 
calculated by Pearson product-moment correlation coefficient. The effect of gender on hsa-
miR-30a-5p expression was investigated (E). Data shown is 1/ΔCt (±SEM). Probability was 
calculated using a one-way-ANOVA with a Bonferroni Multiple Comparison Test. 
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Figure 4.15 – hsa-let-7e Validation 
The exosomal expression of hsa-let-7e was profiled in all stroke patients (this includes 
possible stroke patients) (n=139) (A) and in definite stroke patients (n=102) (B) as compared 
to non-stroke patients (n=34). Probability values were calculated using unpaired Student’s t-
test, vs. non-stroke control patients, *p<0.05. hsa-let-7e expression was also assessed 
specifically in large artery (n=22), cardioembolic (n=40), small vessel (n=37) and 
unclassified (n=40) stroke patients and compared to non-stroke patients (n=34) (C). 
Probability values were calculated using one-way-ANOVA with post-hoc Dunnett’s test, 
*p<0.05. Change in miRNA expression was assessed at 48 hours post-stroke by qRT-PCR 
and relative quantification (RQ) calculated from ΔΔCt following normalisation to a spike 
housekeeper miRNA, cel-miR-39 and compared to miRNA expression in the non-stroke 
control patients. Data shown is RQ ± RQmax/RQmin. Patient age was correlated against 
hsa-let-7e exosomal expression (D). Data shown are ΔCt values. R
2
 value was calculated by 
Pearson product-moment correlation coefficient. The effect of gender on hsa-let-7e 
expression was investigated (E). Data shown is 1/ΔCt (±SEM). Probability was calculated 
using a one-way-ANOVA with a Bonferroni Multiple Comparison Test, *p<0.05. 
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Figure 4.16 – hsa-miR-218-5p Validation 
The exosomal expression of hsa-miR-218-5p was profiled in all stroke patients (this 
includes possible stroke patients) (n=139) (A) and in definite stroke patients (n=102) (B) as 
compared to non-stroke patients (n=34). Probability values were calculated using unpaired 
Student’s t-test, vs. non-stroke control patients, *p<0.05. hsa-miR-218-5p expression was 
also assessed specifically in large artery (n=22), cardioembolic (n=40), small vessel (n=37) 
and unclassified (n=40) stroke patients and compared to non-stroke patients (n=34) (C). 
Probability values were calculated using one-way-ANOVA with post-hoc Dunnett’s test. 
Change in miRNA expression was assessed at 48 hours post-stroke by qRT-PCR and 
relative quantification (RQ) calculated from ΔΔCt following normalisation to a spike 
housekeeper miRNA, cel-miR-39 and compared to miRNA expression in the non-stroke 
control patients. Data shown is RQ ± RQmax/RQmin. Patient age was correlated against 
hsa-miR-218-5p exosomal expression (D). Data shown are ΔCt values. R
2
 value was 
calculated by Pearson product-moment correlation coefficient. The effect of gender on hsa-
miR-218-5p expression was investigated (E). Data shown is 1/ΔCt (±SEM). Probability was 
calculated using a one-way-ANOVA with a Bonferroni Multiple Comparison Test. 
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Figure 4.17 – hsa-miR-223-5p Validation 
The exosomal expression of hsa-miR-223-5p was profiled in all stroke patients (this 
includes possible stroke patients) (n=139) (A) and in definite stroke patients (n=102) (B) as 
compared to non-stroke patients (n=34). Probability values were calculated using Mann-
Whitney U test, vs. non-stroke control patients, *p<0.05. hsa-miR-223-5p expression was 
also assessed specifically in large artery (n=22), cardioembolic (n=40), small vessel (n=37) 
and unclassified (n=40) stroke patients and compared to non-stroke patients (n=34) (C). 
Probability values were calculated using a Kruskal-Wallis H test with post-hoc Dunn’s 
multiple comparisons test. Change in miRNA expression was assessed at 48 hours post-
stroke by qRT-PCR and relative quantification (RQ) calculated from ΔΔCt following 
normalisation to a spike housekeeper miRNA, cel-miR-39 and compared to miRNA 
expression in the non-stroke control patients. Data shown is RQ ± RQmax/RQmin. Patient 
age was correlated against hsa-miR-223-5p exosomal expression (D). Data shown are ΔCt 
values. ρ was calculated by Spearman’s Rank-Order Correlation. The effect of gender on 
hsa-miR-223-5p expression was investigated (E). Data shown is 1/ΔCt (±SEM). Probability 
was calculated using a Kruskal-Wallis H test with post-hoc Dunn’s multiple comparisons 
test. 
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Figure 4.18 – has-miR-520b Validation 
The exosomal expression of hsa-miR-520b was profiled in all stroke patients (this includes 
possible stroke patients) (n=139) (A) and in definite stroke patients (n=102) (B) as compared 
to non-stroke patients (n=34). Probability values were calculated using unpaired Student’s t-
test, vs. non-stroke control patients. hsa-miR-520b expression was also assessed 
specifically in large artery (n=22), cardioembolic (n=40), small vessel (n=37) and 
unclassified (n=40) stroke patients and compared to non-stroke patients (n=34) (C). 
Probability values were calculated using one-way-ANOVA with post-hoc Dunnett’s test. 
Change in miRNA expression was assessed at 48 hours post-stroke by qRT-PCR and 
relative quantification (RQ) calculated from ΔΔCt following normalisation to a spike 
housekeeper miRNA, cel-miR-39 and compared to miRNA expression in the non-stroke 
control patients. Data shown is RQ ± RQmax/RQmin. Patient age was correlated against 
hsa-miR-520b exosomal expression (D). Data shown are ΔCt values. R
2
 value was calculated 
by Pearson product-moment correlation coefficient. The effect of gender on hsa-miR-520b 
expression was investigated (E). Data shown is 1/dCt (±SEM). Probability was calculated 
using a one-way-ANOVA with a Bonferroni Multiple Comparison Test. 
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Figure 4.19 – hsa-miR-660 Validation 
The exosomal expression of hsa-miR-600 was profiled in all stroke patients (this includes 
possible stroke patients) (n=139) (A) and in definite stroke patients (n=102) (B) as compared 
to non-stroke patients (n=34). Probability values were calculated using unpaired Student’s t-
test, vs. non-stroke control patients. hsa-miR-660 expression was also assessed specifically 
in large artery (n=22), cardioembolic (n=40), small vessel (n=37) and unclassified (n=40) 
stroke patients and compared to non-stroke patients (n=34) (C). Probability values were 
calculated using one-way-ANOVA with post-hoc Dunnett’s test. Change in miRNA 
expression was assessed at 48 hours post-stroke by qRT-PCR and relative quantification 
(RQ) calculated from ΔΔCt following normalisation to a spike housekeeper miRNA, cel-miR-
39 and compared to miRNA expression in the non-stroke control patients. Data shown is RQ 
± RQmax/RQmin. Patient age was correlated against hsa-miR-660 exosomal expression (D). 
Data shown are ΔCt values. R
2
 value was calculated by Pearson product-moment correlation 
coefficient. The effect of gender on hsa-miR-660 expression was investigated (E). Data 
shown is 1/dCt (±SEM). Probability was calculated using a one-way-ANOVA with a 
Bonferroni Multiple Comparison Test. 
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Figure 4.20 – hsa-miR-376a-3p Validation 
The exosomal expression of hsa-miR-376a-3p was profiled in all stroke patients (this 
includes possible stroke patients) (n=139) (A) and in definite stroke patients (n=102) (B) as 
compared to non-stroke patients (n=34). Probability values were calculated using unpaired 
Student’s t-test, vs. non-stroke control patients. hsa-miR-376a-3p expression was also 
assessed specifically in large artery (n=22), cardioembolic (n=40), small vessel (n=37) and 
unclassified (n=40) stroke patients and compared to non-stroke patients (n=34) (C). 
Probability values were calculated using one-way-ANOVA with post-hoc Dunnett’s test. 
Change in miRNA expression was assessed at 48 hours post-stroke by qRT-PCR and 
relative quantification (RQ) calculated from ΔΔCt following normalisation to a spike 
housekeeper miRNA, cel-miR-39 and compared to miRNA expression in the non-stroke 
control patients. Data shown is RQ ± RQmax/RQmin. Patient age was correlated against 
hsa-miR-376a-3p exosomal expression (D). Data shown are ΔCt values. R
2
 value was 
calculated by Pearson product-moment correlation coefficient. The effect of gender on hsa-
miR-376a-3p expression was investigated (E). Data shown is 1/ΔCt (±SEM). Probability was 
calculated using a one-way-ANOVA with a Bonferroni Multiple Comparison Test. 
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Figure 4.21 – hsa-miR-549a Validation 
The exosomal expression of hsa-miR-549a was profiled in all stroke patients (this includes 
possible stroke patients) (n=139) (A) and in definite stroke patients (n=102) (B) as compared 
to non-stroke patients (n=34). Probability values were calculated using Mann-Whitney U 
test, vs. non-stroke control patients. hsa-miR-549a expression was also assessed 
specifically in large artery (n=22), cardioembolic (n=40), small vessel (n=37) and 
unclassified (n=40) stroke patients and compared to non-stroke patients (n=34) (C). 
Probability was calculated using a Kruskal-Wallis H test with post-hoc Dunn’s multiple 
comparisons test. Change in miRNA expression was assessed at 48 hours post-stroke by 
qRT-PCR and relative quantification (RQ) calculated from ΔΔCt following normalisation to a 
spike housekeeper miRNA, cel-miR-39 and compared to miRNA expression in the non-
stroke control patients. Data shown is RQ ± RQmax/RQmin. Patient age was correlated 
against hsa-miR-549a exosomal expression (D). Data shown are ΔCt values. ρ was 
calculated by Spearman’s Rank-Order Correlation. The effect of gender on hsa-miR-549a 
expression was investigated (E). Data shown is 1/ΔCt (±SEM). Probability was calculated 
using a Kruskal-Wallis H test with post-hoc Dunn’s multiple comparisons test. 
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4.2.7 miRNA Expression and Clinical Outcome from Stroke 
In the present study we examined the relationship between exosomal expression 
of 7 miRNAs and the clinical outcome of ischaemic stroke patients. These 
miRNAs are miRs -27b, -93, -20b, -17, 30a, 199a and let-7e and were all 
increased in definite stroke patients vs. non-stroke patients and were also all 
increased in small vessel disease vs. non-stroke control patients. In this study we 
have used two measures of clinical outcome: the NIHSS and the mRS, both 
widely used by clinicians in the UK and worldwide. The NIHSS is an impairment 
scale based on 15 measurements and is intended to evaluate both neurological 
outcome and the degree of physical recovery in patients with stroke.  It assesses 
levels of consciousness, extraocular movements, visual fields, facial muscle 
relaxation, extremity strength, sensory function, coordination (ataxia), language 
(aphasia), speech (dysarthria) and hemi-inattention (neglect). It is commonly 
used as an initial assessment tool and to plan post-acute care. Patients can score 
from 0 – 42, with 0 indicating no stroke, 1 to 4 a minor stroke, scores of 5 to 20 
moderate strokes and scores over 21 indicating severe stroke. The second 
measure of clinical outcome used in this study is the modified Rankin scale. This 
is a scale used to measure the degree of disability in a patient post-stroke and 
their level of dependence for carrying out daily activities. It is often used as an 
outcome measure in clinical trials for stroke. Patients can score from 0 – 6.  
Scores of 0 and 1 indicate the patient has either no disability or that they are 
able to carry out all previous activities without assistance despite minor 
symptoms. Scores 2 - 5 indicate increasing levels of disability and a score of 6 
indicates patient death. 
Exosomal hsa-miR-17 expression does not correlate with NIHSS scores at either 
baseline (Figure 4.22A-E) or at day 7 (Figure 4.22F-J). NIHSS scores at baseline 
do not correlate with hsa-miR-17-5p expression (R2 = 0.0028) (Figure 4.22A). If 
these results are broken down further to examine differences in correlation 
between the different stroke subtypes only very small changes are observed: 
large artery (R2 = 0.0058) (Figure 4.22B), cardioembolic (R2 = 0.12) (Figure 
4.22C), small vessel (R2 = 0.00013) (Figure 4.22D) and unclassified (R2 = 0.012) 
(Figure 4.22E). NIHSS scores at day 7 also do not correlate with hsa-miR-17-5p 
expression (R2 = 0.0094) (Figure 4.22F). When broken down further to examine 
the differences between the different stroke subtypes it is clear there are only 
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very small differences between correlations: large artery (R2 = 0.13) (Figure 
4.22G), cardioembolic (R2 = 0.045) (Figure 4.22H), small vessel (R2 = 0.00054) 
(Figure 4.22I) and unclassified (R2 = 0.00038) (Figure 4.22J). 
If exosomal expression of miR-17 is compared between patients with a mRS score 
(at 1 month) of ≤1 (patients with no disability) and patients with a score ≥2 
(patients with slight to significant disability), we can see that there is a slight 
trend towards higher expression of miR-17 in patients with improved outcome 
following stroke (RQ 1.00 ± 0.19 vs. 0.69 ± 0.13, p=0.14) (Figure 4.22K). This 
change is not significant but if the change in expression is broken down to reveal 
differences between differing stroke subtypes it becomes clear that this is most 
likely because miR-17 expression is only associated with improved functional 
recovery in large artery and unclassified stroke patients, although these changes 
are also not significant (Figure 4.22L). 
When examining the relationship between exosomal expression of miRNAs and 
the clinical outcome of ischaemic stroke patients a number of similarities were 
observed between different miRNAs and their relationship to clinical outcome. 
For this reason the results for the following 6 miRNAs have been summarised 
briefly here. The exosomal expression of hsa-miR-20b, hsa-miR-93, hsa-miR-27b, 
hsa-miR-30a, hsa-miR-199a and hsa-let-7e does not correlate with NIHSS scores 
for all stroke patients at baseline or day 7 (Figure 4.23 - Figure 4.28 A and F). 
When broken down further to examine differences between stroke subtypes, 
although there are small changes between stroke subtypes, there is no 
significant correlation between any individual stroke subtype and exosomal 
expression of any one miRNA (Figure 4.23 - Figure 4.28 B-E and G-J). 
204 
 
 
 
Figure 4.22 – has-miR-17 and Clinical Outcome 
NIHSS scores at baseline are correlated against ∆Ct values for hsa-miR-17 expression for all 
definite stroke patients (A), large artery (B), cardioembolic (C), small vessel (D) and 
unclassified stroke patients (E). NIHSS scores at day 7 post-stroke are correlated against 
ΔCt values for hsa-miR-17 expression for all definite stroke patients (F), large artery (G), 
cardioembolic (H), small vessel (I) and unclassified stroke patients (J). R
2
 values are 
calculated by Pearson product-moment correlation coefficient. hsa-miR-17 expression is 
compared between stroke patients with a 1 month mRS ≤ 1 and those with a mRS ≥ 2 (K). 
Probability was calculated using unpaired Student’s t-test. For each stroke subtype hsa-
miR-17 expression was compared between stroke patients with a 1 month mRS ≤ 1 and 
those with a mRS ≥ 2 (L). Probability values were calculated using a one-way-ANOVA with a 
Sidak’s Multiple Comparisons Test. Data shown is RQ ± RQmax/RQmin. Exosomal miRNA 
expression was assessed from miRNA extracted from exosomes harvested from the serum 
of large artery (n=19), cardioembolic (n=32), small vessel disease (n=31) and unclassified 
(n=20) stroke patients.  Change in miRNA expression was assessed by qRT-PCR, data was 
normalised to a spike housekeeper miRNA, cel-miR-39. 
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Figure 4.23 – hsa-miR-20b and Clinical Outcome 
NIHSS scores at baseline are correlated against ∆Ct values for hsa-miR-20b expression for 
all definite stroke patients (A), large artery (B), cardioembolic (C), small vessel (D) and 
unclassified stroke patients (E). NIHSS scores at day 7 post-stroke are correlated against 
ΔCt values for hsa-miR-20b expression for all definite stroke patients (F), large artery (G), 
cardioembolic (H), small vessel (I) and unclassified stroke patients (J). R
2
 values are 
calculated by Pearson product-moment correlation coefficient. hsa-miR-20b expression is 
compared between stroke patients with a 1 month mRS ≤ 1 and those with a mRS ≥ 2 (K). 
Probability was calculated using unpaired Student’s t-test. For each stroke subtype hsa-
miR-17 expression was compared between stroke patients with a 1 month mRS ≤ 1 and 
those with a mRS ≥ 2 (L). Probability was calculated using a one-way-ANOVA with a Sidak’s 
Multiple Comparisons Test. Data shown is RQ ± RQmax/RQmin. Exosomal miRNA 
expression was assessed from miRNA extracted from exosomes harvested from the serum 
of large artery (n=19), cardioembolic (n=32), small vessel disease (n=31) and unclassified 
(n=20) stroke patients. Change in miRNA expression was assessed by qRT-PCR, data was 
normalised to a spike housekeeper miRNA, cel-miR-39. 
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Figure 4.24 – hsa-miR-93 and Clinical Outcome 
NIHSS scores at baseline are correlated against ∆Ct values for hsa-miR-93 expression for all 
definite stroke patients (A), large artery (B), cardioembolic (C), small vessel (D) and 
unclassified stroke patients (E). NIHSS scores at day 7 post-stroke are correlated against 
ΔCt values for hsa-miR-93 expression for all definite stroke patients (F), large artery (G), 
cardioembolic (H), small vessel (I) and unclassified stroke patients (J). R
2
 values are 
calculated by Pearson product-moment correlation coefficient. hsa-miR-93 expression is 
compared between stroke patients with a 1 month mRS ≤ 1 and those with a mRS ≥ 2 (K). 
Probability was calculated using unpaired Student’s t-test. For each stroke subtype hsa-
miR-93 expression was compared between stroke patients with a 1 month mRS ≤ 1 and 
those with a mRS ≥ 2 (L). Probability was calculated using a one-way-ANOVA with a Sidak’s 
Multiple Comparisons Test. Data shown is RQ ± RQmax/RQmin. Exosomal miRNA 
expression was assessed from miRNA extracted from exosomes harvested from the serum 
of large artery (n=19), cardioembolic (n=32), small vessel disease (n=31) and unclassified 
(n=20) stroke patients. Change in miRNA expression was assessed by qRT-PCR, data was 
normalised to a spike housekeeper miRNA, cel-miR-39. 
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Figure 4.25 – hsa-miR-27b and Clinical Outcome 
NIHSS scores at baseline are correlated against ∆Ct values for hsa-miR-27b expression for 
all definite stroke patients (A), large artery (B), cardioembolic (C), small vessel (D) and 
unclassified stroke patients (E). NIHSS scores at day 7 post-stroke are correlated against 
ΔCt values for hsa-miR-27b expression for all definite stroke patients (F), large artery (G), 
cardioembolic (H), small vessel (I) and unclassified stroke patients (J). R
2
 values are 
calculated by Pearson product-moment correlation coefficient. hsa-miR-27b expression is 
compared between stroke patients with a 1 month mRS ≤ 1 and those with a mRS ≥ 2 (K). 
Probability was calculated using unpaired Student’s t-test. For each stroke subtype hsa-
miR-27b expression was compared between stroke patients with a 1 month mRS ≤ 1 and 
those with a mRS ≥ 2 (L). Probability was calculated using a one-way-ANOVA with a Sidak’s 
Multiple Comparisons Test. Data shown is RQ ± RQmax/RQmin. Exosomal miRNA 
expression was assessed from miRNA extracted from exosomes harvested from the serum 
of large artery (n=19), cardioembolic (n=32), small vessel disease (n=31) and unclassified 
(n=20) stroke patients. Change in miRNA expression was assessed by qRT-PCR, data was 
normalised to a spike housekeeper miRNA, cel-miR-39. 
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Figure 4.26 – hsa-let-7e and Clinical Outcome 
NIHSS scores at baseline are correlated against ∆Ct values for hsa-let-7e expression for all 
definite stroke patients (A), large artery (B), cardioembolic (C), small vessel (D) and 
unclassified stroke patients (E). NIHSS scores at day 7 post-stroke are correlated against 
ΔCt values for hsa-let-7e expression for all definite stroke patients (F), large artery (G), 
cardioembolic (H), small vessel (I) and unclassified stroke patients (J). R
2
 values are 
calculated by Pearson product-moment correlation coefficient. hsa-let-7e expression is 
compared between stroke patients with a 1 month mRS ≤ 1 and those with a mRS ≥ 2 (K). 
Probability was calculated using unpaired Student’s t-test. For each stroke subtype hsa-let-
7e expression was compared between stroke patients with a 1 month mRS ≤ 1 and those 
with a mRS ≥ 2 (L). Probability was calculated using a one-way-ANOVA with a Sidak’s 
Multiple Comparisons Test. Data shown is RQ ± RQmax/RQmin. Exosomal miRNA 
expression was assessed from miRNA extracted from exosomes harvested from the serum 
of large artery (n=19), cardioembolic (n=32), small vessel disease (n=31) and unclassified 
(n=20) stroke patients. Change in miRNA expression was assessed by qRT-PCR, data was 
normalised to a spike housekeeper miRNA, cel-miR-39. 
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Figure 4.27 – hsa-miR-30a-5p and Clinical Outcome 
NIHSS scores at baseline are correlated against ∆Ct values for hsa-miR-30a-5p expression 
for all definite stroke patients (A), large artery (B), cardioembolic (C), small vessel (D) and 
unclassified stroke patients (E). NIHSS scores at day 7 post-stroke are correlated against 
ΔCt values for hsa-miR-30a-5p expression for all definite stroke patients (F), large artery (G), 
cardioembolic (H), small vessel (I) and unclassified stroke patients (J). R
2
 values are 
calculated by Pearson product-moment correlation coefficient. hsa-miR-30a-5p expression 
is compared between stroke patients with a 1 month mRS ≤ 1 and those with a mRS ≥ 2 (K). 
Probability was calculated using unpaired Student’s t-test. For each stroke subtype hsa-
miR-30a-5p expression was compared between stroke patients with a 1 month mRS ≤ 1 and 
those with a mRS ≥ 2 (L). Probability was calculated using a one-way-ANOVA with a Sidak’s 
Multiple Comparisons Test. Data shown is RQ ± RQmax/RQmin. Exosomal miRNA 
expression was assessed from miRNA extracted from exosomes harvested from the serum 
of large artery (n=19), cardioembolic (n=32), small vessel disease (n=31) and unclassified 
(n=20) stroke patients. Change in miRNA expression was assessed by qRT-PCR, data was 
normalised to a spike housekeeper miRNA, cel-miR-39. 
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Figure 4.28 – miR-199a-3p and Clinical Outcome 
NIHSS scores at baseline are correlated against ∆Ct values for hsa-miR-199a-3p expression 
for all definite stroke patients (A), large artery (B), cardioembolic (C), small vessel (D) and 
unclassified stroke patients (E). NIHSS scores at day 7 post-stroke are correlated against 
ΔCt values for hsa-miR-199a-3p expression for all definite stroke patients (F), large artery 
(G), cardioembolic (H), small vessel (I) and unclassified stroke patients (J). R
2
 values are 
calculated by Pearson product-moment correlation coefficient. hsa-miR-199a-3p expression 
is compared between stroke patients with a 1 month mRS ≤ 1 and those with a mRS ≥ 2 (K). 
Probability was calculated using unpaired Student’s t-test. For each stroke subtype hsa-
miR-199a-3p expression was compared between stroke patients with a 1 month mRS ≤ 1 
and those with a mRS ≥ 2 (L). Probability was calculated using a one-way-ANOVA with a 
Sidak’s Multiple Comparisons Test.  Data shown is RQ ± RQmax/RQmin. Exosomal miRNA 
expression was assessed from miRNA extracted from exosomes harvested from the serum 
of large artery (n=19), cardioembolic (n=32), small vessel disease (n=31) and unclassified 
(n=20) stroke patients. Change in miRNA expression was assessed by qRT-PCR, data was 
normalised to a spike housekeeper miRNA, cel-miR-39. 
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There is a slight (non-significant) trend toward higher exosomal expression of 
hsa-miR-20b, hsa-miR-93, hsa-miR-27b and hsa-let-7e in patients without a 
disability in comparison to patients with a disability (mRS ≤ 1 vs. mRS ≥ 2, p ≤ 
0.15) (Figure 4.23 - Figure 4.26 K). For these miRNAs the increased miRNA 
expression is primarily associated with improved functional recovery in large 
artery and unclassified patients, although this trend is not significant (Figure 
4.23 - Figure 4.26 L). Changes in exosomal expression of hsa-miR-30a and hsa-
miR-199a are not, on average, associated with improved functional recovery 
((mRS ≤ 1 vs. mRS ≥ 2, p ≥ 0.15) in ischaemic stroke patients (Figure 4.27 - 
Figure 4.28 K). 
We failed to observe a direct correlation between the exosomal expression of 
any one individual miRNA and clinical outcome from stroke. We hypothesised 
that small changes in multiple miRNAs could be associated with improved 
outcome from stroke. To examine whether a panel of multiple miRNAs could be 
used to predict clinical outcome from stroke ΔCt scores from different miRNAs 
were combined to give an aggregate score. Initially, ΔCt scores for miRNAs -17, -
93 and -20b were combined. As these 3 miRNAs belong to one miRNA family we 
hypothesised that their combined score would be biologically significant and 
would detect whether their expression was associated with improved functional 
recovery from stroke (Figure 4.29). We subsequently tested the aggregate ΔCt 
score of all 7 miRNAs previously investigated (miR-17, miR-93, miR-20b, miR-
27b, miR-199a-3p, miR-30a-5p and hsa-let-7e) (Figure 4.30). 
NIHSS scores at baseline do not correlate with the aggregate ΔCt score for miR-
17 family expression (R2 = 0.001) (Figure 4.29A). When broken down further to 
examine the differences in correlation between the different stroke subtypes 
there is very little change: large artery (R2 = 0.015) (Figure 4.29B), 
cardioembolic (R2 = 0.083) (Figure 4.29C), small vessel (R2 = 0.0022) (Figure 
4.29D) and unclassified (R2 = 0.034) (Figure 4.29E). NIHSS scores at day 7 also do 
not correlate with the aggregate ΔCt score for miR-17 family miRNAs (R2 = 0.004) 
(Figure 4.29F); large artery (R2 = 0.14) (Figure 4.29G), cardioembolic (R2 = 0.019) 
(Figure 4.29H), small vessel (R2 = 0.0033) (Figure 4.29I) and unclassified (R2 = 
0.0095) (Figure 4.29J). As shown previously, there is a trend towards higher 
expression of miR-17 family miRNAs in patients without disability in comparison 
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to those with disability (RQ 1.00 ± 0.69 vs. 0.26 ± 0.18, p=0.08) (Figure 4.29K). 
This change is not significant but if we break down the expression to look at the 
differences between differing stroke subtypes it is clear that increased miR-17 
family expression is chiefly associated with improved functional recovery in large 
artery and unclassified stroke patients, and to a lesser extent in cardioembolic 
and small vessel disease stroke patients (Figure 4.29L). Using the aggregate 
miRNA score resulted in a greater difference in miRNA expression, on average, 
between patients with and without disability. However, as the data were much 
more variable, it is difficult to tell whether this improved the sensitivity and 
specificity of using miRNA expression to predict clinical outcome. 
Finally, NIHSS scores at baseline do not correlate with the aggregate ΔCt score 
for 7 selected miRNAs (R2 = 0.0029) (Figure 4.30A); large artery (R2 = 0.039) 
(Figure 4.30B), cardioembolic (R2 = 0.11) (Figure 4.30C), small vessel (R2 = 
0.0044) (Figure 4.30D) and unclassified (R2 = 0.13) (Figure 4.30E). Furthermore, 
NIHSS scores at day 7 also do not correlate with the aggregate ΔCt score for 7 
selected miRNAs (R2 = 0.0021) (Figure 4.30F); large artery (R2 = 0.088) (Figure 
4.30G), cardioembolic (R2 = 0.016) (Figure 4.30H), small vessel (R2 = 0.025) 
(Figure 4.30I) and unclassified (R2 = 0.038) (Figure 4.30J). There is a trend 
towards a higher aggregate miRNA score in patients without disability (RQ 1.00 ± 
2.06 vs. 0.15 ± 0.35, p=0.26) (Figure 4.30K). Using the aggregate the score of 7 
miRNAs increased the variability of the data very significantly, without showing 
any improved association with clinical outcome from stroke. ROC curve analysis 
demonstrated that an aggregate miRNA score was neither specific nor sensitive 
at predicting clinical outcome (by mRS score) (AUC: 0.51) (Figure 4.30L). 
Aggregate miRNA score (of 7 selected miRNAs), therefore, does not predict 
clinical outcome from stroke. 
One striking observation is the difference between the ranges of clinical 
outcome scores for each stroke subtype. We have observed a significant increase 
in expression of 7 miRNAs in small vessel disease patients and yet these patients 
have the ‘smallest’ strokes and best clinical outcome as measured by NIHSS 
scores at baseline and day 7. 
We have identified and validated changes in exosomal packaged miRNA 
expression in stroke patients and across different stroke subtypes. Multiple 
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miRNAs from one miRNA family were dysregulated similarly, giving increased 
confidence in these results. While we have failed to establish a link between 
exosomal miRNA expression and clinical outcome from stroke, these data will 
direct future studies looking into paracrine signalling in stroke and the 
modulation of specific miRNAs as a novel therapy in the setting of experimental 
stroke. 
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Figure 4.29 – miR-17 Family and Aggregate Score 
NIHSS scores at baseline are correlated against aggregate miR-17 family ∆Ct values for all 
definite stroke patients (A), large artery (B), cardioembolic (C), small vessel (D) and 
unclassified stroke patients (E). NIHSS scores at day 7 post-stroke are correlated against 
aggregate miR-17 family ΔCt values for all definite stroke patients (F), large artery (G), 
cardioembolic (H), small vessel (I) and unclassified stroke patients (J). R
2
 values are 
calculated by Pearson product-moment correlation coefficient. miR-17 family miRNA 
expression is compared between stroke patients with a 1 month mRS ≤ 1 and those with a 
mRS ≥ 2 (K). Probability was calculated using unpaired Student’s t-test. For each stroke 
subtype miR-17 family miRNA expression was compared between stroke patients with a 1 
month mRS ≤ 1 and those with a mRS ≥ 2 (L). Probability was calculated using a one-way-
ANOVA with a Sidak’s Multiple Comparisons Test. Data shown is RQ ± RQmax/RQmin.  
Exosomal miRNA expression was assessed from miRNA extracted from exosomes 
harvested from the serum of large artery (n=19), cardioembolic (n=32), small vessel disease 
(n=31) and unclassified (n=20) stroke patients. Change in miRNA expression was assessed 
by qRT-PCR, data was normalised to a spike housekeeper miRNA, cel-miR-39. 
215 
 
 
 
Figure 4.30 – Aggregate dCt and Clinical Outcome 
NIHSS scores at baseline are correlated against aggregate ∆Ct values for 7 miRNAs for all 
definite stroke patients (A), large artery (B), cardioembolic (C), small vessel (D) and 
unclassified stroke patients (E). NIHSS scores at day 7 post-stroke are correlated against 
aggregate ∆Ct values for 7 miRNAs for all definite stroke patients (F), large artery (G), 
cardioembolic (H), small vessel (I) and unclassified stroke patients (J). R
2
 values are 
calculated by Pearson product-moment correlation coefficient. Aggregate ∆Ct values for 7 
miRNAs were compared between stroke patients with a 1 month mRS ≤ 1 and those with a 
mRS ≥ 2 (K). Data shown is RQ ± RQmax/RQmin. Probability was calculated using unpaired 
Student’s t-test. ROC analysis was used to assess whether an aggregate ∆Ct score for 7 
miRNAs could be used to distinguish between patients with a 1 month mRS scores ≥ 2 as 
compared to patients with a mRS ≤ 1 in any stroke subtype, as assessed by ROC analysis 
(L). Exosomal miRNA expression was assessed from miRNA extracted from exosomes 
harvested from the serum of large artery (n=19), cardioembolic (n=32), small vessel disease 
(n=31) and unclassified (n=20) stroke patients. Change in miRNA expression was assessed 
by qRT-PCR, data was normalised to a spike housekeeper miRNA, cel-miR-39. 
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4.3 Pre-Clinical Results 
4.3.1 Ex Vivo Analysis of Cellular and Exosomal miRNA 
Expression 
To further investigate whether changes in miRNA expression observed were a 
direct result of stroke pathology or a result of pre-existing vascular dysfunction 
we assessed exosomal miRNA expression in normotensive WKY and hypertensive 
SHRSP rats and in SHRSP rats that had been subjected to either tMCAO or 
pMCAO. Furthermore, to assess whether expression of miRNAs was selectively 
increased in exosomes, or increased more generally within the circulation, we 
compared exosomal miRNA expression against total serum miRNA expression. 
Initially it was decided that miRNAs would be taken forward for further analysis 
whose expression was most radically altered or those miRNAs who were 
biologically related (belonging to the same miRNA cluster or family). All 7 
miRNAs whose expression was increased in ischaemic stroke patients were 
altered to a similar extent. We therefore selected miRs -17, -93 and -20b, 
belonging to the miR-17 family, for further analysis. These miRNAs from the 
same miRNA family were dysregulated in a similar manner in our human stroke 
patients, and this gave us increased confidence in the biological significance of 
these results. 
Initially we compared miRNA expression between naïve normotensive WKY and 
hypertensive SHRSP rats (Figure 4.31). Total serum expression of miR-17, -93 and 
-20b expression was unchanged between WKY and SHRSP rats, however exosomal 
expression of these miRNAs was increased in SHRSP rats. Total serum miR-17 
expression was unchanged in SHRSP rats as compared to WKY (RQ SHRSP 1.01 ± 
0.38 vs. WKY 1.00 ± 0.28, p=0.99) (Figure 4.31A) whereas exosomal miR-17 
expression was significantly increased in SHRSP rats (RQ 4.59 ± 1.57 vs. 1.00 ± 
0.78, p=0.046) (Figure 4.31B). Total serum miR-93 expression was also 
unchanged in SHRSP rats as compared to WKY (RQ 1.09 ± 0.27 vs. 1.00 ± 0.33, 
p=0.81) (Figure 4.31C). Although there was a trend towards increased exosomal 
miR-93 expression in SHRSP rats, this change was not significant (RQ 2.47 ± 0.32 
vs. 1.00 ± 0.53, p=0.076) (Figure 4.31D). Similarly total serum miR-20b 
expression was unchanged in SHRSP rats as compared to WKY (RQ 1.13 ± 0.37 vs. 
1.00 ± 0.33, p=0.77) (Figure 4.31E) and there was a trend towards increased 
217 
 
 
exosomal miR-20b expression but this was non-significant (RQ 2.01 ± 0.54 vs. 
1.00 ± 0.36, p=0.11) (Figure 4.31F). 
We subsequently profiled miRNA expression in SHRSP rats post-MCAO. We 
initially assessed miR-17 family miRNA expression in historic peri-infarct brain 
tissue collected in a study carried by Dr. Emily Ord. SHRSP rats were subjected 
to a 45 min tMCAO and were subsequently sacrificed at either 24 or 72 hours 
post-tMCAO. At the point of sacrifice brain tissue was dissected into ipsilateral 
and contralateral hemispheres and each hemisphere was further divided into 
infarct, peri-infarct and remainder (any leftover) tissue. Infarct and peri-infarct 
areas were identified by T2-weighted MRI scan. miRs -17, -93 and -20b were 
unchanged in both ipsilateral and contralateral hemispheres at both 24 hours 
and 72 hours post-tMCAO. 
miR-17 expression was unchanged at 24 hours in ipsilateral peri-infarct tissue in 
tMCAO SHRSP rats as compared to sham operated rats (RQ 1.19 ± 0.16 vs. 1.00 ± 
0.08) and contralateral tissue (RQ 0.83 ± 0.09 vs. 1.00 vs. 0.14) (Figure 4.32A). 
Similarly, at 72 hours miR-17 expression was unchanged in ipsilateral peri-infarct 
tissue (RQ 0.83 ± 0.19 vs. 1.00 ± 0.24) and in the equivalent contralateral tissue 
(RQ 0.99 ± 0.17 vs. 1.00 ± 0.16) as compared to matched tissue in sham operated 
rats (Figure 4.32B). 
miR-93 expression was also unchanged at 24 hours in ipsilateral peri-infarct 
tissue in tMCAO SHRSP rats as compared to sham operated rats (RQ 1.18 ± 0.07 
vs. 1.00 ± 0.03) and in contralateral tissue (RQ 1.00 ± 0.03 vs. 1.00 vs. 0.03) 
(Figure 4.32C). At 72 hours miR-93 expression was unchanged in ipsilateral peri-
infarct tissue (RQ 0.91 ± 0.08 vs. 1.00 ± 0.11) and in the equivalent contralateral 
tissue (RQ 1.07 ± 0.09 vs. 1.00 ± 0.05) as compared to matched tissue in sham 
operated rats (Figure 4.32D).  
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Figure 4.31 – Serum miR-17 Family Expression in Naïve WKY and SHRSP Rats 
The total serum expression of hsa-miR-17-5p (A), hsa-miR-93-5p (C) and hsa-miR-20b-5p (E) 
was assessed in both naïve normotensive WKY and hypertensive SHRSP rats (n=5/group). 
Exosomal miRNA expression of hsa-miR-17-5p (B), hsa-miR-93-5p (D) and hsa-miR-20b-5p 
(F) was also assessed in both naïve WKY and SHRSP rats (n=5/group). Statistical probability 
of differences in expression observed were calculated using unpaired Student’s t-test, vs. 
WKY rats. Change in miRNA expression was assessed by qRT-PCR and relative 
quantification (RQ) calculated from ΔΔCt following normalisation to a spike housekeeper 
miRNA, cel-miR-39 and compared to miRNA expression in the WKY rats. Data shown is RQ 
± RQmax/RQmin. 
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Figure 4.32 – miR-17 Family Expression in SHRSP Brain 
The expression of hsa-miR-17-5p (A, B), hsa-miR-93-5p (C, D) and hsa-miR-20b-5p (E, F) was 
assessed in peri-infarct tissue of SHRSP rats at 24 hours (A, C, E) and 72 hours (B, D, F) 
following 45 min tMCAO (coloured bars) or sham operation (grey bars) (n=6/group). 
Statistical probability of differences in expression observed were calculated using unpaired 
Student’s t-test with Bonferroni’s Multiple Comparisons Test, vs. sham operated rats. 
Change in miRNA expression was assessed by qRT-PCR and relative quantification (RQ) 
calculated from ΔΔCt following normalisation to a housekeeper miRNA, U87, and compared 
to miRNA expression in the sham operated rats. Data shown is RQ ± RQmax/RQmin. Brain 
tissue collected by and used with permission of Dr. Emily Ord. 
Finally, miR-20b expression was unchanged at 24 hours in ipsilateral peri-infarct 
tissue in tMCAO SHRSP rats as compared to sham operated rats (RQ 1.11 ± 0.10 
vs. 1.00 ± 0.09) and unchanged in contralateral tissue (RQ 0.91 ± 0.11 vs. 1.00 
vs. 0.19) (Figure 4.32E). At 72 hours miR-20b expression was also unchanged in 
ipsilateral peri-infarct tissue (RQ 0.82 ± 0.16 vs. 1.00 ± 0.34) and in the 
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equivalent contralateral tissue (RQ 0.94 ± 0.11 vs. 1.00 ± 0.19) as compared to 
matched tissue in sham operated rats (Figure 4.32F). 
We subsequently profiled circulating total and exosomal miR-17 family miRNA 
expression in SHRSP rats subjected to tMCAO and pMCAO (Figure 4.33). Serum 
from SHRSP subjected to pMCAO was collected by Dr. Emma Reid. 
Total serum expression of miR-17 was moderately increased in rats at 24 hours 
following tMCAO (RQ 2.21 ± 0.65 vs. 1.00 ± 0.31) and further increased in SHRSP 
at 24 hours following pMCAO (RQ 2.96 ± 2.33 vs. 1.00 ± 0.31) as compared to 
sham operated rats (Figure 4.33A), although all changes were not significant. 
Exosomal expression of miR-17 was moderately decreased in SHRSP following 
tMCAO (RQ 0.47 ± 0.05 vs. 1.00 ± 0.52) and unchanged following pMCAO (RQ 1.10 
± 0.75 vs. 1.00 ± 0.52) (Figure 4.33B). All changes in expression were not 
significant. 
The total expression of miR-93 followed the same pattern and was moderately 
increased in SHRSP at 24 hours following tMCAO (RQ 1.74 ± 0.51 vs. 1.00 ± 0.29) 
and further increased following pMCAO (RQ 2.72 ± 1.53 vs. 1.00 ± 0.29) (Figure 
4.33C). Exosomal expression of miR-93 was somewhat decreased at 24 hours 
following tMCAO (RQ 0.53 ± 0.1 vs. 1.00 ± 0.68) but increased following pMCAO 
(RQ 1.69 ± 0.77 vs. 1.00 ± 0.68) (Figure 4.33D). All changes in expression were 
not significant. 
Similarly, there was a trend towards increased total miR-20b expression 
following tMCAO (RQ 2.16 ± 0.21 vs. 1.00 ± 0.46) and pMCAO (RQ 2.54 ± 1.54 vs. 
1.00 ± 0.46) (Figure 4.33E). Exosomal expression of miR-20b was moderately 
decreased at 24 hours following tMCAO (RQ 0.58 ± 0.08 vs. 1.00 ± 0.29) but 
increased following pMCAO (1.38 ± 0.55 vs. 1.00 ± 0.29) (Figure 4.33F). The 
changes observed here were not significant. 
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Figure 4.33 – Circulating miR-17 Family Expression post-MCAO 
Total expression of hsa-miR-17-5p (A), hsa-miR-93-5p (C) and hsa-miR-20b-5p (E) was 
assessed in serum of SHRSP rats at 24 hours following 45 min tMCAO (n=3), permanent 
MCAO (pMCAO) (n=5) or sham operation (grey bars) (n=3). Exosomal expression of hsa-
miR-17-5p (B), hsa-miR-93-5p (D) and hsa-miR-20b-5p (F) was assessed in the serum of the 
same SHRSP rats. Statistical probability of differences in expression observed were 
calculated using one-way ANOVA with Tukey’s multiple comparisons test. Change in 
miRNA expression was assessed by qRT-PCR and relative quantification (RQ) calculated 
from ΔΔCt following normalisation to a spike housekeeper miRNA, cel-miR-39, and 
compared to miRNA expression in the sham operated rats. Data shown is RQ ± 
RQmax/RQmin. pMCAO surgery and subsequent collection of serum was carried out by Dr. 
Emma Reid and serum was used for these experiments with her permission. 
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4.3.2 Characterisation of Exosomes Isolated from SHRSP serum 
Exosomes were visualised on a transmission electron microscope, as described in 
section 4.2.1.2. Exosomes were embedded and prepared for electron microscopy 
by Mrs Margaret Mullin. 
Electron microscopy of exosomes isolated from the serum of two SHRSP rats 
demonstrated the presence of rounded membrane vesicles (Figure 4.34 A and B). 
Representative images were selected from the images taken of each exosome 
isolation, and the diameter of every vesicle present in each image measured. 
SHRSP 1 had a median vesicle size of 73.0 nm, with an IQR of 59.1 – 90.2 nm 
(Figure 4.34 C). SHRSP 2 had a median vesicle size of 80.9 nm, with an IQR of 
63.9 – 99.3 nm (Figure 4.34 C). These results primarily show that the vast 
majority of vesicles isolated by precipitation from SHRSP serum fall within the 
exosome size range of 30 – 120 nm. 
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Figure 4.34 – TEM of SHRSP Serum Extracellular Vesicles  
Electron-microscopic observation of whole-mounted exosomes purified from SHRSP serum 
by precipitation. Representative images of exosome isolates from two SHRSP serum 
samples (SHRSP 1, A; SHRSP 2, B) obtained by transmission electron microscopy showing 
both larger microvesicles and exosomes. A box and whisker plot to show the diameter of 
vesicles in representative images (n=4) (C). Plots show 5
th
 percentile, Q1, Q2, Q3 and 95
th
 
percentile with values outside of this represented by scatter dots. Diameter was measured 
twice on every vesicle in each representative image and the longest diameter value was 
taken for each vesicle to create this graph. 
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4.3.3 In Vitro Analysis of Cellular and Exosomal miRNA 
Expression 
To assess the in vitro exosomal expression of dysregulated miRNAs (as first 
detected in human stroke patients), three different secondary cell lines were 
used: neuronal (B50), cerebral endothelial (GPNT) and glial (B92). The cells were 
subjected to a 9 hour hypoxic challenge or left entirely in normoxic conditions 
before being reoxygenated for 24 hours. The cells were then harvested to 
investigate total miRNA expression and media was collected, from which 
exosomes were isolated. We were interested to see if exosomal miRNA 
expression was increased in all of these cell lines or only in specific brain cell 
types. 
Total cellular expression of miR-17 was completely unchanged in neuronal (B50) 
cells following hypoxic challenge (RQ 1.00 ± 0.01 [hypoxic] vs. 1.00 ± 0.02 
[normoxic]) (Figure 4.35A). This was also the case for miR-93 (RQ 0.99 ± 0.02 vs. 
1.00 ± 0.04) (Figure 4.35B) and miR-20b (RQ 0.97 ± 0.02 vs. 1.00 ± 0.03) (Figure 
4.35C) expression in B50 cells. 
Cellular expression of miR-17 was not significantly increased in hypoxic cerebral 
endothelial cells (GPNT) as compared to its expression in normoxic cells (RQ 1.24 
± 0.06 vs. 1.00 ± 0.10) (Figure 4.35A). The expression of miR-93 and miR-20b was 
unchanged following hypoxic challenge in cerebral endothelial cells (RQ 1.13 ± 
0.09 vs. 1.00 ± 0.11 and RQ 1.06 ± 0.03 vs. 1.00 ± 0.09) (Figure 4.35 B and C).  
Similarly, cellular expression of miR-17 and miR-93 was not significantly 
increased in hypoxic glial (B92) cells are compared to expression in normoxic 
cells (RQ 1.16 ± 0.06 vs. 1.00 ± 0.02) (Figure 4.35A), (RQ 1.17 ± 0.09 vs. 1.00 ± 
0.03) (Figure 4.35B). Cellular expression of miR-20b was unchanged in hypoxic 
glial cells as compared to normoxic cells (RQ 0.99 ± 0.003 vs. 1.00 ± 0.03) 
(Figure 4.35C). 
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Figure 4.35 – Cellular miR-17 Family Expression (in vitro) 
The expression of hsa-miR-17-5p (A), hsa-miR-93-5p (B) and hsa-miR-20b-5p (C) was 
assessed in both normoxic and hypoxic B50, GPNT and B92 cells (n=3/group). Statistical 
probability of differences in expression observed were calculated using unpaired Student’s 
t-test with Bonferroni’s Multiple Comparisons Test, vs. normoxic cells for each cell type. 
Change in miRNA expression was assessed following 24 hours of reoxygenation post-9 
hour hypoxic challenge, by qRT-PCR. Relative quantification (RQ) was calculated from ΔΔCt 
following normalisation to a spike housekeeper miRNA, cel-miR-39 and compared to miRNA 
expression in the normoxic cells. Data shown is RQ ± RQmax/RQmin. 
Media (from the same experiment as described above) was collected as 
described in section 2.5.1.2 and exosomes were subsequently isolated by 
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ultracentrifugation. Exosomal expression of miR-17 family miRNAs was then 
profiled. Expression of the same miRNAs was also profiled in exosomes isolated 
by precipitation (using Exosome Isolation Reagent) collected by Ms. Emma 
Sigfridsson in identical experiments. 
In general miRs-17, -93 and -20b appeared to be down-regulated in exosomes 
collected by ultracentrifugation from hypoxic B50 and GPNT cells but up-
regulated in B92 hypoxic exosomes, although all changes observed were non-
significant. The data collected were very variable and this isolation method will 
need to be refined further. Data shown here are from a biological n=3. 
Repeating the experiment may also have reduced the variability in the data. As 
the data stands, it is very difficult to interpret. Specifically, miR-17 exosomal 
expression was, on average, decreased in exosomes isolated from hypoxic B50 
cells (RQ 0.35 ± 0.81 vs. 1.00 ± 0.96), unchanged in GPNT cells (1.11 ± 0.19 vs. 
1.00 ± 0.99) and increased in B92 cells (RQ 3.93 ± 10.22 vs. 1.00 ± 0.39) (Figure 
4.36A). miR-93 exosomal expression was, on average, decreased in exosomes 
isolated from hypoxic B50 cells (RQ 0.20 ± 0.90 vs. 1.00 ± 3.64) and GPNT cells 
(0.14 ± 0.14 vs. 1.00 ± 3.91) and increased in B92 cells (5.38 ± 58.40 vs. 1.00 ± 
2.29) (Figure 4.36C). Finally, miR-20b expression was also, on average, 
decreased in hypoxic B50 cells (RQ 0.22 ± 1.48 vs. 1.00 ± 6.04) and GPNT cells 
(0.29 ± 0.25 vs. 1.00 ± 3.12) and increased in B92 cells (4.38 ± 47.36 vs. 1.00 ± 
3.11) (Figure 4.36E). All changes were non significant. 
However, when expression of miR-17 family miRNAs was profiled in exosomes 
isolated by precipitation (n=6) there was a trend towards an increase in 
expression in both B50 and B92 cells (Figure 4.36), although changes observed 
were not statistically significant. Specifically miR-17 expression was increased in 
exosomes isolated from both hypoxic B50 (RQ 1.59 ± 0.26 vs. 1.00 ± 0.51) and 
B92 (RQ 2.22 ± 0.62 vs. 1.00 vs. 1.21) cells (Figure 4.36B). Similarly, the 
exosomal expression of miR-93 was increased by a small amount, on average, in 
hypoxic B50 cells (RQ 1.25 ± 0.18) and by a larger amount in hypoxic B92 cells 
(RQ 1.69 ± 0.42 vs. 1.00 ± 1.12) as compared to their normoxic counterparts 
(Figure 4.36D). The expression of miR-20b was unchanged in exosomes isolated 
from hypoxic B50 cells (1.04 ± 0.08 vs. 1.00 vs. 0.09) and hypoxic B92 cells (0.93 
± 0.08 vs. 1.00 ± 0.24) as compared to normoxic cells (Figure 4.36F). 
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Figure 4.36 – Exosomal miR-17 Family Expression (in vitro) 
The expression of hsa-miR-17-5p (A), hsa-miR-93-5p (C) and hsa-miR-20b-5p (E) was 
assessed in exosomes isolated by ultracentrifugation from the media of both normoxic and 
hypoxic B50, GPNT and B92 cells (n=3/group). Statistical probability of differences in 
expression observed were calculated using unpaired Student’s t-test, vs. normoxic cells for 
each cell type. The expression of hsa-miR-17-5p (B), hsa-miR-93-5p (D) and hsa-miR-20b-5p 
(F) was also assessed in exosomes isolated by precipitation from the media of both 
normoxic and hypoxic B50 and B92 cells (n=6/group). Statistical probability of differences in 
expression observed were calculated using unpaired Student’s t-test with Bonferroni’s 
Multiple Comparisons Test, vs. normoxic cells for each cell type. Change in miRNA 
expression was assessed following 24 hours of reoxygenation post 9 hour hypoxic 
challenge, by qRT-PCR. Relative quantification (RQ) was calculated from ΔΔCt following 
normalisation to a spike housekeeper miRNA, cel-miR-39 and compared to miRNA 
expression in the normoxic exosomes. Data shown is RQ ± RQmax/RQmin. 
Finally, the changes in miR-17 family miRNA expression, detailed in this chapter, 
have been summarised in Table 4.10 to allow for a quick comparison of data 
gleaned in the human study and pre-clinical in vivo and in vitro studies. 
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Table 4.10 – Summary of miR-17 Family Results 
A table summarising results from the OpenArray and validation studies in human ischaemic 
stroke patients, and the in vivo pre-clinical and in vitro studies. The comparison made is 
indicated and unless otherwise stated in human patients comparisons were made at 48 
hours post-stroke onset and in pre-clinical models at 24 hours. The tissue type and whether 
total or exosomal miRNA expression was examined is also indicated. Exosomal (P) 
indicates exosomes isolated via precipitation while exosomal (U) indicates exosomes 
isolated by ultracentrifugation. Arrows indicate the direction of change and where results 
were significant the level of significance is given: *p<0.05, **p<0.01 vs. control. The figure in 
which data can be found is also given. Abbreviations include: NS, non-stroke; LA, large 
artery; CE, cardioembolic; SVD, small vessel disease; U, unclassified.  
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4.4 Discussion 
The causes and consequences of ischaemic stroke are numerous and complex. It 
was hypothesised that miRNAs are dysregulated following ischaemic stroke 
either as a consequence of, or, as regulators of, stroke pathophysiology, and 
subsequently interact with gene networks with far reaching consequences. The 
presented studies focus on the identification of novel exosomal miRNAs with 
potential roles in stroke pathophysiology, using microarray technology. The 
study looked for exosomal miRNAs dysregulated in all ischaemic stroke patients 
but also exosomal miRNAs that were differentially regulated in particular stroke 
subtypes. Validation by qRT-PCR was performed in a large patient population to 
confirm changes in expression of candidate miRNAs identified by microarray. 
More in depth analysis of validated exosomal miRNA expression sought to relate 
changes in exosomal miRNA expression to stroke subtype and clinical outcome 
from stroke. Further studies profiled the expression of selected dysregulated 
human exosomal miRNAs in pre-clinical models of ischaemic stroke to elucidate 
further the origin and cause of dysregulated exosomal miRNA expression. 
Of the 9 miRNAs (-27b, -93b, -20b. –17, -199a-3p, -30-5p, -let-7e, -218 and -223) 
that were found to be up-regulated in exosomes of definite ischaemic stroke 
patients a number have previously been documented in studies profiling miRNA 
expression in human stroke patients. As this is the first study, to our knowledge, 
to profile miRNA expression within exosomes in ischaemic stroke patients, we 
can only make comparisons between the present study and total circulating 
miRNA expression in other studies. 
We have demonstrated increased exosomal expression of miRs-17, -93 and -20b, 
miRNAs that belong to the miR-17 family. Of these miRNAs only miR-17 
expression has been validated by other published studies to be significantly 
dysregulated in human patients following stroke. Total miR-17 expression is 
increased in the plasma of acute ischaemic stroke patients (collected within 7 
days of stroke) in comparison to expression in control patients with either 
vascular risk or other neurological problems (Kim et al., 2015). However, in this 
study the blood pressure and percentage of patients with diabetes (amongst 
other factors) was significantly less in the control patients than the ischaemic 
stroke patients (Kim et al., 2015). Average miR-17 expression was shown to be 
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unchanged in cardioembolic stroke patients but increased in small vessel disease 
patients and even further in large artery patients, although these differences 
were not significant, unlike in the present study. Increased miR-17 expression 
was also associated with plaque enhancement (as assessed by MRI) and a shorter 
stroke-free survival time, during a 33 month follow up period (Kim et al., 2015). 
Total miR-17, miR-93 and miR-20b expression was also detected by microarray 
technology to be increased in whole blood samples from stroke patients, and 
especially in small vessel patients (vs. large artery) as compared to healthy 
control patients, although these changes were not validated by qRT-PCR and the 
number of patients profiled was low (Tan et al., 2009). miR-17 expression has 
been investigated pre-clinically in the setting of ischaemic stroke (Liu et al., 
2013b) and this will be discussed further in Chapter 5. 
Studies investigating total miRNA expression will also inevitably profile exosomal 
expression in part (RNA is usually extracted from total and not separated serum 
or plasma) and so it is difficult to tell whether the changes in exosomal 
expression we have observed in the present study are only found within 
exosomes or whether expression of these miRs is increased within the serum and 
within exosomes.  
The only study to date to compare total and exosomal miRNA expression in 
human stroke patients collected plasma samples from ICH stroke patients, and 
examined the difference in expression of 5 miRNAs between the plasma 
supernatant and microvesicle fractions as separated by ultracentrifugation (Guo 
et al., 2013). In healthy controls, miR-27a (part of the miR-27 family), miR-24 
(clustered with miR-27b) and 3 other miRNAs were not detectable in the 
supernatant but were found in microvesicles. In ICH patients, these miRNAs were 
found both in the supernatant and in the microvesicles, and in some cases at a 
much higher level than in the healthy control patients, although no indication of 
statistical difference is given (Guo et al., 2013). It would be interesting to carry 
out similar analysis on our own samples, but given the limited volume of serum 
that was available for this study, precipitation using exosome isolation reagent 
was deemed the best method to make as much use as possible of the limited 
sample. Pre-clinically, differences between total and exosomal serum expression 
of miR-126 have been investigated in Wistar rats following transient or 
permanent ischaemic stroke (Chen et al., 2015). miR-126 was detected in both 
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total serum and exosomes. There was a trend towards similar directions of 
change in both total and exosomal miR-126 expression at a number of time 
points post-stroke. However serum miR-126 expression was much more variable 
than exosomal miR-126 expression, consistent with more highly regulated 
exosomal microRNA expression (Chen et al., 2015).  
To investigate differences between total and exosomal miRNA expression 
further, we subsequently assessed both total and exosomal expression of miRs-
17, -93 and -20b in pre-clinical clinical models of stroke. These miRNAs were 
selected as they belong to the same miRNA family and this gave us increased 
confidence in the biological significance of their dysregulation following stroke. 
Exosomal (and not total) expression of these miRs was increased in the serum of 
naïve SHRSP rats as compared to WKY rats, although only significantly in the 
case of miR-17. Expression of all three miRs was unchanged in peri-infarct tissue 
harvested from both the ipsilateral and the equivalent tissue from the 
contralateral hemispheres of SHRSP rats in comparison to sham operated rats, 
sacrificed at either 24 or 72 hours post-tMCAO. Finally, circulating total and 
exosomal expression of these miRs was examined in SHRSP following either 
tMCAO, pMCAO or sham surgery and there were no significant increases in miRNA 
expression at 24 hours following stroke.  
The present study was designed to detect exosomal miRNA expression that was 
dysregulated as a direct result of stroke. The non-stroke control population was 
therefore carefully selected and we have shown that there are no significant 
differences between our non-stroke control and stroke patient populations for a 
number of important characteristics, including hypertension, other risk factors 
for stroke and for the prescribed medication patients were receiving. 
Furthermore, the pre-clinical models of stroke used were chosen carefully to 
represent our human patients as best as possible. SHRSP rats are an excellent 
model of human ischaemic stroke, not only do they develop stroke 
spontaneously, they present with a number comorbidities that are often present 
in human patients, including hypertension, nephropathy, insulin resistance, 
hyperinsulinemia, hypertriglyceridemia and hypercholesterolemia (Nagaoka et 
al., 1976). WKY, on the other hand, are normotensive, healthy rats. Our human 
data shows dysregulated miRNA expression post-ischaemic stroke and our pre-
clinical data shows trends towards increased expression of the same miRNAs 
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post-pMCAO. This is consistent with the hypothesis that these miRNAs are 
actively packaged into exosomes as a direct result of ischaemic stroke.  
The in vitro data presented in this study are more conflicting – when we profiled 
miRNA expression in vitro, we were directly assessing the effect of hypoxia 
alone on differing brain cell types and we found no increase in total miRNA 
expression and only a trend towards an increase in glial cell secreted exosomal 
expression that was not significant. The in vitro data presented are very variable 
and so experimental protocols need to be optimised and experiments repeated 
before we can conclude more from these data. However, a recently published 
study profiling the miRNA content of exosomes released by cardiac progenitor 
cells isolated from Sprague Dawley rats following hypoxic insult revealed that 
miR-17 and miR-20 were up-regulated (Gray et al., 2015). Therefore, the fact 
that miRNAs in this family are dysregulated in a similar way in the present study 
is consistent with miR-17 family miRs being packaged into exosomes as a direct 
result of the brain’s response to ischaemic conditions. However, the pre-clinical 
model used in the study (cardiac progenitor cells from healthy rats) (Gray et al., 
2015) cannot be directly compared to data gleaned in our own carefully 
phenotyped human patients and co-morbid pre-clinical models of ischaemic 
stroke. 
Alternatively, the data presented here could also be consistent with the 
hypothesis that aberrant packaging of selected miRNAs into exosomes is part of 
an underlying vascular pathology that renders patients and SHRSP susceptible to 
stroke. In the present study the clinical patient populations were carefully 
selected to ensure that dysregulated miRNA expression observed could be 
concluded to be a direct result of stroke. Seven miRNAs were subsequently 
shown to be especially dysregulated in small vessel disease patients in the 
clinical study. Furthermore miR-17 family miRNAs were increased (some 
significantly) in naïve SHRSP (vs. WKY) but not significantly further increased 
following pre-clinical stroke. SHRSP are accepted by some to be a valid model of 
human cerebral small vessel disease (Bailey et al., 2009, Hainsworth and Markus, 
2008, Wardlaw et al., 2013). This being said, they (and no other animal model) 
can mimic every aspect of human small vessel disease and while useful, SHRSP 
cannot be used to make direct deductions as to the pathogenesis of human SVD 
(Hainsworth et al., 2012). However, SHRSP rats demonstrate modest endothelial 
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and perivascular tissue defects as early as 5 weeks of age (before hypertension 
has set in), including impaired “impaired endothelial tight junctions, poor 
myelination, overactive microglia, and a tendency for glial scarring that can be 
detected by protein expression” (Wardlaw et al., 2013). SHRSP have non-specific 
inflammation and BBB permeability changes at as early as 5 weeks of age 
(Wardlaw et al., 2013) and are also spontaneously hypertensive with blood 
pressure rising progressively from normal levels at age 4 weeks to a plateau at 
around 20 weeks in male rats (Yamori et al., 1976). Cerebrovascular lesions can 
also develop spontaneously, and the incidence of these increases from being 
rare at less than 12 weeks of age to an incident rate of over 80% at 30 weeks of 
age in male rats (Tagami et al., 1987, Yamori and Horie, 1977). The naïve SHRSP 
rats used in this study were 20-22 weeks old and would therefore have many 
characteristics of cerebral small vessel disease. Therefore, the data presented in 
this study could also be interpreted to be consistent with the hypothesis that 
miRNAs detected in this study are packaged into exosomes as a result of 
underlying cerebral vascular disease which predisposes patients to either an 
ischaemic stroke or maybe more specifically a small vessel disease stroke. While 
cerebral ischaemia as a result of stroke may result in a further (but non-
significant) increase in expression of these miRNAs, this may not be the primary 
cause of their increase in expression, which would explain why expression is 
increased in large artery and cardioembolic patients to a lesser extent. 
A previous study within our own research group (Breen, 2015) profiled total 
miRNA expression in serum samples using the same microarray technology as 
used in the present study and compared expression to a similar cohort of 
vascular risk control patients as has been used in the present study. While the 
patient population investigated was smaller, miRNAs selected for validation 
failed to validate in a large patient population (IS: n=55, non-stroke: n=20). 
Some of the miRNAs profiled were examined in the present study including miR-
20b and miR-93 (both unchanged in IS vs. control). Other miRNAs studied are 
related to miRNAs investigated in this study, including miR-27a (miR-27 family) 
and miR-106a (miR-17 family), both of which were unchanged in IS patients in 
comparison to control patients (Breen, 2015). As many of the patient samples 
used in this study were also used in the present study where a number of 
interesting dysregulated miRNAs were identified, this highlights the importance 
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of looking at exosomal packaged miRNA expression. Furthermore, these data 
from the same carefully phenotyped stroke and control patient populations 
(although smaller n) when taken in combination with our data are consistent 
with the hypothesis that a number of miRNAs are selectively and actively 
packaged into exosomes, hence their expression is unchanged when total miRNA 
content is investigated but increased when exosomal miRNA content is analysed. 
Other exosomal miRNAs (not part of the miR-17 family) detected as being 
dysregulated in the present study have been shown to be dysregulated in 
ischaemic stroke patients in other studies. Total miRNA expression was profiled 
in both plasma and CSF samples collected 3 days post-stroke, using microarray 
technology (Sørensen et al., 2014). Expression of miR-27b was one of the 21 
most frequently detected miRNAs in CSF, and was significantly increased in 
ischaemic stroke patients in comparison to patients with other neurological 
diseases such as dementia or multiple sclerosis. Interestingly, miR-199a-3p 
(passenger strand), which we found to be significantly up-regulated in exosomes 
of ischaemic stroke patients was unchanged in the CSF of ischaemic stroke 
patients in this study, although neither of these changes were validated by qRT-
PCR (Sørensen et al., 2014). A separate study profiling total miRNA expression in 
plasma samples collected 24 hours following stroke found miR-199a-5p (lead 
strand) to be upregulated in IS patients in comparison to healthy controls and 
especially in patients with embolic stroke as opposed to thrombotic stroke 
(although results were not validated by qRT-PCR) (Li et al., 2015a). 
Interestingly, the only other passenger strand miRNA we found to be 
dysregulated in our samples, miR-223-5p, has also been profiled in a number of 
other studies. miR-223 is increased in whole blood samples collected from 
ischaemic stroke patients within 6-18 months of their stroke as compared to its 
expression in healthy control patients (Tan et al., 2009). Leukocytes isolated 
from plasma of ischaemic stroke patients within 72 hours of stroke onset had 
significantly higher levels of miR-223 than their healthy control counterparts 
(Wang et al., 2014c). This study also profiled the expression of miR-223 in 
relation to stroke subtype and found that average expression was only 
significantly increased in large artery and small vessel disease, was unchanged in 
unclassified patients and was decreased in cardioembolic patients. Furthermore 
the expression was significantly increased in stroke patients at 24h and 72h post-
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stroke, but not at 48h post stroke (Wang et al., 2014c), the time point at which 
we collected serum from patients in our study. miR-223 was also negatively 
correlated with NIHSS score and infarct volume (Wang et al., 2014c). Subsequent 
studies have shown unchanged miR-223 expression in the serum of stroke 
patients at 24 hours following stroke onset as compared to healthy controls (Jia 
et al., 2015) and in the plasma of large artery patients as compared to healthy 
controls (Duan et al., 2014). Pre-amplified expression of miR-223-5p was 
relatively low in the present study (average Ct: 31.9 including 30 patients where 
the miRNA was not detected), which is why this miRNA was not taken forward 
for further investigation. None of the studies mentioned here provide 
information on which strand of miR-223 they investigated and so we assume they 
were profiling expression of the lead strand, miR-223-3p, which may explain 
differences both in level and profile of expression in relation to stroke subtype. 
A seminal study investigating exosomal paracrine signalling between cardiac 
fibroblasts and cardiomyocytes found that cardiac fibroblasts secrete exosomes 
that contained a relatively high abundance of miRNA passenger strand miRNAs, 
which were previously believed to undergo intracellular degradation (Bang et 
al., 2014b). Specifically they found exosomal miR-21-3p, a passenger strand 
miRNA, was secreted in exosomes and acted to induce cardiomyocyte 
hypertrophy, possibly by the inhibition of proteins SORBS2 and PDLIM5 (Bang et 
al., 2014b). This highlights the possible functional importance of exosomal 
packaged passenger strand miRNAs within our own study and if possible it would 
be interesting to investigate the functional activity of these exosome bound 
miRNAs further. 
In the present study, OpenArray data predicted a decrease in miR-30a-5p 
expression but its exosomal expression was subsequently shown to be increased 
in ischaemic stroke patients, and especially so in small vessel disease patients. 
Total miR-30a expression was profiled in relation to stroke subtype in the plasma 
of ischaemic stroke patients and compared to that of age-matched controls with 
vascular risk, at a number of time points (Long et al., 2013). In this study miR-
30a was found to be decreased in all stroke subtypes at 24 hours, 1 week, 4 
weeks and 24 weeks post-stroke but unchanged at 48 weeks post-stroke in 
relation to control patients (Long et al., 2013). miR-30a was also a specific and 
sensitive diagnostic marker for ischaemic stroke (AUC consistently >0.91 
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regardless of time point chosen) (Long et al., 2013). Importantly this study was 
well powered and used appropriate control patients, similarly to the present 
study. The differences in results observed here (Long et al., 2013) in comparison 
to the presented data could therefore be a direct result of differences in 
exosomal and total miRNA expression. Another possibility would be the time 
point at which miRNA expression was investigated. In the present study exosomal 
miR-30a-5p was shown to be increased at 48 hours post-stroke whereas in that of 
Long and colleagues this time-point was not investigated. Secondary ischaemic 
damage, as a result of inflammation for example, peaks at around 48-72 hours 
post-stroke (see Figure 1.2) and may begin to resolve within a week post 
ischaemic insult. As miRNA expression changes temporally post-stroke it is 
feasible that miR-30a-5p is temporarily increased between 48-72 hours post-
stroke. Further experiments profiling exosomal miRNA expression in samples 
collected at longitudinal time points from the patients recruited in the present 
study would help to resolve this discrepancy. 
Exosomal let-7e miRNA expression was shown (in the present study) to be up-
regulated in the serum of ischaemic stroke patients at 48 hours post-stroke. 
These data are consistent with a couple of studies profiling total miRNA 
expression in IS patients. Total let-7e expression was increased in whole blood 
samples of IS patients collected within 72h of stroke onset in relation to vascular 
risk factor control patients (Jickling et al., 2014). Total let-7e expression was 
also profiled in serum and CSF samples collected from IS patients acutely (24 
hours to 1 week), subacutely (2 weeks) and during recovery (≥3 weeks) and 
compared to expression in healthy control patients (Peng et al., 2015). let-7e 
expression was most increased acutely but significantly increased at all 3 time 
points studied. This was also the case for total let-7e expression within the CSF. 
While its’ serum expression did not correlate with NIHSS scores, it was found to 
be good diagnostic biomarker for stroke in relation to healthy controls (AUC 
0.86) (Peng et al., 2015).  
While studies investigating miRNA expression in the setting of ischaemic stroke 
have shown effects of both age and gender on miRNA expression (for example, 
(Selvamani et al., 2014)), we did not observe any correlation between exosomal 
miRNA expression and age. Furthermore, of the miRNAs we took forward for 
further investigation, only the exosomal expression of let-7e was altered in 
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relation to gender, and only in unclassified male patients (vs. matched females) 
and not in stroke patients as a whole. The stroke and control patient populations 
used in the present study were carefully selected, and although the non-stroke 
control patients were younger (not significantly) they had a very similar gender 
ratio to their stroke patient counterparts. 
As we were interested in exosomal packaged miRNAs released as a cause of or 
directly as a result of ischaemic stroke, the serum samples we used in this study 
(collected at 48h post-stroke) may not be ideal. However, we were keen to 
profile exosomal miRNA expression in as many patients as possible to give the 
study the power needed to detect small changes in miRNA expression. As many 
as 6 in 10 stroke patients arrive at A&E later than 4.5 hours post-stroke onset, 
the therapeutic window for rtPA treatment, often as a result of having had a 
stroke during sleep or not taking symptoms seriously and so delaying arrival at 
hospital (Stroke Association, 2016). Some even arrive as late as 24 hours post-
stroke. For this reason we decided to profile miRNA expression in samples 
collected at 48 hours, a time point for which we had a sample for every patient 
enrolled in the study and one that is still sub-acute. Furthermore, published 
studies that profile total miRNA expression at various time points following 
stroke did not show significant changes in miRNA expression over early time 
points post-stroke (Long et al., 2013, Peng et al., 2015).  
It would be interesting to profile both total and exosomal miRNAs highlighted in 
the present study, in a patient population at risk of stroke (such as our control 
population) with a long-term follow up to determine whether dysregulated 
miRNA expression could be used to identify individuals especially susceptible to 
ischaemic stroke. This would also help to elucidate whether aberrant exosomal 
miRNA signalling is part of an underlying vascular pathology that causes patients 
to have or be susceptible to stroke, or whether these exosomal miRNAs are 
released directly following a stroke and cerebral ischaemia. In the present study 
serum samples were also collected at 7 days, 1 month and 3 months post-stroke 
and are available for exosomal miRNA profiling though there was not sufficient 
time in this study to perform these experiments. 
In the present study it was hypothesised that dysregulated exosomal miRNAs 
could be used as biomarkers, either to phenotype patients where diagnosis was 
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unclear (unclassified patients, and ‘possible’ stroke patients) or as predictors of 
clinical outcome. We investigated the possibility of using the expression of 7 
miRNAs either individually or their combined scores for diagnosis or prognosis 
and in both cases found that no single exosomal miRNA or group of miRNAs in 
this study could be used for this purpose. Although the average expression of 
these miRNAs changed between non-stroke and stroke patients and between 
stroke subtypes, their expression overlapped considerably between groups. ROC 
analysis performed to assess the ability of exosomal miRNA expression to 
differentiate between stroke subtypes showed that the overlap in expression for 
miRNA expression between stroke-subtypes was too great to allow for this 
diagnosis (data not shown). Although there was a trend towards the expression 
of each miRNA being higher in patients with better functional outcome from 
stroke, these changes were not significant. Even when the scores for each miRNA 
were combined, to give extra power to the analysis, ROC analysis showed that 
this score could not sensitively or specifically predict clinical outcome from 
stroke, when comparing 1 month mRS scores of ≤1 and those ≥2. Very few 
published studies present data on this: miRs -30a, -126, let-7b (Long et al., 
2013) and miR-17 (Kim et al., 2015) have been tested for their diagnostic 
capability and miRs -210 (Zeng et al., 2012, Zeng et al., 2011) and -132 (Huang 
et al., 2016) for their prognostic capability. Although it is difficult to assess 
whether the results of the present study are typical of what is observed in 
studies of this kind (as very few have been published in setting of IS) the lack of 
predictive ability of miRNAs is likely reflective of the very heterogeneous stroke 
population, in comparison to other diseases where miRNAs have been more 
successfully used as biomarkers such as heart failure and cancer. 
If circulating dysregulated exosomal miRNAs could be found whose expression 
overlapped less between patient groups these would be ideal candidates for 
diagnostic or prognostic biomarkers. Liquid biopsies are advantageous over other 
types of tissue biopsy as they have a reduced risk to the patient and a reduced 
cost to the health service provider. Tissue biopsies may also result in sample 
bias, depending on the location of the tissue extraction. Furthermore, while RNA 
is very sensitive to degradation miRNAs remain detectable and relatively stable 
following many freeze thaw cycles (data not shown). miRNAs within exosomes 
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are further protected from degradation and so are excellent candidates for 
stable biomarkers that will provide an unbiased comparison between patients.   
The only two licenced interventions for ischaemic stroke are rt-PA and 
thrombectomy and both must be administered within hours of the onset of 
stroke in order to prove successful. Time constraints associated with exosome 
isolations, RNA extractions and subsequent PCR reactions mean that it is unlikely 
that exosomal miRNA expression could ever be used diagnostically in more 
economically developed countries where imaging technologies such as CT and 
MRI are readily available. However, in patients where diagnosis by conventional 
imaging fails, as a result of mild stroke, or technical problems, exosomal miRNA 
expression may provide an additional tool for stratifying patients. Furthermore a 
biomarker to stratify patients according to predicted clinical outcome would be 
useful both in identifying patients that will benefit most from intensive physical 
rehabilitation or other treatment and for informing patients of their prognosis. 
In the present study TaqMan® OpenArray® MicroRNA Panels were used. While a 
low sample input was used (10 ng input RNA vs. 100 ng) Life Technologies 
provide an adapted protocol for samples with low RNA yield. Life Technologies 
report that using 10 ng of input RNA and following their adapted protocol will 
result in detection of 92% of the miRNAs detected when using 100 ng of RNA 
(Life Technologies, 2011). In the present study 553 miRNAs were detected in at 
least 1 sample (out of 39) and of these, 93 were detected in greater than 30% of 
patients in one particular subtype. Ideally candidate miRNAs taken forward for 
validation would have been detected in over 90% of patients. The fact that so 
few miRNAs met this criteria is possibly a result of the lower sample input RNA. 
To get as much out of the data set as possible we examined differences in miRNA 
expression between non-stroke and stroke patients in every miRNA detected in 
at least 30% of patients in one particular stroke subtype. 26 miRNAs were 
detected as being dysregulated in stroke patients. The fact that many miRNAs 
were not detected in a number of samples in the microarray is not the result of 
using exosomal miRNA (vs. total serum miRNA), as when validated by qRT-PCR 
the majority of miRNAs were detectable in every sample. Similar studies using 
microarray technology to profile circulating miRNA expression in human patients 
post-stroke (Table 1.2) often do not report the total number of miRNAs detected 
or the percentage of samples the miRNAs detected were present in, so it is 
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difficult to compare our results to array data collected in other studies. Of these 
studies (Table 1.2) dysregulated miRNAs (detected by microarray) taken forward 
for validation were selected randomly (Tan et al., 2009, Zhang et al., 2016a), if 
they had a fold change of greater than 1.2 (Jickling et al., 2014, Sepramaniam et 
al., 2014) or 2.0 (Li et al., 2015b, Wang et al., 2014b, Zhang et al., 2016a) or if 
the miRNAs had previously been reported in the literature (Li et al., 2015b). 
None of these studies comment on the percentage of samples each miRNA had to 
be present in to be taken forward for validation. 
Of the 13 miRNAs selected for validation from the microarray data, 3 miRNAs 
were detected as being up-regulated in all stroke patients (vs. non-stroke 
control): miR-27b, miR-20b and miR-17. These results were positively validated 
by qRT-PCR and the direction of change was the same. A further 9 miRNAs were 
shown to up-regulated (by qRT-PCR) in definite stroke patients (vs. non-stroke 
control) – of these 7 were up-regulated in the OpenArray study but miR-30a and 
miR-218 were detected as being down-regulated (although non-significantly). 
Very few studies profile miRNA expression in relation to stroke subtype. Stroke 
subtype is rarely taken into account in experimental design and is only 
occasionally commented on following data generation. In the present study we 
were especially interested in differences in miRNA expression between stroke 
subtypes and designed the experiment to include (as much as possible) 
approximately equivalent group sizes for each stroke subtype. In the present 
study we have demonstrated that 7 miRNAs are up-regulated in small vessel 
disease patients (vs. non-stroke controls, by qRT-PCR). Of these 5 were shown to 
be up-regulated in small vessel disease patients in the OpenArray study 
(although only 3 of these changes were significantly different) but miR-30a was 
detected as being down-regulated in the OpenArray (non-significant) and let-7e 
was detected as being switched off in small vessel patients. 
While microarray technology has been used in many studies, of the 9 studies 
(Table 1.2) that use this technology to profile miRNA expression in stroke only 6 
studies (Jickling et al., 2014, Li et al., 2015b, Sepramaniam et al., 2014, Tan et 
al., 2009, Wang et al., 2014b, Zhang et al., 2016a) validate expression of some 
miRNAs by qRT-PCR. Several studies report whether their qRT-PCR data 
validated the changes seen in the microarray, with some miRs changing to a 
greater extent than observed in the array (Tan et al., 2009), others changing to 
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a significantly lesser extent than the array (Li et al., 2015a, Sepramaniam et al., 
2014). Other studies reported miRs that either were unchanged in the array but 
changed by qRT-PCR (Tan et al., 2009) and additional studies either did not 
report any or all their array data (Jickling et al., 2014, Li et al., 2015a) or 
represented their array data by a heat map which made it difficult to interpret 
(Wang et al., 2014b, Zhang et al., 2016b). Of the 13 miRNAs validated by qRT-
PCR, 7 were positively validated and a further 2 miRNAs were shown to be 
significantly different (but in an opposite direction to predicted). This is a 
success rate of over 50% and justifies the use of microarray technology for the 
identification of novel dysregulated miRNAs. Had it been possible to increase the 
quantity of input RNA used in the microarray we hypothesise that this may have 
increased the quality of the data generated and have further increased the 
success rate. 
Microarray technology, developed for high throughput global analysis of changes 
in mRNA levels, has been widely used for analysis of changes in miRNA 
expression in many different diseases. These experiments produce large amounts 
of data and analysis is time consuming. Furthermore, not all dysregulated 
miRNAs identified can be validated by qRT-PCR. Of the 26 miRNAs identified by 
OpenArray as dysregulated in stroke patients only 13 were taken forward for 
validation by qRT-PCR in the larger patient population as the expense and time 
taken to profile even these miRNAs was considerable. This means there are 
other miRNAs, previously uncharacterised in the setting of stroke whose 
expression and role in ischaemic stroke was not investigated further. 
Normalisation of microarray and qRT-PCR data when investigating circulating 
miRNA expression remains challenging as there is not a universal reference gene 
or miRNA for normalisation (Jarry et al., 2014). As RNA extraction, reverse 
transcription and amplification efficiencies can all vary between the samples 
used it is important to have a signal to normalise to. Traditionally an endogenous 
“housekeeper” miRNA or small nucleolar RNA would be used. However, it is 
difficult to find either a single circulating miRNA or panel of miRNAs that are 
stable in samples from patients with disease as profound as ischaemic stroke. 
For this reason in the present study an external control (cel-miR-39 spike in) was 
used. The addition of an external spike can correct for differences in RNA 
recovery and qPCR efficiency but it does not take into account endogenous 
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differences in miRNA expression. However, due to the lack of a suitable 
endogenous control the use of an external control was appropriate for the 
present study. 
In conclusion, in the present study we have identified and validated changes in 
exosomal packaged miRNA expression in stroke patients and across different 
stroke subtypes. Furthermore, multiple miRNAs from one miRNA family were 
dysregulated similarly giving us increased confidence in the biological 
significance of these results. While we have failed to establish a link between 
exosomal miRNA expression and clinical outcome from stroke, these miRNAs 
remain interesting candidates for further investigation. These results will direct 
future studies looking into paracrine signalling in stroke and the modulation of 
specific miRNAs as a novel therapy in the setting of experimental stroke. 
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Chapter 5 Therapeutic Delivery of miRNA 
Loaded Extracellular Vesicles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
244 
 
 
5.1 Introduction 
There is an unmet need for novel treatments for ischaemic stroke. miRNA 
modulation has proved to be therapeutically beneficial in models of pre-clinical 
stroke (see Table 1.4). Although the majority of these studies deliver miRNA 
modulating agents prior to the occurrence of stroke, a number of studies deliver 
therapeutic agents post-stroke, a more clinically relevant delivery time point. 
Of these, a number of studies modulated miRNA expression by the direct 
delivery of mature miRNA mimics or anti-miRs (Selvamani et al., 2012, 
Sepramaniam et al., 2010, Vinciguerra et al., 2014). ICV infusion of an anti-miR 
for miR-320a at reperfusion proved therapeutically beneficial (assessed by 
reduced infarct volume) following 1h tMCAO in Sprague Dawley rats 
(Sepramaniam et al., 2010). ICV injection of a let-7f anti-miR 4 hours post 
embolic MCAO in adult female rats resulted in reduced cortical and striatal 
infarcts and preserved sensorimotor function (Selvamani et al., 2012). miR-103-1 
anti-miR delivered via ICV infusion to the lateral ventricle for 48 hours, starting 
20 mins post-tMCAO in Sprague Dawley rats resulted in reduced infarct volume 
and neurological deficit (Vinciguerra et al., 2014). 
Interestingly, several studies have modulated miRNA expression using 
transfection agents, such as Lipofectamine™ (a cationic liposome formulation 
that complexes with nucleic acid molecules, allowing them to overcome the 
electrostatic repulsion of the cell membrane and to be taken up by the cell). 
miR-124a anti-miR delivered in lipofectamine via ICV stereotactic injection 
following pMCAO in C57 mice resulted in a reduction of infarct volume (Liu et 
al., 2013a). miR-424 mimic with siRNA-MATE was delivered via ICV injection 10 
minutes post-pMCAO in C57BL/6J mice and resulted in reduced cerebral infarct 
and oedema volume (Zhao et al., 2013). Stereotactic injection of miR-139-5p 
mimic with lipofectamine at 12 hours post hypoxia/ischaemia injury in neonatal 
Sprague Dawley rats reduced infarct volume when assessed at both 48 hours and 
7 days (Qu et al., 2014). miR-23a-3p mimic with lipofectamine delivered via ICV 
stereotactic injection at 10 minutes post tMCAO in C57BL/6J mice reduced 
infarct volume (Zhao et al., 2014). miR-181 anti-miR delivered with DOTAP 
either via ICV to the lateral ventricle at 2 hours post-tMCAO or via IV delivery to 
the internal jugular vein at 1 hour post-tMCAO in C57/B6 mice resulted in long 
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lasting (up to 4 weeks) reduced infarct volume, neurological deficit and 
improved behavioural outcome (Xu et al., 2015). Finally, miR-122 mimic was 
delivered in PEG-liposomes via IV delivery to the tail vein or ICV injection at 5 
mins post-tMCAO in Sprague Dawley rats and reduced infarct volume and 
attenuated neurological impairment (Liu et al., 2015a). 
The only study to date to modulate miRNA expression, post-stroke, by a 
different method, used MSCs that had been modified to be miR-133b positive or 
negative (Xin et al., 2013b). The miR modified MSCs were delivered by IV 
injection to the tail vein of Wistar rats, 24 hours post-tMCAO and resulted in 
improved functional recovery (Xin et al., 2013b). 
The majority of these studies modulate miRNA expression via the delivery of 
mature miRNA mimics or anti-miRs either systemically, by stereotactic injection 
or by ICV infusion. While miRNA modulation is undoubtedly achievable via these 
methods, they are not readily transferable to clinical treatment of human stroke 
patients. As time is of the essence in the treatment of ischaemic stroke, invasive 
stereotactic injection and ICV infusion delivery of therapeutic agents may not be 
suitable, aside from the other practical, safety and cost considerations, which 
would be significant. However, if the primary aim of the therapeutic 
intervention is to promote repair and regeneration, then delivery can be delayed 
and stereotactic administration may become a viable option. An example of this 
is the Pilot Investigation of Stem Cells in Stroke (PISCES) clinical trial (Kalladka 
et al., 2016) where human neural stem-cells from an immortalised cell line were 
administered by stereotactic injection 6-60 months following stroke. Systemic 
delivery of miRNA modulating agents is not ideal as the possibility of off-target 
effects is considerable, furthermore it is possible that therapeutic agents 
delivered would not reach or cross the BBB in an efficient manner. 
Intra-nasal delivery is a potential alternative strategy for delivering therapeutic 
agents to the CNS and has been used successfully pre-clinically as a simple 
method to deliver therapeutic agents to the brain. It is practical, non-invasive 
and bypasses the BBB. It was first developed to target neurotrophic factors (e.g. 
nerve growth factor and fibroblast growth factor-2) to the CNS (Frey, 1991). 
Therapeutic agents delivered intra-nasally travel to the central nervous system 
via the olfactory and trigeminal neural pathways (Figure 5.1). The nasal cavities 
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of both humans and rodents are innervated by the olfactory and trigeminal 
nerves. Initial studies attributed the connection between the nasal cavity and 
the CNS to the olfactory pathway alone (Frey et al., 1997, Thorne et al., 1995). 
However, more recently the trigeminal pathway has also been implicated in 
intra-nasal delivery to the CNS – it is thought to be able to deliver therapeutic 
agents to caudal brain regions and the spinal cord (Ross et al., 2004, Thorne et 
al., 2004). Intra-nasal delivery of therapeutic agents results in a very rapid 
transfer to the brain, and this implicates extracellular transport (as opposed to 
axonal) as the primary method of transfer (Lochhead and Thorne, 2012). Studies 
carried out in human patients show that that intra-nasal delivery of therapeutic 
agents to the CNS is possible, and is not a phenomena unique to rodents and 
their significantly smaller brains (Lochhead and Thorne, 2012).  
 
Figure 5.1 – Intra-nasal Delivery Pathways 
This diagram illustrates the olfactory and trigeminal neural pathways. Exosomes delivered 
intra-nasally are believed to cross the olfactory epithelium, bypassing the blood brain 
barrier to deliver agents directly to the central nervous system. Image used with permission 
from (Lochhead and Thorne, 2012). 
No study, to date, has modulated miRNA expression in the setting of ischaemic 
stroke via intra-nasal delivery of a miRNA modulating agent. However studies 
such as those published by Jae-Kyu Roh’s research group in South Korea (Kim et 
al., 2014, Lee et al., 2012) provide evidence that modulating miRNA expression 
intra-nasally may be beneficial for the treatment of neurological disorders. 
Intra-nasal delivery of anti-miR-206 (suspended in PBS) to Tg2576 transgenic 
mice, a pre-clinical model of Alzheimer’s Disease, resulted in anti-miR delivery 
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to the olfactory bulb, cortex and hippocampus within 24 hours (Lee et al., 2012). 
Expression of BDNF, a target of miR-206, is reduced in the Alzheimer’s Disease 
brains. Its expression was increased following delivery of the anti-miR in all 3 
brain regions. Furthermore, mice that were treated with the anti-miR had 
improved hippocampal memory function as compared to vehicle treated animals 
at 1 week following treatment, as assessed by 2 different behavioural tests (Lee 
et al., 2012). Enhancing BDNF expression by intra-nasal delivery of anti-miR-206 
is therefore a novel therapy for the treatment of Alzheimer’s Disease.  
Interestingly, modulation of let-7c by the intra-nasal delivery of an anti-miR 
proved therapeutically effective in a pre-clinical ICH model of stroke (Kim et al., 
2014). Intra-nasal delivery of the anti-miR-let-7c (suspended in DEPC treated 
water) immediately following ICH induction, in Sprague Dawley rats, reduced 
brain water content (at 72 hours post ICH) and reduced staining for markers of 
neutrophil infiltration, activated microglia and apoptosis. Furthermore, animals 
treated with anti-miR had improved neurological function scores as compared to 
vehicle treated animals, but only at 4 and 5 weeks post-stroke (not significantly 
different in the first 3 weeks post-treatment) (Kim et al., 2014). 
In the present study we propose modulating the expression of miRNAs via intra-
nasal delivery of miRNA modulating agents, encapsulated in exosomes, as a 
novel therapy for ischaemic stroke. Exosomes are endogenous transport vesicles 
and so are excellent tools for drug delivery (Johnsen et al., 2014). They are 
small (30 – 120 nm) and can cross the BBB. ‘Self-derived’ exosomes can also 
overcome problems with immunogenicity. Furthermore, some exosomes have 
natural selective properties for target cells – if this power was harnessed or 
modified correctly, exosomes could be used to delivery miRNA modulating 
agents with high specificity, and therefore fewer side effects. 
Exosomes have been used to deliver siRNA specifically to the mouse brain 
(following systemic administration): exosomes targeted to the neuron specific 
RVG peptide and containing BACE1 siRNA significantly reduced BACE1 expression 
in the brain of C57BL/6 mice as compared to mice treated with exosomes alone 
or the siRNA delivered via a cationic liposome-based transfection reagent 
(Alvarez-Erviti et al., 2011). Exosomes have also been used to deliver 
therapeutic agents intra-nasally. A series of papers have demonstrated the rapid 
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uptake of exosomes into the brain (and especially microglial cells) following 
intra-nasal delivery and subsequent therapeutic effect following delivery of 
therapeutic agents (Zhuang et al., 2016, Zhuang et al., 2011). C57BL/6J mice 
treated intra-nasally with exosomes containing curcumin were protected from 
LPS-induced brain inflammation (Zhuang et al., 2011). Furthermore curcumin 
exosomes reduced the progression of experimentally induced autoimmune 
encephalomyelitis and delayed brain tumour growth following injection of brain 
tumour stimulating cells in the GL26 mouse tumour model (Zhuang et al., 2011). 
Subsequently, intra-nasal delivery of exosome like nanovectors, derived from the 
juice of grapefruit, coated with folic acid (to target folate receptor positive 
tumour cells) and loaded with miR-17 resulted in up-regulation of miR-17 
expression and delayed brain tumour growth (Zhuang et al., 2016). These studies 
confirm that exosomes are a novel and powerful way to deliver therapeutic 
agents to the brain. 
In the present study we propose modulating the expression of miR-17 family 
miRNAs: miRs -17, -93 and -20b. The exosomal expression of these miRNAs was 
up-regulated in the serum of human stroke patients, and especially small vessel 
disease patients, at 48 hours post-stroke (Chapter 4). 
Basic bioinformatics was carried out to find out more about the target genes of 
miRs -17, -93 and -20b – miRWalk 2.0 software (an atlas of predicted and 
validated miRNA-target interactions) and  DAVID (a functional annotation tool) 
were used to generate information about target genes. Figure 5.2 gives more 
information on how this was carried out. As the 3 miRNAs belong to one miRNA 
family and have identical seed sequences (the part of the miRNA important for 
miRNA-target interactions), they share a large number of predicted and 
validated gene targets (Figure 4.12) and a relatively high percentage of these 
targets have the potential to be involved in stroke pathophysiology. If miR-93 is 
taken as an example (Figure 5.2) – of its 2147 predicted gene targets 427 miRNA-
gene target interactions have been experimentally validated. Of these 43 (~10%) 
are involved in the regulation of programmed cell death and apoptosis, 27 (~6%) 
are involved in the cellular response to stress and 31 (~7%) are involved in repair 
processes such as proliferation, axonogenesis and angiogenesis. 
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Figure 5.2 – miR-17 Family Bioinformatics Example 
An example of the process used to find out information about the target genes for each 
miRNA in the miR-17 family. The mature miRNA sequence was entered into a gene target 
prediction software: miRWalk 2.0. miRWalk 2.0 combines results from 12 different miRNA-
gene target prediction algorithms. Only gene targets predicted by 7 or more algorithms were 
accepted as predicted hits. To narrow down the list of gene targets, experimentally 
validated targets were investigated using the same software. The list of experimentally 
validated targets was then entered into the Database for Annotation, Visualization and 
Integrated Discovery (DAVID), where the Gene Ontology function for Biological Processes 
was used. This sorted experimentally validated target genes into various biological 
processes. Biological processes that could be involved in the pathophysiology of ischaemic 
stroke were selected and target genes listed. 
Only one study to date has investigated miR-17 family miRNAs in the setting of 
ischaemic stroke (Liu et al., 2013c). The expression of miRNAs in the miR-17-92 
cluster (of which miR-17 is one) were up-regulated in neural progenitor cells 
harvested from C57BL/6J mice 7 days post-pMCAO. However, miR-17 was not 
significantly up-regulated unlike other members of the miR-17-92 cluster. 
miRNAs in the miR-106b-25 cluster (of which miR-93 is one) (see Figure 4.12) 
were down-regulated in neural progenitor cells following pMCAO. miR-93 was not 
significantly down-regulated. Inhibition of miRs -18a and -19a (miR-17-92 
cluster) in neural progenitor cells reduced proliferation and increased apoptosis. 
miR-18a and -19a were subsequently found to target PTEN and FasL, inducers of 
apoptosis (Liu et al., 2013c). The study concluded that the miR-17-92 cluster 
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mediates the proliferation and survival of neural progenitor cells following 
stroke.   
miR-25 (a member of the miR-106b-25 cluster, of which miR-93 is a member) has 
also been demonstrated to be up-regulated following tMCAO in young Sprague 
Dawley rats and further increased following repetitive transcranial magnetic 
stimulation (Guo et al., 2014). ICV injection of anti-miR-25, immediately prior to 
tMCAO surgery, resulted in increased p57 protein expression (a negative 
regulator of cell proliferation) and reduced proliferation in cells of the 
ipsilateral sub-ventricular zone at 7 days post-tMCAO. 
In non-stroke related models of ischaemia, miR-17 and miR-20 are up-regulated 
in exosomes released by cardiac progenitor cells isolated from Sprague Dawley 
rats following hypoxic insult (Gray et al., 2015). miR-93 has been shown to be 
up-regulated in mouse strains with increased perfusion recovery following 
experimentally induced hindlimb ischaemia (Hazarika et al., 2013). 
Furthermore, in vivo overexpression of miR-93 improved perfusion recovery and 
increased capillary density in C57BL/6J and BALB/cJ mice, whilst intravenous 
delivery of anti-miR-93 resulted in reduced perfusion recovery following induced 
hindlimb ischaemia (Hazarika et al., 2013). p21 and p53 were found to be 
targets of miR-93 in this setting (Hazarika et al., 2013). miR-20b has been shown 
to be down-regulated in ischaemia-reperfused Sprague Dawley rat heart and to 
target VEGF and HIF1α (Mukhopadhyay et al., 2012). miR-20b is also down-
regulated in whole blood samples of patients with peripheral arterial disease as 
compared to healthy control patients (Stather et al., 2013).   
There is a clear need for novel, clinically relevant therapeutics to treat 
ischaemic stroke and the various processes of the debilitating ischaemic 
cascade. We therefore propose delivering miRNA-17 family loaded exosomes 
intra-nasally, post-stroke, in our in vivo pre-clinical models of ischaemic stroke 
and subsequently assessing therapeutic efficacy. 
 
251 
 
 
5.1.1 Hypotheses 
The hypotheses of the present study were as follows: 
 Artificial loading of specific miRNAs into extracellular vesicles will prove 
an efficient tool for modulating miRNA expression in vivo and in vitro. 
 Intra-nasal delivery of miRNAs packaged in extracellular vesicles will be 
an effective and clinically relevant method of modulating miRNA 
expression in vivo. 
 Modulation of miR-17 family miRNAs via delivery of miRNA loaded 
extracellular vesicles will result in therapeutic benefit following pre-
clinical stroke or in vitro hypoxic challenge. 
5.1.2 Aims 
The aims of the present study were as follows: 
 To assess the extent of modulation of specific miRNAs following intra-
nasal delivery of extracellular vesicle packaged miR-17 family miRNAs in 
vivo post tMCAO. 
 To assess the therapeutic effect of modulation of miR-17 family miRNAs 
post-stroke by measuring functional recovery (assessed by behavioural 
testing) and infarct size. 
 To assess the extent of modulation and therapeutic effect of modulation 
of miR-17 family miRNAs post-hypoxic challenge in vitro by quantifying 
miRNA expression and using functional assays to assess therapeutic effect. 
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5.2 Methodology 
5.2.1 miRNAs Selected for Therapeutic Delivery 
Following the results of the exosomal miRNA profiling study in human patients, 
we selected miRs -17, -93 and -20b, from the miR-17 family, as interesting 
candidates for modulation in our pre-clinical models of stroke. 
Due to time and cost constraints it was not possible to examine the effect of all 
3 miRNAs in our in vivo pre-clinical model of stroke. miR-17 had previously been 
investigated in the setting of pre-clinical stroke, and the miR-17-92 cluster 
shown to be therapeutic – mediating proliferation and survival of neural 
progenitor cells following stroke (Liu et al., 2013c). As miRs-93 and -20b were 
therefore more novel in the setting of ischaemic stroke they were taken forward 
for further investigation. miR-93 has a higher endogenous level of expression in 
SHRSP rat brain than miR-20b (average Ct 27 vs. 32) and in SHRSP serum 
(average Ct 27 vs. 31) and it was not clear whether both miRNAs would be 
modulated to the same extent following equivalent doses of miRNA modulating 
agents. miRs -93 and -20b were therefore both taken forward for pilot testing in 
vivo to investigate which miRNA showed the greatest change in expression 
following modulation by delivery of miRNA mimic loaded exosomes. 
5.2.2 Loading of miRNAs into Exosomes 
miRNA mimics were synthetically loaded into exosomes by electroporation, using 
a protocol optimised for our group by Dr. Emily Ord. This protocol was developed 
from a protocol originally published by El-Andaloussi and colleagues (El-
Andaloussi et al., 2012) and involves the insertion of miRNAs (by electroporation) 
into EVs, previously isolated from the brains of SHRSP rats. This protocol is 
summarised in Figure 5.3 and is given in detail in sections 2.5.1.3 and 2.5.3. 
During electroporation short duration, high voltage electrical field pulses cause 
the reversible breakdown of the cellular membrane, via the formation of pores. 
The pores allow small molecules (such as oligonucleotides) to be introduced into 
the EV. Uptake of oligonucleotides continues until the pores close. 
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Figure 5.3 – Exosome Electroporation Protocol 
miRNAs were loaded into EVs previously isolated from SHRSP rat brain. 1. The mimic for 
the miRNA of interest was initially mixed in a 1:1 ratio with EVs. Both were diluted in 50 mM 
Trehalose. 2. The mixture was left on wet ice for 45 minutes. 3. A small volume of EV/miRNA 
mimic mixture (125 µL) was added to an electroporation cuvette and given a 400 V pulse in a 
Bio-Rad MicroPulser™. 4. Immediately following electroporation ice cold 1% (w/v) BSA (875 
µL) was added and mixed with the electroporated EVs before being transferred to a falcon 
tube on wet ice and left for 20 minutes. 5. The electroporated EV mixture was then ultra-
centrifuged at 25.4 k rpm for 1.5 hours before the EV pellet was resuspended in DPBS and 
ultra-centrifuged again at 25.4 k rpm for 1.5 hours. 6. The EV pellet was then resuspended in 
200 µL 0.9% (w/v) sodium chloride (sterile) before being stored at -80ºC until use. 
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5.2.3 Delivery of Exosomal miRNAs 
For the in vivo experiments in the present study, miRNA loaded EVs were 
administered intra-nasally in SHRSP rats. A complete protocol is given in section 
2.7.6. This method had previously been used by Dr. Emily Ord, who 
demonstrated successful up-regulation of miR-520b following intra-nasal delivery 
of miR-520b loaded exosomes to naïve SHRSP rats. Four deliveries of 100 µg of 
miR-520b exosomes over 2 days resulted in substantial up-regulation of miR-520b 
in the olfactory bulb tissue and rostral brain tissue.   
For the in vitro experiments in the present study, miRNA loaded EVs were added 
directly to cell culture medium (see section 0 for a complete protocol). This 
method had previously been used by Dr. Emily Ord – miR-520b was up-regulated 
in B50 neuronal cells following delivery of 875 ng exosomes into the cell culture 
medium 1 day after the cells were seeded. miR-520b expression was assessed 2 
days after cells were treated with exosomes. 
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5.3 Results 
5.3.1 Characterisation of miRNA Loaded EVs 
EVs were isolated by sequential centrifugation from 8 SHRSP brain hemispheres. A 
portion of these EVs were subsequently loaded with miRNA-93 or miR-20b via 
electroporation. They were then visualised and quantified using a NanoSight LM10 
(Figure 5.4). These experiments were performed twice (Batch #1 and Batch #2) to 
create enough extracellular vesicles to use in the presented study. The NanoSight 
traces show that while there some extracellular vesicles in each sample that were 
within the exosome size range of 30-120 nm (~15-20%), the majority of EVs were 
moderately larger. The mean particle size of naïve EVs in Batch #1 was 176 nm and 
in Batch#2 was 172 nm. The mean particle size of electroporated EVs in Batch #1 
was 180 nm and in Batch #2 184 nm. 
EVs were subsequently visualised on a transmission electron microscope. EVs 
were isolated or electroporated as usual, before the pellet was resuspended in 
2% paraformaldehyde before being fixed onto Formvar-carbon coated electron 
microscope (EM) grids according the protocol provided in Current Protocols in 
Cell Biology (Théry et al., 2006). Samples were contrasted using uranyl oxalate 
before being contrasted and embedded in a mixture of 4% uranyl acetate and 2% 
methyl cellulose. In this experiment it was difficult to obtain clear images where 
the methyl cellulose film was too thick. Extracellular vesicles were embedded 
and prepared for electron microscopy by Mrs Margaret Mullin. 
Electron microscopy of negatively stained naïve (Figure 5.5A) and electroporated 
(Figure 5.5B) extracellular vesicle samples revealed predominantly cup-shaped 
membrane vesicles. Representative images were selected from the images taken 
for each extracellular vesicle isolation. While image quality and the angle at 
which the EVs embedded in the methyl cellulose membrane made it difficult to 
take accurate measurements, it is clear the majority of vesicles isolated are 200 
nm or less in diameter, as the NanoSight also demonstrated. 
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Figure 5.4 - NanoSight Characterisation of Extracellular Vesicles 
Naïve EVs were isolated from 8 SHRSP brain hemispheres. A portion of these EVs were 
subsequently electroporated with miR-93 or miR-20b. The concentration of particles within 
each sample was determined using a NanoSight LM10. NanoSight traces for each sample 
are shown (A). The black trace indicates the concentration of exosomes with increasing 
particle size, while the grey trace shows the cumulative percentage of exosomes with 
increasing particle size. The concentration of particles of all sizes, the concentration of 
particles sized 30-120 nm, the mean particle size, the mode particle size and the standard 
deviation for each sample is also listed (B).  
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Figure 5.5 - TEM Characterisation of Extracellular Vesicles 
Electron-microscopic observation of whole-mounted EVs. EVs were isolated from 8 SHRSP 
brain hemispheres. A portion of these extracellular vesicles were subsequently 
electroporated with miR-93. Representative images of naïve (A) and miR-93 loaded 
electroporated (B) extracellular vesicles obtained by transmission electron microscopy 
showing both larger microvesicles and exosome sized vesicles. 
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5.3.2 Delivery of miRNA Loaded EVs in vivo 
5.3.2.1 Delivery of miRNA Loaded EVs to SHRSP post-tMCAO 
A protocol was designed to assess the therapeutic effect of modulating miR-17 
family miRNAs post-stroke via intra-nasal delivery of miR-17 family loaded EVs in 
vivo (Figure 5.6). 
 
Figure 5.6 - Animal Study Protocol 
This diagram illustrates the planned protocol for the animal study. Neurological and 
behavioural test training was to start 5 days prior to tMCAO surgery. A pre-stroke cranial 
burrhole was to be performed 4 days prior to tMCAO surgery. 3 days prior to stroke surgery 
a baseline neurological score was to be measured along with baseline blood pressure. On 
Day 0 a 45 minute tMCAO surgery was to be performed. 4 hours post-reperfusion the first 
intra-nasal delivery of miRNA loaded EVs was to be administered, followed by subsequent 
equivalent intra-nasal deliveries at 22, 28 and 46 hours post-reperfusion. Neurological and 
behavioural tests were to be performed on days 3, 7 and 10 post-tMCAO surgery. Finally, on 
day 10 the SHRSP was to have a final blood pressure measurement recorded before being 
sacrificed by transcardial perfusion fixation. 
SHRSP rats were to receive miR-93 or miR-20b loaded EVs and control animals 
were to receive either naïve EVs or sterile saline. The protocol involved the 
measurement of baseline blood pressure and neurological and behavioural scores 
before tMCAO surgery would be performed on Day 0 of the protocol. At 4 hours 
post-reperfusion the first dose of intra-nasal miRNA loaded EVs were to be 
administered. Subsequently on days 1 and 2 of the protocol, miRNA loaded EVs 
were to be administered at 22, 28 and 46 hours post-reperfusion. Behavioural 
tests were to be repeated on days 3, 7 and 10, following which each SHRSP rat 
was to have blood pressure measurements recorded before being sacrificed by 
transcardial perfusion fixation. Subsequently, their brains were to be sectioned 
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and tissue stained with haemotoxylin and eosin (H&E) to identify infarcted tissue 
which would be quantified. The primary end points chosen to demonstrate 
therapeutic effect of miR-17 family loaded EVs were reduced infarct size and 
improved neurological score in SHRSP as compared to SHRSP that received naïve 
EVs (not loaded with any particular miRNA) or sterile saline. 
Due to time and cost constraints the therapeutic effect of only 1 EV packaged 
miRNA could be examined in the full animal study. Therefore, to assess the 
extent of modulation of miR-93 and miR-20b in vivo following post-tMCAO intra-
nasal delivery of these EV packaged miRNAs, a pilot study was designed (Figure 
5.7) in which these EV miRNAs would be delivered post-stroke at the same time 
points as in the planned animal study. However, SHRSP rats would be sacrificed 
at Day 3, rather than Day 10, and miRNA expression measured, to allow for quick 
identification of which miRNA was modulated the most. 
 
Figure 5.7 - Pilot Study Experimental Plan 
This diagram illustrates the protocol for the pilot study which aimed to discover the extent 
of modulation of miRs -93 and -20b following delivery of EV packaged miRNAs. A pre-stroke 
cranial burrhole was performed 4 days prior to tMCAO surgery. On day 0 a 45 minute 
tMCAO surgery was performed. 4 hours post-reperfusion the first intra-nasal delivery of 
miRNA loaded EVs was to be administered (75 µg). Subsequent equivalent intra-nasal 
deliveries were given at 22, 28 and 46 hours post-reperfusion. Finally, on day 3 the SHRSP 
was euthanised and fresh brain tissue harvested and immediately frozen in liquid nitrogen. 
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In the pilot study, animals were euthanised by terminal anaesthesia and removal 
of the heart to allow for the harvesting of fresh tissue, in which miRNA 
expression could be studied (for a full description see section 2.7.7.4). Tissue 
needed for further analysis (in this case, brain) was removed from the body as 
quickly as possible. The brain tissue harvested was then quickly sectioned as is 
shown in Figure 5.8. The cerebellum and olfactory bulbs were initially separated 
from the cerebral hemispheres. The cerebral hemispheres were sectioned into 4 
slices, and in each slice the cortex was separated from the striatum in each 
hemisphere. All brain sections were then placed in eppendorfs and stored in 
liquid nitrogen until they could be placed in a -80ºC freezer for long-term 
storage. The aim of sectioning tissue in this way was to discover areas of the 
brain where modulation of miRNA expression was greatest and to help discover 
the mechanisms by which EVs were taken up by the brain and the pathway by 
which their effect was mediated. 
 
Figure 5.8 – Illustration of Brain Tissue Sectioning 
The brain tissue was carefully but quickly removed from freshly euthanised SHRSP rats. 
The cerebellum and olfactory bulbs were initially separated from the cerebral hemispheres. 
The cerebral hemispheres were subsequently sectioned into 4 slices and in each slice the 
cortex was separated from the striatum in each hemisphere. 
In the pilot study we aimed to profile miRNA expression in 9 SHRSP rats: SHRSP 
that received sterile saline (n=3), miR-93 EVs (n=3) or miR-20b EVs (n=3) post-
tMCAO. Unfortunately there was a high mortality rate in some animal groups. 
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This is illustrated in the Kaplan Meier Analysis of SHRSP survival in the pilot study 
(Figure 5.9). 3 animals received sterile saline but only 1 survived to 72 hours, 3 
animals received miR-93 EVs and all survived to 72 hours and 5 animals received 
miR-20b EVs, of which 2 survived to 72 hours. While the greatest percentage 
survival was observed in animals who received miR-93 EVs, there is no significant 
difference in the survival curves, as assessed by log-rank test. 
 
Figure 5.9 – Kaplan Meier Analysis of Animal Survival in Pilot Study 
Survival probability is plotted over time, showing the greatest percentage survival in 
animals who received miR-93 EVs relative to control (sterile saline) or other treatment (miR-
20b EVs) after tMCAO. The animals used in the pilot study are shown, with time plotted as 
hours post-reperfusion in tMCAO surgery. Animal groups were SHRSP rats who underwent 
tMCAO surgery and received sterile saline (n=3), miR-93 EVs (n=3) or miR-20b EVs (n=5). 
Survival curves were compared by log-rank test with all comparisons non-significant. 
These surgeries were very time intense as a result of the staggered EV delivery 
timings. As there were significant time constraints it was decided to stop the 
pilot study early and examine miRNA expression in the animal tissue collected up 
until that point. miRNA expression was analysed in all animals that survived to 
72 hours (Figure 5.10 and Figure 5.11) and also in animals that were euthanised 
prematurely or found immediately after death (data not shown). 
In this chapter miRNA expression is sometimes expressed as 1/∆Ct rather than 
RQ, as in previous chapters. This is so that any endogenous differences in basal 
miRNA expression following treatment with exosomes or hypoxic challenge can 
be observed between control groups. As an increased ∆Ct actually reflects a 
lower level of miRNA expression data is presented as 1/∆Ct so that the graphs 
reflect the real change of direction.  
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miR-93 expression was not increased in the brain tissue of animals that received 
miR-93 EVs post-tMCAO surgery, as compared to animals that received sterile 
saline (Figure 5.10). Although there is only 1 animal in the saline treated group, 
miR-93 expression appears to be unchanged in the majority of tissue sections 
examined. miR-93 expression was moderately increased in contralateral S1 tissue 
of animals treated with miR-93 EVs. In all other tissue sections harvested from 
animals treated with miR-93 EVs, miR-93 expression was unchanged or even 
slightly decreased as compared to animals treated with saline. 
miR-20b expression was also not increased in the brain tissue of animals that 
received miR-20b EVs post-tMCAO surgery, as compared to animals that received 
sterile saline (Figure 5.11). While it is difficult to make firm conclusions from 
these results due to the low ‘n’ in both animal groups, miR-20b expression 
appeared to be unchanged in the majority of tissue sections examined. Its 
expression was moderately decreased in some brain sections of animals that 
received miR-20b EVs (ipsilateral C3, CB; contralateral C2, CB) as compared to 
SHRSP that received sterile saline. In other brain sections miR-20b expression 
was moderately increased in SHRSP that received miR-20b EVs post-tMCAO 
(ipsilateral S4; contralateral C4, S1) as compared to those who received saline. 
However, as the small changes observed in miR-93 and miR-20b expression, 
following treatment with miR loaded EVs, do not occur in a consistent manner, 
or in a pattern that would be expected following intra-nasal delivery and on the 
whole miRNA expression is unchanged, it is difficult to tell whether the changes 
observed are a result of the intra-nasal exosomal delivery, the stroke itself or 
simply, the low ‘n’ number and variability between the severity of stroke in 
these animals. In Chapter 4 it was demonstrated that total miR-93 and miR-20b 
expression is not altered in either ipsilateral or contralateral peri-infarct tissue 
of SHRSP rats at either 24 or 72 hours post-stroke (Figure 4.32).  
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Figure 5.10 - miR-93 EV Delivery post-tMCAO 
The expression of miR-93 was assessed in the brain tissue of SHRSP rats who received 300 
µg of miR-93 EVs (n=3) or an equivalent volume of sterile saline (n=1) post-tMCAO. miR-93 
expression was assessed in ipsilateral and contralateral cortex (A, B), striatum (C,D) and 
olfactory bulb and cerebellum (E,F) tissue. miRNA expression was assessed at 72 hours 
post-reperfusion from tMCAO surgery, by qRT-PCR. Expression was normalised to that of 
U87. Data shown is 1/∆Ct values (± SEM). Abbreviations include: C1, cortex section 1; S1, 
striatum section 2; O.B., olfactory bulb; CB, cerebellum. 
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Figure 5.11 - miR-20b EV Delivery post-tMCAO 
The expression of miR-20b was assessed in the brain tissue of SHRSP rats who received 
300 µg of miR-20b EVs (n=2) or an equivalent volume of sterile saline (n=1) post-tMCAO. 
miR-20b expression was assessed in ipsilateral and contralateral cortex (A, B), striatum 
(C,D) and olfactory bulb and cerebellum (E,F) tissue. miRNA expression was assessed at 72 
hours post-reperfusion from tMCAO surgery, by qRT-PCR. Expression was normalised to 
that of U87. Data shown is 1/∆Ct values (± SEM). Abbreviations include: C1, cortex section 
1; S1, striatum section 2; O.B., olfactory bulb; CB, cerebellum. 
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As a result of the data presented here it was decided that it would not be 
prudent to proceed with the full animal study when there was uncertainty as to 
the extent of miRNA modulation following intra-nasal delivery of miR-loaded 
EVs. Instead, new experiments were designed to try and elucidate whether 
miRNA expression was altogether unchanged following exosomal miRNA delivery 
(i.e. a problem with the miRNA loaded EVs) or whether intra-nasal delivery was 
not successful as a result of concomitant health issues associated with tMCAO 
surgery. To this end, a small study where miR-20b loaded EVs were delivered to 
naïve rats was carried out. 
5.3.2.2 Delivery of Exosomal miRNAs to Naïve SHRSP 
To examine whether miRNA expression was increased in naïve rats following 
intra-nasal delivery of miRNA loaded EVs, naïve rats were given four deliveries of 
75 µg miRNA loaded EVs over a period of 2 days (total 300 µg). Control animals 
were given an equivalent volume of sterile saline. Rather than delivering the EVs 
at the time points used when delivering post-tMCAO a protocol was followed 
(Figure 5.12) that had previously been successfully used in our group to 
modulate miR-520b expression in naïve rats. The naïve SHRSP rats were 
sacrificed on Day 5 of the protocol and fresh brain tissue harvested and 
immediately frozen. 
 
Figure 5.12 - Delivery of EVs to Naïve SHRSP, Experiment Protocol 
This diagram illustrates the protocol followed for the study which aimed to discover the 
extent of modulation of miR-20b in naïve SHRSP rats following delivery of miR-20b EVs. On 
Days 0 and 1 intra-nasal deliveries of miR-20b EVs (75 µg each time) were given in the 
morning and evening (4 deliveries, 300 µg total) to naïve SHRSP rats. On Day 5 animals were 
euthanised and fresh brain, lung and kidney tissue was harvested and immediately frozen in 
liquid nitrogen.  
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Due to cost constraints only miR-20b EVs (and not miR-93 EVs) were given to 
naïve rats (n=3). As miR-20b has a lower endogenous level of expression in the 
brain than miR-93 this miRNA was chosen as it was hypothesised that a greater 
level of modulation would be observed following modulation of a miRNA with 
lower endogenous expression (as was observed in previous studies, Chapter 3).  
miR-20b expression was unchanged in the brain tissue of naïve SHRSP rats which 
had received 300 µg of miR-20b EVs (via intra-nasal delivery) as compared to 
SHRSP rats which had received saline (Figure 5.13). While no differences in the 
expression of miR-20b between the two animal groups were statistically 
significant, there appeared to be a small decrease in miR-20b expression in some 
brain tissue sections following treatment with miR-20b EVs, similar to what was 
observed following delivery post-tMCAO, as compared to expression in saline 
treated animals. miR-20b expression was decreased in ipsilateral C1, S2, S4 and 
contralateral C2, S1, S2 and O.B. tissue. While miR-20b expression was not 
increased in brain tissue following intra-nasal delivery of miR-20b EVs, 
importantly, it was also not increased in either lung or kidney tissue (Figure 5.13 
E and F). 
As miR-20b expression was not modulated in either naïve (Figure 5.13) or tMCAO 
(Figure 5.11) rats following delivery of miR-20b EVs in comparison to control 
animals this confirmed that failed modulation of miRNA expression in tMCAO rats 
was not a result of health complications associated with tMCAO surgery. 
Dr. Emily Ord had previously successfully delivered miR-520b loaded EVs to naïve 
rats (Figure 5.14). Although the tissue in this experiment was sectioned in a 
different way to the tissue in the present study, there was an obvious and 
significant increase in miR-520b expression in olfactory bulb, L1 and L2 tissue in 
animals that received miR-520b EVs as compared to those who received saline. 
In the ipsilateral hemisphere miR-520b was increased, on average, 4.0 fold in 
olfactory bulb, L1 and L2 tissue and 1.7 fold in L3 tissue in animals that received 
miR-520b EVs as compared to those who received saline: olfactory bulb (RQ 4.21 
± 0.67 vs. 1.00 ± 0.52), L1 (RQ 3.21 ± 1.14 vs. 1.00 ± 0.36), L2 (4.60 ± 1.27 vs. 
1.00 ± 0.24), L3 (1.73 ± 0.36 vs. 1.00 ± 0.43) (Figure 5.14). Similarly, in the 
contralateral hemisphere miR-520b expression was increased 4.9 fold in 
olfactory bulb, L1 and L2 tissue (on average) and 1.6 fold in L3 tissue in animals 
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treated with miR-520 EVs as compared to those who received saline: olfactory 
bulb (RQ 4.21 ± 0.67 vs. 1.00 ± 0.52), L1 (RQ 4.71 ± 1.92 vs. 1.00 ± 0.49), L2 
(5.73 ± 2.83 vs. 1.00 ± 0.41), L3 (1.59 ± 0.35 vs. 1.00 ± 0.61) (Figure 5.14). 
 
Figure 5.13 - miR-20b EV Delivery to Naïve Rats 
The expression of miR-20b was assessed in the brain, lung and kidney tissue of SHRSP rats 
who received 300 µg of miR-20b EVs (n=3) or an equivalent volume of sterile saline (n=3). 75 
µg of miR-20b EVs were delivered in the morning and evening of Day 0 and Day 1 of the 
protocol. miR-20b expression was assessed in ipsilateral and contralateral cortex (A, B), 
striatum (C,D) and olfactory bulb, cerebellum, lung and kidney (E,F) tissue. miRNA 
expression was assessed at Day 4, by qRT-PCR. Expression was normalised to that of U87. 
Data shown is 1/∆Ct values (± SEM). Probability was calculated using a one-way-ANOVA 
with Sidak’s Multiple Comparisons Test. Abbreviations include: C1, cortex section 1; S1, 
striatum section 2; O.B., olfactory bulb; CB, cerebellum. 
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Figure 5.14 – Delivery of miR-520b EVs in vivo 
The expression of miR-520b was assessed in the brain tissue of SHRSP rats who received 
400 µg of miR-520b EVs (n=3) or an equivalent volume of sterile saline (n=4). 100 µg of miR-
520b EVs were delivered in the morning and evening of Day 0 and Day 1 of the protocol. 
miR-520b expression was assessed in ipsilateral (A) and contralateral (B) olfactory bulb and 
cerebral tissue. Cerebral tissue was sectioned into 4 levels, miRNA expression was only 
profiled in L1-L3. Change in miRNA expression was assessed at Day 4 by qRT-PCR and 
relative quantification (RQ) calculated from ΔΔCt following normalisation to U87 and 
compared to miRNA expression in the saline treated rats. Data shown is RQ ± 
RQmax/RQmin. Probability was calculated using a one-way-ANOVA with Sidak’s Multiple 
Comparisons Test: **p<0.01; ***p<0.001. Abbreviations include: O.B., olfactory bulb; L1, 
cerebral level/section 1. Data courtesy of Dr. Emily Ord. 
Modulation of miR-93 and miR-20b expression was not achieved following post-
stroke treatment with miR-93 or miR-20b EVs. miR-20b expression was also not 
modulated in naïve SHRSP rats following treatment with miR-20b EVs. However, 
modulation of miR-520b expression was clearly demonstrated in naïve SHRSP rats 
following treatment with miR-520b exosomes. Basal expression of miR-520b is 
between that of miR-93 and miR-20b (Avg Ct ~30), and so miR-520b should not 
have been more readily modulated as a result of its lower endogenous 
expression. It was therefore hypothesised that in vivo miRNA expression of some 
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miRNAs or miRNA families is more tightly regulated than that of others, making 
it more difficult to modulate expression of miR-93 and miR-20b than miR-520b. 
As we were unable to modulate miRNA expression in vivo we proposed 
modulating miRNA expression and assessing therapeutic effect following delivery 
of miR loaded EVs in our in vitro models of ischaemic stroke. 
5.3.3 Delivery of miRNA Loaded EVs in vitro 
To examine whether delivery of miR-20b and miR-93 loaded EVs would modulate 
miRNA expression and result in therapeutic benefit, EVs were administered in 
our in vitro model of stroke (hypoxic injury with reperfusion). Two protocols 
were designed, the first where miRNA loaded EVs were delivered to cells pre-
hypoxic challenge (to provide proof of concept data) and the second where 
miRNA loaded EVs were delivered to cells post-hypoxic challenge, a more 
clinically relevant route of delivery. Experiments were planned where miRNA 
loaded EVs would be delivered to 3 different cell types: B50 neuronal cells, B92 
glial cells and GPNT cerebral endothelial cells. 
To demonstrate that miRNA expression was increased following administration of 
miRNA loaded EVs, B50 cells were given miRNA loaded EVs pre- and post-hypoxic 
challenge (Figure 5.15 and Figure 5.16). 
Where miR-93 EVs were administered to B50 cells pre-hypoxic challenge there 
was no significant increase in miR-93 expression (Figure 5.15B). miR-93 
expression was slightly decreased in vehicle treated hypoxic cells as compared 
to normoxic cells (1/∆Ct 0.77 ± 0.05 vs. 0.94 ± 0.17). Treatment with naïve EVs 
reduced expression of miR-93 in normoxic cells vs. vehicle treated cells but 
increased expression in hypoxic cells vs. their vehicle treated counterparts. 
While miR-93 expression was slightly increased in normoxic cells treated with 
miR-93 EVs as compared to those treated with naïve EVs (1/∆Ct 0.95 ± 0.16 vs. 
0.79 ± 0.13) it was not increased when compared to vehicle treated cells. miR-
93 expression was slightly increased in hypoxic cells following treatment with 
miR-93 EVs when compared to vehicle treated cells (1/∆Ct 1.05 ± 0.1 vs. 0.77 ± 
0.05) but not when compared to hypoxic cells treated with naïve EVs. All 
comparisons were non-significant. 
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Figure 5.15 - Delivery of miRNA Loaded EVs pre-Hypoxic Challenge 
The experimental protocol for pre-hypoxic challenge EV delivery is given (A). B50 neuronal 
cells were seeded in 12 well plates on Day 0. On Day 1 875ng of miR-93 or miR-20b loaded 
EVs were added to the cell culture medium. Cells were subjected to a 9 hour hypoxic 
challenge on Day 2 before being harvested on Day 3. The expression of miR-93 (B) and miR-
20b (C) was assessed in B50 neuronal cells which had received 875 ng of naïve EVs, miRNA 
loaded EVs or an equivalent volume of PBS (n=3). miRNA expression was assessed at Day 
3, by qRT-PCR. Expression was normalised to that of U87. Data shown is 1/∆Ct values (± 
SEM). Probability was calculated using a one-way-ANOVA with Tukey’s Multiple 
Comparisons Test. 
When miR-20b EVs were administered to B50 cells pre-hypoxic challenge there 
were no changes in miR-20b expression (Figure 5.15C). miR-20b expression was 
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unchanged in vehicle treated cells following hypoxic challenge as compared to 
normoxic cells (1/∆Ct 0.20 ± 0.003 vs. 0.19 ± 0.005). Treatment with naïve EVs 
did not alter miR-20b expression (1/∆Ct hypoxic 0.20 ± 0.0003 vs. normoxic 0.19 
± 0.004). Similarly, treatment with miR-20b EVs did not modulate miR-20b 
expression in B50 cells (1/∆Ct hypoxic 0.20 ± 0.007 vs. normoxic 0.20 ± 0.004).  
Where miR-93 EVs were administered to B50 cells post-hypoxic challenge there 
was also no significant changes in miR-93 expression (Figure 5.16B). miR-93 
expression was slightly increased in vehicle treated hypoxic cells as compared to 
normoxic cells (1/∆Ct 0.86 ± 0.10 vs. 0.76 ± 0.14). Treatment with naïve EVs 
increased expression of miR-93 in normoxic and hypoxic cells vs. their 
counterpart vehicle treated cells (1/∆Ct normoxic 0.94 ± 0.01 vs. 0.76 ± 0.14 
and hypoxic 1.02 ± 0.08 vs. 0.86 ± 0.10). In normoxic cells treated with miR-93 
EVs expression of miR-93 was unchanged as compared to vehicle treated cells 
and decreased as compared to cells treated with naïve EVs (1/∆Ct 0.79 ± 0.03). 
In hypoxic cells treated with miR-93 EVs, expression of miR-93 was slightly 
increased as compared to vehicle treated cells but unchanged in comparison to 
cells treated with naïve EVs (1/∆Ct 1.04 ± 0.12). All comparisons were non-
significant. 
When miR-20b EVs were administered to B50 cells post-hypoxic challenge there 
were no changes in miR-20b expression (Figure 5.16C). miR-20b expression was 
unchanged in vehicle treated cells following hypoxic challenge as compared to 
normoxic cells (1/∆Ct 0.18 ± 0.006 vs. 0.18 ± 0.01). Treatment with naïve EVs 
did not modulate expression of miR-20b in normoxic or hypoxic cells in 
comparison to their counterpart vehicle treated cells (1/∆Ct normoxic 0.19 ± 
0.005 vs. 0.18 ± 0.01 and hypoxic 0.18 ± 0.02 vs. 0.18 ± 0.006). In normoxic cells 
treated with miR-20b EVs, expression of miR-20b was unchanged as compared to 
vehicle or naïve EV treated cells (1/∆Ct 0.21 ± 0.002). In hypoxic cells treated 
with miR-20b EVs, expression of miR-20b was slightly increased as compared to 
vehicle and naïve EV treated cells (1/∆Ct 0.23 ± 0.04). All comparisons were 
non-significant. 
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Figure 5.16 - Delivery of miRNA Loaded EVs Post-Hypoxic Challenge 
The experimental protocol for post-hypoxic challenge EV delivery is given (A). B50 neuronal 
cells were seeded in 12 well plates on Day 0. Cells were subjected to a 9 hour hypoxic 
challenge on Day 2. Immediately following reoxygenation (post hypoxic challenge) 875ng of 
miR-93 or miR-20b loaded EVs were added to the cell culture medium. Cells were harvested 
on Day 4. The expression of miR-93 (B) and miR-20b (C) was assessed in B50 neuronal cells 
which had received 875 ng of naïve EVs, miRNA loaded EVs or an equivalent volume of PBS 
(n=3). miRNA expression was assessed at Day 4, by qRT-PCR. Expression was normalised 
to that of U87. Data shown is 1/∆Ct values (± SEM). Probability was calculated using a one-
way-ANOVA with Tukey’s Multiple Comparisons Test. 
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Modulation of miR-93 and miR-20b expression was not observed in vitro following 
treatment with miRNA loaded EVs. However, this method had previously been 
used by Dr. Emily Ord, who showed significant up-regulation of miR-520b 
following delivery of miR-520b loaded EVs to B50 neuronal cells, in vitro (Figure 
5.16). In the protocol used for this experiment, B50 cells were seeded on Day 0, 
given 875 ng of naïve EVs, miRNA mimic, EV/miRNA mimic mixture or miR-520b 
loaded EVs on Day 1 and RNA harvested on Day 3. There was no significant 
increase in miR-520b expression following treatment with naïve EVs (RQ 1.69 ± 
0.13 vs. 1.00 ± 1.77), miRNA mimic (RQ 2.72 ±0.07 vs. 1.00 ± 1.77) or EV/miRNA 
mimic mixture (RQ 2.89 ± 0.72 vs. 1.00 ± 1.77). However, following treatment 
with miR-520b loaded EVs expression of miR-520b was significantly increased, 
more than 1000-fold (RQ 1364.20 ± 78.10 vs. 1.00 ± 1.77).  
 
Figure 5.17 – Delivery of miR-520b EVs In Vitro 
The expression of miR-520b was assessed in B50 neuronal cells which had received 875 ng 
of naïve EVs, miR-520b mimic, miR-520b/EV mixture, miR-520b loaded EVs or an equivalent 
volume of PBS (n=5). B50 neuronal cells were seeded on Day 0, EVs were added to cell 
culture medium on Day 1 and RNA harvested from cells on Day 3. Change in miRNA 
expression was assessed by qRT-PCR and relative quantification (RQ) calculated from ΔΔCt 
following normalisation to U87 and compared to miRNA expression in the PBS treated cells. 
Data shown is RQ ± RQmax/RQmin. Probability was calculated using a one-way-ANOVA 
with Tukey’s Multiple Comparisons Test. Data courtesy of Dr. Emily Ord. 
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The comparison of the results obtained when modulating miR-93 and miR-20b 
expression with miRNA loaded EVs in the present study and those obtained by Dr. 
Emily Ord, using miR-520b loaded EVs in a previous study, led us to the 
conclusion that there must have been an error in the protocol followed for the 
synthetic loading (by electroporation) of the miRNA mimic into the EVs (Figure 
5.3). As the basal expression of miR-520b in B50 neuronal cells is similar to that 
of miR-93 and miR-20b, there was no other obvious reason why miR-520b 
expression should be modulated so radically following treatment with miRNA 
loaded EVs and miR-93 and miR-20b expression completely unchanged. 
5.3.4 Electroporation Protocol Optimisation 
As a result of the lack of miRNA modulation in the in vitro study we spent a 
considerable amount of time attempting to troubleshoot the EV electroporation 
protocol (Figure 5.3) as we hypothesised that it was at this step a mistake must 
have been made that led to failure of miRNA being loaded into the EVs. 
As the protocol had originally been optimised by Dr. Emily Ord she was 
consulted. After careful re-examination of the protocols used the only difference 
that could be found was the type of electroporation cuvette used. While the 
type of electroporation cuvette to be used was not specified in the protocol, Dr. 
Ord had optimised the protocol using short electrode (1.1 cm) electroporation 
cuvettes with a 1 mm electrode gap (Cell Projects Ltd). In the present study long 
electrode (2.2 cm) electroporation cuvettes, also with a 1 mm electrode gap 
(Cell Projects Ltd) had been used. Both cuvettes hold the same volume but the 
long electrode cuvettes are designed to be compatible for use with specific 
electroporators that require longer electrodes.  
As a result of this discovery it was hypothesised that the EVs had been 
successfully electroporated and miRNA mimic loaded into the EVs but at a lower 
efficiency than previously estimated. The reduced efficiency of miRNA loading 
into the EVs would result in a lower level of miRNA modulation following delivery 
with the same low concentration of EVs used by Dr. Ord. To test this hypothesis 
two different concentrations of miR-93 and miR-20b loaded EVs (from the two 
batches of miRNA loaded EVs we had created) were delivered to normoxic B50 
neuronal cells (Figure 5.18). 
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Figure 5.18 – Electroporation Optimisation Results 
The expression of miR-93 (A) and miR-20b (B) was assessed in B50 neuronal cells which 
had received 1 µg or 5 µg of miRNA loaded EVs from the first or second batch of miRNA 
loaded EVs made or an equivalent volume of PBS (n=1). B50 neuronal cells were seeded on 
Day 0, EVs were added to cell culture medium on Day 1 and RNA harvested from cells on 
Day 3. Change in miRNA expression was assessed by qRT-PCR and relative quantification 
(RQ) calculated from ΔΔCt following normalisation to U87 and compared to miRNA 
expression in the PBS treated cells. Data shown is RQ ± RQmax/RQmin. Probability was 
calculated using a one-way-ANOVA with Tukey’s Multiple Comparisons Test: *p<0.05; 
**p<0.01. 
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miR-93 expression was unchanged following delivery of 1 µg of miR-93 EVs (Batch 
#1) (RQ 1.29 ± 0.09 vs. 1.00 ± 0.12) as compared to vehicle treated cells but 
significantly increased following delivery of 5 µg of miR-93 EVs (Batch #1) (RQ 
1.76 ± 0.02 vs. 1.00 ± 0.12) (Figure 5.18A). Similarly, miR-93 expression was 
unchanged following delivery of 1 µg of miR-93 EVs as compared to vehicle 
treated cells (Batch #2) (RQ 1.33 ± 0.07 vs. 1.00 ± 0.12) but significantly 
increased following delivery of 5 µg of miR-93 EVs (Batch #2) (RQ 1.38 ± 0.005 
vs. 1.00 ± 0.12) (Figure 5.18A). 
miR-20b expression was unchanged following delivery of 1 µg of miR-20b EVs 
(Batch #1) (RQ 1.35 ± 0.19 vs. 1.00 ± 0.22) as compared to vehicle treated cells 
but significantly increased following delivery of 5 µg of miR-20b EVs (Batch #1) 
(RQ 3.78 ± 0.75 vs. 1.00 ± 0.22) (Figure 5.18B). Similarly, miR-20b expression 
was unchanged following delivery of 1 µg of miR-20b EVs (Batch #2) as compared 
to vehicle treated cells (RQ 1.19 ± 0.07 vs. 1.00 ± 0.22) but significantly 
increased following delivery of 5 µg of miR-20b EVs (Batch #2) (RQ 2.33 ± 0.007 
vs. 1.00 ± 0.22) (Figure 5.18B).  
These results suggest that the EVs were electroporated, and miRNAs loaded into 
them, but not at a level sufficient to modulate expression in vivo or in vitro at 
the concentrations at which they had been successfully delivered in the past. 
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5.4 Discussion 
There is an unmet need for novel treatments that not only result in reperfusion 
but also address specific aspects of stroke pathophysiology, such as cell death, 
cerebral oedema, oxidative stress and inflammation. As these processes are part 
of an ischaemic cascade which begins within minutes of stroke onset and rapidly 
progresses, the success of any ischaemic stroke treatment is dependent on early 
and effective administration of therapy. Furthermore, therapeutic agents used 
must be able to cross the BBB to prove effective.  
It was hypothesised that intra-nasal delivery of miR-17 family miRNAs, packaged 
in extracellular vesicles, would be therapeutically beneficial when delivered 
following experimentally induced stroke in SHRSP rat. The present study was 
carefully thought out and aimed to assess both the extent of modulation and 
possible mechanisms of therapeutic efficacy. When modulation of miR-93 and 
miR-20b was not observed in SHRSP, following delivery of miRNA-loaded EVs 
post-stroke, further studies investigated modulation of miRNA expression 
following delivery of miR-20b loaded EVs to naïve rats. Subsequent studies 
profiled miRNA expression in B50 neuronal cells following delivery of miRNA 
loaded EVs. As miRNA expression was not modulated following delivery of miR 
loaded EVs in either the in vivo and in vitro parts of the study, experimental 
protocols were re-examined to find the cause of the problem. 
One possible cause of the negative results obtained is the fact that long 
electrode electroporation cuvettes were used instead of short electrode 
cuvettes, at a critical stage in the experiment, where miRNAs are loaded into 
EVs. Although the protocol was optimised using short electrode electroporation 
cuvettes, the long electrode cuvettes are compatible with the shock 
compartment of the Bio-Rad MicroPulser™ Electroporator (used by our group). 
The protocol specified that a 400 V electrical pulse was delivered. We initially 
hypothesised that the longer electrode cuvettes were resulting in reduced 
electrical field strength, although the voltage applied was the same. Electrical 
field strength is determined by the following equation: 
𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙 𝑓𝑖𝑒𝑙𝑑 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ (𝑉/𝑐𝑚) =
𝑝𝑒𝑟𝑚𝑒𝑎𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑡𝑎𝑔𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑚𝑒𝑚𝑏𝑟𝑎𝑛𝑒
(0.75 𝑋 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑒𝑙𝑙/𝑣𝑒𝑠𝑖𝑐𝑙𝑒)
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Permeation voltage of the membrane is temperature dependent, which is why 
cooling of electroporation cuvettes before use is important. To calculate the 
voltage to be set on the electroporator, the field strength is multiplied by the 
width of the gap between the electrodes in the cuvette: 
𝑉𝑜𝑙𝑡𝑎𝑔𝑒 = 𝑐𝑟𝑖𝑡𝑖𝑐𝑎𝑙 𝑓𝑖𝑒𝑙𝑑 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ (𝑉/𝑐𝑚) 𝑋 𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑑𝑒 𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒 
It is clear from these equations that electrode length does not determine field 
strength or voltage delivered. Cell Projects, manufacturers of the electrodes 
used in the present study, have confirmed that there should be no difference in 
the electrical field strength delivered between the two types of electrodes, and 
that both are compatible with the Bio-Rad electroporator used. And yet, if data 
generated following electroporation with the 2 different cuvettes is compared, 
it appears that only the short electrodes successfully electroporated EVs, 
resulting in loading of miRNA mimics. 
As our NanoSight data and TEM images show, the naïve EVs isolated from the 
brain of SHRSP and electroporated EVs did not fall within the size range typically 
associated with exosomes (30 – 120 nm). EVs used in the present study to deliver 
miRNAs were larger than this: the mean particle size as assessed by NanoSight 
was between 172 – 184 nm. A previous study has shown that larger 
microparticles (500 nm – 1 µM) do not successfully cross the BBB following intra-
nasal delivery and instead were delivered to the lungs and intestines (Zhuang et 
al., 2011). These results suggest that particle size is an important factor for 
translocation to the brain following intra-nasal delivery. However, the majority 
of EVs used in the study were significantly smaller than the smallest 
microparticles delivered in the study mentioned and no modulation of miRNA 
expression was observed in the lung or kidney. Furthermore, particle size should 
not affect miRNA modulation in vitro and no modulation of miRNA expression 
was observed in vivo or in vitro.  
However, as electrical field strength is partially determined by the diameter of 
the vesicles being electroporated, this may have affected electroporation 
conditions. Larger particles require a smaller applied voltage to deliver the same 
electrical field strength to the solution. The optimised protocol suggested 
applying a voltage of 400V. When applying a voltage of 400 V to larger particles 
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this would result in greater electrical field strength. One would hypothesise that 
too great a voltage would either increase loading efficiency or result in damage 
to the EV membrane. However, this theory is contradicted by TEM images of 
electroporated EVs which demonstrated the presence of intact vesicles.  
Other similar studies have demonstrated successful uptake of therapeutic cargo 
(either miRNA or siRNA) by exosomes at a range of electroporation settings and 
these are summarised in Table 5.1. It is clear that optimal electroporation 
settings differ depending on both the cargo being loaded and the cell type from 
which the exosomes were generated. In general the percentage of cargo loaded 
is relatively low (~25%), with only one group demonstrating ~55% of cargo loaded 
into exosomes following electroporation (Bala et al., 2015, Momen-Heravi et al., 
2014). The percentage of cargo loaded was not calculated in the present study. 
However, it is evident that if only relatively small percentages of cargo are 
loaded into the exosomes following electroporation, if electroporation 
conditions are sub-optimal then the percentage of cargo loaded may decrease 
dramatically. This is demonstrated by several studies which show that several 
parameters including electroporation voltage (Momen-Heravi et al., 2014, 
Wahlgren et al., 2012), siRNA aggregation (Kooijmans et al., 2013) and  exosome 
aggregation (Hood et al., 2014) can significantly affect the efficiency of cargo 
loading into exosomes. While the voltage used in the present study was the same 
as that used in other studies (Alvarez-Erviti et al., 2011, Kooijmans et al., 2013) 
the electrode distance was smaller (0.1 cm vs. 0.4 cm) meaning that the critical 
field strength delivered was significantly higher. However, as these same 
electroporation settings had been used successfully within our group previously 
this is unlikely to be the cause of the negative results observed in the present 
study. Furthermore, trehalose was used in our electroporation buffer (as 
recommended by (Hood et al., 2014)) to prevent exosome aggregation and we 
did not observe significant exosome aggregation by TEM (data not shown). 
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Table 5.1 – Summary of studies using electroporation to load cargo into exosomes. 
This table gives information about the cell type used to generate the exosomes (and unless otherwise stated exosomes were isolated from cell culture 
medium), electrode distance in the electroporation cuvettes used, electroporation settings, the cargo loaded and the approximate percentage of cargo 
loaded into exosomes following electroporation. A ‘–’ indicates there was no information presented in the study on the specific category.  
Reference 
Cell Type Used to 
Generate Exosomes 
Electroporation 
Cuvette: 
Electrode 
Distance 
Electroporation 
Settings 
Cargo 
Percentage of 
Cargo Loaded 
(Alvarez-Erviti et al., 2011) 
Nature Biotechnology 
Primary dendritic cells harvested 
from murine bone marrow. 
4 mm 400 V, 125 µF 
GAPDH siRNA, BACE1 
siRNA 
~25% 
(El-Andaloussi et al., 2012) 
Nature Protocols 
Bone marrow dendritic cells and 
HEK cells 
4 mm 
400 mV, 125 µF, 10-
15 ms pulse 
siRNA ~25% 
(Wahlgren et al., 2012) 
Nucleic Acids Research 
HeLa and lung cancer cells HTB-
177. Exosomes from human 
plasma. 
4 mm 150 V, 100 mF MAPK1 siRNA 
~15-35%, depending 
which exosomes were 
used. 
(Shtam et al., 2013) 
Cell Communication & 
Signalling 
HeLa and HT1080 human 
fibosarcoma cells.  
4 mm 
700 V, 350 ms pulse, 
20 times 
RAD51 and RAD52 
siRNA 
- 
(Kooijmans et al., 2013) 
J. of Controlled Release 
Human embryonic kidney 
HEK293T and mouse 
neuroblastoma Neuro2A.  
4 mm 400 V, 125 µF 
Fluorescently labelled 
siRNA 
~25% 
(Hood et al., 2014) 
Analytical Biochemistry 
Mouse B16-F10 melanoma cells. 4 mm 
750 V/cm, single 
pulse <1 ms 
Supramagnetic iron 
oxide nanoparticles 
(SPION5) 
- 
(Tian et al., 2014) 
Biomaterials 
Human breast cancer cell lines 
MDA-MB-231 and MCF-7. 
4 mm 350 V, 150 mF Doxorubicin up to 20% 
(Momen-Heravi et al., 2014) 
Nanomedicine 
Murine B cells. 2 mm 150 V, 100 µF 
miR-155 mimic or 
inhibitor 
~55% 
(Bala et al., 2015) 
Nature Scientific Reports 
Murine B cells.  2 mm 150 V, 100 µF miR-155 mimic presumed as above 
Present Study SHRSP brain homogenate. 1 mm 
400 V, 10-15 ms 
pulse 
miR-93 and miR-20b 
mimic 
- 
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The protein content of EV suspensions was measured by BCA protein assay and 
used as an estimate of the concentration of EVs within each sample, as 
recommended in the Nature Protocols study which was used as the basis for our 
protocol (El-Andaloussi et al., 2012). An alternative method would be to use a 
NanoSight to measure the number of EVs within each sample. As the NanoSight 
measurements could be variable depending on how concentrated or dilute a 
sample was, it was decided that BCA protein assay was the best way to measure 
EV concentration. However, if errors were made at this stage in the experiment, 
it is possible that EV samples (naïve or electroporated) could be over-diluted and 
so result in a lower than calculated dose of EVs being delivered. However, as 
BCA assays were used regularly in our group and by Dr. Emily Ord in her 
experiments, I do not believe that this explains the differences observed in 
miRNA modulation between the two experiments. 
A further possibility is that differences in the biology of the miRNAs themselves 
could explain differences in miRNA modulation. The miRNA mimics used in the 
present study were purchased from Life Technologies. Mimics used in 
experiments performed by Dr. Emily Ord were also purchased from Life 
Technologies. Furthermore, Life Technology miRNA mimics have been used 
regularly in our research group and without problem in the past. As the data 
presented in Chapter 3 shows, it is easier to modulate miRNAs with lower 
endogenous expression or they can be modulated to a greater extent with 
identical doses of miRNA modulating agents. However, as the endogenous 
expression of miR-520b is between that of miR-93 and miR-20b this does not 
explain differences in miRNA modulation observed. 
It is difficult to discover the exact reason for the failure of miRNA modulation 
following delivery of miRNA loaded EVs and it is possible that it is the combined 
result of a number of small errors. The protocols were optimised by a member of 
our research group, using the same animals and equipment as were to be used in 
the present study. It was therefore believed that no further optimisation was 
needed before starting the in vivo study shown here. With hindsight it is clear 
that time and money could have been saved if a couple of small optimisation 
experiments had been carried out in vitro prior to starting the in vivo study. If 
time had permitted a further experiment could have been carried out to 
examine differences in miRNA expression between loaded and naïve exosomes. If 
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RNA was extracted from both naïve and loaded exosomes then qRT-PCR could be 
used to examine differences between miR-93 and miR-20b expression in each – 
this would give an indication of whether or not electroporation had been 
successful. 
Other methods of loading cargo into exosomes include transfection of exosome 
producing cells, cell activation and simple incubation. The most commonly used 
method for loading miRNA into exosomes in the literature is that of transfecting 
the exosome producing cells so that they over-express a certain miRNA which is 
then packaged into exosomes endogenously by the cell (Chen et al., 2014, 
Katakowski et al., 2013, Kosaka et al., 2012, Munoz et al., 2013, Ohno et al., 
2013, Pan et al., 2012, Zhang et al., 2010, Xin et al., 2013b). While this method 
has been used to successfully to generate exosomes that modulate miRNA 
expression both in vitro and in vivo the cell engineering necessary to optimise 
conditions so that large amounts of the desired miRNA are loaded into exosomal 
lumen can be extremely time intensive. This method would also be problematic 
if patients’ own cells were to be used as exosome donors to generate non-
immunogenic exosomes. miRNA can be loaded into exosomes following simple 
incubation of exosomes and cargo (Bryniarski et al., 2013) and also by using 
chemical transfection reagents. However chemical transfection was found to be 
a less successful method than electroporation at loading siRNA into exosomes 
when the two methods were compared (Shtam et al., 2013, Wahlgren et al., 
2012). Cells can also be activated to induce modulation of exosome loading (Xin 
et al., 2012). This method has been used in the setting of ischaemic stroke, 
when mesenchymal stromal cells (MSCs) were treated with brain extracts from 
rat MCAO brain, resulting in increased expression of miR-133b in exosomes 
produced by the MSCs (Xin et al., 2012). This method is problematic in that it is 
difficult to control the response of the cells to the activating agent. A 
subsequent study by the same group used lentiviral vectors to transfect the 
cells, resulting in over-expression of miR-133b and subsequent increased loading 
of miR-133b into exosomes (Xin et al., 2013b). 
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The discovery that miRNAs were not efficiently loaded into EVs, a critical step in 
all the experiments presented in this study, was extremely disappointing. The 
data presented in this study is therefore uninterpretable in the context of 
currently published literature. These experiments are important and if the 
technical issues had been corrected in time would have determined whether 
intra-nasal delivery of miRNA loaded EVs held promise as a novel therapy in the 
setting of pre-clinical experimental stroke. Intra-nasal delivery of miRNA loaded 
EVs post-stroke, is novel, clinically relevant and remains a therapy of interest in 
the pre-clinical stroke studies carried out by our research group. 
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Chapter 6 General Discussion 
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6.1 Summary 
Stroke remains a largely unmet clinical need. The primary treatment for stroke 
is still rt-PA which was first tested in a clinical trial over twenty years ago. 
Furthermore it is estimated that less than 10% of patients receive this treatment 
(Adeoye et al., 2011, Menon et al., 2015, Saver et al., 2013). Recent advances in 
mechanical clot retrieval have demonstrated that endovascular treatment is an 
additional treatment option offering improved outcome (e.g MR CLEAN clinical 
trial (Berkhemer et al., 2015)). Furthermore, the creation of specialised stroke 
units is associated with improved outcome (Stroke Unit Trialists' Collaboration, 
2013). Despite this and although stroke incidence has fallen as a result of 
interventions improving control of cardiovascular risk, stroke remains one of the 
highest causes of death and serious disability worldwide. Numerous pre-clinical 
studies have significantly improved our understanding of the ischaemic cascade 
and the pathophysiology of stroke. They have further demonstrated that 
neuroprotective and neuro-restorative strategies may hold promise but these 
have failed to make the transition from “bench to bedside” despite appearing to 
be highly effective in rodents. This thesis has investigated whether miRNAs 
(especially those packaged within exosomes) are dysregulated following 
ischaemic stroke and whether they can be modulated therapeutically to improve 
outcome following stroke. 
Early studies (Chapter 3) investigated whether candidate miRNAs, miR-494 and 
miR-21, held promise as therapeutic agents for ischaemic stroke. While data 
supporting the therapeutic use of miR-494 was lacking, data concerning miR-21 
modulation held more promise. miR-21 is increased significantly in the brain of 
SHRSP rats at 72 hours following tMCAO. While modulation of miR-21 expression 
in vitro did not result in modulation of PTEN or PDCD4 (target gene) expression 
or in  increased cell survival in cerebral endothelial cells it was hypothesised 
that this could be a result of miRNA mimics not being functionally processed by 
the cells to which they were delivered. Further experiments would address 
whether or not this was the case and carry out more comprehensive gene 
expression and functional outcome assays to determine exactly what effect miR-
21 modulation has in vitro. Wire myography experiments revealed abnormal 
basal nitric oxide activity in the aortae of miR-21-/- mice, consistent with a 
detrimental phenotype associated with a loss of miR-21 expression (Breen, 
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2015). Further experiments would address the effect of gain or loss of miR-21 
expression on cerebral blood vessels, such as the MCA, providing information of 
the importance of miR-21 modulation in the brain and whether or not its 
modulation was likely to prove therapeutically beneficial in the setting of 
ischaemic stroke. 
This thesis has primarily focussed on the identification of dysregulated exosomal 
miRNAs in human ischaemic stroke patients and subsequent investigation of 
these same miRNAs in pre-clinical models of stroke (Chapter 4). Exosomes were 
isolated from serum of stroke patients that had been collected 48 hours post-
stroke onset. Profiling of exosomal miRNA content in ischaemic stroke patients 
found 9 miRNAs whose expression was increased significantly in the serum of 
ischaemic stroke patients in comparison to non-stroke controls. Of these, 7 
miRNAs were significantly increased in the serum of SVD stroke patients in 
comparison to non-stroke controls. While exosomal miRNA signalling has been 
demonstrated in other cardiovascular disease settings (Bang et al., 2014a, 
Hergenreider et al., 2012) this is the first study, to our knowledge, to profile 
exosomal miRNA expression in ischaemic stroke patients. Other studies have 
demonstrated that specific miRNA sequences are preferentially selected for 
extracellular transport (Montecalvo et al., 2012) or are packaged differently 
(Palma et al., 2012) demonstrating that miRNAs are not randomly secreted in 
exosomes from cells. The data presented in this thesis are consistent with our 
hypothesis that specific miRNAs are actively packaged into exosomes as a result 
of ischaemic stroke (or contribute to the cause thereof) and that as a result the 
circulating exosomal miRNA profile is significantly altered. When total miRNA 
expression was profiled in the serum of the same stroke (and control) population 
(albeit smaller ‘n’) there were no significantly dysregulated miRNAs detected 
(Breen, 2015) highlighting the importance of profiling exosomal miRNA. 
Furthermore, these data in conjunction with the presented study are consistent 
with the hypothesis that a number of miRNAs are selectively and actively 
packaged into exosomes. 
Importantly, in comparison to a number of studies that have profiled total 
miRNA expression in ischaemic stroke patients the present study had access to a 
non-stroke patient population that was aged, hypertensive and had significant 
risk of stroke. Therefore differences in exosomal miRNA expression can be more 
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readily attributed to ischaemic stroke (vs. more general cardiovascular disease). 
Profiling of miR-17 family miRNA expression in our pre-clinical models revealed 
significantly higher miR-17 expression in naïve SHRSP rats as compared to 
normotensive WKY rats but no significant differences between total and 
exosomal circulating miRNA expression in SHRSP following either tMCAO or 
pMCAO. SHRSP are believed by some to be a model of human cerebral SVD (in 
part; no animal model can fully mimic human SVD). In human patients exosomal 
miRNA expression was significantly increased in SVD stroke subtype versus other 
stroke subtypes - it is therefore possible that the presented data are consistent 
with the hypothesis that dysregulated miRNAs detected in human SVD stroke 
patients are packaged into exosomes as a result of underlying cerebral vascular 
disease which predisposes patients to suffer a stroke. Cerebral ischaemia as a 
result of ischaemic stroke may result in further increases in expression of these 
miRNAs, explaining why exosomal miRNA expression was increased in large 
artery and cardioembolic patients but to a much lesser extent. 
It has been suggested that embolic MCAO (Overgaard et al., 1992) is a more 
clinically relevant model of human stroke (Hossmann, 2012) than tMCAO. 
Embolic MCAO involves the insertion of an embolus at the origin of the MCA, 
occluding blood supply to the brain. The embolus is subsequently broken down 
by the administration of rtPA. Reperfusion is therefore protracted (as opposed to 
immediate with removal of intraluminal suture in tMCAO model) and so the 
infarct expands into the penumbral area within 3 hours. When reperfusion is 
immediate this infarct expansion is delayed, unnaturally, by 6-12 hours 
(Hossmann, 2012). However, as the majority of patients (77.5%) in the present 
study did not receive rtPA, these patients are perhaps best reflected by the 
pMCAO model which we used in this study. Furthermore, as we examined miRNA 
expression in our pre-clinical tMCAO model at 24 and 72 hours post-stroke when 
infarct expansion would have completed we would not expect to see significant 
differences by using an embolic model of stroke. However, future studies should 
take this issue into consideration. 
While the presented study gave no indication that exosomal miRNAs would be 
useful as biomarkers or predictors of clinical outcome this may well reflect the 
extremely heterogeneous nature of a stroke patient population and is also 
consistent with the idea that dysregulated miRNA expression is not only changed 
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as a result of ischaemic stroke but predisposes to some degree. Further studies 
would investigate (if possible) exosomal miRNA expression at more acute time 
points (<48 hours, as used in present study) as well as longer time points and 
would compare both total and exosomal miRNA expression at all time points. 
Finally, the use of exosomal packaged miRNAs as a therapeutic agent was 
investigated. Electroporation was used to load exosomes harvested from the 
brains of SHRSP rats with miR-93 or miR-20b mimic. miR-93 and miR-20b 
exosomes were subsequently delivered in vivo via intra-nasal delivery to SHRSP 
and in vitro to a neuronal cell line. While miRNA loaded exosomes did not 
modulate miRNA expression it is believed that this was the result of technical 
problems. Future studies would optimise electroporation conditions further and 
investigate efficacy of alternative methods of loading miRNA into exosomes, 
such as transfection of exosome producing cells which has been used successfully 
to load exosomes with miRNAs previously (Johnsen et al., 2014). The in vivo 
experiments that had been planned are important and remain of interest but 
delivery times and stroke model used could be refined to make the model as 
clinically relevant as possible, as has been discussed above. 
6.2 Future Perspectives 
As has already been discussed no neuroprotective or neuro-restorative strategies 
have yet made the transition from “bench to bedside” despite promising results 
in rodent stroke models. While this translational roadblock has now been 
recognised and suggestions have been made as to how to overcome this, this is a 
huge challenge for pre-clinical stroke research. Every effort therefore should be 
made to ensure that all pre-clinical studies, including our own, adhere to basic 
good practice guidelines (ARRIVE and STAIR amongst others (Fisher et al., 2009, 
Kilkenny et al., 2010, Macleod et al., 2009, STAIR, 1999)). Furthermore, pre-
clinical study design should be improved to avoid “preventable attrition” 
(Dirnagl, 2016). This includes increasing internal validity by randomisation and 
blinding to improve reproducibility. Larger group sizes should be used in animal 
studies to increase statistical power and to reduce the reporting of inflated 
effect sizes. Furthermore the publication of negative results should be 
encouraged – it is estimated that only 50% of clinical medicine studies are ever 
published (Chan et al., 2014) and it is thought that this percentage could be 
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significantly less in pre-clinical medicine (Dirnagl, 2016). Furthermore the use of 
appropriate animal models (both comorbid and aged) would improve external 
validity. While some of these suggestions come at a cost, making them 
unfeasible for some research groups, every effort should be made to ensure 
studies are carefully planned and rigorously performed to overcome this 
translational roadblock that is holding back the development of desperately 
needed novel treatments for ischaemic stroke patients. 
A further challenge in the search for novel therapeutic interventions for stroke is 
that of delivery. As “time is brain” (Saver, 2006) it is important to deliver 
therapeutic interventions as rapidly as possible following stroke. For this reason 
delivery methods commonly used in pre-clinical ischaemic stroke studies such as 
invasive stereotactic injection or ICV infusion delivery of therapeutic agents may 
not be suitable for use in a clinical setting, aside from other safety and cost 
considerations. As therapeutic agents must cross the BBB to be effective, 
systemic delivery is not always an option. Relatively novel, non-invasive delivery 
methods, such as intra-nasal, where therapeutic agents can rapidly cross the BBB 
(Lochhead and Thorne, 2012) have already been used to deliver miRNA 
modulating agents with therapeutic effect in pre-clinical models of Alzheimer’s 
Disease and ICH (Kim et al., 2014, Lee et al., 2012). However, the PISCES trial 
(in which neural stem cells were administered between 6-60 months post-stroke) 
(Kalladka et al., 2016) has demonstrated that if the primary aim of the 
intervention is to promote repair and regeneration then delivery can be delayed 
and stereotactic administration may become a viable option.  
miRNAs are attractive candidates for therapeutic modulation in the setting of 
ischaemic stroke, as a result of their ability to alter the expression of multiple 
genes involved in stroke pathophysiology. Due to their small size and conserved 
sequence miRNA modulating agents are now readily available for most miRNAs. 
However, given the potential of one miRNA to target many genes, off-target 
effects are a significant consideration (van Rooij and Kauppinen, 2014). This 
highlights the importance of targeted delivery of miRNA modulating agents – a 
challenge which may be circumvented by the use of targeted exosomes (Johnsen 
et al., 2014). Despite the many challenges associated with successful and 
therapeutically effective miRNA modulation, a successful phase II clinical trial in 
which miR-122 was modulated to treat hepatitis-C virus infection resulted in 
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long-lasting dose-dependent antiviral activity and was well tolerated (Janssen  
et al., 2013). This proves that miRNA modulation is feasible therapeutically in 
human patients and is an inspiration for future studies seeking to modulate 
miRNA expression following ischaemic stroke. 
In the present study microarray technology was used to identify dysregulated 
exosomal miRNAs. While array technology is a useful tool for profiling large 
numbers of miRNAs in numerous samples simultaneously, some studies have used 
RNA Sequencing (RNA-Seq) and Next Generation Sequencing (NGS) technologies 
to investigate changes in RNA and non-coding RNA expression both in human 
patients and in pre-clinical models of stroke (Dykstra-Aiello et al., 2015, Meller 
et al., 2016, Zhang et al., 2016a). RNA-Seq is a deep-sequencing technology that 
involves the conversion of a RNA population to a library of cDNA fragments, to 
which adapters are attached on to one or both ends. Sequencing experiments 
can be performed with or without amplification, with each molecule being 
sequenced in a high-throughput manner, with the reads (short sequences) 
subsequently aligned to a reference genome (Wang et al., 2009). RNA-Seq is 
beneficial in comparison to microarray technology in that it has the ability to 
identify novel RNAs, including lncRNAs. Microarray technology, on the other 
hand, is limited by its ability only to detect previously identified transcripts or 
miRNAs. Furthermore RNA-Seq can profile changes in differing RNA types in 
parallel, for example profiling mRNAs, lncRNAs, miRNAs, snoRNAs and piwi-
interacting RNAs (piRNAs) in the same samples (for example, (Muller et al., 
2015)). This can give an in depth understanding of interactions within the 
transcriptome, such as interactions between RNA-RNA and miRNA-mRNA, and 
helps to identify functionality of dysregulated RNAs. Finally, RNA-Seq has greater 
sensitivity for RNAs with low expression. Therefore, if RNA-Seq had been used in 
the present study, there may not have been problems with the low sample input 
and a larger number of dysregulated miRNAs may have been identified. 
However, the cost of RNA-Seq is prohibitive (~10 times that of microarray) and 
so only a small number of samples would have been profiled. The benefits and 
limitations of each have to be weighed against each other. If RNA-Seq 
technology becomes more widely used and the price falls it would be interesting 
to use this technology in the cohort of patients examined in the present study. 
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Finally, exosomes remain an exciting prospect in the drive towards personalised 
medicine. Numerous studies have demonstrated both the importance of exosome 
based paracrine signalling and the suitability of using exosomes for drug 
delivery. However this field is still in relative infancy and a number of questions 
still need to be answered (Johnsen et al., 2014). These include whether or not 
exosome producing cells would need to be self-derived to be non-immunogenic, 
which method of exosome loading is most appropriate and whether this changes 
for the type of cargo being loaded. Perhaps the most interesting question is 
whether the further development of targeting (via peptides on the surface) of 
exosomes will allow for specific drug delivery in vivo – if exosomes were to be 
used to deliver miRNA mimics or anti-miRs this would substantially reduce the 
possibility of off-target effects following intravenous delivery. 
6.3 Concluding Remarks 
In summary, the findings presented in this thesis confirm (as was hypothesised) 
that packaging of miRNAs into exosomes is significantly dysregulated in stroke 
patients and that as a result the circulating exosomal miRNA profile is altered. 
Further studies are needed to elucidate the functional importance of this 
dysregulation and whether exosomal miRNAs can be used therapeutically in the 
setting of ischaemic stroke. 
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